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In the past decades, China has experienced one of the fastest ageing processes in the world. 
Alongside the demographic transition, there is a dramatic increase in age-related disability. 
Currently, vision loss is the leading cause of age-related disability in developing countries. 
Age-related eye diseases (AREDs), mainly including age-related macular degeneration 
(AMD), glaucoma, cataract and diabetic retinopathy, are primarily degenerative diseases in 
older people, whose burden is expected to increase with demographic ageing. This thesis aims 
to estimate the prevalence and burden of AREDs in China. 
Methods 
I searched three Chinese and three English bibliographic databases, namely China National 
Knowledge Infrastructure (CNKI), Wanfang, Chinese Biomedicine Literature Database 
(CBM-SinoMed), PubMed, Embase and Medline for studies of the prevalence of age-related 
macular degeneration (AMD), cataract, glaucoma, and diabetic retinopathy (DR) in China. For 
diseases where a single study could contribute multiple stratum-specific (e.g. age-specific and 
sex-specific) data points, a multilevel mixed-effects meta-regression was applied to generate 
the stratum-specific prevalence estimates of disease. For diseases where only study-level 
prevalence estimates were available, a random-effects meta-analysis was conducted to 
generate the pooled prevalence. By applying the estimated stratum-specific prevalence (or 
pooled prevalence) to the corresponding population data, available from the United Nations 
Population Division (UNPD), the national number of affected people was determined. By 
taking the geographic effects, the national number of cases was finally distributed into the six 
geographic regions (East China, North China, Northeast China, Northwest China, South 
Central China, Southwest China) in China. 
Results 
For estimating the prevalence and burden of AMD, 25 eligible studies were identified in the 
systematic review. The prevalence of any AMD ranged from 2.44% (95% CI: 1.85-3.22) in 
people aged 45-49 years to 18.98% (95% CI: 15.05-23.66) in people aged 85-89 years. 
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Prevalence of early AMD ranged from 1.79% (95% CI: 1.05-3.02) to 10.05% (95% CI: 6.17-
15.97), and, in the case of late AMD, from 0.38% (95% CI: 0.16-0.97) to 3.88% (95% CI: 
1.68-9.13). In late AMD, the prevalence of geographic atrophy (GA) was 0.15% (95% CI: 
0.05-0.47) in people aged 45-49 years and 1.09% (95% CI: 0.35-3.36) in those aged 85-89 
years, and the prevalence of neovascular AMD (NVAMD) ranged between 0.24% (95% CI: 
0.11-0.50) and 2.79% (95% CI: 1.33-5.77). In people aged 45-89 years, the number of people 
with any AMD was 12.01 million (95% CI: 9.29-15.46) in 1990 and 26.65 million (95% CI: 
20.62-34.27) in 2015. Within the same period, the number of people with early AMD increased 
from 9.44 million (95% CI: 7.74-11.15) to 20.91 million (95% CI: 17.16-24.68), and those 
with late AMD rose from 2.58 million (95% CI: 1.56-4.30) to 5.74 million (95% CI: 3.46-
9.59). In late AMD, the number of people living with GA ranged from 0.87 million (95% CI: 
0.40-1.83) in 1990 to 1.93 million (95% CI: 0.89-4.08) in 2015, and NVAMD from 1.71 
million (95% CI: 1.16-2.47) to 3.81 million (95% CI: 2.57-5.51). It is projected the number of 
people with any AMD in 2050 will be 55.19 million (95% CI: 43.04-70.30). Among different 
regions, the South Central owed the most AMD cases (5.50 million in 2000 and 7.52 million 
in 2010), whereas North-West China the least (0.66 million in 2000 and 0.95 million in 2010). 
For estimating the prevalence and burden of glaucoma, 30 studies met the inclusion criteria in 
the systematic review. In males, the prevalence of POAG ranged from 0.74% (95% CI: 0.48-
1.14) in individuals aged 45-49 years to 3.02% (95% CI: 1.92-4.73) in those aged 85-89 years. 
The prevalence of POAG in females was slightly lower than that in males across the whole 
age spectrum from 45 to 89 years, ranging from 0.54% (95% CI: 0.35-0.84) to 2.24% (95% 
CI: 1.41-3.53). For PACG, the prevalence increased from 0.48% (95% CI: 0.39-0.60) in males 
aged 45-49 years to 3.44% (95% CI: 2.66-4.45) in males aged 85-89 years. The prevalence of 
PACG was consistently higher in females than in males, ranging from 0.91% (95% CI: 0.74-
1.11) in females aged 45-49 years to 6.33% (95% CI: 4.98-8.02) in females aged 85-89 years. 
The pooled prevalence of secondary glaucoma was 0.15% (95% CI: 0.10-0.23). In people aged 
45-89 years, the number of people affected by POAG increased from 2.35 million (95% CI: 
1.54-3.60) in 1990 to 5.22 million (95% CI: 3.40-7.98) in 2015, PACG from 3.22 million (95% 
CI: 2.70-3.84) to 7.14 million (95% CI: 5.97-8.53), and secondary glaucoma from 0.34 million 
(95% CI: 0.23-0.53) to 0.76 million (95% CI: 0.51-1.17). In 2015, more than half (54.42%) of 
the glaucoma cases were PACG, followed by POAG (39.79%) and secondary glaucoma 
(5.79%). By 2050, the number of all glaucoma cases in China will be 25.16 million (95% CI: 
18.96-33.86). %). In both 2000 and 2010, East China owed the most POAG cases (1.02 million 
in 2000 and 1.39 million in 2010) and PACG cases (1.24 million in 2000 and 1.68 million in 
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2010), whereas Northwest China the least (POAG: 0.19 million in 2000 and 0.27 million in 
2010; PACG: 0.32 million in 2000 and 0.46 million in 2010).  
For estimating the prevalence and burden of cataract and cataract blindness, 55 studies met the 
eligibility criteria and were included in the systematic review and meta-analysis. In males, the 
prevalence of any cataract (including post-surgical cases) ranged from 6.71% (95% CI: 5.06-
8.83) in people aged 45-49 years to 73.01% (95% CI: 65.78-79.2) in elderly aged 85-89 years. 
In females, the prevalence of any cataract increased from 8.39% (95% CI: 6.36-10.98) in 
individuals aged 45-49 years to 77.51% (95% CI: 71.00-82.90) in those aged 85-89 years. For 
age-related cataract (ARC, including post-surgical cases), in males, the prevalence rates 
ranged from 3.23% (95% CI: 1.51-6.80) in adults aged 45-49 years to 65.78% (95% CI: 46.72-
80.82) in those aged 85-89 years. The prevalence of ARC in females was 4.72% (95% CI: 
2.22-9.76) in the 45-49 years age group and 74.03% (95% CI: 56.53-86.21) in the 85–89 years 
age group. The pooled prevalence rate of cataract blindness (including post-surgical cases) by 
best corrected visual acuity (BCVA) <0.05 among middle-aged and older Chinese was 2.30% 
(95% CI: 1.72-3.07), and those of cataract blindness by BCVA <0.10 and cataract blindness 
by presenting visual acuity (PVA) <0.10 were 2.56% (95% CI: 1.94-3.38) and 4.51% (95% 
CI: 3.53-5.75) respectively. In people aged 45-89 years, the number of any cataract cases was 
50.75 million (95% CI: 42.17-60.37) in 1990 and 111.74 million (95% CI: 92.94-132.84) in 
2015, and that of ARC rose from 35.77 million (95% CI: 19.81-59.55) in 1990 to 79.04 million 
(95% CI: 44.14-130.85) in 2015. By 2050, it is projected that the number of people (45-89 
years of age) affected by any cataract will be 240.83 million (95% CI: 206.07-277.35), and 
that of those with ARC will be 187.26 million (95% CI: 113.17-281.23). During 2000 and 
2010, South Central China consistently owed the most cases of any cataract (23.50 million in 
2000 and 31.79 million in 2010), whereas Northwest China the least (3.37 million in 2000 and 
4.87 million in 2010). 
For estimating the prevalence and burden of DR. A total of 31 studies provided information 
on the prevalence of DR and 21 explored potential risk factors for DR. The pooled prevalence 
of any DR, nonproliferative DR (NPDR) and proliferative DR (PDR) was 1.14% (95% CI: 
0.80-1.52), 0.90% (95% CI: 0.56-1.31) and 0.07% (95% CI: 0.02-0.14) in general population; 
In people with DM, the pooled prevalence rates were 18.45% (95% CI:14.77-22.43), 15.06% 
(95% CI:11.59-18.88) and 0.99% (95% CI: 0.40-1.80) for any DR, NPDR and PDR, 
respectively. The prevalence of any DR in DM patients peaked between 60 and 69 years of 
age, and increased steeply with the duration of DM. DM patients residing in rural China were 
at a higher risk to have DR than those in urban areas. In addition, insulin treatment, elevated 
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FBG level and higher HbA1c concentration were confirmed to be associated with a higher 
prevalence of DR in people with DM, with meta-ORs of 1.99 (95% CI: 1.34-2.95), 1.33 (95% 
CI: 1.12-1.59) and 1.15 (95% CI: 1.09-1.20) respectively. In 2010, a total of 13.16 million (95% 
CI: 8.95-18.00) Chinese aged 45 years and above were living with DR, among whom the most 
were in South Central China (3.71 million) and the least were in Northwest China (0.87 
million). 
Conclusions 
This thesis presents a comprehensive estimation of the prevalence and burden of AREDs in 
China. With the dramatic ageing trend in the next three decades, the prevalence and burden of 
AREDs will continue to increase. More elaborate epidemiological studies are still required for 
better estimation of the disease burden of AREDs. Primary and secondary prevention, 
treatment and effective government response are urgently needed to optimise public health 




Age-related eye diseases (AREDs), primarily including age-related macular degeneration, 
cataract, glaucoma, and diabetic retinopathy, are degenerative diseases in older people. Visual 
impairment caused by AREDs is associated with decreased mobility and physical performance, 
diminished quality of life, increased risks of falls and accidents, fractures, etc. Globally, there 
are 285 million people with visual impairment, among whom 40 million are blind. Tellingly, 
65% of those with visual impairment and 82% of those with blindness are over 50 years. With 
a rapid demographic shift towards ageing, increasing prevalence of diabetes and wide usage 
of electronic devices, an upward trend in the prevalence of AREDs is expected worldwide, 
this is also true for the most populous country China, where the number of older population 
aged over 60 years is projected to be 440 million and account for more than 30% of the total 
population by 2050. Although global estimates of visual impairment revealed the proportions 
of AREDs as causes of visual impairment and blindness in general population, the limited 
numbers of surveys hampered their ability exploring the variations of AREDs prevalence 
within specific countries, in addition, there is still no subnational estimate of AREDs in China 
up to date. An in-depth analysis in exploring the epidemiology of AREDs across China is 
essential, as a means of informing public health policymaking and health resource allocating 
at both the national and local levels. In this study, I systematically searched and reviewed all 
publicly available information on the epidemiology of AREDs in China. By using meta-
analysis and meta-regression approaches, I estimated the prevalence of AREDs and the 
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Chapter 1 General Introduction 
1.1 Background 
Over the course of the past two centuries and into the 21st century, the world has been 
undergoing unprecedented demographic transitions, both in developed and developing 
countries (Bongaarts, 2009, Lee, 2003, Rechel et al., 2013, Shetty, 2012). For most developed 
countries, the shift to an ageing society was completed during the last century (Lee, 2003, 
World Health Organization, 2011a, Rechel et al., 2013, United Nations, 2015a), whereas 
demographic transitions began later, and are still underway in the developing world (Bongaarts, 
2009, World Health Organization, 2011a, Guilmoto and Jones, 2015, Shetty, 2012). The 
world’s most populous country, China, has benefited from its large population in terms of both 
economic and social development, yet the population is ageing (Banister et al., 2012, Guilmoto 
and Jones, 2015, Mai et al., 2013). As a consequence, diseases associated with ageing have 
become a significant cause of concern for the whole society, and will bring great challenges 
to the Chinese health systems as well as to individuals (World Health Organization, 2011a, 
Banister et al., 2012, Beard et al., 2016).  
Among all common age-related diseases, chronic and degenerative diseases have long 
occupied policy priorities and public attention, such as dementia, stroke, diabetes and other 
cardiovascular diseases (Beard et al., 2016, Prince et al., 2015, Prospective Studies 
Collaboration, 2002). However, age-related eye diseases (AREDs), primarily including age-
related macular degeneration, cataract, glaucoma, and diabetic retinopathy, despite also being 
degenerative diseases (Gohdes et al., 2005, Li et al., 2011, Wong et al., 2006a), are relatively 
neglected in policy and by the public (Voleti and Hubschman, 2013, McCarty et al., 2001b, Li 
et al., 2011). Visual impairment caused by AREDs is associated with decreased mobility and 
physical performance, diminished quality of life, increased risks of falls and accidents, 
fractures, etc. (Klein and Klein, 2013, Ng et al., 2007). According to the World Health 
Organization (WHO) estimates, there were 285 million individuals globally living with visual 
impairment. Of these, 40 million were blind in 2010, among whom 80% could have been 
prevented or treated (Pascolini and Mariotti, 2011, Stevens et al., 2013). Eye diseases are 
largely seen in elderly populations, with 65% of those with visual impairment and 82% of 
those with blindness being over 50 years old (Pascolini and Mariotti, 2011, Chader and Taylor, 
2013).  
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With rapid demographic shifts towards ageing, increasing prevalence of diabetes and wide 
usage of electronic devices, an upward trend in the prevalence of AREDs worldwide is 
expected (Voleti and Hubschman, 2013, Pizzarello et al., 2004). This is also true for China, 
where the number of people aged over 60 years is projected to be 440 million, and account for 
more than 30% of the total population by 2050 (Banister et al., 2012). However, our 
understanding of the burden of AREDs in elderly is surprisingly limited (Wong et al., 2006a, 
Klein and Klein, 2013). Although global estimates of visual impairment revealed the 
proportion of AREDs as causes of visual impairment and blindness (Pascolini and Mariotti, 
2011), no national epidemiological survey has revealed the epidemiology and variations of 
AREDs in China (Zhou et al., 2007). Furthermore, there exists no up-to-date sub-national 
estimate of AREDs in China. 
In this study, I will estimate the burden of AREDs in China from 1990 to 2015, with a 
projection to the year 2050. Furthermore, I will also explore the different distribution of the 
burden of AREDs at both the national and sub-national levels. The difference in the prevalence 
by demographic and geographic factors will also be investigated. 
This chapter starts with a brief overview of the global demographic transition, and the 
transitions in health associated with ageing populations. Then, the chapter focuses on ageing 
vision, with an emphasis on common AREDs. In addition, as a background setting for this 
study, special attention is paid to the Chinese context. Finally, the systematic review and meta-
analysis method is explained as a prevailing approach to disease burden estimation. 
1.2 Demography of ageing 
1.2.1 Ageing as a global phenomenon 
The global population is getting older, indicative of improvements in health and economics 
(United Nations, 2015a, Kinsella and Phillips, 2005, Rechel et al., 2013). The WHO defines 
‘elderly’ as any person aged 65 years and above. Although this cut-off has been widely 
accepted in many developed countries, its usefulness is questionable in many developing 
countries, where a cut-off age of 60 years may be more appropriate (Juni, 2015, World Health 
Organization, 2002). According to this study context, the cut-off of 60 years is adopted across 
the whole thesis. 
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Generally, without considering the migration factor, the dynamic of the demographic structure 
is mainly driven by three factors: fertility rate, mortality rate and life expectancy (Kinsella and 
Phillips, 2005, United Nations, 2015a, World Health Organization, 2015b, Bongaarts, 2009). 
The total fertility rate (TFR), which refers to the average number of children a woman would 
bear over the course of her lifetime according to a given set of age-specific fertility rates 
throughout her childbearing years (normally between the ages of 15 and 49 years), is one of 
the important determinants of population's age structure (He et al., 2016, United Nations, 
2015a). The decline of TFR is occurring almost everywhere in the world, and this trend 
steadily lowers the proportion of children and young people in a population, thus leading to a 
relative increase in the proportion in older age groups. According to the estimates and future 
projections from the United Nations (UN), TFR has dramatically decreased from 4.9 children 
per woman in 1950 to 2.5 in 2015, and is expected to decline to 2.2 in 2050. In most areas 
(Figure 1.1), TFR has already dropped below or near the general replacement-level (2.1 
children per woman) for maintaining the current population size, except in Africa (Wilson, 
2004, He et al., 2016, United Nations, 2004). 
 
Figure 1.1. Total fertility rate by region: 1950-2050 (data source: (United Nations, 2015b)) 
Note: The classification of world regions is based on the United Nations Statistics Division, 
Department of Economic and Social Affairs regional groupings. The projections are based on 
the medium scenario (United Nations, 2015b). 
The national and subnational disease burden of age-related eye diseases in China 
General introduction   4 
In addition to TFR, the size and age composition of a population is also influenced by mortality 
to a large extent (United Nations, 2015a, United Nations, 2004, Guilmoto and Jones, 2015, 
Kinsella and Phillips, 2005). Mortality levels and trends determine the proportion of the 
population that eventually survives to old age. In parallel to the decline in fertility, mortality 
has also declined considerably over the past decades (United Nations, 2015a, Bongaarts, 2009, 
Guilmoto and Jones, 2015). Life expectancy (at birth) refers to the average number of years a 
newborn infant would live if prevailing patterns of mortality at the time of birth were to stay 
the same throughout their life (United Nations Population Fund, 2012). By summarising the 
information of mortality pattern across all age groups - children and adolescents, adults and 
the elderly - life expectancy at birth can be seen as a reflection of the overall mortality level in 
a population (World Health Organization, 2017b, Bongaarts, 2009). The improvement of life 
expectancy at birth can be driven by mortality reduction in different age groups (United 
Nations, 2015a, World Health Organization, 2015b). In countries where child mortality rates 
have been reducing at a stable level, reduction in mortality among elderly persons has become 
an important contribution of population ageing (United Nations Population Fund, 2012). 
Changes in life expectancy at birth according to the contribution of mortality decline at 
different age groups is shown in Figure 1.2, which presents different driving patterns of 
improvement in life expectancy between 1995-2000 and 2010-2015 for the whole world and 
its six regions. At the global level, mortality reduction in older population accounted for one-
quarter of the total gain in the life expectancy at birth, while in North America this share was 
as high as 71%.  
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Figure 1.2. Contribution of mortality reduction at different age groups to improvements 
in the life expectancy at birth between 1995-2000 and 2010-2015, for the world and six 
regions (source: (United Nations, 2015a)) 
Globally, from 1950 to 2015, life expectancy at birth has risen by more than 23 years, from 
46.8 years to 70.5 years. Such increases in life expectancy are a result of advances in economic 
development, nutrition, education, sanitation and medical care (Guilmoto and Jones, 2015, 
World Health Organization, 2015b, Lunenfeld and Stratton, 2013). In addition, it is projected 
that the global life expectancy at birth will keep increasing to 77.1 years by 2050. All regions 
have experienced an increase in life expectancy since 1950. Of all the six regions, Asia has 
made the largest gains in survival, with life expectancy having increased by 30 years - from 
42.1 years in 1950 to 71.6 years in 2015. Largely due to the lower development levels in many 
African countries, the African region showed the shortest life expectancy over the same period 
(Figure 1.3) (World Health Organization, 2011b, United Nations, 2015a).  
 
Figure 1.3. Life expectancy at birth by region: 1950-2050 (both sexes, data source: 
(United Nations, 2015b)) 
Note: The classification of world regions is based on the United Nations Statistics Division, 
Department of Economic and Social Affairs regional groupings. The projections are based on 
the medium scenario (United Nations, 2015b). 
The remarkable increase in life expectancy accompanied by falling fertility rates has reshaped 
the age structure by shifting the majority of the population from younger to older age groups 
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(Bongaarts, 2009, Kinsella and Phillips, 2005). Worldwide, the number of individuals aged 60 
years and above is growing faster than any other age group. Figure 1.4 shows the population 
pyramids in 1950, 2000 and 2050, which illustrate the changes in the size and age structure of 
the global population over time. Over the last half-century, the proportion of children aged 0-
14 years has steadily declined from 34.4% in 1950 to 26.1% in 2015. In the following three 
decades, the proportion of children is projected to drop to 21.3%. In 2050, for the first time in 
human history, the older population will surpass the younger (United Nations, 2015b). 
 
Figure 1.4. World population pyramid, 1950-2050 (source: (United Nations, 2002)) 
In 2015, there were 7.3 billion people, among whom 12.3% (901 million) were aged 60 years 
or over. According to the projections by the United Nation's Population Division (UNPD) 
(United Nations, 2015b), the share of older people is expected to increase in the years to come, 
causing almost every society in the world to face the implications of population ageing (Figure 
1.5). From 2015 to 2050, the global population is projected to increase to 9.7 billion. In this 
timeframe, the population aged 60 years and above will increase by 123.2%, to 2.1 billion, 
accounting for 21.5% of the total world population. Geographically, this ageing process is 
especially advanced in Europe and North America, where more than one in five persons were 
60 years or older in 2015 already. By 2050, older persons are expected to account for more 
than one-third of the population in Europe and more than one-fourth in North America. The 
ageing process is also occurring rapidly in Latin America and the Caribbean, Asia and Oceania, 
where nearly one-fourth of the population will be elderly in 2050. Despite being at the earlier 
stages of demographic transition, the African region will almost double its proportion of older 
population to around 10% by 2050 (World Health Organization, 2015b, United Nations, 
2015b).  
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Figure 1.5. Proportion of people aged 60 years or over by region, 1950-2050 (both sexes, 
data source: (United Nations, 2015b)) 
Note: The classification of world regions is based on the United Nations Statistics Division, 
Department of Economic and Social Affairs regional groupings. The projections are based on 
the medium scenario (United Nations, 2015b). 
This global ageing process is not only an issue of changing proportions of younger and older 
persons in a population. As population ageing continues to take place, the number of people 
aged 80 years and over is growing even faster than the number of older population overall 
(United Nations, 2005). As a larger proportion of old people survive to more advanced ages, 
this progressive demographic ageing of the older population itself has become a notable issue 
of concern, and it is essential to differentiate among the age groups of older people (United 
Nations, 2002). Figure 1.6 shows the age distribution of the older population itself as estimated 
by the UNPD from 1950 to 2050. It shows how the share of the oldest among the old persons 
(those over 80 years) within the older population was 7% in 2013, but it is projected to reach 
20% in 2050. In terms of absolute numbers, there were 14.2 million people aged 80 years and 
over worldwide in 1950. Since then, the number of the oldest persons increased by 782.1% to 
125.3 million in 2015, and is projected to increase by another 246.8% over the next three 
decades, reaching nearly 434.4 million in 2050 (United Nations, 2015b). Undoubtedly, the 
twenty-first century is expected to be the century of human population ageing (United Nations, 
2004). 
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Figure 1.6. Share of the global older population by age group, 1950-2050 (source: (United 
Nations Population Fund, 2012)) 
1.2.2 Ageing in China 
The People’s Republic of China, which was established in 1949, is the most populous country 
in the world. In the global context, China has not been spared from population ageing process 
and it is facing numerous challenges at a relatively early stage of development (United Nations, 
2015a, Smith and Majmundar, 2012). In the past decades, largely due to improved health care 
and living standards, China has experienced one of the fastest demographic transitions in the 
world, which can also be regarded as the combination impact of low fertility, rising life 
expectancy and the cumulative effect of past changes in the birth and death rates (Banister et 
al., 2012, Li, 2015a, Department of Ageing and Life Course, 2015).  
Of all of the determinants of demographic structure, the decline in total fertility rate is the key 
factor in the population dynamics of the Chinese population. From 1950 to 1995, the total 
fertility rate fell from approximately 6 children per woman to under 2, and from 2000 it started 
to hover around 1.5 children per woman (Figure 1.7). This decline, which has been especially 
rapid in the period of 1970-1980, was mainly reinforced by the “later, longer, fewer” (later 
marriage and age at first birth, longer inter-birth intervals, and fewer births) campaign, which 
was then followed by the formal introduction of the one-child policy in 1979. Due to the central 
and local government efforts leading up to its strict adoption, most parents in urban areas had 
only one child. However, in most rural areas where son preference was prevalent, this policy 
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was only partially implemented and rural parents with a first-born daughter were allowed to 
have a second child after five years (Choukhmane et al., 2013, Hesketh et al., 2005, Zeng and 
Hesketh, 2016). In the long run, the total fertility rate in China fell below the replacement level 
of 2.1 children per woman from the early 1990s (He et al., 2016). After a gradual decline until 
1995, the total fertility rate has stabilised at near 1.7 children per woman (Hesketh et al., 2005). 
According to the UNPD estimates, the total fertility rate in China was 1.6 children per woman 
in 2015 and is projected to reach 1.7 by 2050 (United Nations, 2015b). From 2015, the one-
child policy was formally replaced by a universal two-child policy, which allows almost all 
Chinese couples to have two children. However, in contemporary China, the impact of the new 
policy on the improvement of the total fertility rate level may be less than expected (Zeng and 
Hesketh, 2016, Attané, 2016). 
 
Figure 1.7. Total fertility rate in Mainland China: 1950-2050 (data source: (United 
Nations, 2015b)) 
Note: The projections are based on the medium scenario (United Nations, 2015b). 
While longevity gains have occurred globally, prolonging of lifespan as a result of a highly 
compressed process of mortality decline has also obviously played an important role in 
China’s ageing process (Li, 2015a, Department of Ageing and Life Course, 2015). Since 1950, 
life expectancy at birth for both sexes in China has successfully increased by more than 30 
years, from 43.4 years to 75.4 years in 2015 (Figure 1.8). This is almost 9 years higher than 
the average level of less developed countries (67.0 years in 2015), and only about 3 years 
lower than the average level of the more developed countries (78.3 years in 2015) (Guilmoto 
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and Jones, 2015, United Nations, 2015b). Although remarkable improvement in life 
expectancy has occurred in both sexes, Chinese women were advantaged relative to Chinese 
men in terms of survival rates. The life expectancy at birth for women was 3 years higher than 
that for men in 2015 (77.0 vs. 74.0 years). With this trend continuing in the next three decades, 
the national life expectancy at birth is projected to increase to 82.5 years, and the sex difference 
will shrink to 1.7 years (83.4 in females vs. 81.7 in males) by 2050 (United Nations, 2015b). 
 
Figure 1.8. Life expectancy at birth in Mainland China: 1950-2050 (data source: (United 
Nations, 2015b)) 
Note: The projections are based on the medium scenario (United Nations, 2015b). 
As a combined result of early and steep fertility decline, long-term sub-replacement fertility, 
and greater longevity, a significant change in China’s population age structure has occurred 
(Figure 1.9). The low level of fertility rates brought the decline in the number of young people, 
whereas the improved life expectancy increased the number of older people within the society 
(Lee and Reher, 2011, Lee, 2003). In 1950, the proportion of children aged 0-14 years was 
34.3%, and that of people aged 60 or over was 7.5%, shaping a typical population pyramid 
with a broad base of young people. During the last few decades, characterised by a large 
economic growth, the proportion of children aged 0-14 years has rapidly declined to 17.2%, 
whereas that of people aged 60 or more grew to 15.2% in 2015. As a consequence, China’s 
population pyramid shape has shifted from "triangular" to "irregular". According to the UNPD 
estimates, the proportion of older population will surpass that of younger population by 2020 
in China, 30 years ahead of the global trend (United Nations, 2015b). Furthermore, in the 
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coming decades up to 2050, the proportion of children aged 0-14 years is projected to drop to 
13.5%, and those aged 60 and over are set to form a larger share of the population (36.5%), 
with the population pyramid moving to an olive shape (United Nations, 2015b, Zhang et al., 
2012). 
 
Figure 1.9. China population pyramid, 1950-2050 (source: (United Nations, 2002)) 
Over a period of roughly half a century, China has completed its demographic transition from 
a low rate of natural increase, due to high fertility and high mortality, to a low rate of natural 
increase as a result of low fertility and low mortality (Lee and Reher, 2011). If the current 
demographic transitions continue, it is estimated that by 2025 China will be surpassed by India 
in overall population size and become the second most populous country in the world. 
However, the ageing process is more rapid in China than in India, or even in most other 
developing countries worldwide (Guilmoto and Jones, 2015, Department of Ageing and Life 
Course, 2015, Mai et al., 2013). According to UNPD estimates, the total population was 1.4 
billion at the end of 2015, of which 209.2 million were older people aged 60 years and over, 
or 15.2% of the total population. The share of older people is expected to continue to increase 
almost continuously in the coming years (Figure 1.10), and by 2050, one in three Chinese 
persons will be 60 years or older.  
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Figure 1.10. Proportion of people aged 60 years or over in Mainland China: 1950-2050 
(data source: (United Nations, 2015b)) 
Note: The projections are based on the medium scenario. 
Population ageing is now a prominent phenomenon across the whole country, largely due to 
improved survival of the elderly. Consequently, the group of the oldest among the old 
population, those aged 80 years or more, have gone through remarkable growth - from 0.3% 
in 1950 to 1.6% in 2015 of the total population. This is expected to reach 8.9% in the next 
three decades until 2050 (United Nations, 2015b). As the fastest growing segment of the older 
population, the 80+ years accounted for only 3.7% of the older population in 1950, and then 
increased to 10.7% in 2015 (Figure 1.11). This trend is expected to accelerate in the next three 
decades, with the share of 80+ years within the older population projected to be five times as 
large as it is at present by the year 2050. With an overall size of 120.6 million, China will 
inevitably face large challenges linked to the ageing population by 2050, with almost one in 
four older people being 80 years and older. Over time, this pronounced upward shift in the age 
structure is prone to generate a substantial increase in the demand for both formal and informal 
medical and long-term care services in China. 
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Figure 1.11. Share of the older population by age group in Mainland China, 1950-2050 
(data source:(United Nations, 2015b)) 
China is an unevenly developed country and, as such, disparities remain between the urban 
and the rural, the rich and the poor. These disparities contribute to varying patterns in lifestyle, 
morbidity and mortality rates across regions (Woo et al., 2002, Peng et al., 2010). With the 
nationwide ageing trend, the proportion of older population has increased from 7.1% to 12.1% 
in urban areas, and from 7.8% to 13.7% in rural areas between 1982 to 2005. Due to rapid 
urbanisation and inner labour migration, this urban-rural disparity is likely to grow (Wang et 
al., 2005, Cai et al., 2012). It is estimated that the proportion of the older population will reach 
14.8% in urban areas and 21.8% in rural areas by the year 2030 (Cai et al., 2012). In addition, 
people living in rural areas and the poor are generally more disadvantaged in terms of survival 
and health (Yu et al., 2012, Peng et al., 2010, Zhang et al., 2012). This exacerbates the 
challenge of dealing with population ageing in rural and less developed areas. In such 
circumstances, the increasing degenerative disease burden and social implications associated 
with ageing have become one of the most important agendas for the Chinese government. As 
a result, studies estimating the burden of degenerative diseases are necessary and timely to 
inform policy making (Woo et al., 2002, Department of Ageing and Life Course, 2015). 
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1.3 Health transition 
1.3.1 Global Health transition 
The previous section explained the demographic transition occurring both globally and in the 
context of China between 1950 and 2015, with projections until the year 2050. In parallel with 
this phenomenon of demographic ageing, a fundamental epidemiological transition has also 
been taking place across the world - albeit with considerable variations between different 
populations (Kinsella and Phillips, 2005, McCracken and Phillips, 2012, Omran, 2005). Health 
transition, which is also referred as a combination of demographic and epidemiological 
transitions, is a broad set of changes in the patterns and causes of morbidity (illness) and 
mortality (death) (Kinsella and Phillips, 2005, World Health Organization, 2011a, McCracken 
and Phillips, 2012). As initially categorized by Omran (Omran, 2005), health transition 
involves a sequence of three stages (Table 1.1). The first stage, the ‘Age of Pestilence and 
Famine’, is marked by fluctuating mortality at high levels and high prevalence of infectious 
and parasitic diseases, such as tuberculosis, influenza and diarrhoea. The second stage, the 
‘Age of Receding Pandemics’, is a transitional phase characterised by decreasing mortality, a 
decline in the prevalence of infectious diseases and an increase in the prevalence of chronic 
degenerative diseases. Gradually, the second stage gives way to the third stage, the ‘Age of 
Degenerative and Man-Made Diseases’. In this stage, mortality continues to decline until it 
stabilises at a low level, and the major causes of death are chronic degenerative diseases and 
man-made diseases, such as cardiovascular disease, diabetes and cancer. Since Omran’s 
concept, another widely acknowledged and adopted stage, the ‘Age of Delayed Degenerative 
Diseases’, has been added to this transition theory. During this fourth stage, major 
degenerative causes of death in the third stage remain as prevalent killers, but more 
concentrated in the older population (Olshansky and Ault, 1986).  
Table 1.1. The four stages of health transition 
Stage Life expectancy Mortality Morbidity 
Stage 1 
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Stage Life expectancy Mortality Morbidity 





Age of Degenerative and Man-
Made Diseases 
>50 years Lower mortality 
with a peak in 
older people 
Non-communicable 
diseases and injuries 
Stage 4 
Age of Delayed Degenerative 
Diseases 







in advanced ages 
At the global level, population ageing has emerged as a significant trend in almost every 
country. Improved longevity has brought non-communicable diseases (NCDs) to the fore as 
the most important source of global disease burden, responsible for 56.3% in 2015, with this 
projected to rise substantially to almost two thirds in 2030 (World Health Organization, 2015a). 
Generally, health transition is highly associated with modernisation and urbanisation, 
especially improvements in the standard of living and education (Defo, 2014, Omran, 2005). 
Health transition firstly emerged in industrialized countries, almost a century ago. For most 
developed countries, this transition has stabilised at the fourth stage (Santosa et al., 2014). 
Evidence from the Global Burden of Disease (GBD) project (Figure 1.12) suggests that, when 
measured by the Disability Adjusted Life Years (DALYs) - a summary measure of the overall 
burden of disease - 86.6% of all the disease burden was caused by NCDs in high-income 
countries in 2015. This share will become even larger in the next decade (Alwan, 2011, 
Institute for Health Metrics and Evaluation, 2015, Mathers and Loncar, 2006, GBD 2015 
DALYs and HALE Collaborators, 2016). However, the emergence of NCDs is not limited to 
affluent countries. The proportion of the total burden of disease in middle-income countries 
attributable to NCDs was 68.8% in 2015, and has a larger potential to increase remarkably to 
76.2% by 2030. Even in the poorest low-income countries, NCDs are predicted to be an 
increasingly important cause of morbidity and mortality, where the proportion of disease 
burden will increase from 42.4% in 2015 to more than half of all the disease burden in 2030 
(World Health Organization, 2011a, World Health Organization, 2015a). 
The national and subnational disease burden of age-related eye diseases in China 
General introduction   16 
 
Figure 1.12. Share of disease burden by broad cause and the World Bank income group: 
2015 and 2030 (data source: (World Health Organization, 2015a)) 
Note: HIC, high-income countries; MIC, middle-income countries; LIC, low-income countries 
(World Health Organization, 2015a). 
Susceptibility to NCDs increases with age, and with the trend in worldwide population ageing, 
the rise in the burden of NCDs presents important challenges for global health in the 21st 
century. According to the GBD estimates, NCDs have become the dominant causes of disease 
burden in older population irrespective of their economic status (Beard et al., 2016, Prince et 
al., 2015). As shown in Figure 1.13, almost 90% of the total disease burden in people aged 60 
years and older was attributable to NCDs in 2015, and its predominant order did not vary 
greatly by the income group. In the next decade, it is projected that this predominant 
contribution of NCDs in the older population will become even more pronounced. By 2030, 
the share of NCDs attributable to the total disease burden will be more than 90% in every 
region of the world, even in low-income countries. However, older people in those settings die 
or are disabled at a relatively younger age than those in high-income countries. Historically, 
despite the fact that health transition is increasingly placing the greatest burden of disease on 
non-communicable conditions, which are more associated with older population, NCDs in 
poor settings receive low priority in health policies and financing. The potential challenges of 
NCDs to economies, health care systems, informal care and individuals may be much larger 
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in the middle- and lower-income countries than in other well-developed economies (Yu et al., 
2012, World Health Organization, 2011a, Sousa et al., 2009).  
 
Figure 1.13. Disease burden in older population by broad cause and world bank income 
group: 2015 and 2030 (data source: (World Health Organization, 2015a)) 
Note: HIC, high-income countries; MIC, middle-income countries; LIC, low-income countries 
(World Health Organization, 2015a). 
1.3.2 Health transition in ageing China 
As stated in the previous section, NCDs have replaced communicable diseases as the most 
important contributing factor to the global disease burden, regardless of development levels. 
Compared with other low- and middle-income countries, China is catching up quickly with 
the high-income countries in terms of its disease burden profile. It is widely acknowledged 
that China has already stepped into the fourth stage of health transition (Santosa et al., 2014). 
According to the GBD estimates, NCDs showed a strikingly increasing trend in the share of 
disease burden in China in the last two decades (Figure 1.14). In 2015, 81.3% of the disease 
burden was contributed by NCDs, which was much higher than the contemporary global level 
of 56.3%, and only slightly lower than that of high-income countries (86.6%). The older 
population has seen an increasing share of NCDs as the source of disease burden during the 
last two decades, although at a relatively slower pace. From the beginning of the 21st century, 
the share of total burden of disease attributable to NCDs started to fluctuate around 93%.  
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Figure 1.14. Share of disease burden by broad cause in China from 1990 to 2015: in 
general population and older population (data source: (Institute for Health Metrics and 
Evaluation, 2015)) 
Figure 1.15 presents the change in leading causes of disease burden measured by DALYs 
from 1990 to 2015. In general population, lower respiratory infections, cerebrovascular disease 
and neonatal preterm birth were the three leading causes of disease burden in 1990; by 2015, 
no communicable diseases, maternal and perinatal conditions, or nutritional deficiencies 
remained at the list of leading causes. Instead, during this period, the disease burden due to a 
subset of NCDs increased significantly, including ischaemic heart disease, low back and neck 
pain and sensor organ disease. Due to the limitation of GBD data availability, the group of 
people aged 70 years and over (instead of 60 years and over due to the availability of GBD 
data) was chosen to illustrate the decomposition of disease burden in older population 
(Institute for Health Metrics and Evaluation, 2015). From 1990 to 2015, for people aged 70 
years and older, the top ten causes of disease burden were exclusively NCDs, with 
cerebrovascular disease, ischemic heart disease, sense organ disease, Alzheimer disease, lung 
cancer, low back and neck pain all climbing up the ranks. Although a few data are available 
to allow projections of the future disease burden in China, along with the trends in urbanisation, 
rising incomes and longevity, it appears inevitable that NCDs will keep rising, with age-related 
diseases being the fastest-growing group. 
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Figure 1.15. Leading causes of disease burden in China from 1990 to 2015: in general 
population and people aged 70 years and over (source: (Institute for Health Metrics and 
Evaluation, 2015)) 
Health transition in China has promoted NCDs into the leading source of the disease burden. 
Among these long-term diseases, conditions with severe disability rates, or of long duration, 
may confer an even larger burden than those that have no impact on life, or are of shorter 
duration (World Health Organization, 2008, GBD 2015 Disease and Injury Incidence and 
Prevalence Collaborators, 2016). With advancing age, sensory and motor performance 
decreases. The incidence of disabilities related to mobility and independence grows, while 
decreasing people’s ability to live in full health. To a large extent, this phenomenon is 
particularly prevalent in the oldest age groups, despite the benefits from longevity (World 
Health Organization, 2011c, Motl and McAuley, 2010). In China, the fast-growing number of 
older persons and the increasing disease burden attributable to NCDs have left a relatively 
high proportion of older people with disabilities. With the ageing trend, this number is 
expected to continuously grow. It was reported that there were 9.4 million completely disabled 
and more than 18.9 million partially disabled older people in 2006 (Wang, 2009). The Years 
Lived with Disability (YLDs) is an indicator calculated by multiplying the prevalence of a 
disorder by the short- or long-term loss of health associated with that disability (GBD 2015 
Disease and Injury Incidence and Prevalence Collaborators, 2016). When assessed by YLDs, 
the top causes of disability in the general Chinese population in 1990 were lower back and 
neck pain, sensory organ diseases and skin diseases. Over more than two decades, lower back 
and neck pain and sensory organ diseases remained the top two causes of disability, whereas 
the third leading cause - skin diseases - were replaced by depressive disorders in 2015 (Figure 
1.16). In older people (aged 70 years and over due to the availability of GBD data), the 
spectrum of leading causes of disability was different, with sensory organ disease identified 
as the leading cause, and lower back and neck pain the second in both 1990 and 2015. In this 
group, the third leading cause of disability was chronic obstructive pulmonary disease (COPD) 
in 1990, which was then replaced by Alzheimer disease in 2015. 
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Figure 1.16. Leading causes of disability in China from 1990 to 2015: in general 
population and people aged 70 years and over (source: (Institute for Health Metrics and 
Evaluation, 2015)). 
In the coming few decades, the older Chinese population is likely to rise to a historically 
unprecedented level. Rising disability burden and corresponding long-term care needs will 
become the most important challenges for the society (Woo et al., 2002, Department of Ageing 
and Life Course, 2015). The opposite is true for China where, unlike in the developed world - 
which firstly became richer, and then older - the population is ageing while the economy is 
still growing. Thus, it is important to realise that there will only be limited resources to support 
the upcoming long-term care needs for older people in the Chinese context (Woo et al., 2002, 
Zhang et al., 2012). These challenges should be placed as foci for investment in health 
infrastructure. The Chinese central government has initiated policies to encourage private and 
foreign investment in building nursing homes and care homes. However, it is still a common 
perception that these profit-driven institutions will serve primarily older people from wealthier 
families, and thus the informal care pattern, usually from family members, will still be the 
predominant pattern of long-term care in China (Zimmer and Kwong, 2003, Chu and Chi, 
2008).  
1.4 Ageing and the eye 
1.4.1 Introduction 
The classical sensory function senses of the human body include vision, hearing, smell, taste, 
and touch (Correia et al., 2016). Among these five senses, visual sense has often been 
considered as the most important (Wang et al., 2014a). Sight is essential for determining 
directions, identifying people and objects, adjusting movement and social behaviour and, thus, 
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deemed as essential for conducting daily activities. When vision is impaired or absent, a 
person’s ability to function will be largely affected (Leo et al., 1999). In addition, although 
vision loss is not a life-threatening condition, it is widely regarded as highly associated with 
disability, placing a huge burden on caregivers and society (West et al., 2002, Li et al., 2011). 
As the lifespan increases globally, there is a dramatic increase in age-related disability, 
including especially eye-related diseases. Currently, vision loss is the leading cause of age-
related disability in developing countries, where 94 million older people are affected (Figure 
1.17). This may also be the situation in China, where sense organ diseases are the leading 
causes of disability in older population, as noted in the previous section (Atal et al., 2016, 
Institute for Health Metrics and Evaluation, 2015). With the unprecedented rate of growth of 
the older population, combating preventable vision loss must be listed as one of the leading 
public health priorities. Furthermore, there is a continuing need for an up-to-date 
understanding of the magnitude and characteristics of vision loss. In this section, the nature, 
burden and impacts of vision loss will be presented, with an emphasis on age-related eye 
conditions. 
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Figure 1.17. Global prevalence of moderate and severe disability in older people in 2011 
(source: (International Federation on Ageing, 2012)) 
1.4.2 Ageing effects on the eye 
The human eye is the organ of sight. It serves as an important tool in many activities during 
daily life, collecting information from surrounding environments (Agarwal et al., 2002). As 
one of the most important and sensitive organs in the body, the eye contains several incredibly 
complex structures. Each part is essential for clear vision, and any damage may lead to severe 
visual impairment, or even blindness (World Health Organization, 2014b, Fairchild, 2013). 
Figure 1.18 shows the schematic diagram of the horizontal cross-section of a human eye, 
highlighting the important parts such as the cornea, iris, pupil, lens, retina, fovea and optic 
nerve. These structures are separated by three chambers, namely, the anterior, posterior and 
vitreous chambers (Myers, 2003).  
 
Figure 1.18. Anatomy of the human eye with some key structures labelled (source: 
(Fairchild, 2013)) 
Compromised function of the eye is becoming increasingly prevalent with ageing. Advancing 
age has been revealed as one important factor that increases the chance of developing age-
related eye diseases (Lin et al., 2016, Chader and Taylor, 2013). At the biological level, the 
ageing process is associated with gradual accumulation of a wide variety of molecular and 
cellular damages, ultimately leading to impairment of anatomic and physiological functions 
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(Tosato et al., 2007, Michael and Bron, 2011). Figure 1.19 presents several age-related 
dysfunctions of major structures and the corresponding diseases. 
 
Figure 1.19. Major age-related eye diseases and the affected structures (source: (Lin et 
al., 2016)). 
The cornea is the front transparent outer coating through which, as the principle refractive 
element of the eye that is responsible for nearly two-thirds of the eye’s refractive power, 
incoming light rays pass and move through into the anterior chamber (Myers, 2003, Agarwal 
et al., 2002). With ageing, the functioning of the corneal endothelium, the innermost layer of 
cells in the cornea, begins to deteriorate. Since the endothelium cannot be regenerated, the 
overall endothelial cell density reduces during this process, resulting in a fluid buildup in the 
cornea, known as corneal swelling (Fuchs’ Endothelial Dystrophy) (Cerulli and Missiroli, 
2008). In addition, ageing itself is associated with decreased tear production, making dry eye 
syndrome more prevalent in older people (Sharma and Hindman, 2014, Mathers, 2000). 
The iris is a thin, circular and multi-level structure. Iris colour, which varies due to the amount 
of pigments formed by melanocytes, gives a specific characteristic to eye colour. The centre 
of the iris is the pupil, which regulates the amount of light entering the inner globe of the eye. 
Pupil varies with different illumination levels. Its size is controlled by dilator and sphincter 
muscles of the iris. Pupil size increases in the dark and decreases in the bright light chamber 
(Myers, 2003, Agarwal et al., 2002). With ageing, the iris becomes less reactive and more 
difficult to dilate, while pupil size also diminishes, so that less light enters the eye (Salvi et al., 
2006). 
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The lens is located directly behind the iris and the pupil. It is a biconvex transparent structure 
that provides around a third of the eye’s refractive power, and works together with the cornea 
to reflect light into the retina. Similar to the cornea, the lens is adjustable to focus light rays. 
Ciliary muscles control the shape and curvature of the lens through the accommodation 
process, focusing on different objects that are either nearby, or at a distance. The lens becomes 
“fatter” to increase optical power when focusing on near objects, and becomes “flatter” to 
decrease optical power when focusing on distant objects (Fairchild, 2013, Agarwal et al., 
2002). In the lens, a decline of accommodation initiates in infancy. At younger ages, 
accommodation for near sight is achieved by ciliary muscle contraction, which relaxes zonular 
tension and changes the lens to become more globular. Over time, lens fibre and zonules stiffen, 
gradually restricting the rate and amplitude of accommodative power, a process known as 
presbyopia (Michael and Bron, 2011, Bron et al., 2000). During ageing, the accumulation of 
yellow pigments in the lens also decreases the transmission of blue light. The loss of the 
ultraviolet (UV) ray filter function thus increases phototoxic lesions of the retina (Lin et al., 
2016, Bron et al., 2000). Furthermore, ageing brings opacities in the lens, ultimately leading 
to lens opacification or even cataract (Zhang et al., 2016, Michael and Bron, 2011). 
After the lens, light rays pass through the vitreous humour and reach the retina. The retina is 
the most important part of the eye, which lies on the inner surface of the eye. The retina is 
responsible for the transduction of light energy into neural signals by means of photoreceptors, 
the only neurons that are directly sensitive to light (Lin et al., 2016, Agarwal et al., 2002). The 
human eye contains two types of photoreceptors: rods and cones. There are approximately 126 
million photoreceptors in the retina - 120 million rods and 6 million cones. Rods support the 
black and white vision and mainly function in low light, and are spread evenly in the retina, 
except at the fovea. Cones provide daytime vision and the perception of colour, their density 
reaching the peak in the centre of the retina, namely, macular (Agarwal et al., 2002). The fovea 
is located near the centre of the macula. It is a small pit that contains the largest amount of 
cones. The macula is the only part of the retina where neuronal and vascular circuits bend 
sideways, so the photoreceptors can receive light rays directly. Therefore, the macula is 
responsible for clear central vision, while the fovea provides sharpest detailed vision. The 
peripheral parts of the retina, which are composed predominately of rods, are responsible for 
providing grainier or peripheral vision (Fairchild, 2013, Agarwal et al., 2002). With ageing, 
oxidative damage accumulates within the retina, resulting in age-related retinal dysfunction, 
or even visual loss, together with pupillary miosis and reduced crystalline lens light 
transmission. The macula is especially susceptible to environmental stressors. Due to fewer 
cell layers, the progressive damage of the macula is a common disease, known as age-related 
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retinal disorders -including age-related macular degeneration (Bonnel et al., 2003, Gao and 
Hollyfield, 1992). 
The last key structure after the retina is the optic nerve, which is responsible for transferring 
visual signals from the retina to the vision centres in the brain via electrical impulses. The 
optic nerve is small and nearly unmyelinated from infancy, and then grows rapidly and 
becomes medullated (Tezel et al., 2007, Agarwal et al., 2002). The optic nerve lies in the back 
of the retina and is composed of the axons of retinal ganglion cell and glial cells. In the area 
of the retina where the optic nerve leaves the eye, a blind spot exists - because of the absence 
of photoreceptors (Fairchild, 2013, Agarwal et al., 2002). With advancing ages, the 
leptomeninges and fibrous septa become broader, resulting in a progressive loss of ganglion 
cells and, thereafter, vision damage. Moreover, in the case of glaucoma, intraocular fluid in 
the cavity behind the eye’s lens drains too slowly, or stops draining altogether, leading to 
damages in the optic nerve and vision loss (Burgoyne and Morrison, 2001, Weinreb and Khaw, 
2004). 
1.4.3 Visual impairment 
1.4.3.1 Definition and classification 
Visual impairment generally refers to any condition of the eye or visual system that cannot be 
corrected to within normal limits. According to the International Classification of Disease 
(ICD) 10th version, visual function is classified into four levels: normal vision, moderate visual 
impairment, severe visual impairment and blindness. Moderate visual impairment is defined 
as best corrected visual acuity of equal to or greater than 6/60 but less than 6/18, and severe 
visual impairment as best corrected visual acuity of equal to or greater than 3/60 but less than 
6/60 (Stevens et al., 2013). Blindness is defined as best corrected visual acuity of less than 
3/60 in the better eye or visual field loss in each eye to less than 10° from fixation. Furthermore, 
moderate visual impairment and severe visual impairment are grouped into the category “low 
vision”, and low vision combined with blindness represents all visual impairment (Dandona 
and Dandona, 2006, World Health Organization, 2014b). 
1.4.3.2 Burden of visual impairment 
In 2010, approximately 285 million people globally were visually impaired, of whom 246 
million were suffering from low vision and 39 million people were blind (Pascolini and 
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Mariotti, 2011). Geographically, more than 90% lived in developing countries. Figure 1.20 
provides a closer look at the global distribution of visually impaired people. The most 
populous countries harboured a large burden of visual impairment. China reported that there 
were 75 million visually impaired people in 2010, representing more than one-fourth of all the 
global visual impairment cases. Approximately 80% of visual impairments can be prevented 
or corrected. However, if no preventive actions are taken and the current trends remain 
unchanged, the number of blind people is projected to increase four times by 2020 in China. 
In addition, visual impairments are more common among older people than in any other age 
groups. Of all visually impaired people globally, about 65% were aged 50 and older, although 
this age group only comprised about 20% of the world's population (Pascolini and Mariotti, 
2011). As the population of older people continues to grow in China, the number of people 
suffering from vision-related disability will also increase accordingly.  
 
Figure 1.20. Number of people (in thousands) visually impaired and corresponding 
proportion of the global impairment by WHO region and country (source: (Pascolini and 
Mariotti, 2011)) 
Note: AFR, African region; AMR, region of the Americas; EMR, Eastern Mediterranean 
region; EUR, European region; SEAR, south-east Asian region (without India); WPR, Western 
Pacific region (without China). 
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Historically, visual impairment and blindness have been one of the most feared disabilities 
known to mankind (Loo et al., 2009, Saaddine et al., 2003). Epidemiological studies indicate 
that visual impairment results in higher rates of falls, hip fracture, poor nutrition, medical 
errors, and mortality, especially among older people. Furthermore, visual impairments trigger 
depression and suicidal ideation (Rees et al., 2010, Lam et al., 2008). All these serious events 
place affected people at a vulnerable status of health and wellbeing, while also having a 
“snowball effect” on their families, caregivers and the community (Lamoreux et al., 2008, 
Cacciatore et al., 2004). In addition to causing excess diseases and mortality, visual 
impairments also lead to tremendous economic burden, especially when indirect costs are 
taken into account (International Federation on Ageing, 2012, John and David, 2013). Globally, 
the direct costs of vision loss were $2.3 trillion in 2010, whereas the indirect costs, such as lost 
productivity and provision of informal and family care reached $652 billion. With an 
increasing elderly population in many countries, it seems likely that more people will be at 
risk of visual impairment. It is projected that this total cost will increase to $2.8 trillion for 
direct costs and $760 billion for indirect costs by 2020 (International Federation on Ageing, 
2012). The social and economic implications of visual impairment represent serious public 
health, social and economic concerns. It is, therefore, vital that the prevention and management 
of visual diseases becomes a major public health and clinical priority (Dandona and Dandona, 
2006, Pizzarello et al., 2004, World Health Organization, 2017a). Indeed, proven cost-
effective preventive and curative interventions are available for prevention of avoidable visual 
impairment, such as low-cost medicines, intra-ocular lens implants and other treatments, and 
ophthalmic interventions (International Federation on Ageing, 2012, Pizzarello et al., 2004).  
1.4.3.3 Causes of visual impairment 
In 1999, the WHO and the International Agency for the Prevention of Blindness launched the 
Global Initiative for the Elimination of Avoidable Blindness, widely known as Vision 2020: 
The Right to Sight. Their aim was to halt and reverse the estimated doubling of avoidable 
visual impairment globally between 1990 and 2020 (Pizzarello et al., 2004). The initial 
framework identified five conditions as immediate priorities: cataract, trachoma, 
onchocerciasis, childhood blindness and refractive errors and low vision, all of which are 
preventable or treatable. However, over time, significant shifts have occurred in the pattern of 
causes of visual impairment, which also varies from country to country, necessitating a more 
up-to-date and geography-based approach to national, supra-national, continental and global 
prevention strategies and local programs (World Health Organization, 2014b, Bourne et al., 
2013). 
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Globally, the most common causes of visual impairment in 2010 were identified as 
uncorrected refractive error (43%), cataract (33%), glaucoma (2%), age-related macular 
degeneration (1%), diabetic retinopathy (1%) and a large proportion of undetermined causes 
(18%). The major causes of blindness were cataract (51%), glaucoma (8%), age-related 
macular degeneration (5%) and the undetermined causes (21%). This new spectrum has 
promoted a redefinition of the Vision 2020 scheme (Pascolini and Mariotti, 2011), which 
should include the blindness prevention as well as the rehabilitation and education of persons 
with irreversible and unavoidable visual impairment (World Health Organization, 2013). 
In China, no national statistic on the main causes of visual impairment has been available until 
recently. Local epidemiological surveys have identified different spectrums (Huang et al., 
2009, Xu et al., 2006, Li et al., 2008). In the latest five-year National Plan for Eye Health, 
cataract, uncorrected refractive error, diabetic retinopathy, glaucoma, age-related macular 
degeneration, and retinopathy of prematurity were listed as program priorities, most of which 
were age-related conditions (National Health and Family Planning Commission of the People's 
Republic of China, 2016). 
1.4.4 Age-related macular degeneration 
1.4.4.1 Definition and classification 
Age-related macular degeneration (AMD) is a degenerative disease of the macula that 
becomes more clinically apparent with advanced age (Jager et al., 2008, Lim et al., 2012). It 
is most common among elderly people living in developed countries (Lim et al., 2012, Wong 
et al., 2014). AMD develops slowly and asymptomatically in its early stages, but can lead to 
progressive loss of central vision at late or advanced stages (Coleman et al., 2008). 
Accompanying this central vision loss, motion sensitivity, contrast sensitivity, visual acuity 
and delayed dark adaption are also affected (Kuyk and Elliott, 1999, Faria et al., 2015, Owsley 
et al., 2016). 
AMD is characterised by the formation of drusen (extracellular deposits of lipid and protein 
between the retinal pigment epithelium and Bruch’s membrane) and pigmentary abnormalities 
in the macula (hyper- or hypo- pigmentation of the retinal pigment epithelium) (Coleman et 
al., 2008, Jager et al., 2008). Drusen can be classified into small (<63um in diameter), medium 
(63-124um in diameter), and larger (>124um in diameter) by diameter of the optic disc, and 
also into hard (with discrete margins and uniform colouring) and soft (with indistinct edges, 
The national and subnational disease burden of age-related eye diseases in China 
General introduction   29 
usually large and confluent) by appearance of edges (Jager et al., 2008, Klein et al., 1992). 
Drusen size, number and degree of confluence are associated with the development of AMD, 
providing the basis of AMD classification. However, the presence of a limited number of small, 
hard drusen is ubiquitous in older people and can be considered a part of normal ageing (Jager 
et al., 2008, Coleman et al., 2008). The presence of soft drusen, particularly when the drusen 
is large, can be considered indicative of AMD (Bird et al., 1995). 
Multiple schemes have been adopted for the grading of AMD, by affected area, type and size 
of drusen, the extent of geographic atrophy (GA) and the occurrence of aberrant choroidal 
neovascularization (Klein et al., 1991, Bird et al., 1995, Group, 2005, Seddon et al., 2006). 
Widely adopted classification systems include the Wisconsin age-related maculopathy grading 
system (WARMGS), which divides AMD into six semi-quantitative stages based on the 
presence and severity of drusen and pigmentary irregularities (Klein et al., 1991). In 1995, the 
International Classification and Grading System Study group developed a more standardised 
but complicated classification system (Bird et al., 1995). Thereafter, this classification has 
been simplified in some epidemiological studies, such as the Rotterdam study and the 
European Eye Study (EUREYE) (Vingerling et al., 1995, Augood et al., 2006). More recently, 
the Age-related Eye Disease Study group adopted a new classification system to provide 
reliable detection of change indicating progression to advanced AMD (Group, 2005). In 2006, 
another modification of the AREDS grading system was published, known as the Clinical 
Age-Related Maculopathy Grading System (CARMS) (Seddon et al., 2006). To standardise 
all previous classification systems, the Beckman Initiative for Macular Research Classification 
Committee suggested a more clinically useful AMD classification in 2013 (Ferris III et al., 
2013). In China, the widely adopted classification system is “Age-related Macular 
Degeneration Clinical Diagnosis Standard”, proposed by the China Medical Association in 
1986 (CMA1986). Unlike the above-mentioned classification systems which classify AMD 
into early and late stages, the CMA1986 system broadly classifies AMD into “dry” and “wet”, 
where “dry” includes both early AMD and GA and “wet” refers to neovascular AMD 
(NVAMD) (China Medical Association, 1987). Although these schemes share many similar 
features, a universal classification of the AMD subtype for either clinical or research purposes 
is still lacking (Hunter et al., 2014, Klein et al., 2014). 
Despite the aforementioned complicated grading schemes, the clinical course of AMD can be 
broadly divided into two stages: early and late (advanced) (De Jong, 2006, Gottlieb, 2002, Lim 
et al., 2012). Early AMD is characterised by soft drusen and/or pigmentary changes of the 
retinal pigment epithelium and retina, without visible choroidal vessels (Gottlieb, 2002, De 
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Jong, 2006). Late AMD includes two types: GA (geographic atrophy) and NVAMD. Typical 
symptoms in late AMD include decreased night vision and progressive loss of central vision 
(Rickman et al., 2013). GA is characterised by the development of one or more sharply 
delineated areas of chorioretinal atrophy near the fovea but without involving the foveal centre. 
In the last stage of GA when the atrophy expands into the foveal centre, the central vision will 
be lost (Holz et al., 2001, Holz et al., 2007). NVAMD is characterised by the formation of 
abnormal blood vessels growth from the tiny blood vessels into the choroid. This choroid 
breaks Bruch’s membrane and spreads into the macular. The new blood vessels are very fragile, 
leaking blood and fluid with subsequent fibrous scarring. This process can result in rapid and 
severe loss of vision (Nowak, 2006, Jager et al., 2008). 
Moreover, in major epidemiological studies, AMD can also be divided into two broad 
categories: dry (non-exudative) and wet (exudative) (Jager et al., 2008, Lim et al., 2012). Dry 
AMD is the most common form of AMD, accounting for about 90% of all the diagnosed cases 
(Evans and Syed, 2013, Damico et al., 2012). Dry AMD is formed from drusen deposit, 
pigment disruption and eventually GA (Rickman et al., 2013). GA is the end-stage form of dry 
AMD, when the deterioration of the retina has reached the most significant level. However, 
dry AMD progresses slowly, and only a minority of dry AMD progresses to GA (Cook et al., 
2008). Confusingly, dry AMD includes both early AMD and GA (Figure 1.21), even though 
the clinical difference is considerable (Gehrs et al., 2006, Rickman et al., 2013, Cook et al., 
2008). Wet AMD, which is also known as neovascular and exudative AMD, is a result of the 
neovascularization of the choriocapillaris (Nowak, 2006, Gehrs et al., 2006). The wet AMD is 
the most severe form that may lead to rapid vision loss in absence of treatment, although it 
accounts for only about 10% of all advanced AMD cases, approximately 90% of the severe 
loss of central vision manifest wet AMD (Chen et al., 2010, Bressler, 2002). 
 
Figure 1.21. Age-related macular degeneration (source: (Gottlieb, 2002)) 
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Note: A, early age-related macular degeneration; B, Late dry age-related macular 
degeneration. C, Wet age-related macular degeneration. 
1.4.4.2 Burden and impact 
AMD is the leading cause of blindness and visual impairment globally, especially in developed 
countries (Lim et al., 2012, Kawasaki et al., 2010). Conservatively, 14 million people were 
blind or severely visually impaired because of AMD in 2002, according to WHO estimates 
(Gehrs et al., 2006). Previous studies that adopted standardised classification protocols, and 
were based on fundus photography, have illustrated different prevalence estimates (Augood et 
al., 2006, Vingerling et al., 1995, Mitchell et al., 1995). According to the latest synthesis of 
global AMD prevalence in 2014, the prevalence of early, late, and any AMD was 8.01%, 
0.37%, and 8.69% in people aged 45 to 85 years. Correspondingly, 170 million had some form 
of AMD worldwide, this represents 2.3% of the global population and 18.9% of the older 
population, and was equivalent to more than half of the contemporary US population (Wong 
et al., 2014, United Nations, 2015b). Given the global ageing trend, the prevalence of AMD is 
projected to keep increasing, and the number of people with AMD is also likely to reach to 
196 million by 2020, and 288 million by 2040, with an overall increasing rate of 68.8%. 
Likewise, the number of people with early AMD will increase from 154 million in 2014 to 
177 million in 2020 and, finally, reach 260 million in 2040, with an increasing rate of 68.4%. 
However, the severe form of late AMD will show a much faster rate of growth over this period 
(92.6%), from 10 million in 2014 to almost 19 million in 2040 (Wong et al., 2014). This 
increasing burden raises important issues such as the impact on health-related quality of life, 
specialised assistance and services, and economic burden, both at individual and government 
levels. 
Although AMD is not a life-threatening disease and early AMD has limited impact, visual 
impairment from late AMD often significantly diminishes patients’ quality of life, 
psychological well-being and ability to function independently, such as seeing fine details, 
reading, watching, driving or even recognising people (Soubrane et al., 2007, Bonastre et al., 
2002, Lamoureux et al., 2010). Up to one-third of affected individuals will experience various 
degrees of disability and depression, even when only one eye is affected (Casten et al., 2004, 
Mitchell and Bradley, 2006). Moreover, the decreased mobility performance of this type of 
vision loss is also remarkable, with the consequences especially profound among older people. 
Consequently, AMD is significantly associated with increased incidence of falls and other 
injuries, resulting in an increasing economic and social burden on the individuals, caregivers 
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and community (Hassan et al., 2002, Brody et al., 2001, Lamoureux et al., 2010, Bonastre et 
al., 2002). 
The impacts of AMD, especially the associated visual loss, are not only limited to individuals 
but also affect whole communities. In addition to the devastating effects on individual life, the 
economic burden arising in the affected population is also relatively high (Bonastre et al., 2002, 
Brown et al., 2005). Despite the global ageing trend, AMD will not manifest in every country 
to the same extent, with the developed ageing entity suffering a heavier economic burden 
(Velez-Montoya et al., 2014). Multiple studies have been conducted to evaluate the economic 
burden of AMD around the world (Cruess et al., 2007, Cruess et al., 2008). For Canada, the 
annual cost for an individual with bilateral wet AMD was $ 11,334 in 2006, which was more 
than eight times higher than the annual cost of individuals free from wet AMD ($ 1,412) 
(Cruess et al., 2007). Another study indicated that the annual societal cost for an individual 
with bilateral wet AMD was € 12,445 in Germany, € 7,879 in Canada, € 7,349 in France, 
€5,732 in Spain, and € 5,300 in the United Kingdom in 2004. Almost half (23%-63%) of the 
abovementioned societal costs were direct medical costs. Therefore, the direct cost of bilateral 
wet AMD on treatments and health professionals in these countries was estimated to be €268 
- €1311million (Cruess et al., 2008). In China, an economic analysis of wet AMD has indicated 
that the cost was $4,856 per affected eye annually, whereas the cost of the whole disease course 
can reach to $33,999 in 2013 (Zhang et al., 2015). However, for a developing country whose 
gross national income per capita ($7,930 in 2015) was only a fraction of that in developed 
countries, these costs are a huge burden for both individuals and families (World Bank, 2015). 
Furthermore, with the rising number of individuals with AMD, the economic burden is 
projected to rise as well.  
1.4.4.3 Risk factors 
AMD is a multifactorial disease. A number of risk factors for AMD have been identified, 
including demographics (e.g. age, sex and ethnicity), environmental factors (e.g. cigarette 
smoking, light exposure, cardiovascular diseases) and genetics (e.g. complement factor H 
polymorphisms) (Chen et al., 2010, Smith et al., 2001, Cook et al., 2008). Some of these risk 
factors are described below. 
Demographic factors 
As the disease term implies, the association between ageing and AMD is consistently strong 
(Wong et al., 2014, Lim et al., 2012, Bonastre et al., 2002). With the increase in age, the 
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prevalence of AMD increases exponentially. Compared with subjects younger than 60 years, 
subjects aged between 60-80 years showed a three-fold increase in the risk of developing late 
AMD (VanNewkirk et al., 2000). For those 75+ years old, the Beaver Dam Eye Study revealed 
a much higher prevalence of both NVAMD (5.2% vs.0.1%) and GA (2.1% vs. 0%) in people 
aged 75 years and over than those aged 43-54 years (Klein et al., 1992).  
Female sex has also been suggested as a risk factor for AMD, but existing evidence and 
strength of association is inconsistent (Klein et al., 1997b, Klein et al., 2007). Pooled data from 
the Beaver Dam Eye Study, the Rotterdam study of the elderly, and the Blue Mountains Eye 
Study indicated that females have a higher prevalence of AMD when compared with males 
(odds ratio [OR]: 1.15), this possibly due to the lack of protective effects of oestrogens in 
postmenopausal women (Smith et al., 1997). However, no such significant sex differences in 
the prevalence of AMD were reported in other synthesis studies (Smith et al., 2001, Rudnicka 
et al., 2012, Chakravarthy et al., 2010). 
Among different ethnic groups, AMD prevalence was found to vary. In the ten-year follow-
up of the Beaver Dam Eye Study, both iris and hair colour were associated with the 
development of AMD. Compared with individuals with blue eyes, those with brown eyes were 
more likely to have soft indistinct drusen (risk ratio [RR]: 1.53), but less likely to develop 
pigment epithelial depigmentation (RR: 0.58). Furthermore, individuals with brown hair were 
at lower risk of developing pigmentary abnormalities than those with blond hair (RR: 0.73), 
indicating an ethnic difference (Tomany et al., 2003). In the Baltimore Eye study, large drusen 
(>125um) were found to be more prevalent in older whites than in older blacks (15% vs. 9%). 
As such, pigmentary abnormalities were also more common in older whites than in older 
blacks (7.9% vs. 0.4%). The overall prevalence of AMD was 2.1% for older whites but 0% for 
older blacks (Friedman et al., 1999). However, the results from the National Health and 
Nutrition Examination Survey III did not show significant difference among non-Hispanic 
whites, non-Hispanic blacks and Mexican-Americans (Klein et al., 1999). Outside the United 
States, two meta-analyses of AMD prevalence in people of European and Asian ancestry 
indicated similar prevalence of late AMD in people aged 40-79 years (0.59 vs. 0.56%), 
however, the prevalence of early signs was relatively higher in Europeans than in Asians (8.8% 
vs. 6.8%) (Kawasaki et al., 2010, Rudnicka et al., 2012).  
Environmental factors 
Cigarette smoking has been consistently implied as a risk factor for AMD in numerous studies, 
with both onset and disease progression of AMD strongly associated with smoking (Cano et 
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al., 2010, Smith et al., 2001, Chakravarthy et al., 2010, Thornton et al., 2005). Pooled findings 
from the Beaver Dam Eye Study, the Rotterdam study of the elderly, and the Blue Mountains 
Eye Study summarised the dramatic influence that cigarette smoking has on the incidence of 
AMD. Current smokers had increased incidence of GA and late AMD (GA and NVAMD) 
when compared with non-smokers, with ORs of 2.83 (95% confidence interval [CI]: 1.15-6.93) 
and 2.35 (95% CI: 1.30-4.27) respectively. Of particular interest, former smokers were not 
more likely to develop late AMD, GA or NVAMD than non-smokers in the same synthesised 
analysis, indicating the benefits of smoking cessation (Smith et al., 2001). In addition, the 
pack-year smoking of cigarettes was found to have a strong association with the risk of 
developing AMD in white people, and the OR increased with the amount smoked. Individuals 
with more than 40 pack-years of cigarettes smoking showed an OR of 3.43 (95% CI 1.28-9.20) 
for GA and 2.49 (95% CI: 1.06-5.82) for NVAMD. Smoking cessation was associated with 
reduced OR of AMD, with the risk in those who had stopped smoking for more than 20 years 
was comparable to non-smokers (Khan et al., 2006b, Cano et al., 2010). 
Exposure to light can cause damage to the retina. Excessive exposure to sunlight or ultraviolet 
radiation has been found to be associated with AMD in some studies (Fletcher et al., 2008, 
Cruickshanks et al., 2001, Tomany et al., 2003, Khan et al., 2006a, Tomany et al., 2004, 
McCarty et al., 2001a, Reibaldi et al., 2016). The Beaver Dam Eye Study suggested that leisure 
time spent outdoors in, both, the teens (13-19 years) and thirties (30-39 years) was significantly 
associated with the five-year incidence of early AMD (OR: 2.09 [95% CI: 1.19-3.65]) but not 
of late AMD (Cruickshanks et al., 2001). In its ten-year follow-up, individuals who 
experienced the summer sun more than five hours per day in teens (13-19 years) and thirties 
(30-39 years) at the baseline examination were more likely to develop increased retinal 
pigment (RR: 3.17 [95% CI: 1.24-8.11]) and early AMD (RR: 2.14 [95% CI: 0.99-4.61]) 
(Tomany et al., 2004). In addition, the different risks of developing AMD in individuals with 
different iris and hair colours implied the melanin’s protective effects on sunlight’s direct 
oxidative damage (Tomany et al., 2003). However, despite this strong evidence, other 
epidemiological studies failed to confirm this positive association between sunlight exposure 
and AMD, partly because of difficulties in quantifying the exposure to sunlight (Khan et al., 
2006a, McCarty et al., 2001a). 
Cardiovascular disease and its risk factors may also be risk factors for AMD, although the 
evidence for this has not been consistent (Klein et al., 1993, Klein et al., 1997a, Delcourt et 
al., 2001, Smith et al., 2001, Erke et al., 2014). Five population-based studies, namely, the 
Singapore Malay Eye Study, Singapore Indian Eye Study, Singapore Chinese Eye Study, 
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Singapore Cardiovascular Cohort Study, and Singapore Prospective Study Program were 
synthesised in order to analyse the latest data on cardiovascular risk factors and AMD. The 
pooled data showed hypertension (OR: 1.24 [95% CI: 1.04-1.47), lower total cholesterol (OR: 
0.77 [95% CI: 0.62-0.95]), higher HDL cholesterol (OR: 1.34 [95% CI: 1.06-1.69]), and higher 
body mass index (OR: 1.28 [95% CI: 1.01-1.62]) were significantly associated with the 
presence of AMD (Shin et al., 2014). However, other studies showed that neither a history of 
stroke nor heart attack was positively associated with the incidence or progression of AMD 
(Klein et al., 2003). 
Genetic factors 
Over the last decades, increasing evidence has supported the role of genetic polymorphisms in 
AMD. Initial evidence came from twin and family studies. Studies found that, compared with 
first-degree relatives of individuals without AMD, the first-degree relatives of patients with 
AMD were more likely to develop this disorder at a younger age, and had a higher risk to 
develop a late AMD during their lifetime (Heiba et al., 1994, Klein et al., 2001, Seddon et al., 
1997). More recent studies reveal a number of underlying genetic modifiers in AMD, with 
variants at chromosome 1q32 and 10q26 being among the most convincing ones (Chen et al., 
2010, Swaroop et al., 2007). Further variants at other loci, such as APOE, LIPC, C2/BF genes, 
also made a substantial contribution to the genetic risk for AMD (Swaroop et al., 2007). 
1.4.5 Glaucoma 
1.4.5.1 Definition and classification 
Glaucoma is a common and heterogeneous group of optic neuropathies characterised by both 
glaucomatous optic neuropathy (structural damage) and the gradual loss of visual field 
(functional loss) in at least one eye (Foster et al., 2002, Weinreb et al., 2014, Quigley, 2011). 
The development of glaucomatous optic neuropathy is a result of the loss of the retinal 
ganglion cells (RGCs) axons and the corresponding support vasculature. When loss of optic 
nerve tissue is significant, visual field loss occurs. The defects of vision loss in glaucoma are 
opposite to that in age-related macular degeneration, which usually leads to reduced peripheral 
visual acuity before affecting the central vision (Quigley et al., 1982, Quigley, 2011, Barton 
and Hitchings, 2013). 
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There are a number of classificatory systems for glaucoma, for example, according to its 
aetiology (primary and secondary), age of onset (infantile, juvenile, and adult), occurrence 
type (acute and chronic), intraocular pressure (IOP) (normal tension and high tension), and 
angle structure (open angle and angle closure) (Foster et al., 2002, Myint, 2013, Baker, 2008). 
Primary glaucoma is a set of conditions that solely cause glaucoma in the absence of other 
ocular or systemic pathology, and it is often, although not always associated with IOP 
elevation. The most common primary glaucoma includes primary open angle glaucoma 
(POAG) and normal tension glaucoma (Barton and Hitchings, 2013, Foster et al., 2002, 
Weinreb and Khaw, 2004, Kwon et al., 2009). In contrast, secondary glaucoma is mainly 
caused by other separate pathological processes, especially IOP elevation. Common secondary 
glaucoma includes pigmentary dispersion glaucoma, exfoliative glaucoma, neovascular 
glaucoma, and traumatic glaucoma (Barton and Hitchings, 2013, Whitmore et al., 2005).  
Anatomically, glaucoma can be further classified as open-angle versus closed angle glaucoma 
by the appearance of the iridocorneal angle. Open-angle glaucoma can be either primary or 
secondary, in the absence of significant iridotrabecular contact. POAG can be diagnosed in 
the context of an open iridocorneal angle (with or without IOP elevation) and no underlying 
secondary cause. Secondary open-angle glaucoma is much less frequent than POAG, and it 
can be diagnosed in the presence of an open iridocorneal angle and an underlying cause for 
IOP elevation (Whitmore et al., 2005, Foster et al., 2002). Angle-closure glaucoma occurs with 
clinically visible anatomical obstruction to aqueous outflow in the iridocorneal drainage angle, 
the iris, therefore, blocks aqueous outflow and leads to elevated IOP. It can also be primary or 
secondary (Congdon and Friedman, 2003). In primary angle-closure glaucoma (PACG), pupil 
block is the commonest cause of angle closure, other anatomical features may also play a role, 
such as peripheral iris thickness and conformation, anterior placement of the lens-iris 
diaphragm. In secondary angle-closure glaucoma, the underlying cause can close the angle by 
local iris directly or pathological changes in the iridocorneal angle result to the closure of the 
angle (secondary pupillary block) (Foster et al., 2002, Congdon and Friedman, 2003). The 
simplified classification of Glaucoma is shown in Figure 1.22. 
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Figure 1.22. Simplified classification of Glaucoma. 
1.4.5.2 Burden and impact 
Glaucoma is the second leading cause of blindness worldwide, after cataracts. However, the 
public health impact of glaucoma may be even greater than that of cataracts because of the 
irreversible blindness it causes (World Health Organization, 2013, World Health Organization, 
2014a). In 2010, approximately 60.5 million people were suffering from different kinds of 
primary glaucoma, among whom 44.7 were from POAG and 15.7 from PACG. With the global 
ageing trend, the population affected by glaucoma is also expected to increase. By 2020, 
around 79.6 million people will live with primary glaucoma, among whom 58.6 million will 
with POAG whereas 21.0 million with PACG. Compared with POAG, PACG is generally 
associated with a higher risk of blindness. In 2010, 4.5 million people with POAG and 3.9 
million people with PACG were bilaterally blind, and these numbers are projected to rise to 
5.9 million and 5.3 million by 2020 respectively (Quigley and Broman, 2006). By 2040, the 
number of people with POAG or PACG is projected to keeping rising to 111.8 million (Tham 
et al., 2014).  
Glaucoma affects people disproportionally, the distribution of glaucoma shows large variation 
in respect to age, sex and ethnicity. Globally, people residing in Africa are more likely to have 
POAG and those in Asia are more likely to have PACG (Tham et al., 2014, Quigley and 
Broman, 2006). For China alone, the number of people with POAG was 8.3 million in 2010, 
accounting for almost one-fifth of the total POAG cases worldwide. However, almost half of 
the global PACG cases (7.5 million) resides in China (Foster and Johnson, 2001). Although 
PACG comprised only 47% of primary glaucoma (POAG and PACG), given the fact that 
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PACG appears to be more visually damaging, it seems the public health impact arising from 
PACG will be much larger (Foster and Johnson, 2001). Among 1.7 million people bilaterally 
blind from glaucoma in China, 91% were caused by PACG (Foster and Johnson, 2001, 
Congdon and Friedman, 2003). 
Similar to any other ocular disease with potential blindness outcomes, glaucoma is associated 
with diminished quality of life and psychological disturbances, such as anxiety and depression 
(Ramulu, 2009, Varma et al., 2011). In extreme situations where severe visual impairment or 
blindness results, the associated consequences will be catastrophic to both affected individuals 
and their families (Zhou et al., 2013, Zhou et al., 2014, Ramulu, 2009, Rouland et al., 2005). 
As glaucoma is primarily a disease of the elderly, its social and economic burden will also 
increase as life expectancy and the total number of the older population continue to increase. 
The direct medical costs of glaucoma mainly include ocular hypotensive medication, physician 
and hospital visits, and glaucoma-related procedures. Direct non-medical costs consist of 
transportation, and nursing home care. Finally, indirect costs mainly refer to lost productivity, 
which includes both the productivity lost at work and productivity costs borne by caregivers 
(Varma et al., 2011). In the United States, the direct medical cost of glaucoma was $2.9 billion 
for 2 million US citizens, accounting for 17.8% of the total medical cost of major visual 
disorders in 2004 (Rein et al., 2006). In Australia, this cost was AUS$144.2 million for 
300,000 Australian citizens affected by glaucoma (Taylor et al., 2006). According to recent 
economic studies, patients with glaucoma are more likely to receive medications rather than 
surgeries as their first-line therapy (Rouland et al., 2005, Bateman et al., 2002, Jampel et al., 
2003). As new expensive anti-glaucoma medications become available on the market, the 
direct medical cost of glaucoma is also expected to rise accordingly (Rouland et al., 2005). 
Although the economic burden of glaucoma is still unknown in China, given the fact that 
treatment costs are directly related to the severity of glaucoma and PCAG is most prevalent in 
China, it is plausible to expect the existence of a larger social and economic burden. 
1.4.5.3 Risk factors 
Identifying risk factors for developing glaucoma is of special importance as it will help to 
identify those at high risk, therefore early medical detection and treatment can be initiated 
accordingly. In recent years, substantial evidence has emerged as to the risk factors for 
glaucoma, among which elevated IOP remains the sole known modifiable one. Other non-
modifiable risk factors for glaucoma include age, ethnicity, central corneal thickness, and 
family history, etc. (Quigley, 2011). 
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Elevated IOP remains the most important primary and prognostic risk factor for POAG 
(Palmberg, 2001, Stewart et al., 2000), although POAG can occur with or without ocular 
hypertension. The reduction of IOP can slow the progression of glaucoma and has become the 
primary focus of glaucoma treatment (Barton and Hitchings, 2013, Crowston and Weinreb, 
2005). In the Barbados Eye Study, individuals with elevated IOP (>21mmHg) were eleven 
times more likely to have POAG than those with normal IOP (≤21 mmHg) (Leske et al., 1995). 
However, elevated IOP alone cannot explain the formation of glaucoma, because a 
considerable proportion of glaucoma patients do not present IOP elevation. Moreover, 
recurrence of glaucoma after treatment indicates that some other IOP-independent risk factors 
may also play a role (Yanagi et al., 2011).  
Ageing is also proven as a crucial risk factor for glaucoma. In ageing eyes, increased 
accumulation of extracellular material will present in both the trabecular meshwork and 
uveoscleral outflow pathway, leading to a reduction of the aqueous humour outflow. Older 
age is also a measure of the length of exposure to other risk factors. In the Early Manifest 
Glaucoma Trial, individuals aged 68 years and over were 1.5 times more likely to develop 
early glaucoma than those younger than 68 years (Leske et al., 2003). 
A number of studies have indicated that an African-derived race is associated with higher risk 
of developing POAG than other ethnicities, whereas PACG is more common among the 
Chinese (Quigley and Broman, 2006, Tham et al., 2014). The reasons are probably the 
differences in the anterior chamber and angle anatomy, as African descendants generally have 
larger optic discs with a smaller neuroretinal rim, and thinner cornea thickness (Boland and 
Quigley, 2007). However, Chinese are more likely to have shallower central anterior chamber 
depth, and some other nonpupil-block mechanisms may also contribute to the formation of 
PACG significantly (He et al., 2006, Congdon and Friedman, 2003). 
A positive family history of glaucoma is another well-established risk factor. Siblings and 
offspring of glaucoma sufferers are more likely to have a higher IOP (Wolfs et al., 1998). In 
the Baltimore Eye Survey, the association between POAG and family history was even 
stronger in a sibling (OR: 3.7) than a parent (OR: 2.2) or child (OR: 1.1) (Tielsch et al., 1994). 
Although the POAG pedigrees do not show a simple Mendelian pattern of inheritance, a 
polygenic or multifactorial influence has been suggested (Wiggs, 2007). 
The national and subnational disease burden of age-related eye diseases in China 
General introduction   40 
1.4.6 Cataract 
1.4.6.1 Definition and classification 
Cataract is defined as a clouding or loss of transparency due to opacification of the crystalline 
lens. Lenticular opacities lead to scattered light, thus impinging the amount of light rays to the 
retina. Common syndromes of cataract include reduced visual acuity, blurry vision, monocular 
diplopia, loss of contrast and increased sensitivity to glare (Asbell et al., 2005). At the end 
stages, a cataract can affect a large part of the lens’ central area, resulting in impeded central 
vision, sight loss or even blindness (Solomon and Donnenfeld, 2003, Brian and Taylor, 2001). 
Cataract is most commonly seen in older people. Over the last two decades, epidemiological 
studies of cataract have been supported by the development of a number of grading systems 
to classify and grade lens opacities, including the Oxford Clinical Cataract Classification 
System (OCCGS) (Sparrow et al., 1986), the comprehensive Lens Opacities Classification 
System (LOCS) (Chylack et al., 1988, Chylack et al., 1989, Chylack et al., 1993), the 
Wisconsin Cataract Grading System (Wisconsin system) (Leske et al., 1988), and the Age-
Related Eye Disease Study Grading System (AREDS) (Group, 2001). These lens classification 
systems were based on a comparison between the clinical appearance of the lens (or the lens 
photographs) and a series of standard photographs, however, various assessment methods and 
cut-offs in different grading systems make between-study comparison complicated and 
difficult. Recently, a consensus has been partially reached on the WHO Simplified Cataract 
Grading System (WHOSCGS) (Thylefors et al., 2002). All above-mentioned systems have 
demonstrated their advantages in previous epidemiological studies. However, the complicated 
grading methods that largely rely on the training and reliability of the grades may make 
combining results from different studies very difficult, and introduce additional variability. 
Although the aetiology of cataract is not fully understood, cataracts can be broadly divided 
into a number of subtypes from an etiological perspective: age-related, congenital, traumatic, 
complicated, drug-induced cataracts, etc. (World Health Organization, 1993, Gupta et al., 
2014). Of these, age-related cataract is the most common form which mainly affects 
individuals aged fifty years and over (Asbell et al., 2005, Michael and Bron, 2011). Congenital 
cataract is the rarest form of cataract, which presents in utero or at birth. Traumatic cataract 
refers to cataract that is caused by blunt or penetrating ocular trauma. Complicated types occur 
mainly secondary to other ocular disorders, such as uveitis and myopia. Finally, drug-induced 
cataract is induced by exposure drugs, such as oral, topical, or inhaled steroids (Shiels and 
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Hejtmancik, 2013, Gupta et al., 2014). According to the study context, only the age-related 
cataract will be discussed and analysed in the thesis. 
Age-related cataract may occur everywhere in the lens. Depending on the different locations 
where cataract may occur, an age-related cataract can be divided into three main types, namely: 
cortical; nuclear; and posterior subcapsular cataract, with these different forms occurring 
independently or in combination (Michael and Bron, 2011, Vinson, 2006, Taylor, 1999). 
Cortical cataract is the clouding of lens cortex, which is comprised of the new fibres between 
the adult nucleus and the capsule. It is generated by deterioration of the architecture of the 
young fibre cells of the lens. This form of cataract is most common in diabetic patients. Visual 
damage depends on the location of opacification (Asbell et al., 2005, Michael and Bron, 2011). 
A nuclear cataract occurs in the centre of the lens, or nucleus. Post-translational modification 
to the structure of the crystallins in the centre of the lens results in a reduction of lens’ 
transparency. It is generally regarded as a result of oxidation and progresses slowly. The 
nucleus gradually becomes harder and opaque, associated with yellowing of the lens, with this 
sclerosis progressing relatively slowly over the years. In its early stages, it does not 
significantly affect vision or increase the refractive power of the lens (myopic shift). However, 
with continued progression, colour discrimination and vision will eventually be lost (Asbell et 
al., 2005). A posterior subcapsular cataract occurs from the anterior to the posterior capsule. 
In this form of cataract, lens fibres migrate to the posterior pole of the lens, and the 
accumulation finally forms a granular layer of enlarged and hydrated cells between the back 
of the lens and capsule. Although posterior subcapsular cataract is less prevalent and often 
occurs in combination with cortical or nuclear cataracts in their late stages, it has a profoundly 
debilitating effect on vision and a more severe degree of blurring and glare due to the central 
area of the lens being affected. This form of cataract is most common in diabetic patients and 
long-term steroid users (Vinson, 2006). 
1.4.6.2 Burden and impact 
Cataract is the leading cause of blindness. According to the latest WHO statistics in 2010, 
cataract was responsible for more than half of all cases of blindness and two-thirds of all 
individuals with visual impairment worldwide. Of these, over 20 million are visually disabled 
because of the presence of cataract (World Health Organization, 2013). Since cataract is 
primarily an age-related disease, it is estimated that its burden will increase corresponding 
with ageing, and become an emerging public health concern (World Health Organization, 
2014b). There is still no estimate of the global prevalence of age-related cataract, this largely 
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due to the difficulty of combining prevalence data from different population groups, especially 
in cases where different grading systems were adopted. In a synthesised analysis using data 
from two population-based studies in Australia (the Blue Mountains Eye Study and Melbourne 
Visual Impairment Project), it was estimated that, in 2001, there were 1.7 million Australians 
with clinically significant age-related cataract in either eye, and up to 320,000 with cataract 
surgery history. As populations age, it is estimated that these two figures would keep growing 
by two-thirds during the next two decades, reaching to 2.7 million and over 500,000 in 2021, 
respectively (Rochtchina et al., 2003). In China, different epidemiological surveys have been 
conducted across the nation, demonstrating various prevalence estimates ranging from less 
than 10% to more than 50% (Sheng et al., 2016, Zhou and Jia, 2011). By taking a low-medium 
estimate of 18%, it was speculated that there was around 30 million affected older population 
in 2010 (Bao et al., 2008, Li et al., 2009, Zhao et al., 2001, United Nations, 2015b). However, 
only 6.26 million of the population were diagnosed with cataracts in 2012 in China, thus this 
difference of estimates implies a serious rate of under-diagnosis (Li, 2016). 
At an individual level, vision loss arising from cataract is the leading cause of morbidity, 
functional impairment and diminished quality of life in older people. From a clinical 
perspective, a cataract can be regarded as a conquered disease because of the highly effective 
surgery that is available. Yet, for older people who are referred to receive surgical treatment, 
complications still exist - in spite of the guarantee of positive vision outcome associated with 
treatment. Perioperative complications include lens capsular tear, loss of nuclear material into 
the vitreous, vitreal loss, and others. Postoperative complication includes endophthalmitis. 
Even after a long term, there is still a probability of developing retinal detachment and cystoid 
macular oedema (Abdelkader et al., 2015). 
However, the accessibility of cataract surgical services varies between countries, and in many 
countries the availability of cataract extraction is limited (Brian and Taylor, 2001, Nirmalan 
et al., 2004). In China, where economic development is heavily uneven across the country, 
cataract still accounts for a large amount of vision loss in older people (Zhao et al., 2010). The 
burden of disability due to cataract can be further compounded by inequality in health care. A 
critical indicator to reflect how a cataract is being eliminated is the cataract surgery rate, which 
refers to the number of cataract surgeries per million people per year (Zhu et al., 2014). In 
China, it was estimated that the cataract surgery rate was only 446 per million per year, almost 
the lowest in Asia and comparable to some West African countries - where well-developed 
ophthalmic infrastructures are insufficient (He et al., 2007, Shen et al., 2013, Zhang et al., 
2010a). This low speed of eliminating cataract, in conjunction with a population that is 
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increasing in both size and age, will inevitably escalate the health and economic burden of 
cataract on society. This will especially affect rural and poor areas, where access to appropriate 
ophthalmological care is limited due to many significant barriers (e.g. lack of knowledge and 
concern over the poor quality of local services) (Zhao et al., 2010, He et al., 2007, Lam et al., 
2009). In the latest national eye health plan (2016-2020), the central government has listed 
improving cataract surgery rate and its coverage as one priority to eliminate cataract 
significantly (National Health and Family Planning Commission of the People's Republic of 
China, 2016). 
Although several studies have demonstrated a high success rate (over 90%) of good clinical 
outcomes in both developed and developing countries, this is not the case for China. In a 
survey covering nine provinces, 17.7% of the cataract-operated eyes had visual acuity less 
than 20/200 (Zhao et al., 2010). Currently, cataract surgery has become the most commonly 
performed surgical procedure. Yet, given the large number of individuals undergoing this 
surgery, a failure rate of 17.7%, or even at the best 10%, will translate into a large number of 
individuals who suffer from the poor surgical outcomes and complications. 
The economic burden of cataract for a society extends beyond the disability. In the United 
States, cataract ranks as the second costliest vision problem, only inferior to refractive error 
(John and David, 2013). The direct medical cost of cataract mainly stems from the surgical 
procedure, which nears $ 12 billion in 2015 (Ianchulev et al., 2016). In Australia, cataract has 
become the largest contributor to the allocated health system expenditure, reaching $459 
million in 2009 (Access Economics, 2010). Until recently, there were no national estimates of 
the economic burden of cataract for China, this being largely due to the difficulty of 
quantifying the costs in a nation with large variation in costs of cataract management between 
rural and urban populations, and in different provinces (Zhang et al., 2010a, Fang et al., 2010). 
1.4.6.3 Risk factors 
Research on the aetiology of cataract is of merit in expanding our understanding of the 
mechanisms by which cataract develops. More practically, it can also provide useful clues on 
preventions of cataract. Multiple factors have been suggested to have contributions to the 
development of cataract (Table 1.2), including demographics (age, sex, ethnicity), 
environmental factors (UV exposure, lifestyle, specific health problems) and genetic factors 
(Asbell et al., 2005, Taylor, 1999).  
Table 1.2. Summary of risk factors for age-related cataract (source: (Asbell et al., 2005)) 
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Risk factor Cataract type Evidence 
Demographic factors   
Age Cortical, Nuclear, 
posterior subcapsular 
(PS) 
Conclusive for nuclear and cortical 
cataract formation; but less strong for 
PS 
Female sex Cortical, nuclear Robust for slightly increased risk of 
cortical; weaker for nuclear 
Ethnicity Cortical, less nuclear, 
PS 
Robust for increased risk of cortical in 
black people; some evidence for higher 
risk of nuclear and PS in white people; 
limited for excess PS in Chinese 
Environmental factors   
Ultraviolet B Cortical Robust with dose-response relation for 
cortical 
Cigarette smoking Nuclear, PS Robust with dose-response relation for 
nuclear; some evidence for PS 
Diabetes Cortical, PS Robust; risk related to duration and 
control of diabetes; associated with 
cataract surgery at an early age 
Steroid use PS Robust; associated with high doses and 
long-term use; inhaled administration 




Cortical, nuclear, PS Strong, linking markers of low 
socioeconomic status with all types 
Genetic factors   
 Cortical, nuclear Robust for genetic component to both 
cortical and nuclear in white people; 
could be the source of racial variation 
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1.4.7 Diabetic retinopathy  
1.4.7.1 Definition and classification 
Diabetic retinopathy (DR), one of the major complications of diabetes mellitus, is a chronic, 
progressive disease caused by pathological changes of the neurovascular retina. Like all other 
diabetic complications, DR develops with the progression of diabetes and, thus, is more 
common in older diabetic patients. In early stages, vascular occlusion and dilations occur, 
while in late stages, there is a proliferation of new blood vessels and fibrous tissues (World 
Health Organization, 2006, Cheung et al., 2010).  
Different sets of classification systems have been developed for describing the severity of 
retinopathy and macular oedema (Early Treatment Diabetic Retinopathy Study Research 
Group, 1991b). The most widely applied system is the Early Treatment of Diabetic 
Retinopathy Study (ETDRS) severity scale. This scale is based on the grading of stereo 
photographs of 7 fields, and classifies DR into 13 complex levels ranging from level 10 
(absence of retinopathy) to level 85 (severe vitreous haemorrhage or retinal detachment 
involving the macula) (Early Treatment Diabetic Retinopathy Study Research Group, 1991b, 
Wu et al., 2013). This scale has shown satisfactory reproducibility and validity and, thus, is 
regarded as the “golden standard” for grading the severity of DR. However, the fine granularity 
makes it rather complicated to be utilised in daily clinical practice (Ting et al., 2016, Wu et al., 
2013). In April 2002 the Global Diabetic Retinopathy Group at the International Congress of 
Ophthalmology produced a simplified international clinical diabetic retinopathy and diabetic 
macular oedema disease severity scale (Wilkinson et al., 2003). This new scale classifies DR 
into five stages based on severity, with the first three stages as low risk, the fourth as severe 
non-proliferative diabetic retinopathy (NPDR) and the fifth as proliferative diabetic 
retinopathy (PDR). DMO is simply classified as apparently present or apparently absent 
(Wilkinson et al., 2003). Compared with the ETDRS scale, this classification system is much 
more user-friendly and easy to adopt in clinical settings (Wu et al., 2013, Ting et al., 2016). 
In accordance with the international clinical diabetic retinopathy and diabetic macular oedema 
disease severity scale, DR is generally divided into NPDR and PDR according to the presence 
of new blood vessel growth within the retina in epidemiological studies (Figure 1.23) 
(Mohamed et al., 2007, Ting et al., 2016). NPDR is characterised by damage to retinal 
endothelium and the resultant capillary occlusion, with common clinical features including 
microaneurysms, haemorrhages and cotton wool spots in the retinal periphery. PDR occurs 
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with further retinal ischemia and is characterised by the proliferation of neovascularization on 
the interface between the retina and the vitreous cavity. These fragile blood vessels may 
rupture and result in vitreous haemorrhage, subsequent fibrosis and tractional retinal 
detachment. Diabetic macular oedema (DMO), which is frequently the principal cause of 
vision loss due to DR, can occur in any stage of DR. DMO is characterised by increased 
vascular permeability and the deposition of hard exudates at the central retina. Severe NPDR, 
PDR and DMO together are categorised as vision-threatening DR (VTDR) (Porta and 
Bandello, 2002, Mohamed et al., 2007). 
 
Figure 1.23. Diabetic Retinopathy (source: (Mohamed et al., 2007)) 
Note: A, Moderate NPDR with microaneurysms, retinal haemorrhages, and macular oedema 
characterised by increased vascular permeability and deposition of hard exudates at the 
central retina; B, PDR with new vessels and fibrous tractional bands arising from the optic 
disc. 
1.4.7.2 Burden and impact 
Diabetes has been proven to be associated with a range of ocular diseases, but the main cause 
of blindness that is directly linked to diabetes is DR. It was estimated that at least 75% of the 
patients suffering from diabetes for more than 20 years will have some kind of DR (World 
Health Organization, 2006). In 2010, there were 285 million adults with diabetes globally, and 
this figure is expected to increase to 439 million by 2030. During this period, the increasing 
rate of the number of adults with diabetes is especially high in developing countries in 
comparison to developed countries (69% vs. 20%) (Shaw et al., 2010). Among people with 
diabetes, the overall prevalence of diabetic retinopathy is more than one-third. In 2010, 
approximately 93 million people were living with DR, among whom 76 million were with 
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NPDR, 17 million with PDR and 21 million with DMO. The number of people living with 
VTDR has also reached 28 million (Yau et al., 2012). Considering these global trends, and the 
lack of proper action taken, another global estimate indicated an even larger burden, where the 
number of people with DR will increase from 126.6 million in 2010 to 191.0 million by 2030, 
and the number with VTDR will also grow from 37.3 million to 56.3 million (Zheng et al., 
2012). The WHO estimated that DR was the fifth leading cause of visual impairment 
worldwide in 2010 (Pascolini and Mariotti, 2011, Stefánsson et al., 2000). Given that DR can 
be largely prevented with existing screening and treatment approaches, the WHO placed DR 
as one of the priority eye conditions that can be partly prevented or treated (World Health 
Organization, 2014b, Pizzarello et al., 2004). In China, approximately 114 million adults aged 
18 years or older were living with diabetes in 2010, which accounts for 40% of the worldwide 
diabetic population (Xu et al., 2013). Previous synthesised analysis of the prevalence of DR 
in China revealed that the prevalence of DR, NPDR and PDR was 23.0%, 19.1% and 2.8% in 
diabetic patients respectively (Liu et al., 2012). Extrapolating these prevalence rates to the 
population of diabetes cases in China, approximately 26 million diabetic patients were living 
with DR in China in 2010, among whom 22 million were with NPDR and 4 million were with 
PDR. These numbers are expected to escalate with an ageing population in the foreseeable 
future. 
DR is the leading cause of visual impairment in the working-age population. At the individual 
level, visual and functional impairments associated with DR have been shown to reduce 
health-related quality of life and increase dependency in activities of daily living to a large 
extent, resulting in anxiety and depression (Lamoureux et al., 2004, Sharma et al., 2005). At 
the societal level, DR is also notably associated with high direct (medical care) and indirect 
costs (reduced productivity). In the United States, the direct costs for DR were $493 million 
in 2004 and, given the reduction of work function associated with DR and its affected 
population, indirect costs were expected to account for a larger proportion of the total cost 
(John and David, 2013, Rein et al., 2006). In Germany, in the year 2002, the medical cost of 
DR covered by the German statutory health insurance was €2.23 billion, and the societal cost 
was €3.51billion (Happich et al., 2008). In China, although the economic burden has not been 
estimated, the annual costs of screening and grading alone were estimated to more than £540 
million in 2015 (Li, 2015b). 
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1.4.7.3 Risk factors 
Risk factors for DR have been previously examined in many epidemiological and clinical 
studies, with consistent factors including the duration of diabetes; the level of glycemia; the 
presence of high blood pressure; dependence on insulin; pregnancy; levels of selected serum 
lipids; nutritional and genetic factors (Klein, 2007). However, considerable variation still 
exists in the consistency and strength of this evidence, especially in cases where the stages of 
DR are different (Yau et al., 2012). 
Duration of diabetes is a prerequisite of DR. Once being diagnosed, DR is generally more 
prevalent in the older-onset group than in the younger-onset group (Klein et al., 1984b, Klein 
et al., 1984a), and patients with type 1 diabetes have a higher prevalence of DR compared with 
those with type 2 diabetes (Ting et al., 2016). It was estimated that the OR of DR increased by 
1.07±0.2 per year of duration of diabetes (Wong et al., 2008b). 
Multiple studies have consistently shown poor glycemic control to be an independent risk 
factor for the development and progression of DR (Varma et al., 2007, Wong et al., 2006b, 
UK Prospective Diabetes Study Group, 1998, van Leiden et al., 2003). Elevated haemoglobin 
A1c (HbA1c) reflects poorly controlled diabetes, and it was estimated that a 1% increase in 
HbA1c was associated with a 22% increase in the prevalence of DR (Varma et al., 2007). Even 
in patients with a good HbA1c level of 7.0%, the absolute risk of retinal laser treatment was 
as high as 7.9 per 1000 patient-years (Varma et al., 2007, UK Prospective Diabetes Study 
(UKPDS) Group, 1998). This implies the importance of optimal glycemic control in diabetic 
patients. 
High blood pressure is also an independent risk factor for the development of RD in both type 
1 and type 2 diabetic patients. In the Los Angeles Latino eye study, the OR of DR was 1.26 
for every 20 mm Hg increase in blood pressure (Varma et al., 2007). The decreased systolic 
blood pressure of 10 mm can bring a declined risk of DR and the need for laser treatment by 
more than one-third (Cheung et al., 2010). 
Genetic predispositions are also of etiological importance for DR. Previous twin studies and 
familial aggregation studies have indicated significant familial clustering, with siblings and 
relatives of diabetic patients with DR having demonstrated a two to three-fold risk of DR 
compared with relatives of diabetic patients without DR (Diabetes Control and Complications 
Trial Research Group, 1997, Leslie and Pyke, 1982). As the severity of DR increases, the 
degree of familial clustering also increases. It was estimated that heritability was as high as 
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27% for DR and 52% for PDR (Hietala et al., 2008, Cho and Sobrin, 2014). Numerous genes 
have been studied for association with DR through linkage analysis, candidate gene 
association studies and genome-wide association studies, but more efforts are still needed to 
ascertain these associations in future studies. 
1.5 Systematic review and meta-analysis 
1.5.1 Systematic review 
Synthesis of evidence (literature review) is necessary to summarise available evidence in a 
specific research area, and it can be conducted both qualitatively (literature review) and 
quantitatively through appropriate statistical methods (meta-analysis). A conventional 
literature review has been conducted to collect and summarise the available evidence in a 
narrative way, and thus it may be particularly prone to unsystematic bias in presenting a 
comprehensive and sound overview of the given evidence (Cook et al., 1997, Impellizzeri and 
Bizzini, 2012). In light of this shortcoming, review methods have been advanced in the 1970s 
to systematically examine the existing evidence from all available primary studies, known as 
a systematic review with meta-analysis (Cook et al., 1997, Haidich, 2011).  
Systematic review refers to an approach that identifies all relevant empirical evidence in a 
specific research area. It is a transparent process for identifying, appraising, summarising and 
(if appropriate) synthesising all the available evidence in specific research areas (Kitchenham, 
2004, Cook et al., 1997). Compared with the conventional literature review, a systematic 
review is becoming increasingly popular in contemporary research contexts. High-quality 
systematic reviews should be conducted systematically and easily replicated with pre-defined 
and reproducible methods. Possible methods for reducing bias include clear study objectives 
and methods, comprehensive search for relevant studies, independent reviewers to validate 
included studies, and systematic presentation of the results (Moher et al., 2009, Cooper, 2016).  
Typically, the process of systematic review involves defining a particular research topic, and 
then conducting the literature review with a transparent and replicable search strategy. The 
comprehensive search of literature is the key feature of a systematic review, which aims to 
identify as much relevant evidence as possible. In this process, the search for relevant studies 
should not only be limited to published studies, but also include unpublished studies (grey 
literature), such as government reports, theses, etc., to reduce the potential effect of publication 
bias. Further efforts should also be made to contact the authors for clarification on some key 
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issues, if this is deemed necessary. Then, the articles are assessed based on preset inclusion 
and exclusion criteria. For those that meet the inclusion criteria, full-text papers are assessed 
in detail. Data extraction will then be performed to extract key findings (Kitchenham, 2004, 
Moher et al., 2009, Higgins and Green, 2008). A number of guidelines have been developed 
to standardise the systematic review process and its reporting format, including the guidance 
for conducting a systematic review, published by the Cochrane Collaboration (Higgins and 
Green, 2008), the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) by the Centre for Review and Dissemination at the University of York (Moher et 
al., 2009), the Meta-analysis of Observational Studies in Epidemiology (MOOSE) statement 
by the MOOSE group (Stroup et al., 2000), and the Guidelines for Accurate and Transparent 
Health Estimates Reporting (GATHER) statement by the GATHER working group (Stevens 
et al., 2016). Given the study context in this thesis, the PRISMA guidelines and GATHER 
statement are adopted in reporting the disease burden estimates of AREDs in China. 
A systematic review is especially useful in disease burden research, especially for diseases 
that are not cost-effective to be included in national surveillance systems or large-scale surveys. 
For disease burden studies that adopt the systematic review approach, epidemiological studies 
(case-control, cross-sectional or cohort studies) have typically been used to evaluate the long-
term exposures that may cause disease or death, or summarise the frequency of diseases (e.g. 
incidence, prevalence) (Lopez et al., 2006, Wong et al., 2014, Tham et al., 2014). For this kind 
of research, randomly designed trails are of limited utility because of ethical concerns (Stroup 
et al., 2000). With an increasing amount of epidemiological research, it has become possible 
to critically appraise both published and unpublished literature. For observational studies, the 
lack of a control group may limit the ability to control potential confounding variables, and 
thus generate considerable bias (Impellizzeri and Bizzini, 2012).  
1.5.2 Meta-analysis 
1.5.2.1 Introduction 
With attempts to reduce individual subjectivity, a systematic review with statistical 
aggregation of data is generally referred to as a quantitative systematic review, namely, a meta-
analysis (Egger et al., 2008, Impellizzeri and Bizzini, 2012). A systematic review with meta-
analysis refers to a complete process of identifying, appraising, synthesising and combining 
evidence from multiple independent studies (Copetti et al., 2013, Lau et al., 1997). If correctly 
performed, meta-analysis can be used to summarise results from many types of studies. 
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Typically, meta-analysis is used to synthesise results from randomised controlled trials, where 
small sample size studies cannot provide stable estimates, but the approach of meta-analysis 
pooling a group of individual studies can achieve a more powerful and reliable inference. 
However, the difference in study design, sample size and other characteristics - such as the 
investigated population, or the outcome measurement - may also lead to the variability or 
heterogeneity between individual studies (Haidich, 2011, Lau et al., 1997).  
Unlike meta-analyses of randomised controlled trials, which are largely based on the 
assumption that the overall effect of an experiment is unbiased and can provide causation, 
meta-analysis for observational studies is based on the assumption that the variation arises 
from multiple confounding factors, biases, or both. For meta-analysis of observational studies, 
exploration of possible sources of heterogeneity is the main aim for providing insights, rather 
than the overall combination of studies, which is often biased (Egger et al., 2008, Stroup et al., 
2000, Impellizzeri and Bizzini, 2012, Barendregt et al., 2013). In some cases, the study 
characteristics can be used to conducted sub-group analysis, or as covariates in meta-
regression models (Thompson and Higgins, 2002). 
1.5.2.2 Heterogeneity assessment 
An important part of meta-analysis is testing the heterogeneity of the combining studies. This 
is generally defined as the variability in the underlying effect size between studies that cannot 
be solely explained by chance (within-study variation) (Haidich, 2011, Borenstein et al., 2009). 
The significance of the heterogeneity is generally tested by using a Cochran's Q statistic, which 
assumes that the study effects follow a normal distribution (Higgins et al., 2003). However, 
the statistical power for testing heterogeneity is generally low, due to a small number of 
included studies, which implies a higher-than-expected probability of false negative result. To 
compensate for this shortcoming, a higher level of cut-off significance is generally adopted 
(e.g. p<0.10 instead of the classic p<0.05). In circumstances where the Q statistic is significant, 
the potential causes of heterogeneity could be further investigated by subgroup analysis or 
meta-regression, and the reduction of between-study variance represents the amount of 
variation explained by the covariates (Huedo-Medina et al., 2006).  
Several approaches have been developed to estimate the magnitude of the between-study 
variance, 𝜏2 . One popular approach is the DerSimonian-Laird method. However, in 
circumstances where the included studies are few, the estimation of 𝜏2  may not be an 
approximation for the population estimate (Huedo-Medina et al., 2006). Another popular 
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statistic for measuring the heterogeneity is the 𝐼2 parameter, which represents the percentage 
of total variation across all included studies that is due to heterogeneity rather than chance 




) ∗ 100% 
Where 𝑄 is Cochran’s heterogeneity statistic and 𝑑𝑓 denotes the degrees of freedom.  
Compared with the 𝜏2 , the magnitude of 𝐼2  is independent from the number of included 
studies, but it may be influenced by the precision of the studies. As a result, 𝐼2 can be classified 
into three categories by cut-off values of 25% and 75%, which suggest low, moderate and high 
heterogeneity respectively (Huedo-Medina et al., 2006, Higgins et al., 2003).  
In the process of meta-analysis, the investigation of heterogeneity is crucial before deciding 
the statistical methods for polling results, and whether the result should be interpreted by 
groups. The selection of the analysis model should be based on the research context and 
characteristics of the included studies. In cases where heterogeneity is highly suspected, three 
approaches are recommended (West et al., 2010, Higgins and Green, 2008, Huedo-Medina et 
al., 2006): 
1) Categorise the included studies into different homogeneous subgroups and then 
summarise, using fixed-effect models; 
2) Accommodate heterogeneity by using random-effects models; 
3) Explore possible sources of heterogeneity by using meta-regression. 
1.5.2.3 Classical meta-analytic approach 
Broadly speaking, two main models are available for frequentist meta-analytic approach, 
namely, fixed-effect model and random-effects model. The fixed-effect model is based on the 
assumption that all included studies come from the same population, so that variance across 
studies is solely attributed to sampling variability and no between-study variation exists 
(Borenstein et al., 2009). The pooled result is thus calculated as a weighted average of all 
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Where  is the true value of the effect size and 𝑖
2 is the variance in studies i=1, 2,…, k. 
In contrast, the random-effects model assumes that the included studies are only a sample from 
an unknown population and thus between-study variance should be taken into account, too.  
?̂?~𝑁(𝑖,𝑖
2) 
In this model, the distribution of 𝑖 has a mean of  and a heterogeneity variance of 𝜏
2, in 
some circumstances, the distribution of 𝑖 is a normal distribution. 
𝑖~𝑁(, 𝜏
2) 
Meta-regression is another preferable method to conduct analysis in circumstances where one 
or more confounding factors are associated with the effect size. Meta-regression can be used 
to explain the source of heterogeneity. Its advantage over the sub-group analysis is a more 
compelling assessment of heterogeneity (Thompson and Higgins, 2002). In meta-regression, 
variables at study-level can attribute to a proportion of the total heterogeneity. Both fixed and 
random-effects models can be applied in meta-regression, but the latter is more realistic and 







Where 𝛽𝑖𝑗 is the 𝑗th variable in a model where 𝑚 study-level covariates are included.  
1.5.2.4 Bayesian meta-analytic approach 
Bayesian methods have been widely adopted in meta-analysis approach (Dixon-Woods et al., 
2005, Van Houwelingen et al., 2002, Wong et al., 2014), in contrast to the frequentist paradigm, 
which relies solely on the likelihood from the collected data. Bayesian statistics attribute the 
results to a posterior probability distribution based on a prior probability distribution (external 
evidence about the effect of interest) and the likelihood (evidence from the collected data) 
(Copetti et al., 2013). The prior probability distribution may come from results in previous 
studies or purely from experts’ beliefs, which may yield a variety of prior distributions. The 
choice of prior distribution should be made with caution, because the choice can affect the 
results to a considerable extent. For example, if an unreliable prior distribution dominates the 
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likelihood, an inaccurate or over-influenced posterior distribution cannot be avoided (Sutton 
and Abrams, 2001). The two sources of evidence (likelihood function and prior distribution) 
combinedly contribute to the posterior probability of the effect of interest. 
𝑃(𝜑|𝑑𝑎𝑡𝑎) ≈ 𝑃(𝜑)𝑃(𝑑𝑎𝑡𝑎|𝜑) 
𝑃(𝜑|𝑑𝑎𝑡𝑎) is the posterior distribution based on the prior distribution 𝑃(𝜑) and the likelihood 
based on the observed data 𝑃(𝑑𝑎𝑡𝑎|𝜑). 
The choice of prior distribution is a major source of controversy in Bayesian meta-analysis 
approach, so in many circumstances, prior distributions are defined as “non-informative” or 
“reference” to reflect a position of prior ignorance - i.e., prior distributions can be broadly 
distributed over a wide range of values. In these situations, Bayesian meta-analysis often yields 
very similar results as the classical frequentist meta-analysis, because the posterior estimate 
will only rely on the likelihood function. However, this “non-informative” approach should 
also be used with caution because all values within the pre-set broad range are equally likely, 
and even the choice of “non-informative” prior may have considerable effects on the results 
of the analysis (Lambert et al., 2005, Sutton and Abrams, 2001). Although the application of 
Bayesian approaches has increased in recent decades, it is still limited when compared with 
the classical frequentist meta-analyses (Copetti et al., 2013) 
In Bayesian models where many study-level covariates are included, high-dimensional 
integration may be needed. Common methods for calculating the posterior distribution in a 
Hierarchical Bayesian model include Markov Chain Monte Carlo (MCMC) approach, which 
simulates high dimensional joint probability distributions. In addition, Gibbs Sampling is also 
used in this practice (Brooks, 1998, Spiegelhalter et al., 1996).  
1.6 Rationale for proposed research 
As discussed in preceding sections, the older population in China is expected to increase 
substantially. This is expected to lead to several age-related health problems that will grow in 
importance over time. From a public health perspective, investigating the disease burden of 
AREDs is of significant importance, because it is a key indicator of eye care plan at both the 
national level and the local level. However, the study of AREDs in China has been somewhat 
overlooked when compared with other diseases of ageing. There remains a lack of knowledge 
and awareness of the burden of AREDs among policymakers and the general public in China. 
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Furthermore, although vision-threatening conditions have been revealed and cost-effective 
approaches may also exist, many affected individuals remain unaware of the need to seek 
ophthalmic screening and medical treatment. Finally, the lack of well-trained professional 
ophthalmologists, especially in resource-poor areas, is perpetuated. These factors may 
contribute to the continued increase of the AREDs burden in the foreseeable future. 
To date, no blind surveillance system or national investigation on AREDs exists to provide the 
disease burden estimates for AREDs in China. Furthermore, most Chinese epidemiological 
studies on AREDs are local investigations, which can only represent the disease burden in 
particular circumstances. The approach of systematic review and meta-analysis has emerged 
as a popular and useful tool in collecting the existing local surveys and understanding the 
epidemiology of ARMDs. Therefore, a systematic review and meta-analysis is adopted in this 
thesis to provide a better approximation of the AREDs burden in China at the national level, 
or even the sub-national level. 
1.7 Research aims and objectives 
The main aim of this thesis is to quantify the disease burden of AREDs in China. This aim will 
be achieved through the following specific objectives: 
1) To quantify the prevalence and disease burden of four major AREDs (AMD, 
glaucoma, cataract and DR) from 1990 to 2015, by using existing survey data; 
2) To identify individual and cluster-level factors underlying the prevalence of AREDs 
and to explore the relative importance of variations at different scales; 
3) To predict the prevalence and disease burden of AREDs from 2020 to 2050 (if 
possible); 
4) To estimate the disease burden of AREDs at sub-national level, by applying the 
corresponding population data and risk factor characteristics. 
1.8 Outline of this thesis 
Chapter 2 describes the overall methods of this thesis; Chapters 3-6 demonstrate the 
prevalence and burden of AMD, glaucoma, cataract and DR respectively. Finally, Chapter 7 
discusses the main findings of the thesis and highlights the important issues arisen from this 
work that may inform policymaking. 
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Chapter 2 Overall methods 
Overall, the study approach in this thesis could be classified into five stages (Figure 2.1): 
➢ Stage 1- Systematic review; 
➢ Stage 2- Meta-analysis and meta-regression of prevalence data; 
➢ Stage 3- Estimation of the national number of cases; 
➢ Stage 4- Identification of potential correlates of or risk factors for AREDs; 
➢ Stage 5- Estimation of the regional number of cases. 
 
Figure 2.1. Overall study design flowchart  
2.1 Systematic review 
2.1.1 Literature search 
To derive studies that reported prevalence data on AREDs in China, four systematic reviews 
were separately carried out for AMD, glaucoma, cataract and DR (see Chapters 3-6 for more 
details). In Chinese scientific society, the Chinese bibliographic databases consist of a large 
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sheer volume of studies that are important data sources for understanding the epidemiology of 
diseases in China (Xia et al., 2008, Cohen et al., 2015). Therefore, three major Chinese 
bibliographic databases, namely China National Knowledge Infrastructure (CNKI), Wanfang 
database, Chinese Biomedicine Literature Database (CBM-SinoMed) were selected for the 
literature search. Searchable databases in the CNKI platform include China Academic Journals 
Full-text Database (1994 onwards, 63904806 records in total), China Doctoral Dissertations 
Full-text Database (1984 onwards, 364992 records in total), China Masters' Theses Full-text 
Database (1984 onwards, 3508873 records in total), China Proceedings of Conference Full-
text Database (1953 onwards, 2303841 records in total), International Proceedings of 
Conference Full-text Database (1981 onwards, 788716 records in total), China Core 
Newspapers Full-text Database (2000 onwards, 16540597 records in total), and China 
Yearbooks Full-text Database (1949 onwards, 31496104 records in total). Wanfang database 
and CBM-SinoMed are similar platforms which cover different ranges of literature (Xia et al., 
2008). PubMed, Embase and Medline were also searched to identify English-language articles 
that reported the epidemiology of AREDs in Chinese population. In the literature search, 
different search strategies were respectively developed for each disease and bibliographic 
database. Both peer-reviewed articles and grey literature (conference proceedings, master and 
doctoral dissertations) were searched. The reference lists of included studies and relevant 
reviews (if any) were additionally searched for any potentially eligible studies. 
All identified records from bibliographic databases were imported into NoteExpress (version 
3.2.0.7103) for screening. After removing duplicate records within and between databases, the 
screening process was conducted in two stages to select studies that reported data of interest: 
title and abstract screening followed by a full-text review. Generally, only studies that were 
published from January 1, 1990 onwards and conducted in China (including Mainland China, 
Hong Kong, Macao and Taiwan) were included. The specific selection criteria were not 
unified for the systematic reviews of each disease. For example, in the systematic reviews of 
AMD, glaucoma and cataract, only individual studies that were conducted in the general 
Chinese population were included. This was done to guarantee the generality of prevalence 
estimation. Given the disease nature of DR, only individual studies that were conducted in 
people with diabetes were eligible. Other selection criteria are detailed in the following 
chapters. 
The process of systematic review was conducted in accordance with the PRISMA guidelines 
and GATHER statement (Moher et al., 2009, Stevens et al., 2016). 
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2.1.2 Data extraction and quality assessment 
Relevant data were extracted from the included studies using a pilot tested and refined data 
extraction table. Generally, the extracted data included the following parts: 
(1) Characteristics of the study, including authors, year of publication, study setting, year of 
investigation, sampling method, study design, disease assessment; 
(2) Characteristics of the investigated sample, including sample size, age structure (age range, 
mean or median age, or midpoint of the age range), sex (male, female or mixed) and 
residence (urban, rural or mixed); 
(3) Prevalence data. Throughout this study, the prevalence of AREDs was defined based on 
the number of affected individuals, rather than the number of affected eyes. Wherever a 
study reported prevalence data by stratum (e.g. age group, sexes, geographic locations), 
multiple data points were extracted for different strata from the single study. 
(4) Data on risk factors. In studies where risk factors for AREDs were reported using 
multivariate logistic regression, the definition and effect (OR and corresponding 95% CI) 
of each risk factor were extracted. 
According to the Reporting of Observational Studies in Epidemiology (STROBE) guideline, 
quality of the included studies was assessed in terms of five core components-sample 
population, sample size, participation rate, outcome assessment, and analytical methods. Each 
bias component was scored as 2 for low risk, 1 for moderate risk and 0 for high risk and unclear. 
The quality of each study was represented by the total score (Table 2.1) (Von Elm et al., 2007, 
Song et al., 2018). 
Table 2.1. Quality score scale for assessing the risk of bias 
Bias type Low risk (score=2) Moderate risk (score=1) High risk (score=0) 
Selection (sample 
population) 
1) Sample from the 
general population, 




3) Rationale for case 
and control 
selection explained. 
1) Sample selected from large 
population but selection criteria 
not defined; 
2) Sample selection ambiguous but 
may be representative; 
3) Rationale for cases and controls 
not explained; 
4) Eligibility criteria not explained; 
1) Highly select population 
making it difficult to 
generalise finding; 
2) Sample selection 
ambiguous and sample 
unlikely to be 
representative. 
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Bias type Low risk (score=2) Moderate risk (score=1) High risk (score=0) 








1) Sample size calculation 
performed and reasons for not 
meeting sample size given; 
2) Sample size calculation not 
performed but all eligible persons 
studied. 
1) Sample size estimation 
unclear or only sub-
sample studied. 
Selection 
(participation rate)  
1) High response rate 
(>85%). 
1) Moderate response rate (70-85%). 1) Low response rate 
(<70%); 









1) Assessment from administrative 
database or register; 
2) Assessment from hospital record 
or interviewer. 
1) Assessment from non-
validated data or generic 




methods to control 
for bias) 
1) Analysis 
appropriate for the 




1) Analysis does not account for 
common adjustment. 
1) Data confusing. 
2.2 Meta-analysis and meta-regression 
As above stated, the extracted prevalence data were organised in a hierarchical structure. To 
take into account the wide variety of strata (e.g. age, sex and setting) reported in the literature, 
meta-regression approaches were adopted to construct stratum-specific prevalence of AREDs. 
Given that: 
prevalence = p =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑎𝑓𝑓𝑒𝑐𝑡𝑒𝑑 𝑐𝑎𝑠𝑒𝑠
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑒𝑥𝑎𝑚𝑖𝑛𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
 
Then, the prevalence estimates were stabilised by using the logit link, 
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logit(𝑝) = ln (
𝑝
1 − 𝑝











Given the disease nature of AREDs, age is the most important factor of interest, therefore the 
abovementioned equations were generally adopted to construct the relation of prevalence and 
age (the base equation). In situations where sex was a statistically significant factor for the 
development of disease after controlling the effect of age, sex could also be added into the 
base equations to generate the age- and sex-specific prevalence estimates. Similarly, this 
approach could also be used to develop regional prevalence estimates, if geographic 
characteristics (e.g., latitudes, longitudes and locations) statistically influenced the 
development of AREDs. 
However, this meta-regression approach might not be applicable to all cases. For diseases 
where only study-level prevalence data were available, a random-effects (DerSimonian and 
Laird method) meta-analysis was conducted to calculate the pooled prevalence and 95% CI 
(Barendregt et al., 2013, Higgins and Green, 2008). To evaluate the robustness of the pooled 
prevalence, a leave-one-out sensitivity analysis was conducted by removing one study at one 
time (Wallace et al., 2009). Potential publication bias was assessed by visual inspection of 
funnel plots. When the number of individual studies was ten and more, Egger's regression test 
for funnel plot asymmetry and Begg’s rank correlation test were additionally performed to 
examine the existence of publication bias (Egger et al., 1997, Begg and Mazumdar, 1994, 
Peters et al., 2006). 
2.3 Estimation of the national number of cases 
At this stage, the stratum-specific (e.g. age-specific, or age- and sex-specific) prevalence was 
applied to the corresponding stratum-specific population data, available from the UNPD 
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(United Nations Population Division) (United Nations, 2015b). This was done for the years 
1990, 2000, 2010, 2015. To account for the uncertainty in demographic projections, UNPD 
developed different scenarios by combining multiple assumptions for fertility, mortality and 
international migration. The main scenarios in UNPD population projections are the low, 
medium, and high variants, among which the medium (or standard) variant is the most likely 
scenario with medium fertility, normal mortality and normal international migration, whereas 
the low and high variants reasonably represent the corresponding lower and upper limits of 
population projections. The disparity among those three scenarios is caused by different levels 
of fertility, where the total fertility rates in the low and high scenarios are respectively one-
half child less and one-half child more than that in the medium scenario. Therefore, differences 
in population size in the low, medium, and high scenarios from 2015 to 2050 are only 
presented in people under 35 years of age (United Nations, 2015b). Given the study topic of 
AREDs, the target samples in this study are mainly middle-aged and older Chinese (≥45 
years), therefore only the most likely scenario (the medium variant) was taken to generate the 
projections of AREDs cases. In the projections of national number of cases for the years 2020, 
2030, 2040 and 2050, I applied the stratum-specific (e.g. age-specific, or age- and sex-specific) 
prevalence to the corresponding stratum-specific population data in the middle variant 
scenario. Throughout this thesis, the burden of disease refers to the number of affected cases. 
The national number of people living with AREDs in one specific year was set as the “national 
envelope” and therefore provided a basis for the subsequent “risk factor-based model” of 
regional distribution. 
2.4 Identification of potential correlates of or 
risk factors for AREDs 
The effects of different variables on AREDs prevalence were examined using the meta-
analysis of risk factor approach or the meta-regression approach. Among studies that reported 
the epidemiology of AREDs, some might explored potential risk factors for AREDs by using 
multivariate logistic regression. In the data extraction stage, those data on risk factors were 
collected and grouped by definitions. For factors that had been investigated in at least three 
individual studies, a random-effects (DerSimonian Laird method) meta-analysis was 
performed to evaluate the overall effect of a specific factor and its statistical significance. 
However, when the extracted data on potential risk factors were not sufficient for conducting 
the abovementioned meta-analysis of risk factors, a meta-regression approach, as described in 
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stage 2, was used to explore the potential correlates of AREDs. Common correlates that could 
be examined in the meta-regression approach included study-level or stratum-level 
characteristics, for example, sex, year of investigation, study setting, geography (latitudes, 
longitudes, or features associated with geographic locations). The specific approaches adopted 
in each systematic review varied and can be found in the following chapters. 
2.5 Estimation of the regional number of cases 
In this study, the subnational number of cases was generated for the six geographic regions in 
China, namely, East China, North China, Northeast China, Northwest China, South Central 
China, Southwest China (Table 2.2 and Figure 2.2) (Zhang et al., 2013, National Bureau of 
Statistics, 2012, National Bureau of Statistics, 2002). As stated in stage 4, the identification of 
potential correlates of or risk factors for AREDs could be conducted using the meta-regression 
approach or the meta-analysis of risk factor approach. In the meta-regression approach, the 
prevalence estimates in each geographic region could be directly generated by taking their 
corresponding geographic features., The sum of regional cases should be adjusted to ensure 
that the regional burden of AREDs (number of cases) exactly fit the “national envelope”. This 
was done by multiplying the regional number of cases by an “adjustment index”, which was 
calculated as follows: 
Adjustment index = 𝑁𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑎𝑠𝑒𝑠 𝑆𝑢𝑚 𝑜𝑓 𝑟𝑒𝑔𝑖𝑜𝑛𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑎𝑠𝑒𝑠⁄  
In the meta-analysis approach, a “risk factor-based model”, as initially proposed by the Child 
Health Epidemiology Reference Group (CHERG), and has, since, been adopted widely in 
disease burden research (Rudan et al., 2004, Fowkes et al., 2013, Adeloye et al., 2015), was 
carried out to split the “national envelope” into the six regions. First, the prevalence of risk 
factors, as identified in stage 4, at the national level and in each of the six geographic regions 
was obtained. The data sources varied according to the type of risk factors. Second, the 
regional number of cases was calculated using the following equation: 
𝑁𝑟𝑒𝑔𝑖𝑜𝑛 = (𝑃𝑜𝑝𝑟𝑒𝑔𝑖𝑜𝑛) ∗ (𝑃𝑟𝑒𝑣𝐴𝑅𝐸𝐷𝑠𝑛𝑎𝑡𝑖𝑜𝑛) ∗ (1




Where 𝑁𝑟𝑒𝑔𝑖𝑜𝑛 refers to the number of cases in each of the six geographic regions, 𝑃𝑜𝑝𝑟𝑒𝑔𝑖𝑜𝑛 
indicates the regional population size, 𝑃𝑟𝑒𝑣𝐴𝑅𝐸𝐷𝑠𝑛𝑎𝑡𝑖𝑜𝑛 is the estimated prevalence of AREDs 
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at the national level (stage 2), 𝑃𝑟𝑒𝑣𝑅𝐹𝑟𝑒𝑔𝑖𝑜𝑛 is the prevalence of a risk factor in one region and 
𝑃𝑟𝑒𝑣𝑅𝐹𝑛𝑎𝑡𝑖𝑜𝑛 is the national prevalence of a specific risk factor. 𝑂𝑅𝑅𝐹𝑛𝑎𝑡𝑖𝑜𝑛  is the estimated 
OR of a specific risk factor (stage 4). Finally, the regional number of cases was adjusted by 
multiplying the “adjustment index”. 
Table 2.2. The six geographical regions in China 
Region Included provinces 
North China Beijing Municipality, Hebei province, Inner Mongolia 
Autonomous Region, Shanxi province, Tianjin Municipality; 
Northeast China Heilongjiang province, Jilin province, Liaoning province; 
East China Anhui province, Fujian province, Jiangsu province, Jiangxi 
province, Shandong province, Shanghai Municipality, Zhejiang 
province; 
South Central China Guangdong province, Guangxi Zhuang Autonomous Region, 
Hainan province, Henan province, Hubei province, Hunan 
province; 
Southwest China Chongqing Municipality, Guizhou province, Sichuan province, 
Tibet Autonomous Region, Yunnan province; 
Northwest China Gansu province, Ningxia Hui Autonomous Region, Qinghai 
province, Shaanxi province, Xinjiang Uyghur Autonomous 
Region; 
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Figure 2.2. The six geographical regions in China 
2.6 Ethical self-assessment 
This study was based on publicly available and published information, thus no ethical approval 
was needed. A level-one ethical self-assessment was carried out by Dr Kit Yee Chan, based 
on institutional policy (see Appendix table 1). 
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Chapter 3 The national and subnational 
prevalence and burden of age-related 
macular degeneration in China 
3.1 Summary 
In this chapter, I applied the systematic review and meta-regression approach, as described in 
Chapter 2, to estimate the age-specific prevalence of AMD and its subtypes, namely early 
AMD and late AMD (GA and NVAMD). Overall, the prevalence of AMD and its subtypes all 
increased with advancing age. By applying the age-specific population data in China, the 
national numbers of people affected by AMD and its subtypes in China were demonstrated 
from 1990 to 2050. For any AMD, its prevalence was additionally lower in rural settings and 
decreased with increasing latitudes. Therefore, the regional prevalence and burden of any 
AMD were generated by taking the effects of age, setting and latitude.  
The work presented in this chapter has been published in the Journal of Global Health cited as 
“Song, P., Du, Y., Chan, K. Y., Theodoratou, E., Rudan, I., & on behalf of the Global Health 
Epidemiology Research Group (GHERG). (2017). The national and subnational prevalence 
and burden of age-related macular degeneration in China. Journal of Global Health, 7(2), 
020703. http://doi.org/10.7189/jogh.07.020703”.  
I was fully involved in all aspects of this project, including study design, development of 
search strategies, systematic review, data extraction, data analysis, interpretation of findings. 
I prepared the first draft of manuscript for publication, which has been subsequently revised 
for several rounds according to the comments from anonymous peer reviewers and the journal 
editors during the publishing process. The specific contributions of co-authors are as follows: 
Rudan, I. conceptualised and designed the study, Du, Y. conducted the dual systematic review 
and data extraction, Rudan, I., Chan, K. Y. and Theodoratou, E. critically reviewed the 
manuscript and approved the final manuscript. 
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3.2 Background 
Age-related macular degeneration (AMD), a degenerative disease of the macula, is a leading 
cause of severe and irreversible loss of vision globally, and most notably in developed 
countries (Lim et al., 2012, Jager et al., 2008, Wong et al., 2014). In 2010, it was estimated 
that AMD was the third most common cause of blindness, and the fourth leading cause of 
visual impairment worldwide (Pascolini and Mariotti, 2011). Although AMD is not a life-
threatening disorder, up to one-third of the affected individuals will experience various degrees 
of disability and depression during the course of the disease, even when only one eye is 
affected (Casten et al., 2004, Mitchell and Bradley, 2006). Moreover, AMD is notably 
associated with falls and other injuries, resulting in increased economic and social burden for 
the individual, caregiver and community to bear (Hassan et al., 2002, Brody et al., 2001, 
Lamoureux et al., 2010, Bonastre et al., 2002). Ageing is consistently documented as the most 
important risk factor for AMD (Wong et al., 2014, Lim et al., 2012, Bonastre et al., 2002). In 
addition, other factors, such as cigarette smoking, female sex, ethnicity, and genetic 
predisposition may also play a role (Thornton et al., 2005, Wong et al., 2014, Swaroop et al., 
2007). The combined effect of continuous exposure to different risk factors and different 
demographic ageing speed resulted in the global epidemic of AMD showing substantial 
variation across different ethnic groups and geographic regions (Wong et al., 2014, Rudnicka 
et al., 2012, Kawasaki et al., 2010, Reibaldi et al., 2016).  
The clinical course of AMD can be broadly divided into two stages: early and late (advanced) 
(De Jong, 2006, Gottlieb, 2002, Lim et al., 2012). Early AMD is characterised by soft drusen 
and/or pigmentary changes, but many early cases do not progress to the advanced form 
(Gottlieb, 2002, De Jong, 2006). Late AMD includes two types: geographic atrophy (GA) and 
neovascular (exudative) AMD (NVAMD). Compared with early AMD, late AMD is far less 
frequent but most damaging to the sight (Rickman et al., 2013). According to the latest global 
estimate of AMD prevalence, both early and late AMD were most frequent in populations of 
European ancestry (11.20% and 0.50%). Early AMD is least common in Asians (6.81%) while 
late AMD is least common in populations of African ancestry (0.28%) (Wong et al., 2014). 
With Asia having the largest share of the world’s population, and understanding that AMD is 
an age-driven disorder, it was estimated that Asia had the greatest number of people with AMD 
in 2014 (59 million). Furthermore, this number is expected to increase at the fastest pace in 
Asia in comparison to other regions - to 113 million by 2040. China, the most populous country 
in the world, is experiencing the most rapid ageing trend among all developing countries. It 
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has been estimated that more than one-third of Chinese people living in China will be aged 60 
years and over by 2050 (United Nations, 2015b). It is, therefore, important to have an up-to-
date summary of the magnitude and distribution of AMD in the general population to inform 
stakeholders and guide eye-related health policy-making and health services allocation in 
China. 
In the last two decades, an increasing number of epidemiological studies of AMD have been 
conducted in China. The estimates were, however, contingent upon the characteristics of 
individual studies: the age structure of the study sample, case definition and classification of 
AMD (Li et al., 2009, Zhou et al., 2007, Zhang et al., 2015). Another important feature of 
AMD is that its prevalence is likely to be associated with geographic factors. In the most recent 
global geo-epidemiology analysis of AMD, both latitude and longitude were inversely 
correlated with AMD prevalence, providing a new clue to study the geographic distribution of 
AMD (Reibaldi et al., 2016).  
Until recently, there were no systematic estimates of AMD prevalence in China. With that said, 
the sheer volume of data available on the prevalence of AMD in Chinese bibliographical 
databases makes it possible to summarise the prevalence and burden of AMD from a modelling 
perspective (Fung, 2008, Xia et al., 2008). Moreover, the large territory area with great 
variation of latitude and longitude in China provides a good opportunity to explore the 
influence of geographic factors within the same country. In this study, I undertook a 
comprehensive systematic review, in both Chinese and English databases, to retrieve 
population-based studies of AMD prevalence in China from 1990 onwards. Based on the 
existing evidence, I estimated and projected the prevalence and burden of AMD and its sub-
types. The aims of this study were to 1) ascertain the AMD prevalence in China by using 
epidemiological modelling; 2) estimate and project the overall prevalence and number of 
people living with AMD at the national level from 1990 to 2050; 3) estimate the regional 
prevalence and number of people with AMD from 2000 to 2010. 
3.3 Methods 
3.3.1 Systematic review 
For developing epidemiological models to estimate the prevalence of AMD and its subtypes 
in the general population, a systematic review was conducted in accordance with the Preferred 
Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and the 
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Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) statement 
(Moher et al., 2009, Stevens et al., 2016). 
3.3.1.1 Search strategy 
To ensure that all possible informative studies are included, a comprehensive literature search 
(title, abstract and keywords) was conducted in order to identify relevant studies. First, three 
Chinese bibliographic databases and three English bibliographic databases were searched from 
inception to 17 September 2016. These were the China National Knowledge Infrastructure 
(CNKI), Wanfang, Chinese Biomedicine Literature Database (CBM-SinoMed), PubMed, 
Embase and Medline. The source of studies in the three Chinese databases included journal 
articles, abstracts, dissertations and conference proceedings, whereas those in the three English 
databases included journal articles only. A combination of search terms for prevalence 
(prevalence, incidence, mortality, morbidity, epidemiology), AMD (age-related macular 
degeneration, age-related maculopathy, retina* macula* age related degeneration, retina* 
macular degeneration, macular degeneration) and China (China, Chinese, Hong Kong, Macau, 
Taiwan) was adopted for the comprehensive search. The final search strategy is presented in 
Appendix table 2. Note that the search strategy for the different bibliographic databases was 
slightly different based on the database’s specific search features. Snowball searching of 
reference lists of publications retrieved in the first step was then conducted to further identify 
studies of interest. Only studies published since 1990 were retrieved and no language 
restrictions were imposed. 
3.3.1.2 Inclusion and exclusion criteria 
Only population-based studies that quantified the prevalence of AMD were included in this 
study. This is because studies conducted at institutional sites tend to have poor 
representativeness of the surrounding general population, especially for affected people living 
in poor and rural areas where access to health is not universal. Studies that relied on self-
reported diagnosis were also excluded, due to recall bias. Studies that only reported the number 
of eyes affected by AMD, rather than the number of affected individuals, were also excluded 
because no prevalence of AMD could be derived from such studies. Duplicate publications of 
the same study were compared and the study providing more details was retained. Some 
additional criteria were also applied to ensure the quality of included studies. The detailed 
selection criteria are shown in Table 3.1. 
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Table 3.1. Selection criteria of studies on AMD prevalence in China in the systematic 
review 
Inclusion criteria 
1) Community-based study of AMD in China (including Hong Kong, Macao and 
Taiwan); 
2) Studies conducted to examine the epidemiology of AMD; 
3) Studies reported numerical prevalence measure of AMD. 
Exclusion criteria 
1) Multiple publications of the same study; 
2) Studies with no professional assessment methods or relied on self-reported diagnoses; 
3) Studies that were conducted in a group of people with characteristics that were clearly 
unrepresentative, e.g. those with visual impairment, diabetic patients; 
4) Studies with inconsistencies between reported methods and presented results. 
3.3.1.3 Study selection and data extraction 
Before reviewing the retrieved records, duplicates were removed manually. Records were 
screened for relevance in two stages: screening of titles and abstracts followed by the retrieval 
and check of full-text articles. All non-English or non-Chinese language documents were 
reviewed after translation into English by Google Translate. The quality of each included study 
was assessed in terms of five core components-sample population, sample size, participation 
rate, outcome assessment, and analytical methods. Each bias component was scored as 2 for 
low risk, 1 for moderate risk and 0 for high risk and unclear. The quality of each study was 
represented by the total score (Table 2.1) (Von Elm et al., 2007, Song et al., 2018). For studies 
that fulfilled the criteria, three main categories of data were extracted: characteristics of the 
study, characteristics of the investigated population, and prevalence estimates of AMD and its 
subtypes. The data extraction tables were pilot tested on ten randomly selected included studies 
and refined accordingly before the final extraction.  
The final data extraction table included:  
1) Characteristics of the study: authors, publication year, study setting, year of survey, 
sampling method, study design (cross-sectional or cohort), AMD assessment method, 
and AMD grading system; 
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2) Characteristics of the investigated population: number of the sample, population type 
(urban, rural or mixed), sex (male, female or mixed), and age (age range, mean or 
median age, or midpoint of the age range); 
3) Prevalence data: number of people with AMD and the number of participants who had 
been tested, by age group, sex, setting and AMD subtype where available. 
The geographic indicators of interest (latitude, longitude and average annual insolation) were 
assigned to each study accordingly. The latitude and longitude data were obtained using 
Google Maps GPS coordinates (http://www.gps-coordinates.net/). The average annual 
insolation data (i.e., the amount of solar radiation incident on the surface of the earth) on the 
horizontal surface, expressed in kWh/m2/day, was obtained from the National Aeronautics and 
Space Administration (NASA) Atmospheric Science Data Centre 
(http://eosweb.larc.nasa.gov/sse/). When study settings were defined as larger regions, such as 
at provincial, or regional levels, the mean centre point of the setting was calculated and the 
corresponding geographic data of the centre point was used. Studies that reported raw 
prevalence data in more than one geographic area (e.g. a single study presented prevalence of 
AMD for three different cities) were recorded separately for each geographic area. For studies 
that reported aggregated AMD prevalence data for different geographic areas, the average 
geographic data of the different areas were calculated and recorded. For studies with missing 
data of survey year, three years were subtracted from the published year to impute the survey 
year, which was based on the average time from survey to publication in studies with available 
data (see Appendix table 3). In studies where censoring age groups were reported, e.g. older 
than 80 years, the missing age band was taken as the same width as other age groups in the 
same study.  
The classification systems used to define AMD and its subtypes include the Wisconsin age-
related maculopathy grading system (WARMGS) (Klein et al., 1991), the International 
Classification and Grading system (IC) (Bird et al., 1995), the Clinical Age-Related 
Maculopathy Grading System (CARMS) (Seddon et al., 2006), and the “Age-related Macular 
Degeneration Clinical Diagnosis Standard” proposed by the China Medical Association in 
1986 (CMA1986) (China Medical Association, 1987). For studies adopting different 
classification systems, the prevalence of any AMD, early AMD, late AMD, which included 
GA and NVAMD, was extracted or calculated (if necessary) separately according to the 
definitions below: 
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1) Early AMD: any soft drusen (distinct or indistinct) and pigmentary abnormalities, or 
large soft drusen 125 μm or more in diameter with a large drusen area (>500 μm 
diameter circle) or large soft indistinct drusen in the absence of signs of late-stage 
disease; 
2) Late AMD: the presence of geographic atrophy or pigment epithelial detachment, 
subretinal haemorrhage or visible subretinal new vessel, or subretinal fibrous scar or 
laser treatment scar. 
3.3.2 Statistical analysis 
3.3.2.1 Epidemiological modelling of AMD prevalence 
Due to high heterogeneity between studies that reported prevalence rates for any AMD, early 
AMD, late AMD, GA and NVAMD (Appendix table 4), random-effects models were adopted 
throughout the analysis. In the data3 extraction process, data were stratified by age, sex and 
setting. Some studies provided more than one data point. To take this hierarchical data 
structure into account, a multilevel mixed-effect meta-regression was conducted (Hox et al., 
2010, Viechtbauer, 2010). Given that:  




Then, the binomial distribution of prevalence rates was transferred to the normal distribution 
by using the logit link: 
logit(𝑝) = log𝑒 (
𝑝
1 − 𝑝
) = log𝑒(𝑜𝑑𝑑𝑠) = 𝛼 + 𝛽1 ∗ 𝑥1 + 𝛽2 ∗ 𝑥2 + ⋯ 𝛽𝑛 ∗ 𝑥𝑛 
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3.3.2.2 Estimation of national number of people with AMD 
from 1990 to 2015 
To develop the overall “envelope” of AMD cases in China from 1990 to 2015, five models 
were first developed to establish the prevalence of any AMD, early AMD, late AMD, GA and 
NVAMD as a function of age: 
logit(𝑝) = 𝛼 + 𝛽1 ∗ (𝑎𝑔𝑒) 





The total number of AMD cases (“envelope”) in China was calculated by multiplying the age-
specific prevalence of AMD for each 5-year age group estimated in the above models with the 
corresponding 5-year population subgroups in China, available from the United Nations 
Population Division (UNPD) (United Nations, 2015b). This was performed for any AMD, 
early AMD, late AMD, GA and NVAMD separately in the years 1990, 2000, 2010 and 2015. 
3.3.2.3 Effects of demographic and geographic factors on the 
prevalence of AMD 
To investigate whether study-level demographic and geographic factors might affect the 
prevalence of AMD, variables of interest were added into the multilevel mixed-effect meta-
regression to test the significance (Higgins and Green, 2008). As a rule, at least seven data 
points should be available for each variable (Vittinghoff and McCulloch, 2007). These 
variables included sex, setting, latitude, longitude and average annual insolation. Investigation 
year was also tested so as to assess if there were any significant time trends. All variables that 
individually associated AMD prevalence in univariable analyses were included in the 
subsequent multivariable regression model, where variables that were not statistically 
significant were removed, starting from the one with the highest p value. 
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3.3.2.4 Projection of national number of people with AMD 
from 2020 to 2050 
For the projection to the year 2050, age-specific prevalence rates of AMD were assumed to be 
constant over the next 34 years, the number of individuals with AMD from 2020 to 2050 was 
calculated by multiplying the age-specific prevalence rates to the corresponding UNPD 
Prospects data in the medium scenario (United Nations, 2015b). 
3.3.2.5 Estimation of regional number of people with AMD 
from 2000 to 2010 
Based on the final multivariable regression models that take the effects of demographic and 
geographic factors into consideration, the estimated national AMD cases were distributed into 
six geographical regions, namely, East China, North China, Northeast China, Northwest China, 
South Central China, Southwest China (Table 2.2 and Figure 2.2) (Zhang et al., 2013, 
National Bureau of Statistics, 2012, National Bureau of Statistics, 2002). This method was 
initially proposed by the Child Health Epidemiology Reference Group (CHERG), and has, 
since, been adopted widely in disease burden research (Rudan et al., 2004, Fowkes et al., 2013, 
Adeloye et al., 2015). First, AMD prevalence in each geographic region was calculated, based 
on the final regression equation. Second, the regional number of people with AMD was 
estimated by multiplying the regional AMD prevalence and corresponding population for the 
years 2000 and 2010, where regional population data were available from the fifth and sixth 
census (National Bureau of Statistics, 2002, National Bureau of Statistics, 2012). Finally, the 
regional AMD cases were adjusted to fit the national AMD “envelope”.  
The overall study design is shown in Figure 3.1. Non-dichotomous variables were analysed 
as continuous. A two-sided p value less than 0.05 was regarded as statistically significant for 
all analyses. All statistical analyses were performed in R Studio (version 1.0.136) built on R 
(version 3.3.0). All included studies in the analysis were mapped by ArcGIS software (Version 
10.1). The China base map was obtained as a shapefile from the Global Administrative Areas 
(GADM) database (GADM, 2015, version 2.0; www.gadm.org). 
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Figure 3.1. Overall study design flowchart for the prevalence and burden of AMD study 
in China 
3.4 Results 
3.4.1 Summary of systematic review 
Figure 3.2 shows the process of systematic review for studies included in the final meta-
analysis. In brief, the initial search identified 2016 citations. After removing 750 duplications, 
986 apparently irrelevant citations by title and abstract review, and 15 citations with no 
sufficient information on methods and results, 265 papers were reviewed at the full-text level 
to assess their eligibility. Ultimately, 25 AMD prevalence studies were included in the final 
analysis. 
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Figure 3.2. Systematic review flow diagram of studies on AMD prevalence in China 
Note: *Reason 1-Articles with no numerical measures of AMD prevalence; *Reason 2-Studies 
that were not population-based; *Reason 3-Multiple publications of the same study; *Reason 
4-Studies that were not based in China; *Reason 5-Studies that had no professional 
assessment methods or relied on self-reported diagnoses; *Reason 6-Studies that were 
conducted in people with unrepresentative characteristics of general population (hypertensive 
patients, people with reduced vision, etc.); *Reason 7- Articles with inconsistency between 
reported methods and presented results. 
A full list of included studies is shown in Appendix table 5, the included data involved 3016 
AMD cases in a total of 43420 examined individuals. Table 3.2 shows the main characteristics 
of the studies. The detailed characteristics and quality score of every study can be found in 
Appendix table 6 and Appendix table 7. All included studies were cross-sectional studies 
that assessed AMD by using fundus imaging. Almost half of the retained studies were 
published in the past six years (44.0%), with CMA1986 the most widely adopted grading 
system (48.0%), followed by WARMGS (24.0%) and CARMS (20.0%). All the included 
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studies were with an overall quality score of at least 6. The geographic distribution of the 25 
included studies is demonstrated in Figure 3.3. 
Table 3.2 Main characteristics of the included studies on AMD prevalence in China 
(n=25) 
Characteristic Number of studies (%) 
Year published  
1990-1999 7 (28.0) 
2000-2009 7 (28.0) 
2010-2016 11 (44.0) 
Setting  
Urban 7 (28.0) 
Rural 9 (36.0) 
Mixed 9 (36.0) 
Sample size  
600-1000 5 (20.0) 
1001-2000 5 (20.0) 
2001-3000 7 (28.0) 
3001-5000 4 (16.0) 
5001-8000 4 (16.0) 
Grading system  
CMA1986 12 (48.0) 
WARMGS 6 (24.0) 
CARMS 5 (20.0) 
IC 1 (4.0) 
Other 1 (4.0) 
Quality score  
10 6 (24.0) 
9 8 (32.0) 
8 4 (16.0) 
7 2 (8.0) 
6 5 (20.0) 
Note: CAM 1986, the “Age-related Macular Degeneration Clinical Diagnosis Standard” 
proposed by the China Medical Association in 1986; WARMGS, the Wisconsin age-related 
maculopathy system; CARMS, the Clinical Age-Related Maculopathy Grading System; IC, the 
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International Classification and Grading system; Other, definition in the "Ophthalmology" 
(7th version). 
 
Figure 3.3. Geographic distribution of the included studies on AMD prevalence in China 
3.4.2 Age-specific prevalence of AMD 
In each model (Figure 3.4), a substantial number of data points were available for constructing 
the relationship between AMD prevalence and age. The age spectrum ranged from around 35 
years to less than 90 years. However, for GA and NVAMD, few data points were available at 
younger ages (30-40 years). In this study, to ensure that the estimated prevalence was 
comparable, the lower bound of age range was set as 45 years and the upper bound as 89 years 
where data were available for model construction at all AMD subtype groups. 
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Figure 3.4. Prevalence of AMD and its subtypes by age in retained studies 
Note: The size of each bubble is proportional to the sample size. There were 124 data points 
for constructing the relation between prevalence and age for any AMD, 67 for early AMD, 67 
for late AMD, 35 for GA and 54 for NVAMD. 
The estimated age-specific prevalence of any AMD, early AMD, late AMD, GA and NVAMD 
is shown in Figure 3.5 and Table 3.3. The prevalence of any AMD ranged from 2.44% (95% 
CI: 1.85-3.22) in people aged 45-49 years to 18.98% (95% CI: 15.05-23.66) in people aged 
85-89 years. Prevalence of early AMD ranged from 1.79% (95% CI: 1.05-3.02) to 10.05% 
(95% CI: 6.17-15.97), and, in the case of late AMD, from 0.38% (95% CI: 0.16-0.97) to 3.88% 
(95% CI: 1.68-9.13). In late AMD, the prevalence of GA was 0.15% (95% CI: 0.05-0.47) in 
people aged 45-49 years and 1.09% (95% CI: 0.35-3.36) in those aged 85-89 years, and the 
prevalence of NVAMD ranged between 0.24% (95% CI: 0.11-0.50) and 2.79% (95% CI: 1.33-
5.77). 
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Figure 3.5. Estimated age-specific prevalence of AMD and its subtypes in China, with 
95% confidence intervals 
Table 3.3. Estimated age-specific prevalence of AMD and its subtypes in China 
Age 
group 
Any AMD Early AMD Late AMD GA NVAMD 
45-49 
years 
2.44  1.79  0.38  0.15  0.24  
(1.85-3.22) (1.05-3.02) (0.16-0.97) (0.05-0.47) (0.11-0.50) 
50-54 
years 
3.21  2.23  0.51  0.19  0.32  
(2.45-4.19) (1.32-3.74) (0.22-1.24) (0.06-0.58) (0.16-0.67) 
55-59 
years 
4.20  2.78  0.68  0.24  0.44  
(3.22-5.45) (1.67-4.62) (0.30-1.60) (0.08-0.72) (0.22-0.89) 
60-64 
years 
5.47  3.47  0.91  0.31  0.60  
(4.23-7.06) (2.09-5.71) (0.41-2.09) (0.11-0.90) (0.30-1.19) 
65-69 
years 
7.11  4.31  1.22  0.40  0.82  
(5.52-9.12) (2.61-7.05) (0.55-2.76) (0.14-1.15) (0.41-1.60) 
70-74 
years 
9.20  5.36  1.63  0.52  1.11  
(7.17-11.72) (3.26-8.68) (0.74-3.67) (0.18-1.48) (0.56-2.19) 
75-79 
years 
11.81  6.63  2.18  0.66  1.52  
(9.26-14.96) (4.05-10.68) (0.98-4.94) (0.23-1.93) (0.76-3.01) 
80-84 
years 
15.05  8.18  2.91  0.85  2.06  
(11.85-18.92) (5.01-13.09) (1.29-6.70) (0.28-2.54) (1.01-4.16) 
85-89 
years 
18.98  10.05  3.88  1.09  2.79  
(15.05-23.66) (6.17-15.97) (1.68-9.13) (0.35-3.36) (1.33-5.77) 
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Note: Data are % (95% CI). 
3.4.3 National number of people with AMD from 1990 
to 2015 
By applying the age-specific prevalence of AMD to the national population in 1990, 2000, 
2010 and 2015, the number of people living with AMD in China was estimated (Appendix 
table 8). During this period, the national prevalence of any AMD slightly decreased by 0.41%, 
from 5.26% (95% CI: 4.07-6.76) in 1990 to 5.24% (95% CI: 4.05-6.73) in 2015. This declining 
trend was also witnessed in early AMD and late AMD, with decreasing rates of 0.50% and 
0.07% respectively. In late AMD, GA also showed a decreasing trend within this time frame, 
whereas the prevalence of NVAMD increased slightly (Table 3.4). Despite this decreasing 
prevalence trend during 1990-2015, the overall number of people with any AMD or its 
subtypes all increased dramatically due to the rapidly ageing population. The national number 
of people with any AMD increased by 121.80%, from 12.01 million (95% CI: 9.29-15.46) in 
1990 to 26.65 million (95% CI: 20.62-34.27) in 2015. Within the same period, the number of 
people with early AMD increased from 9.44 million (95% CI: 7.74-11.15) to 20.91 million 
(95% CI: 17.16-24.68), and those with late AMD rose from 2.58 million (95% CI: 1.56-4.30) 
to 5.74 million (95% CI: 3.46-9.59), which yielded increasing rates of 121.60% and 122.55% 
respectively. In late AMD, increase in the number of people living with GA was similar to 
those with NVAMD (121.99% vs. 122.84%), which ranged from 0.87 million (95% CI: 0.40-
1.83) to 1.93 million (95% CI: 0.89-4.08), and 1.71 million (95% CI: 1.16-2.47) to 3.81 million 
(95% CI: 2.57-5.51) throughout this time frame respectively (Table 3.4). In 2015, the age 
group that contributed the most cases of any AMD, early AMD, late AMD, GA and NVAMD 
was 60-64 years (Figure 3.6). 
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Table 3.4. Estimated prevalence and number of people living with AMD in China from 1990 to 2015, by AMD type 
AMD type 
Prevalence of AMD 
(%, 95% CI) 
Number of people with AMD (million, 95% CI) 
Relative rate of change 
(%, 1990-2015) 
1990 2000 2010 2015 1990 2000 2010 2015 Prevalence AMD cases 
Any AMD 
5.26  5.16 5.24 5.24  12.01  16.31  22.43 26.65  
-0.41 +121.80 
(4.07-6.76) (3.99-6.64) (4.05-6.73) (4.05-6.73) (9.29-15.46) (12.62-20.99) (17.36-28.85) (20.62-34.27) 
Early AMD 
4.13  4.05 4.11 4.11  9.44  12.81  17.60 20.91  
-0.50 +121.60 
(3.39-4.88) (3.33-4.79) (3.37-4.85) (3.37-4.85) (7.74-11.15) (10.51-15.13) (14.45-20.78) (17.16-24.68) 
Late AMD 
1.13  1.11 1.13 1.13  2.58  3.50 4.83 5.74  
-0.07 +122.55 
(0.68-1.88) (0.67-1.85) (0.68-1.88) (0.68-1.88) (1.56-4.30) (2.11-5.86) (2.91-8.07) (3.46-9.59) 
GA 
0.38  0.37 0.38 0.38  0.87  1.18 1.62 1.93  
-0.33 +121.99 
(0.17-0.80) (0.17-0.79) (0.17-0.80) (0.17-0.80) (0.40-1.83) (0.54-2.50) (0.75-3.43) (0.89-4.08) 
NVAMD 
0.75  0.74 0.75 0.75  1.71  2.32 3.21 3.81  
+0.05 +122.84 
(0.51-1.08) (0.50-1.06) (0.50-1.08) (0.51-1.08) (1.16-2.47) (1.57-3.36) (2.16-4.64) (2.57-5.51) 
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Figure 3.6. Estimation of the national number of people with AMD and contributing age 
groups in China from 1990 to 2015, by AMD type 
3.4.4 Effects of demographic and geographic factors 
on the prevalence of AMD 
Findings from the univariable meta-regression analyses (Table 3.5) showed that age, setting 
and latitude were significantly associated with the prevalence of any AMD. For early AMD, 
age, sex, setting and latitude also had a significant influence on the prevalence. For late AMD, 
age and latitude were found to be significantly associated with the prevalence. However, in 
late AMD, only age was found to be significantly associated with the prevalence of GA, and 
age, sex, latitude and insolation were significantly associated with the prevalence of NVAMD. 
For any AMD and all subtypes, the investigation year was identified to have no influence on 
prevalence rates and increased age was the only constantly significant risk factor. 
Table 3.5. Meta-regression of AMD prevalence (logit form), univariable analyses 
Variable Number of studies β (95 % CI) p value 
Any AMD    
Intercept 25 [-2.489] ([-2.764]-[-2.215]) <0.001 
Age 25 0.056 (0.052- 0.060) <0.001 
Sex-male$ 19 0.069 ([-0.004]-0.141) 0.063 
Setting-rural 16 [-0.829] ([-1.304]-[-0.354]) <0.001 
Latitude 25 [-0.076] ([-0.119]-[-0.033]) <0.001 
Longitude 25 0.023 ([-0.017]-0.064) 0.262 
Insolation 25 [-0.551] ([-1.132]-0.030) 0.063 
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Variable Number of studies β (95 % CI) p value 
Investigation year 25 [-0.014] ([-0.045]-0.017) 0.370 
Early AMD    
Intercept 10 [-2.982] ([-3.528]-[-2.436]) <0.001 
Age 10 0.045 (0.039-0.052) <0.001 
Sex-male$ 7 0.197 (0.054-0.339) 0.007 
Setting-rural 7 [-1.037] ([-1.833]-[-0.241]) 0.011 
Latitude 10 [-0.127] ([-0.181]-[-0.072]) <0.001 
Longitude 10 0.052 ([-0.033]-0.137) 0.233 
Insolation 10 [-0.864] ([-2.155]-0.428) 0.190 
Investigation year 10 0.003 ([-0.103]-0.109) 0.954 
Late AMD    
Intercept 10 [-4.548] ([-5.308]-[-3.787]) <0.001 
Age 10 0.071 (0.055-0.088) <0.001 
Sex-male$ 7 0.321 ([-0.053]-0.696) 0.093 
Setting-rural 7 [-0.229] ([-1.715]-1.257) 0.763 
Latitude 10 [-0.167] ([-0.247]-[-0.086]) <0.001 
Longitude 10 0.045 ([-0.078]-0.169) 0.472 
Insolation 10 0.066 ([-1.915]-2.046) 0.948 
Investigation year 10 0.054 ([-0.090]-0.198) 0.464 
GA    
Intercept 6 [-5.517] ([-6.557]-[-4.478]) <0.001 
Age 6 0.050 (0.028-0.072) <0.001 
Sex-male$ 2 0.089 ([-0.449]-0.627) 0.746 
Setting-rural 4 1.261 ([-0.734]-3.255) 0.215 
Latitude 6 [-0.048] ([-0.274]-0.179) 0.681 
Longitude 6 [-0.115] ([-0.280]-0.050) 0.173 
Insolation 6 [-1.522] ([-3.914]-0.871) 0.213 
Investigation year 6 0.081 ([-0.105]-0.266) 0.394 
NVAMD    
Intercept 15 [-4.756] ([-5.360]-[-4.152]) <0.001 
Age 15 0.063 (0.046-0.079) <0.001 
Sex-male$ 6 0.376 (0.070-0.682) 0.016 
Setting-rural 9 0.433 ([-0.827]-1.693) 0.501 
Latitude 15 0.074 ([-0.061]-0.209) 0.282 
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Variable Number of studies β (95 % CI) p value 
Longitude 15 [-0.078] ([-0.142]-[-0.014]) 0.017 
Insolation 15 0.973 (0.290-1.656) 0.005 
Investigation year 15 [-0.057] ([-0.133]-0.020) 0.149 
Note: $ the estimate of sex effect was based on studies that provided AMD prevalence for both 
males and females; coefficients represent log odds ratios (ORs). 
Although most studies provided multiple data points of prevalence rates, these data were 
mainly stratified by age groups. For AMD subtype groups (early AMD, late AMD, GA and 
NVAMD), and after controlling the difference of age structures, insufficient data were 
available for conducting multivariable meta-regression that simultaneously included all 
statistically significant factors identified in the univariable analyses. Thus, here the 
multivariable regression model was only conducted and reported for any AMD. The formula 
generated from the multivariable regression is shown below: 
logit(𝑝) = −4.230 + 0.056 ∗ 𝑎𝑔𝑒 + (−0.6013) ∗ 𝑠𝑒𝑡𝑡𝑖𝑛𝑔𝑟𝑢𝑟𝑎𝑙 + 0.053 ∗ 𝑠𝑒𝑡𝑡𝑖𝑛𝑔𝑢𝑟𝑏𝑎𝑛
+ (−0.060) ∗ 𝑙𝑎𝑡𝑖𝑡𝑢𝑑𝑒 + 𝑢𝑖 
Where 𝑝  indicates the prevalence of any AMD; 𝑠𝑒𝑡𝑡𝑖𝑛𝑔𝑟𝑢𝑟𝑎𝑙 =1 for rural setting and =0 
otherwise; 𝑠𝑒𝑡𝑡𝑖𝑛𝑔𝑢𝑟𝑏𝑎𝑛=1 for urban setting and =0 otherwise; 𝑙𝑎𝑡𝑖𝑡𝑢𝑑𝑒 refers to the absolute 
value of latitude; 𝑢𝑖=variance of the study level random effect. 
3.4.5 Projection of national number of people with 
AMD from 2020 to 2050 
No secular trend of the prevalence of any AMD, early AMD, late AMD, GA and NVAMD 
was observed in the included studies, thus age-specific prevalence was assumed as constant 
for the projection analysis. By applying the age-specific prevalence of AMD to the national 
population in 2020, 2030, 2040 and 2050, the numbers of people with AMD were projected 
(Appendix table 8). Unlike the slightly fluctuating trend of AMD prevalence from 1990 to 
2015, the prevalence rates of all subtypes of AMD will increase notably during 2020 and 2050. 
In 2020, the prevalence of any AMD will be 5.39% (95% CI: 4.18-6.93) and is expected to 
increase by 41.66%, reaching to 7.64% (95% CI: 5.96-9.73) in 2050. Among all subtypes of 
AMD, NVAMD will show the greatest increasing rate of 57.48%, from 0.78% (95% CI: 0.52-
1.12) in 2020 to 1.22% (95% CI: 0.83-1.75) in 2050, whereas the increasing rate of early AMD 
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will be the smallest (38.45%), from 4.23% (95% CI: 3.47-4.99) to 5.21% (95% CI: 4.31-6.08) 
during this period (Table 3.6). 
From 2020 to 2050, the number of cases of any AMD in China will rise by 76.72%, from 31.23 
million (95% CI: 24.18-40.14) to 55.19 million (95% CI: 43.04-70.30). The increasing rate of 
late AMD cases will be greater than that of early AMD cases (91.12% vs. 72.70%), with the 
number of people affected by early AMD increasing from 24.47 million (95% CI: 20.10-28.87) 
in 2020 to 42.26 million (95% CI: 35.15-49.05) in 2050, and those affected by late AMD from 
6.76 million (95% CI: 4.08-11.28) to 12.92 million (95% CI: 7.89-21.26). In late AMD, the 
number of people with GA will increase by 80.78%, from 2.26 million (95% CI: 1.04-4.78) in 
2020, to 4.09 million (95% CI: 1.89-8.59) in 2050. Furthermore, the number of those with 
NVAMD will grow even further (96.45%), from 4.50 million (95% CI: 3.04-6.50) to 8.84 
million (95% CI: 6.00-12.66) (Table 3.6). From 2020 to 2050, the age groups to contribute 
the most cases will shift from 65-69 years to 80-84 years for any AMD, late AMD, GA and 
NVAMD, and from 65-69 years to 75-79 years for early AMD (Figure 3.7). 
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Table 3.6. Projected prevalence and number of people living with AMD in China from 2020 to 2050, by AMD type 
AMD type 
Prevalence of AMD (%, 95% CI) Number of people with AMD (million, 95% CI) 
Relative rate of change 
(%, 2020-2050) 




5.39 6.15 6.75 7.64 31.23 40.40 50.22 55.19 
+41.66 +76.72 
(4.18-6.93) (4.77-7.88) (5.25-8.62) (5.96-9.73) (24.18-40.14) (31.36-51.78) (39.07-64.18) (43.04-70.30) 
Early AMD 
4.23 4.78 5.21 5.85 24.47 31.42 38.78 42.26 
+38.45 +72.71 
(3.47-4.99) (3.94-5.62) (4.31-6.08) (4.87-6.79) (20.10-28.87) (25.90-36.90) (32.10-45.28) (35.15-49.05) 
Late AMD 
1.17 1.37 1.54 1.79 6.76 8.98 11.45 12.92 
+53.28 +91.21 
(0.70-1.95) (0.83-2.26) (0.94-2.54) (1.09-2.94) (4.08-11.28) (5.45-14.87) (6.97-18.9) (7.89-21.26) 
GA 
0.39 0.45 0.50 0.57 2.26 2.95 3.69 4.09 
+44.92 +80.78 
(0.18-0.83) (0.21-0.94) (0.23-1.04) (0.26-1.19) (1.04-4.78) (1.36-6.20) (1.71-7.76) (1.89-8.59) 
NVAMD 
0.78 0.92 1.04 1.22 4.50 6.03 7.76 8.84 
+57.48 +96.45 
(0.52-1.12) (0.62-1.32) (0.71-1.50) (0.83-1.75) (3.04-6.50) (4.09-8.67) (5.26-11.13) (6.00-12.66) 
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Figure 3.7. Projection of the national number of people with AMD and contributing age 
groups in China from 2020 to 2050, by AMD type 
3.4.6 Regional number of people with any AMD from 
2000 to 2010 
The total numbers of AMD cases in China in 2000 and 2010 were distributed across the six 
geographical regions according to the final multivariable model that took into account three 
main factors: age, setting and latitude (Appendix table 9). In 2000, the national prevalence of 
AMD in China was 5.16% (95% CI: 3.99-6.64), with the regional prevalence estimates ranging 
from 2.69% (95% CI: 1.67-4.29) in North-East China to 6.64% (95% CI: 5.12-8.52) in South 
Central China. In 2010, the prevalence was still the highest in South Central China (6.74% 
[95% CI: 5.20-8.65]) and the lowest in North-East China (2.65% [95% CI: 1.66-4.20]), with 
the overall prevalence in Chinese population increasing to the level of 5.24% (95% CI: 4.05-
6.73). During 2000 to 2010, the overall prevalence of AMD increased by 1.44%, and the most 
marked increase was in Southwest China (6.51%) while the prevalence rate of AMD declined 
by 1.37% in North-East China (Table 3.7). 
Table 3.7. Estimated prevalence and number of people living with any AMD in China 
from 2000 to 2010, by geographical region 
Region 
Prevalence of any AMD 
(%, 95% CI) 
Number of people with any 
AMD (million, 95% CI) 
Relative rate of change 
(%, 2000-2010) 
2000 2010 2000 2010 prevalence AMD cases 
North China 
3.28  3.36  1.23  1.82  
+2.40 +48.18 
(2.35-4.55) (2.42-4.64) (0.88-1.70) (1.31-2.51) 
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Region 
Prevalence of any AMD 
(%, 95% CI) 
Number of people with any 
AMD (million, 95% CI) 
Relative rate of change 
(%, 2000-2010) 
2000 2010 2000 2010 prevalence AMD cases 
North-East China 
2.69  2.65  0.76  1.11  
-1.37 +46.70 
(1.67-4.29) (1.66-4.20) (0.47-1.21) (0.69-1.76) 
East China 
5.46  5.57  5.32  7.33  
+1.99 +37.67 
(4.39-6.74) (4.49-6.86) (4.29-6.57) (5.91-9.04) 
South Central China 
6.64  6.74  5.50  7.52  
+1.54 +36.74 
(5.12-8.52) (5.20-8.65) (4.24-7.05) (5.80-9.64) 
South-West China 
5.68  6.05  2.85  3.70  
+6.51 +29.97 
(4.50-7.11) (4.81-7.56) (2.26-3.56) (2.94-4.62) 
North-West China 
3.29  3.40  0.66  0.95  
+3.23 +44.65 
(2.44-4.43) (2.53-4.55) (0.49-0.89) (0.71-1.28) 
China 
5.16  5.24  16.31  22.43  
+1.44 +37.50 
(3.99-6.64) (4.05-6.73) (12.62-20.99) (17.36-28.85) 
Estimates of the number of people living with AMD in different regions are shown in Table 
3.7 and Figure 3.8. With the ageing trend of the Chinese population, the total number of people 
living with AMD in China increased by 37.50%, from 16.31million (95% CI: 12.62-20.99) in 
2000 to 22.43 million (95% CI: 17.36-28.85) in 2010. In 2000, more than one-third (33.72%) 
of Chinese AMD cases were found living in South Central China (5.50 million [95% CI: 4.24-
7.05]) and only 4.05% were in North-West China (0.66 million [95% CI: 0.49-0.89]). In 2010, 
this distribution of AMD cases remained the same across the six geographical regions, with 
most (33.53%) of the AMD cases in South Central China (7.52 million [95% CI: 4.24-7.05]) 
and the least (4.24%) in North-West China (0.95 million [95% CI: 0.71-1.28]). From 2000 to 
2010, the most striking increases in the number of AMD cases were in North China (48.64%) 
and North-East China (47.06%), and the least in South-West China (29.97%). In 2010, the age 
groups that contributed the most AMD cases was 55-59 years in all of the six geographic 
regions. 
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Figure 3.8. Estimation of the regional number of people with any AMD and contributing 
age groups in China from 2000 to 2010 
3.5 Discussion 
3.5.1 Statement of principal findings 
In this systematic review and meta-analysis, data-driven estimates and projections of AMD 
prevalence and burden in China were presented, both at the national level and at the regional 
levels. The results from this synthesised population-based data show that the burden of AMD 
in China is substantial. From 1990 to 2015, the prevalence of AMD fluctuated at around 5.2%, 
which translates to a total of 26.65 million affected individuals in 2015. By 2050, the 
prevalence of AMD is expected to increase to 7.64%, with the corresponding number of 
affected individuals to 55.19 million. Substantial regional variation was found across the 
country, with AMD prevalence being the highest in South Central China and the lowest in the 
North-East. In terms of the total number of AMD cases, the greatest burden was in the South 
Central area, and the smallest in North-West China.  
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3.5.2 Strengths and limitations 
To the best of my knowledge, this study is the first attempt to estimate the prevalence and the 
burden of AMD in China and to make future projections. The comprehensive search strategies 
and strict inclusion and exclusion criteria ensured a well-designed analysis. Furthermore, the 
current study provided estimates of the prevalence and the number of affected AMD cases by 
AMD subtype, with this additional information being of particular clinical and public health 
relevance. Indeed, such information offers valuable, detailed insights into the burden of AMD 
in China. Critically, this study used the best available data to portray a complete picture of the 
public health burden of AMD in different regions. Therefore, it can serve as the basis for health 
policy making and resource allocation for AMD prevention and treatment initiatives. From a 
global perspective, this study complements the most recent Global AMD study, where 
insufficient data were available for national estimates and projections (Wong et al., 2014). 
However, this study is not free from limitations. First, significant heterogeneity existed 
between all of the included studies, despite the strict inclusion and exclusion criteria applied. 
Like any meta-analysis, the findings of this study are only as good as the included primary 
investigations. Included studies did not come from across the country, thus the ability to 
generate provincial estimates of AMD prevalence and cases may be limited. Second, one 
NVAMD-like disease, polypoidal choroidal vasculopathy, is markedly more common in 
Asians (Wong et al., 2014, Liu et al., 2007, Lee et al., 2009), and taking into consideration that 
most population-based studies may have limited ability to distinguish between these two 
diseases (as suggested previously (Wong et al., 2014)), the prevalence and burden of NVAMD 
in the current study may be overestimated. In addition, as suggested by a previous meta-
analysis, studies using fundus imaging with classifications, rather than the internationally 
recognised grading systems, are more likely to diagnose late AMD (Rudnicka et al., 2012). In 
this study, almost half of the included studies adopted the grading system proposed by the 
Chinese Medical Association, which may also have contributed to the peculiarly elevated 
prevalence rate of late AMD. A further point to raise is that only a limited set of variables were 
included and explored in the meta-regression analysis. This means that there could have also 
been further explanatory variables that may influence the presence of AMD. Moreover, the 
included demographic and geographic variables were mainly aggregate level data, and 
although efforts were made to extract data stratified by age, sex and location, the variation at 
the individual level may still be hidden. This may include smoking exposure, the habit of 
wearing sunglasses, and others. A further limitation of the study is that the estimates of 
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regional prevalence and burden of AMD were based on the assumption that the pooled 
prevalence estimate for a specific region was homogeneous across all included provinces 
within this region, but this is quite unrealistic. Additionally, for regions that contributed only 
a few, or no actual AMD prevalence data points to the model, the model-based estimates may 
diverge quite considerably from the true prevalence. Finally, as reported in both previous 
reviews and substantiated in the current study, the prevalence of AMD and all its subtypes was 
stable over time (Rudnicka et al., 2012, Wong et al., 2014). Based on this assumption, the 
projections of the national prevalence and burden of AMD were actually based on the model-
based age-specific prevalence and demographic changes during the next three decades. 
Thereby, the uncertainty of these projections may be largely dependent on the accuracy of age-
specific prevalence model and the UNPD population projection. Bearing these limitations in 
mind, estimates presented in the current study should be interpreted judiciously. 
3.5.3 Interpretation of findings 
In this study, the overall prevalence of AMD among the Chinese population was lower than 
the estimates in the Global AMD study, which reported an overall AMD prevalence of 6.86% 
in people living in Asia (Wong et al., 2014). In the Global AMD study, the prevalence 
estimates for Asia were based on eleven studies conducted across Asia, among which, six 
came from South Asia (India, Singapore, and Thailand), three from China and two from Japan. 
Given the fact that AMD prevalence increases with decreasing latitude, as detected in both 
this study and a previous global geo-epidemiology study of AMD (Reibaldi et al., 2016), it is 
not surprising that the overall prevalence of AMD in the current study is lower than that in 
Asia - as estimated by the Global AMD study. Moreover, the eleven studies in the Global 
AMD study were each published in the 21st century, whereas those included in this study 
distributed from 1990 to 2014. Although no secular trend of AMD was detected in either the 
Global AMD study or this study, the difference of the estimated AMD prevalence in these two 
studies can still be partly explained by the difference of ageing demographic structure (Wong 
et al., 2014, Reibaldi et al., 2016, Rudnicka et al., 2012). 
In line with previous population-based investigations and synthesised analysis (Kawasaki et 
al., 2010, Wong et al., 2014, Klein et al., 2007), this study confirms two common notions of 
AMD with strong evidence. First, AMD is a degenerative and progressive disease, with the 
prevalence of AMD dramatically increasing with age, and with age also found to be the only 
constant risk factor in the presence of any AMD and all its subtypes. Second, the prevalence 
of early AMD was found to be much higher than that of late AMD. This finding, however, 
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should not be misinterpreted as late AMD contributing a smaller burden. Rather, most 
individuals with early AMD may not go on to develop the late-stage disease, and late AMD is 
a much more severe disease than early AMD (Rudnicka et al., 2012, Lamoureux et al., 2010). 
In this study, the prevalence of late AMD in Chinese people in 2015 was found to be even 
higher than that of people living in Europe (1.13% vs. 0.75), the continently highest prevalence 
of both early and late AMD as revealed by the Global AMD study (Wong et al., 2014). In view 
of the large population size in China, this striking finding highlights an urgent need for action 
on the prevention and treatment of late AMD, given its clinical significance. Compared with 
GA, the group of NVAMD represents a larger burden in Chinese population because the 
prevalence and number of people with NVAMD were estimated as around twice higher than 
those of GA. This phenomenon has been reported in some individual investigations (Owen et 
al., 2003, Eye Diseases Prevalence Research Group, 2004a), although it has not been 
universally acknowledged (Rudnicka et al., 2012). This finding is still of particular importance 
for the secondary prevention, especially for NVAMD, whose progress to sight loss could be 
slowed considerably by current treatment approaches - such as the use of anti-vascular 
endothelial growth factor agents (Cook et al., 2008, Brechner et al., 2011). 
In this study, AMD was found to be more prevalent in urban populations than in rural 
populations, with possible explanations for this disparity being the difference in environments 
(e.g. UV exposure), as well as lifestyles (e.g. education, profession and level of physical 
activity). While it is not possible to say precisely what the determinants are, this study clearly 
shows that people living in rural areas with a self-sustained economy are less likely to be 
affected by AMD (Cheung et al., 2013, Ye et al., 2014). 
A gradient of decreasing prevalence of AMD was noted in increasing latitude, which suggests 
that the special climate and environmental factors in geographical areas approximating the 
equator may accelerate the development of AMD. One common hypothesis is that AMD is 
associated with the amount of insolation (Reibaldi et al., 2016). However, the indicator of 
average annual insolation was only found to be significantly associated with late AMD in this 
present study. There are two possible reasons for this. First, annual insolation data were 
averaged over a 22-year period (July 1983 - June 2005), which may represent a considerable 
time-lag (Wild et al., 2005, Shi et al., 2008). Second, the relation between insolation and the 
prevalence of AMD may not be a monotone function, the global geo-epidemiology study of 
AMD revealed higher prevalence rates of AMD in locations with insolation ≤3 kWh/m2/day 
compared with those with insolation >3 kWh/m2/day (Reibaldi et al., 2016). Although this 
interesting relation was not studied further because of limited data availability, the negative 
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relation between latitude and AMD prevalence is an interesting hypothesis to explore in future 
Chinese AMD epidemiological studies. 
Male sex was indicated as a risk factor for early AMD and NVAMD in the univariable 
regression analysis of this study. This is in contrast to previous reviews and individual 
investigations of populations of European ancestry, where females were reported to have a 
higher risk of developing NVAMD (Rudnicka et al., 2012, Eye Diseases Prevalence Research 
Group, 2004a, Klein et al., 1997b). However, this study is underpowered to further confirm 
the observed sex difference in multivariable regression analysis. In the multivariable analysis 
of the prevalence of any AMD, no evidence of sex difference was found after adjusting for a 
priori demographic and geographic variables. This finding is consistent with the previous 
Global AMD study (Wong et al., 2014). 
Variation in AMD prevalence and burden was noted in different geographic locations in China. 
The variation was mainly driven by the different demographic structures and the intrinsic 
environmental characteristics of these regions. According to the estimates for the six regions, 
AMD epidemics continue to be concentrated in the most populous South Central China. Taken 
together, these findings are of a particular public health interest in national health service 
allocation. Based on this study, more epidemiological investigations are required in order to 
make the regional estimates of subtypes of AMD in the future.  
3.5.4 Implications for policy, practice and future 
research 
This work has important implications both in academic and public health areas. Future 
epidemiological studies of AMD in China would benefit from greater standardisation and 
improved design, ideally adopting internationally recognised grading systems and presenting 
results for different subtypes. In addition, as AMD is a priority eye disease that may lead to 
severe visual impairment or even blindness, its potential burden on individuals and health 
systems is particularly large in resource-limited settings (Lim et al., 2012, Jager et al., 2008, 
Gottlieb, 2002). Thus, localised epidemiological surveys should be conducted in socio-
economically disadvantaged provinces, such as Tibet. From the national perspective, the 
public health impact of AMD is not only limited to the number of affected people, but also 
brings about multiple diagnostic and treatment challenges arising from this condition (Brown 
et al., 2005, Soubrane et al., 2007). It is prudent to address the importance of primary 
prevention, such as smoking cessation (Khan et al., 2006b, Thornton et al., 2005), lifestyle 
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modification, antioxidant therapy (Wong et al., 2011), and the use of hats and sunglasses 
(Tomany et al., 2004). In the meanwhile, the treatment of NVAMD is already available 
(although rather expensive) (Damico et al., 2012, Takeda et al., 2007, Brechner et al., 2011). 
Given the remarkable potential economic burden on the society, government efforts must be 
taken to ensure the availability of health services to address AMD from the points of diagnosis 
and treatment, and even prevention when available.  
3.6 Conclusions 
To conclude, this systematic review and meta-analysis provides the first comprehensive and 
up-to-date estimate of AMD prevalence and burden in China. The results from this study 
indicate that the burden of AMD is substantial in China, with great variance among different 
subtypes and geographic regions. In the next decade and beyond, the ageing demographic will 
make this burden even larger. Improved epidemiological studies are still needed to inform 
optimal implementation of eye care programmes in China. 
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Chapter 4 The national and subnational 
prevalence and burden of glaucoma in 
China 
4.1 Summary 
In this chapter, I applied the systematic review and meta-regression approach to estimate the 
age- and sex-specific prevalence of POAG and PACG respectively. The national numbers of 
people living with POAG and PACG were generated for the years 1990, 2000, 2010, 2015, 
2020, 2030, 2040 and 2050 by applying the national demographic data. For secondary 
glaucoma, the meta-analysis approach, rather than the meta-regression approach, was adopted 
because only study-level prevalence estimates were available. Although not precisely enough, 
the national number of people with secondary glaucoma was also generated under the 
assumption that the prevalence of secondary glaucoma was, and will still be constant during 
1990-2050. By using the meta-regression approach, as described in Chapter 2, males were 
found to have a higher risk of developing POAG, but a lower risk of developing PACG than 
females. In addition, the prevalence of POAG and PACG varied geographically, where urban 
dwellers were at a higher risk of developing POAG than rural dwellers, and people in 
Northeast China were more likely to have PACG than people in East China. By taking the 
abovementioned geographic variation, the regional numbers of people living with POAG and 
PACG were respectively estimated.  
The work presented in this chapter has been published in the Journal of Global Health cited as 
“Song, P., Wang, J., Bucan, K., Theodoratou, E., Rudan, I., Chan, K. Y., & on behalf of the 
Global Health Epidemiology Research Group (GHERG). (2017). National and subnational 
prevalence and burden of glaucoma in China: A systematic analysis. Journal of Global Health, 
7(2), 020705. http://doi.org/10.7189/jogh.07.020705”.  
I conducted all aspects of research work in this project, including designing and 
conceptualising the study, developing search strategy, systematic review, extracting data, 
analysing data, interpreting findings and preparing the first draft of manuscript for publication. 
The specific contributions of co-authors are as follows: Rudan, I. conceptualised and designed 
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the study, Wang, J. conducted the dual systematic review and data extraction, Bucan, K., 
Theodoratou, E., Rudan, I., and Chan, K. Y. critically reviewed the manuscript and approved 
the final manuscript. During the publishing process, the manuscript was additionally revised 
for several rounds according to the comments from anonymous peer reviewers and the journal 
editors. 
4.2 Background 
Glaucoma, the second leading cause of blindness, is an optic neuropathy characterised by 
progressive structural and functional changes of the optic nerve, leading to a typical 
appearance of the optic disc and visual field damage if untreated (Weinreb et al., 2014, 
Weinreb and Khaw, 2004, Foster et al., 2002, Congdon and Friedman, 2003, Pascolini and 
Mariotti, 2011). People with glaucoma-induced visual impairment generally suffer from 
decreased vision-related quality of life (including reduced vision-dependent mobility, 
increased incidence of falls), and place a huge burden on caregivers and communities (Ramulu, 
2009, Rouland et al., 2005, Varma et al., 2011, Traverso et al., 2005). Glaucoma is often 
associated with a long and asymptomatic initial phase, and is usually unnoticed until its later 
stages, when extensive and irreversible damage has occurred (Quigley, 1996, Topouzis et al., 
2008). In the late stage of the disease, the effects of medical and surgical treatment can be 
unsatisfactory, underscoring the importance of early detection and treatment (Weinreb et al., 
2014, Nduaguba and Lee, 2006, Weinreb and Khaw, 2004). As glaucoma has an uncertain 
prognosis, it requires lifelong management and follow-up to prevent further loss of vision 
(Rulli et al., 2013, Weinreb et al., 2014, Schwartz, 2005). The recognition of glaucoma’s 
pervasive nature and adverse impact on both individuals and society, and the documentation 
of the magnitude and distribution of glaucoma is of pronounced importance to inform 
clinicians and researchers, and will guide policymakers in health services allocation (Traverso 
et al., 2005, Quigley and Broman, 2006, Tham et al., 2014).  
Globally, 64.3 million individuals, or 3.5% of the world's population, have glaucoma; of these, 
about 5.7 million people are visually impaired and 3.1 million are blind (Pascolini and Mariotti, 
2011, Tham et al., 2014). Of the many subtypes of glaucoma, primary open-angle glaucoma 
(POAG) is the most common in nearly all regions, accounting for more than two-thirds (68.6%) 
of all glaucoma cases (Tham et al., 2014, Quigley and Broman, 2006). Geographically, POAG 
is believed to be particularly prevalent in Africa (4.2%), and least prevalent in Asia (2.3%); 
however, more than half (53.4%) of the global POAG cases are in Asia due to the relatively 
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large population size of this region (Tham et al., 2014, Chan et al., 2016). Compared with 
POAG, primary angle-closure glaucoma (PACG) is a less common subtype, but is more 
visually damaging (Wong et al., 2006a). PACG also disproportionally affects the global 
population; it is least common in North America (0.3%), but is the predominant type of 
glaucoma in Asian populations (1.1%) (Tham et al., 2014). More than three quarters (76.7%) 
of the global PACG cases are in Asia (Tham et al., 2014, Chan et al., 2016). Given the positive 
association of glaucoma prevalence and advanced age, glaucoma is expected to become an 
even larger public health concern in the coming decades (United Nations, 2015a, Shetty, 2012, 
Wong et al., 2006a). This dramatic increase of glaucoma burden is also expected to be the case 
for the largest developing country - China - where rapid ageing of the population is underway 
(Foster and Johnson, 2001, World Health Organization, 2015b, Woo et al., 2002).  
The last three decades have seen a proliferation of population-based studies in China. The 
mounting volume of data on the prevalence of glaucoma in Chinese bibliographical databases 
allows me to explore the burden of glaucoma in China from a modelling approach (Xia et al., 
2008, Fung, 2008, Song et al., 2016). However, epidemiological studies on glaucoma to date 
have been restricted to specific demographic and geographic features in China, and are 
therefore not generalisable to the overall Chinese population (Wang et al., 2010b, Song et al., 
2011, Sun et al., 2012, Cheng et al., 2013a). Because of the uncertainty and variation 
surrounding the epidemiological surveys on glaucoma, a systematic synthesis of the 
prevalence of glaucoma in China is particularly needed. The first study to pool the prevalence 
of primary glaucoma in China was published in 2013, which revealed an overall prevalence of 
0.7% for POAG, and 1.4% for PACG (Cheng et al., 2013a). The meta-analysis was based on 
14 articles from 12 population-based studies published before 2009. No study has yet 
systematically appraised research into the prevalence of primary glaucoma in China published 
over the last nine years. Furthermore, considering that different subtypes of glaucoma may 
require different strategies for screening, prevention and treatment, there is a pressing need for 
a more updated effort to provide finer quantification of the relative magnitude across the main 
types of glaucoma, namely, POAG, PACG and secondary glaucoma, which is missing in the 
2013 study (Chan et al., 2016).  
To fill the gaps in the evidence matrix, in this study I used a comprehensive systematic review 
to synthesise the best available evidence from 1990 onwards. Based on the retained evidence, 
the prevalence and burden of glaucoma and its subtypes were assessed at both the national and 
subnational levels. The aims of this present study were: 1) to estimate glaucoma prevalence in 
China by using epidemiological modelling; 2) to estimate and project the overall prevalence 
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and number of people with glaucoma at the national level from 1990 to 2050; and 3) to estimate 
the regional prevalence and number of people with glaucoma from 2000 to 2010. 
4.3 Methods 
4.3.1 Systematic review  
The comprehensive systematic review was conducted and reported in line with the Preferred 
Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and the 
Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) statement 
(Moher et al., 2009, Stevens et al., 2016). 
4.3.1.1 Search strategy 
A systematic literature search was performed to identify all relevant articles that have reported 
the prevalence of glaucoma in the general Chinese population. The searched databases 
included three Chinese and three English electronic databases: China National Knowledge 
Infrastructure (CNKI), Wanfang, Chinese Biomedicine Literature Database (CBM-SinoMed), 
PubMed, Embase, and Medline. The search strategy combined controlled vocabularies (e.g. 
Medical Subject Heading terms) and free text terms of prevalence (prevalence, incidence, 
mortality, morbidity, epidemiology), glaucoma and China (China, Chinese, Hong Kong, 
Macau, Taiwan); the specific search strategies for each database were adapted to fit their 
specific features (Appendix table 10). The searches were restricted to studies that were 
published between January 1990 and August 2017. No language restrictions were applied to 
the searches or search results. The reference lists of all included full-text articles were also 
scrutinised in detail to identify additional data sources.  
4.3.1.2 Inclusion and exclusion criteria 
The inclusion and exclusion criteria adopted in this study were developed based on the 
examination guidelines for glaucoma-related population-based studies (Foster et al., 2002, 
Quigley et al., 1993, Tham et al., 2014). To be included in this systematic review, studies had 
to be population-based and report the prevalence of glaucoma. I excluded studies that were 
hospital-based or conducted in a population that was not representative of the general 
population. Reviews, commentaries, studies that only adopted qualitative methods and studies 
that reported the number of eyes with glaucoma instead of the number of individuals were also 
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excluded because they were not able to provide numerical estimates of glaucoma prevalence. 
Studies that did not include clear assessment methods of glaucoma or relied on self-reported 
diagnosis were also excluded. Although different case definitions and examination methods 
exist in identifying glaucoma cases, a remarkable similarity of glaucoma prevalence was noted 
across surveys despite variations in survey methodology and glaucoma definition (Rudnicka 
et al., 2006, Kapetanakis et al., 2016, Tham et al., 2014, Eye Diseases Prevalence Research 
Group, 2004b). In this systematic review, studies were not excluded on the basis of their 
specific definitions of glaucoma or adopted instrumentation; the assessment of glaucoma 
should be independent of intraocular pressure (IOP) measurements, but rely on structural or 
functional evidence of glaucomatous optic neuropathy evaluated by optic disc evaluation or 
visual field testing (Tham et al., 2014, Foster et al., 2002). Therefore, studies were eligible to 
contribute data if the following standardised assessments were carried out in suspected cases 
of glaucoma: anterior chamber angle/depth evaluation by slit-lamp examination or gonioscopy, 
optic disc evaluation by ophthalmologists using slit-lamp biomicroscopy or fundus 
photography and visual field testing with automated static perimetry. 
4.3.1.3 Study selection and data extraction 
Search results from the six bibliographic databases were merged together and duplicate 
references were removed within and between the databases. All records were screened in two 
stages: screening of titles and abstracts, followed by the retrieval and screening of full-text 
articles. For multiple articles that reported results of the same individual study, those with the 
most comprehensive or most recent data were kept. Disagreements were resolved by 
consensus through discussion. According to the STROBE guideline, the quality of each 
included study was assessed in terms of sample population, sample size, participation rate, 
outcome assessment, and analytical methods. Each of the five bias components was scored as 
2 for low risk, 1 for moderate risk and 0 for high risk and unclear. The total score represented 
the overall quality of each study (Table 2.1) (Von Elm et al., 2007, Song et al., 2018). 
For the purpose of this study, glaucoma was classified into three main types: POAG, PACG 
and secondary glaucoma. Relevant data on different subtypes of glaucoma were separately 
extracted from the studies included. The pilot tested and refined extraction table included three 
modules: 
1) Characteristics of the study: author(s), publication year, study setting (urban, rural or 
mixed), study location, geographic region, survey year, sampling method, study 
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design (cross-sectional or cohort), whether anterior chamber angle/depth evaluation, 
IOP measurement, optic disc evaluation and visual field testing were conducted; 
2) Characteristics of the investigated population: number of the sample, sex (male, 
female or mixed), and age (age range, mean or median age, or midpoint of the age 
range); 
3) Prevalence estimates: the number of participants who had been tested and the number 
of people with glaucoma, by age group, sex, setting and glaucoma subtype, where 
available. 
The sites where the studies were classified into six geographic regions following definitions 
of National Bureau of Statistics of China: East China, North China, Northeast China, 
Northwest China, South Central China, and Southwest China (Table 2.2 and Figure 2.2) 
(National Bureau of Statistics, 2002, National Bureau of Statistics, 2012). Missing data on 
survey years were imputed for two studies by subtracting three years from the published year, 
which was based on the average time from survey to publication in studies with available data 
(see Appendix table 11). In case of censoring age groups, e.g. older than 80 years, the same 
width as other age groups in the same study was used to impute the missing age band. 
4.3.2 Statistical analysis 
4.3.2.1 Epidemiological modelling of glaucoma prevalence 
Prevalence of POAG, PACG and secondary glaucoma was stabilised by using the logit 
transformation (Barendregt et al., 2013). In this study, random-effects models were used 
throughout because of significant heterogeneity in the reported prevalence of POAG, PACG 
and secondary glaucoma between studies (Appendix table 12). For POAG and PACG, one 
individual study might have contributed multiple outcome measurements in the data extraction 
stage; to take into account the occurrence of different data points from the same study, a 
multilevel mixed-effect logistic regression approach was adopted (Hox et al., 2010, 
Viechtbauer, 2010). Before constructing epidemiological models of the prevalence for POAG 
and PACG, the association of prevalence estimates and each individual variable, i.e., age, sex 
(male and female), setting (urban, rural and mixed), geographic region, and survey year, was 
explored using a univariable meta-regression; this was done for POAG and PACG separately. 
Age and sex were found to be the only common factors that were significantly associated with 
prevalence estimates of both POAG and PACG. For the purpose of estimating the national 
prevalence of POAG and PACG, an age- and sex-adjusted model was developed. Given that: 
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The prevalence of glaucoma was established as a function of age and sex: 











Finally, the age- and sex-specific prevalence of POAG and PACG was generated based on the 
above-mentioned model. The lower bound of age range was set as 45 years and the upper 
bound as 89 years because enough data were available for model construction in this broad 
age range.  
For secondary glaucoma, 12 individual studies provided prevalence estimates. Therefore the 
overall prevalence of secondary glaucoma was derived from the study-specific estimates using 
a random-effects meta-analysis model (DerSimonian and Laird method) (Higgins and Green, 
2008). To evaluate the robustness of pooled prevalence, a leave-one-out sensitivity analysis 
was conducted by removing one study at one time (Wallace et al., 2009). Potential publication 
bias was assessed by visual inspection of funnel plots, Egger's regression test for funnel plot 
asymmetry and Begg’s rank correlation test (Egger et al., 1997, Begg and Mazumdar, 1994, 
Peters et al., 2006). 
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4.3.2.2 Estimation of national number of people with 
glaucoma from 1990 to 2015 
The national number of people with glaucoma (glaucoma “envelopes”) from 1990 to 2015 was 
derived by multiplying the prevalence of glaucoma with the population in China, available 
from the United Nations Population Division (UNPD) (United Nations, 2015b). For POAG 
and PACG, the numbers of age- and sex-specific cases were calculated by using their age- and 
sex-specific prevalence for each 5-year age group estimated in the above models. In view of 
the limited data availability, the age- and sex-specific prevalence of secondary glaucoma was 
not estimated, thus the overall prevalence pooled from 12 studies were used (Appendix figure 
8). This was performed for the years 1990, 2000, 2010 and 2015 consecutively. 
4.3.2.3 Projection of national number of people with 
glaucoma from 2020 to 2050 
For the projection of people with glaucoma to the year 2050, the prevalence of POAG, PACG 
and secondary glaucoma was assumed to be constant over the next 33 years. This assumption 
was partly supported by the multivariable meta-regression model, where no significant 
changes of POAG and PACG prevalence with survey year were observed after adjusting the 
effects of age and sex. Bases on the same procedures adopted in the estimation of national 
population with glaucoma from 1990 to 2015, the numbers of people with glaucoma from 
2020 to 2050 were projected by taking UNPD Prospects data, which took into account 
mortality rates and fertility rates in its population projection (United Nations, 2015b).  
4.3.2.4 Effects of demographic and geographic factors on the 
prevalence of POAG and PACG 
To investigate whether the prevalence of POAG and PACG varied across different strata of 
the population, the associations of prevalence estimates and variables of interest were assessed 
by multivariable meta-regression, adjusting the effects of age and sex. Before model fitting, 
all variables were tested for correlation to avoid multicollinearity. The variables were selected 
based on knowledge, previous studies and the availability of data in this present study, which 
included setting (urban, rural and mixed), geographic region, and survey year. As a rule, at 
least seven data points should be available for each variable (Vittinghoff and McCulloch, 
2007). 
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4.3.2.5 Estimation of regional number of people with POAG 
and PACG from 2000 to 2010 
The regional population with glaucoma was estimated at an envelope condition. This method 
was initially proposed by the Child Health Epidemiology Reference Group (CHERG) and has 
been widely adopted in disease burden research (Rudan et al., 2004, Fowkes et al., 2013, 
Adeloye et al., 2015). The national glaucoma cases were set as the glaucoma envelope, for 
POAG and PACG separately. Then the “POAG envelope” and the “PACG envelope” were 
split into the six subnational regions according to the different distributions of risk factors 
identified in the multivariable meta-regression models. This was conducted for the years 2000 
and 2010, where regional population data were available from the fifth and sixth censuses of 
China (National Bureau of Statistics, 2002, National Bureau of Statistics, 2012). 
The overall study design is shown in Figure 4.1. All analyses were performed using R, version 
3.3.0 (R Foundation for Statistical Computing, Vienna, Austria). The China base map was 
obtained as a shapefile from the Global Administrative Areas (GADM) database (GADM, 
2015, version 2.0; www.gadm.org) and all maps were drawn by ArcMap version 10.1 
(Environmental Systems Research Institute, Redlands, CA). A two-sided p-value of less than 
0.05 indicated statistically significant difference for all analyses. 
 
Figure 4.1. Overall study design flowchart for the prevalence and burden of glaucoma 
study in China 
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4.4 Results 
4.4.1 Summary of systematic review 
The initial search identified a total of 10609 citations for screening, after elimination of 
duplicates, 5387 records remained. After screening titles and abstracts, 623 potentially relevant 
full-text articles were reviewed for eligibility, of which 30 reported the prevalence of glaucoma 
and were included in the systematic review (Figure 4.2). A full list of the included studies is 
shown in Appendix table 13. 
 
Figure 4.2. Systematic review flow diagram of studies on glaucoma prevalence in China 
Note: *Reason 1-Studies that were not population-based; *Reason 2-Studies that were 
conducted in people with unrepresentative characteristics of general population (diabetic 
patients, people with reduced vision, etc.); *Reason 3-Articles with no numerical measure of 
glaucoma prevalence; *Reason 4-Studies that relied on self-reported diagnoses or didn’t 
conduct standardised assessments (anterior chamber angle/depth evaluation by slit-lamp 
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examination or gonioscopy, optic disc evaluation by ophthalmologists using slit-lamp 
biomicroscopy or fundus photography and visual field testing with automated static perimetry) 
in at least glaucoma suspects; *Reason 5-Multiple publications of the same study; *Reason 6-
Studies that were not based in China; *Reason 7-Articles with inconsistency between reported 
methods and presented results. 
The 30 studies, published between 1995 and 2016, reported the prevalence of glaucoma with 
a geographical distribution covering all the six regions in China (Figure 4.3). The included 
studies were all cross-sectional, of which 20 studies reported the prevalence of POAG, 25 
focused on PACG and 12 on secondary glaucoma. The detailed characteristics and quality 
score of every study are listed in Appendix table 14 and Appendix table 15, and the main 
characteristics of the 30 studies are summarised in Table 4.1. More than half of the 30 studies 
were published in the past seven years, underlining the necessity for conducting my revision 
of the estimate. The included studies were generally larger, with the majority (60%, n=18) 
being conducted in rural areas. Anterior chamber angle/depth evaluation, IOP measurement 
and optic disc evaluation were mostly undertaken in all participants, whereas visual field 
testing was largely used in glaucoma suspects. More than half of the included studies were 
with a quality score of nine or above. 
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Figure 4.3. Geographical distribution of the included studies on glaucoma prevalence in 
China (n=30) 
Table 4.1. Main characteristics of the included studies on glaucoma prevalence in China 
(n=30) 
Characteristic Number of studies (%) 
Year published  
1990-1999 2 (6.7) 
2000-2009 12 (40.0) 
2010-2017 16 (53.3) 
Setting  
Urban 6 (20.0) 
Rural 18 (60.0) 
Mixed 6 (20.0) 
Sample size  
500-1500 6 (20.0) 
1501–2500 7 (23.3) 
2501–5000 9 (30.0) 
>5000 8 (26.7) 
Geographic regions   
North China 12 (40.0) 
Northeast China 5 (16.7) 
East China 4 (13.3) 
South Central China 4 (13.3) 
Southwest China 3 (10.0) 
Northwest China 2 (6.7) 
Anterior chamber angle/depth evaluation  
In all participants 28 (93.3) 
In glaucoma suspects 2 (6.7) 
IOP measurement  
In all participants 29 (96.7) 
In glaucoma suspects 1 (3.3) 
Optic disc evaluation  
In all participants 28 (93.3) 
In glaucoma suspects 2 (6.7) 
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Characteristic Number of studies (%) 
Visual field testing  
In all participants 4 (13.3) 
In glaucoma suspects 26 (86.7) 
Quality score  
10 4 (13.3) 
9 15 (50.0) 
8 8 (26.7) 
7 3 (10.0) 
4.4.2 Age- and sex-specific prevalence of POAG and 
PACG 
Based on a substantial number of data points from the included studies, the sex-specific 
relationship between age and the prevalence of POAG and PACG was constructed (Figure 
4.4). The informative data points covered a wide age spectrum from the mid-30s to the 9th 
decade, with the majority concentrating between the mid-40s to the mid-80s. Therefore, in the 
estimation of age- and sex-specific prevalence of POAG and PACG, the age range was set as 
from 45 years to 89 years.  
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Figure 4.4. Age- and sex-specific prevalence of POAG and PACG based on the 
informative data points from the included studies 
Note: The size of each bubble is proportional to the sample size. Overall, there were 86 data 
points for constructing the sex-specific relation between age and prevalence for POAG, and 
103 for PACG. 
Table 4.2 and Figure 4.5 show the estimated age- and sex-specific prevalence of POAG and 
PACG respectively. Generally, the prevalence of POAG and PACG both increased steadily 
with advanced age, and this positive relationship between age and prevalence rate was similar 
between sexes, but more pronounced for PACG. In males, the prevalence of POAG ranged 
from 0.74% (95% CI: 0.48-1.14) in individuals aged 45-49 years to 3.02% (95% CI: 1.92-4.73) 
in those aged 85-89 years. The prevalence of POAG in females was slightly lower than that in 
males across the whole age spectrum from 45 to 89 years, ranging from 0.54% (95% CI: 0.35-
0.84) to 2.24% (95% CI: 1.41-3.53). In contrast, the prevalence of PACG was consistently 
The national and subnational disease burden of age-related eye diseases in China 
Prevalence and burden of glaucoma  109 
higher in females than in males. In females, the prevalence of PACG ranged from 0.91% (95% 
CI: 0.74-1.11) in those aged 45-49 years to 6.33% (95% CI: 4.98-8.02) in those aged 85-89 
years. In males, the prevalence of PACG increased from 0.48% (95% CI: 0.39-0.60) in people 
aged 45-49 years to 3.44% (95% CI: 2.66-4.45) in elderly aged 85-89 years.  
Table 4.2. Estimated sex-specific prevalence of POAG and PACG in China, by age group 
Age 
group 
Prevalence of POAG (%, 95% CI) Prevalence of PACG (%, 95% CI) 
Male Female Male Female 
45-49 
years 
0.74 0.54 0.48 0.91 
(0.48-1.14) (0.35-0.84) (0.39-0.60) (0.74-1.11) 
50-54 
years 
0.88 0.65 0.62 1.16 
(0.57-1.34) (0.42-0.99) (0.51-0.75) (0.98-1.38) 
55-59 
years 
1.05 0.77 0.79 1.49 
(0.69-1.60) (0.51-1.18) (0.66-0.94) (1.28-1.74) 
60-64 
years 
1.25 0.92 1.01 1.90 
(0.83-1.90) (0.61-1.41) (0.86-1.20) (1.65-2.20) 
65-69 
years 
1.50 1.10 1.30 2.43 
(0.98-2.27) (0.72-1.68) (1.09-1.54) (2.10-2.81) 
70-74 
years 
1.79 1.32 1.66 3.10 
(1.17-2.72) (0.86-2.02) (1.38-1.99) (2.64-3.64) 
75-79 
years 
2.13 1.57 2.12 3.94 
(1.38-3.27) (1.02-2.43) (1.73-2.59) (3.28-4.73) 
80–84 
years 
2.54 1.87 2.70 5.00 
(1.63-3.93) (1.20-2.92) (2.15-3.39) (4.06-6.16) 
85-89 
years 
3.02 2.24 3.44 6.33 
(1.92-4.73) (1.41-3.53) (2.66-4.45) (4.98-8.02) 
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Figure 4.5. Estimated age- and sex-specific prevalence of POAG and PACG in China, 
with 95% confidence intervals 
4.4.3 Pooled prevalence of secondary glaucoma 
during 1990 and 2017 
Based on the random-effects meta-analysis, the prevalence of secondary glaucoma was pooled 
as 0.15% (95% CI: 0.10-0.23) in the general Chinese population (Figure 4.6). After removing 
each study at one time, the pooled prevalence of secondary glaucoma ranged from 0.14% (95% 
CI: 0.09-0.23) to 0.16% (95% CI: 0.11-0.25) (Figure 4.7). No single study was found to 
significantly influence the pooled prevalence of secondary glaucoma. Potential publication 
bias was detected by visual evaluation of the funnel plot and Egger’s test (t= -5.323, p< 0.001), 
whereas Begg’s test indicated that no publication was evident (z= 0.274, p= 0.783) (Figure 
4.8). 
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Figure 4.6. Pooled prevalence of secondary glaucoma in the general Chinese population 
(n=12) 
 
Figure 4.7. Leave-one-out sensitivity analysis of the influence of single study on the 
pooled prevalence of secondary glaucoma 
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Figure 4.8. Publication bias of the studies on the prevalence of secondary glaucoma in 
the general population and people with DM 
Note: (A) Funnel plot; (B) Egger’s test; (C) Begg’s test. 
4.4.4 National number of people with glaucoma from 
1990 to 2015 
By extrapolating the estimated age- and sex-specific prevalence of POAG and PACG to 
UNPD data, the numbers of people with POAG and PACG were generated (Appendix table 
16). For secondary glaucoma, its pooled prevalence was assumed as constant over the time 
frame of this research. At the national level, the overall prevalence of glaucoma was listed in 
Table 4.3. From 1990 to 2015, the prevalence of all glaucoma ranged from 2.59% (95% CI: 
1.96-3.49) to 2.58% (95% CI: 1.94-3.47), indicating a slightly relative decreasing rate of 
0.39%. For different subtypes of glaucoma, the overall prevalence of POAG ranged from 1.03% 
(95% CI: 0.67-1.58) in 1990 to 1.02% (95% CI: 0.67-1.57) in 2015, which yielded a relative 
decreasing rate of 0.97%. Similarly, the prevalence of PACG decreased by 0.71%, from 1.41% 
(95% CI: 1.18-1.68) in 1990 to 1.40% (95% CI: 1.17-1.68) in 2015.  
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Table 4.3. Estimated prevalence and number of people with glaucoma in China from 1990 to 2015, by glaucoma type 
Glaucoma 
type 
Prevalence of glaucoma (%, 95% CI) Number of people with glaucoma (million, 95% CI) 
Relative rate of change 
(%, 1990-2015) 
1990 2000 2010 2015 1990 2000 2010 2015 Prevalence Cases 
POAG 
1.03 1.01 1.03 1.02 2.35 3.21 4.39 5.22  
-0.97 +122.13 
(0.67-1.58) (0.66-1.55) (0.67-1.57) (0.67-1.57) (1.54-3.60) (2.09-4.91) (2.86-6.72) (3.40-7.98) 
PACG 
1.41 1.38 1.40 1.40 3.22 4.37 6.01 7.14 
-0.71 +121.74 
(1.18-1.68) (1.16-1.65) (1.17-1.68) (1.17-1.68) (2.70-3.84) (3.66-5.23) (5.03-7.18) (5.97-8.53) 
Secondary 
glaucoma 
0.15 0.34 0.47 0.64 0.76 
- +123.53 
(0.10-0.23) (0.23-0.53) (0.32-0.73) (0.43-0.99) (0.51-1.17) 
All 
glaucoma  
2.59 2.55 2.58 2.58 5.92 8.05 11.04 13.12 
-0.39 +121.62 
(1.96-3.49) (1.92-3.44) (1.94-3.47) (1.94-3.47) (4.47-7.97) (6.07-10.87) (8.32-14.89) (9.88-17.68) 
Note: All glaucoma includes POAG, PACG and secondary glaucoma. 
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With the ageing of Chinese population during 1990-2015, the total number of people living 
with glaucoma increased dramatically (Table 4.3). The number of people with all glaucoma 
in China was 5.92 million (95% CI: 4.47-7.97) in 1990 and 13.12 million (95% CI: 9.88-17.68) 
in 2015, indicating an overall increasing rate of 121.62% throughout this period. This 
increasing trend was also witnessed in different subtypes of glaucoma. For POAG, the affected 
cases increased by 122.13%, from 2.35 million (95% CI: 1.54-3.60) in 1990 to 5.22 million 
(95% CI: 3.40-7.98) in 2015. Similarly, the number of people with PACG increased by 
121.74%, ranging from 3.22 million (95% CI: 2.70-3.84) in 1990 to 7.14 million (95% CI: 
5.97-8.53) in 2015. Even for secondary glaucoma, whose overall prevalence was assumed as 
constant, the number of affected people also increased by 123.53% during 1990 to 2015, from 
0.34 million (95% CI: 0.23-0.53) to 0.76 million (95% CI: 0.51-1.17). In 2015, more than half 
(54.42%) of the glaucoma cases were PACG, followed by POAG (39.79%) and secondary 
glaucoma (5.79%). From 1990 to 2015, the age group that contributed the most cases shifted 
from 55-59 years to 60-64 years for both POAG and PACG (Figure 4.9). 
 
Figure 4.9. Estimated sex-specific number of people with POAG and PACG in China 
from 1990 to 2015, with contributing age groups 
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4.4.5 Projection of national number of people with 
glaucoma from 2020 to 2050 
In the projection analysis, the age- and sex-specific prevalence estimates of POAG and PACG, 
and the overall prevalence estimate of secondary glaucoma were all assumed as constant. By 
applying these estimates to the medium scenario UNPD data up to the year 2050, the numbers 
of people with glaucoma were projected (Appendix table 16 and Table 4.4). Unlike the slight 
declining trend of glaucoma prevalence between 1990 and 2015, from 2020 to 2050, the 
overall prevalence of all glaucoma is expected to increase from 2.64% (95% CI: 1.99-3.55) to 
3.48% (95% CI: 2.63-4.69), which is a 32% increase. For different subtypes of glaucoma, the 
prevalence of POAG will also increase during this period, but at a lower rate (27%). In 2020, 
the prevalence of POAG is projected to be 1.05% (95% CI: 0.68-1.60), and then reach 1.33% 
(95% CI: 0.86-2.04) in 2050. The prevalence of PACG will show a greater increasing rate 
between 2020 and 2050, from 1.44% (95% CI: 1.21-1.72) to 2.01% (95% CI: 1.66-2.42), i.e. 
by 40%. 
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Table 4.4. Projected prevalence and number of people with glaucoma in China from 2020 to 2050, by glaucoma type 
Glaucoma 
type 
Prevalence of glaucoma (%, 95% CI) Number of people with glaucoma (million, 95% CI) 
Relative rate of change 
(%, 2020-2050) 
2020 2030 2040 2050 2020 2030 2040 2050 Prevalence Cases 
POAG 
1.05 1.14 1.21 1.33 6.06 7.51 9.04 9.59 
+26.67 +58.25 
(0.68-1.60) (0.75-1.75) (0.79-1.86) (0.86-2.04) (3.95-9.27) (4.90-11.50) (5.89-13.86) (6.23-14.72) 
PACG 
1.44 1.64 1.79 2.01 8.36 10.75 13.30 14.49 
+39.58 +73.33 
(1.21-1.72) (1.37-1.95) (1.49-2.14) (1.66-2.42) (7.00-9.98) (9.00-12.84) (11.08-15.97) (12.01-17.48) 
Secondary 
glaucoma 
0.15 0.87 0.99 1.12 1.08 
- +24.14 
(0.10-0.23) (0.58-1.33) (0.66-1.51) (0.74-1.71) (0.72-1.66) 
All 
glaucoma  
2.64 2.93 3.15 3.48 15.28 19.26 23.47 25.16 
+31.82 +64.66 
(1.99-3.55) (2.22-3.93) (2.38-4.24) (2.63-4.69) (11.53-20.58) (14.56-25.84) (17.71-31.54) (18.96-33.86) 
Note: All glaucoma includes both primary glaucoma and secondary glaucoma. 
 
The national and subnational disease burden of age-related eye diseases in China 
Prevalence and burden of glaucoma  117 
The projected number of people living with glaucoma in China is also shown in Table 4.4. 
Between 2020 and 2050, the number of all glaucoma cases in China is expected to increase 
from 15.28 million (95% CI: 11.53-20.58) to 25.16 million (95% CI: 18.96-33.86), i.e. by 65%. 
The increasing rates for POAG and PACG will also be notable within the same period. The 
number of people with POAG is expected to increase from 6.06 million (95% CI: 3.95-9.27) 
to 9.59 million (95% CI: 6.23-14.72), and those with PACG from 8.36 million (95% CI: 7.00-
9.98) to 14.49 million (95% CI: 12.01-17.48), which will translate into the rates of increase 
between 2020 and 2050 of 58% and 73%, respectively. Due to the forecasted trend in 
population ageing over the next three decades, the number of secondary glaucoma cases is 
anticipated to also increase slightly, from 0.87 million (95% CI: 0.58-1.33) in 2020 to 1.08 
million (95% CI: 0.72-1.66) in 2050; i.e. an increase by 24.14%. During this period, PACG 
will remain the predominant subtype of glaucoma in China, followed by POAG and secondary 
glaucoma. From 2020 to 2050, the age group in which most POAG cases will be concentrated 
will shift from 65-69 years to 75-79 years, and the age group for PACG will shift from 65-69 
years to 80-84 years (Figure 4.10). 
 
Figure 4.10. Projected sex-specific number of people with POAG and PACG in China 
from 2020 to 2050, with contributing age groups 
The national and subnational disease burden of age-related eye diseases in China 
Prevalence and burden of glaucoma  118 
4.4.6 Effects of demographic and geographic factors 
on the prevalence of POAG and PACG 
Based on univariable and multivariable meta-regression models (Table 4.5), the effects of 
selected demographic and geographic factors on the risk of POAG and PACG were assessed. 
The univariable meta-regression indicated that age, sex and study setting were significantly 
associated with POAG, while PACG was associated with age, sex and geographic region. No 
evidence for secular trends was observed. After adjusting for age and sex in a multivariable 
meta-regression, the odds ratio (OR) for each increase in age by 10 years was 1.43 (95% CI: 
1.33-1.55) for POAG, and 1.65 (95% CI: 1.51-1.80) for PACG. Males still showed a higher 
risk of POAG (1.36 [95% CI: 1.17-1.59]), but a lower risk of PACG (0.53 [95% CI: 0.46-
0.60]) in comparison with females. People living in urban areas were more likely to have 
POAG compared with those in rural areas, with an OR of 1.54 (95% CI: 1.02-2.35). Among 
the six geographic regions, people in Northeast China were at a higher risk (1.77 [95% CI: 
1.07-2.94]) of having PACG than people in East China. 
Table 4.5. Odds ratios for POAG and PACG in terms of age, sex, setting and geographic 
region from multilevel univariable and multivariable meta-regression models, with 95% 
confidence intervals 
Variable 
Unadjusted Age and sex-adjusted 
POAG PACG POAG PACG 
Age (per decade increase) 1.38 (1.30-1.47)* 1.58 (1.49-1.67)* 1.43 (1.33-1.55)* 1.65 (1.51-1.80)* 
Sex$     
Female Reference Reference Reference Reference 
Male 1.39 (1.19-1.62)* 0.53 (0.46-0.60)* 1.36 (1.17-1.59)* 0.53 (0.46-0.60)* 
Setting     
Rural Reference Reference Reference Reference 
Urban 1.68 (1.13-2.51)* 0.90 (0.64-1.28) 1.54 (1.02-2.35)* 0.82 (0.54-1.23) 
Mixed 0.93 (0.37-2.33) 1.13 (0.67-1.90) 2.18 (0.68-6.99) 0.64 (0.25-1.62) 
Geographic region     
East Reference Reference Reference Reference 
North 1.44 (0.45-4.61) 1.81 (0.93-3.52) 1.29 (0.36-4.69) 1.23 (0.77-1.97) 
Northeast 1.48 (0.31-7.02) 2.87 (1.37-6.01)* 1.41 (0.26-7.74) 1.77 (1.07-2.94)* 
Northwest 0.80 (0.10-6.33) 1.87 (0.79-4.41) 0.44 (0.05-4.07) 1.38 (0.76-2.49) 
South Central 2.14 (0.45-10.14) 1.54 (0.72-3.28) - 0.89 (0.51-1.53) 
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Variable 
Unadjusted Age and sex-adjusted 
POAG PACG POAG PACG 
Southwest 1.48 (0.37-6.00) 1.51 (0.69-3.29) 0.94 (0.17-5.16) 1.24 (0.70-2.22) 
Investigation year (per 
decade increase)^ 
1.07 (0.58-1.98) 0.76 (0.50-1.15) 1.47 (0.51-4.25) 1.18 (0.92-1.50) 
Note: * statistically significant; $ the effect of sex was estimated based on studies that reported 
sex-specific glaucoma prevalence; ^ the secular trend was evaluated based on studies that were 
conducted after the year 2000. 
4.4.7 Regional number of people with POAG and 
PACG from 2000 to 2010 
By taking the effects of age, sex and setting, the national POAG cases were distributed to the 
six geographic regions in China (Table 4.6 and Figure 4.11; Appendix table 17 for more 
details). In 2000, the overall prevalence of POAG was 1.01% (95% CI: 0.66-1.55) in China, 
ranging from 0.96% (95% CI: 0.60-1.53) in Southwest China to 1.08% (95% CI: 0.75-1.54) 
in Northeast China. In 2010, the overall prevalence of POAG in China rose to 1.03% (95% CI: 
0.67-1.57), and the regions with the highest prevalence of POAG were Northeast China (1.05% 
[95% CI: 0.71-1.54]) and East China (1.05% [95% CI: 0.69-1.59]), and that with the lowest 
POAG prevalence was Northwest China (0.98% [95% CI: 0.62-1.53]). From 2000 to 2010, 
the prevalence of POAG has risen in China, with an exception of Northeast China, where the 
prevalence of POAG decreased by 2.47%. The most marked increasing rate was observed in 
Southwest China (3.68%). In both 2000 and 2010, the distribution of POAG cases across the 
six geographic regions was similar, with the most cases in East China and the least in 
Northwest China. From 2000 to 2010, the greatest increase rate was in North China (46.13%), 
and the least in Southwest China (26.51%). In 2010, the age groups that contributed the most 
POAG cases was 55-59 years across the six regions, except Northwest China, where people 
aged 45-49 years owed the largest share of POAG cases. 
Table 4.6. Estimated prevalence and number of people with POAG in China from 2000 
to 2010, by geographic region 
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Region 
Prevalence of POAG 
(%, 95% CI) 
Number of people with 
POAG (million, 95% CI) 
Relative rate of change 
(%, 2000-2010) 
2000 2010 2000 2010 Prevalence Cases 
North China 
1.01  1.02  0.38  0.55  
+1.00 +46.13 
(0.67-1.53) (0.68-1.54) (0.25-0.57) (0.37-0.83) 
Northeast 
China 
1.08  1.05  0.30  0.44  
-2.47 +45.03 
(0.75-1.54) (0.71-1.54) (0.21-0.43) (0.30-0.64) 
East China 
1.04  1.05  1.02  1.39  
+1.00 +36.34 
(0.69-1.58) (0.69-1.59) (0.67-1.54) (0.91-2.10) 
South Central 
China 
1.01  1.01  0.83  1.13  
+0.72 +35.65 
(0.65-1.56) (0.65-1.57) (0.53-1.29) (0.73-1.75) 
Southwest 
China 
0.96  1.00  0.48  0.61  
+3.68 +26.51 
(0.60-1.53) (0.63-1.59) (0.30-0.77) (0.38-0.97) 
Northwest 
China 
0.97  0.98  0.19  0.27  
+1.00 +41.49 
(0.62-1.51) (0.62-1.53) (0.12-0.30) (0.18-0.43) 
China 
1.01  1.03  3.21  4.39  
+1.05 +36.97 
(0.66-1.55) (0.67-1.57) (2.09-4.91) (2.86-6.72) 
 
Figure 4.11. Estimation of the regional number of people with primary glaucoma and 
contributing age groups in China from 2000 to 2010 
The number of people with PACG in China was distributed based on the multivariable meta-
regression model of PACG and features of the six geographic regions (Table 4.7 and Figure 
4.11; Appendix table 18 for more details). In 2000, the overall prevalence of PACG in China 
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was 1.38% (95% CI: 1.16-1.65), with the highest regional prevalence estimate in Northeast 
China (2.04% [95% CI: 1.82-2.26]) and lowest in South Central China (1.12% [95% CI: 0.95-
1.32]). In 2010, the national prevalence of PACG rose by 1.30%, reaching to 1.40% (95% CI: 
1.17-1.68), and the region with the highest prevalence of PACG was still Northeast China 
(2.06% [95% CI: 1.84-2.30]) and that with the lowest PACG prevalence was still South 
Central China (1.11% [95% CI: 0.94-1.31]). Within this time frame, the prevalence of PACG 
decreased in North China, East China and South Central China, but increased in Northeast 
China, Southwest China and Northwest China. The region with the greatest increasing rate of 
PACG prevalence was Southwest China (5.06%), and that with the greatest decreasing rate 
was South Central China (-0.52%). From 2000 to 2010, East China consistently harboured the 
largest share of PACG cases, while Northwest China has had the smallest share. Overall, the 
number of people with PACG increased from 4.37 million (95% CI: 3.66-5.23) to 6.01 million 
(95% CI: 5.03-7.18), which is a 37% increase over this period. This increase was also 
witnessed in every region, being the most marked in Northeast China (51%) and the least in 
Southwest China (28%). In 2010, the age groups that contributed the most POAG cases was 
55-59 years across all the six geographic regions. 
Table 4.7. Estimated prevalence and number of people with PACG in China from 2000 
to 2010, by geographic region 
Region 
Prevalence of PACG 
(%, 95% CI) 
Number of people with 
PACG (million, 95% CI) 
Relative rate of 
change (%, 2000-2010) 
2000 2010 2000 2010 Prevalence Cases 
North China 
1.48  1.47  0.55  0.79  
-0.47 +44.00 
(1.42-1.53) (1.41-1.52) (0.53-0.57) (0.76-0.82) 
Northeast China 
2.04  2.06  0.57  0.86  
+1.27 +50.59 
(1.82-2.26) (1.84-2.30) (0.51-0.64) (0.77-0.96) 
East China 
1.27  1.27  1.24  1.68  
-0.03 +34.94 
(0.99-1.63) (0.99-1.63) (0.97-1.59) (1.30-2.15) 
South Central China 
1.12  1.11  0.93  1.24  
-0.52 +33.99 
(0.95-1.32) (0.94-1.31) (0.79-1.09) (1.05-1.46) 
Southwest China 
1.51  1.59  0.76  0.97  
+5.06 +28.20 
(1.22-1.87) (1.28-1.97) (0.61-0.94) (0.78-1.20) 
Northwest China 
1.60  1.63  0.32  0.46  
+1.58 +42.31 
(1.26-2.03) (1.27-2.07) (0.25-0.41) (0.36-0.58) 
China 1.38  1.40  4.37  6.01  +1.30 +37.31 
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Region 
Prevalence of PACG 
(%, 95% CI) 
Number of people with 
PACG (million, 95% CI) 
Relative rate of 
change (%, 2000-2010) 
2000 2010 2000 2010 Prevalence Cases 
(1.16-1.65) (1.17-1.68) (3.66-5.23) (5.03-7.18) 
4.5 Discussion 
4.5.1 Statement of principal findings 
Based on rigorous systematic review of existing evidence on glaucoma prevalence in China, 
this study offers a comprehensive estimate of the prevalence and burden of glaucoma in China 
at both national and subnational levels, and compares the relative magnitude of three main 
subtypes of glaucoma, i.e., POAG, PACG and secondary glaucoma, in the general mainland 
Chinese population. From 1990 to 2015, the prevalence of glaucoma fluctuated at around 2.6%, 
corresponding to 5.92 million and 13.12 million people with glaucoma in the years 1990 and 
2015, respectively. By 2050, the prevalence of glaucoma will rise to 3.48%, which equivalents 
to a total of 25.16 million affected people. Substantial evidence demonstrated that PACG was 
the predominant subtype of glaucoma in the general Chinese population, followed by POAG 
and secondary glaucoma. The geographic variations in the prevalence of POAG and PACG 
were also assessed, with urban dwellers at a higher risk of developing POAG than rural 
dwellers, and people living in Northeast China being more prone to PACG than people in East 
China. Because of the uneven population distribution in China, from 2000 to 2010, East China 
consistently had the largest share of both POAG and PACG cases, and Northwest China the 
least. 
4.5.2 Strengths and limitations 
To the best of my knowledge, this study is the most up-to-date and comprehensive systematic 
review and meta-analysis to explore and present the national and subnational prevalence and 
burden of glaucoma in China. The principal strengths of this study are a reasonable coverage 
of the Chinese population, a comprehensive literature search, and a stringent approach to 
selecting studies for inclusion. Ultimately, this systematic review was built upon 30 
individuals studies, which was more than double the number of studies included in the first 
systematic review on glaucoma in China (Cheng et al., 2013a). With a wide geographical scope 
covering all the six geographic regions of China, the included studies ensured a sufficient 
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power to conduct the estimates for both the whole nation and subnational regions. Furthermore, 
with the aim of limiting between-study heterogeneity due to methodological variations, the 
assessments of glaucoma in the studies included were based on structural or functional 
evidence of glaucomatous optic neuropathy, rather than IOP measurements, which in part 
guaranteed a very good detection ability of early-stage glaucoma. In addition, POAG in this 
study included persons with IOP at all levels (Tham et al., 2014, Foster et al., 2002). Moreover, 
the prevalence and burden of secondary glaucoma in China was developed for the first time, 
which added new evidence to the epidemiology of glaucoma both domestically and globally.  
Despite the strengths of this study, there are also multiple limitations. First, given the diversity 
of studies included in study design, targeted population, methods and settings, a relatively high 
degree of heterogeneity among studies included was observed. Although the estimates of 
POAG and PACG prevalence were generated based on meta-regression, by taking the effects 
of age, sex and geographic factors together, some factors other than chance may also be 
attributable to the observed variance, but could not be fully controlled. In this study, a key 
issue was that I didn’t choose to exclude studies based on consensus criteria for the definitions 
and grading systems of glaucoma, but rather relied on the examinations. This is because 
previous studies suggested a remarkable similarity among surveys with different survey 
methods and glaucoma definitions (Rudnicka et al., 2006, Kapetanakis et al., 2016, Tham et 
al., 2014, Eye Diseases Prevalence Research Group, 2004b). This approach for defining 
eligible studies has been widely adopted in previous systematic reviews on glaucoma 
prevalence, but it might still be influenced by the inherent subjectivity of interpreting 
ophthalmic images (Chan et al., 2016, Tham et al., 2014, Kapetanakis et al., 2016, Rudnicka 
et al., 2006). Second, compared with primary glaucoma, secondary glaucoma has been under-
examined in epidemiological studies (Chan et al., 2016, Tham et al., 2014, Yamamoto et al., 
2005). In this study, despite the extensive efforts to identify all the available evidence without 
language restrictions, the number of eligible studies that provided the estimate of secondary 
glaucoma prevalence was still not sufficient. Given that there was moderate heterogeneity 
between studies that reported the prevalence of secondary glaucoma, I acknowledge issues 
about the appropriateness of roughly reporting an overall prevalence of secondary glaucoma. 
Third, the projections of glaucoma were only based on the assumption that the prevalence 
estimates will be constant, thus, changes in the number of people with glaucoma only reflect 
changes in demographic features of the next three decades. Although this assumption has been 
commonly adopted in the projection of disease burden, the power of projection analysis 
beyond the period of studies conducted is limited (Tham et al., 2014, Wong et al., 2014, Chan 
et al., 2016). Forth, only the effects of age, sex, setting and geographic region were assessed 
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in subgroup analyses by using both univariable and multivariable meta-regression; however, 
other relevant factors that were not obtained from the included studies may have also had a 
role. In addition, all these factors were aggregate level data, thus hampering the opportunity 
to explore the differences in effects at the individual level, or interaction between 
factors(Welch et al., 2017, Song et al., 2017a). Fifth, the estimates of glaucoma prevalence 
were generated at the regional level at best. Any estimates at the provincial level were not 
possible, owing to the limited availability of data in each province. Taken collectively, the 
results presented in this study should be interpreted with caution. 
4.5.3 Interpretation of findings 
The overall estimated prevalence of POAG in this study was slightly higher than that in the 
previous systematic review (1.0% vs. 0.7%) (Cheng et al., 2013a). The disparity between these 
two estimates might be explained by the combined effect of the different age and sex structures, 
and the different geographic features of the participants included in these two systematic 
reviews. Surprisingly, despite the substantial variation in the studies that were included as the 
basis for both reports, and further differences in adopted methods of meta-analysis, the 
prevalence of PACG in these two studies was almost identical - both at the level of 1.4%. This 
similarity in PACG prevalence supports the current understanding of the magnitude of PACG 
in China. 
The prevalence estimates of POAG and PACG were notably associated with advanced age in 
both sexes; this strong positive relationship matches the natural history of primary glaucoma, 
which was described in many previous studies. This association confirms the commonly 
accepted notion that primary glaucoma is an age-related disease (Eye Diseases Prevalence 
Research Group, 2004b, Gabelt and Kaufman, 2005, Quigley, 2011, Foster et al., 2000, 
Friedman et al., 2008, Xu et al., 2008). With increasing longevity, a striking increase in the 
prevalence and burden of glaucoma is likely, especially for primary glaucoma.  
The distribution patterns of POAG and PACG by sex were opposite, with POAG being the 
predominant subtype of glaucoma in males, and PACG in females. The female predilection 
for PACG has been widely acknowledged in previous studies, and could be linked to the 
aetiology of disease, differences in biological factors and environmental exposures between 
sexes (Friedman et al., 2008, Xu et al., 2008, Vajaranant et al., 2010, Cheng et al., 2013a, 
Cheng et al., 2014). However, the evidence of sex effect on POAG is still conflicting 
(Rudnicka et al., 2006, Kapetanakis et al., 2016, Vajaranant et al., 2010, Tham et al., 2014). 
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The findings in the present study disagree with the first systematic review of glaucoma 
prevalence in China, where a male predilection for POAG was not reported (Cheng et al., 
2013a). The discrepancy between these two studies might be explained by the inadequate study 
power to confirm associations. Further studies are still needed to explore the different effects 
of sex on the development of glaucoma, especially POAG, and for deciding different public 
health policies.  
In view of the general understanding that secondary glaucoma is caused by other ocular or 
systematic disorders that may lead to an increase in intraocular pressure, rather than a normal 
degenerative process with ageing, it was expected that no effects of age, sex or geographic 
factors would be seen (Quigley, 2011, Yamamoto et al., 2005). Only a pooled overall 
prevalence was generated for secondary glaucoma, with no separate subgroup analysis. In this 
study, the prevalence of secondary glaucoma was largely lower than that for East Asia (0.15% 
vs. 0.39%) (Chan et al., 2016). However, this relatively lower prevalence of secondary 
glaucoma, presented in this study, still needs to be confirmed with new data. There is little 
doubt that secondary glaucoma is less frequent in comparison with primary glaucoma; 
however, the disease burden caused by secondary glaucoma should never be underestimated 
or neglected, bearing in mind its visually destructive effects (Foster et al., 2000, Quigley, 
2011).  
In China, PACG was estimated to be responsible for the largest share of glaucoma, followed 
by POAG and secondary glaucoma. This finding confirms previous studies, which concluded 
that Chinese people might be more likely to develop PACG than any other ethnic groups in 
the world (Eye Diseases Prevalence Research Group, 2004b, He et al., 2006). Mechanisms 
underlying this phenomenon are controversial, but may be associated with the difference of 
anterior chamber and angle anatomy among races (Wong et al., 2006a, Congdon et al., 2002, 
Leung et al., 2010). In addition, given that PACG is more common in females than males, and 
females have a longer life expectancy than males, the burden of PACG is considerably 
concerning (United Nations, 2015b). The visual damages of PACG are more severe than of 
the other main subtypes of glaucoma, presenting an even greater public health challenge with 
a considerable social and economic impact (Foster and Johnson, 2001, Wong et al., 2006a).  
The higher prevalence of POAG in urban than in rural settings is in agreement with findings 
from studies conducted in China, and also with many other regions across the world (Tham et 
al., 2014, Cheng et al., 2013a, Chan et al., 2016). The reasons for this are not certain, but may 
be partly related to a higher myopia prevalence in urban areas, and to other potential risk 
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factors for POAG that vary greatly between urban and rural areas. Hypertension, diabetes, diet, 
physical activity and air pollution may also play a role (Tham et al., 2014, Chan et al., 2016, 
Kwon et al., 2009, Bonovas et al., 2004). With rapid urbanisation, the prevalence and burden 
of POAG may continue to increase in China (Gong et al., 2012, Zhang and Song, 2003). For 
PACG, people in Northeast China had the highest prevalence. An explanation for this 
geographic variation is an evolutionary modification of shallower anterior chambers that resist 
corneal freezing (Qu et al., 2011, Casson et al., 2007). However, these geographic variations 
might also be a product of differences in the studies included among regions. Future studies 
should be undertaken to assess geographical risk factors for glaucoma in more detail, to 
improve locally relevant policy-making on glaucoma. 
4.5.4 Implications for policy, practice and future 
research 
The findings of this study add insight to the knowledge of the epidemiology of glaucoma and 
have clear policy implications for China. Together with ageing demography, glaucoma, 
especially primary glaucoma, will place an ever-increasing burden on the already stretched 
health-care services in China, unless proactive preventive strategies are put in place. Despite 
advances in medical treatment, a cost-effective approach for detecting and diagnosing 
glaucoma is still lacking (Barton and Hitchings, 2013, Hernández et al., 2008a, Hernández et 
al., 2008b, Vaahtoranta‐Lehtonen et al., 2007). Indeed, a strong need remains for the 
development of an appropriate prevention and treatment framework to counter the growing 
burden of glaucoma in China, especially in rural and poor areas where medical resources are 
unevenly distributed. National and local efforts are also needed for the formulation of better 
medical systems and effective public health strategies informed by evidence, such as 
reallocating medical resources, improving access to health care, and health education on the 
importance of early examination. 
In the meantime, the need to scale up reliable data on glaucoma epidemiology in places where 
primary data have never been available has been highlighted in the present study. This is 
essential for both researchers and policymakers to improve understanding of the magnitude 
and distribution of this problem and the main risk factors. For a comprehensive assessment of 
glaucoma epidemiology in China, more robust evidence from studies using consistent methods 
across populations and further reviews of the prevalence of glaucoma are needed to 
corroborate the statements in the present study more reliably. 
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4.6 Conclusions 
In conclusion, this contemporary systematic review and meta-analysis suggests a substantial 
burden of glaucoma in China, with considerable variation among the different age groups, 
sexes, study settings and geographic regions. PACG is the predominant subtype of glaucoma 
in the general Chinese population, followed by POAG and secondary glaucoma. In the next 
three decades, the prevalence and burden of glaucoma will continue to increase with the 
current ageing trend. More elaborate epidemiological studies are needed to optimise public 
health strategies for mitigating this important health problem. 
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Chapter 5 The national and subnational 
prevalence and burden of cataract and 
cataract blindness in China 
5.1 Summary 
In this chapter, a systematic review was first conducted to derive all studies that reported the 
prevalence of cataract in China. Due to the vast heterogeneity in case definitions, the reported 
prevalence of cataract in China varied greatly between studies. After comparing the various 
definitions across studies, I chose the most commonly adopted definitions of cataract, ARC 
and cataract blindness. This was done to guarantee the possibility of subsequent quantitative 
syntheses, but might, in turn, restrict the ability of international comparison. By using the 
meta-regression approach, the age- and sex-specific prevalence of cataract and ARC was 
estimated. The prevalence of cataract blindness, however, was pooled by a random-effects 
meta-analysis because only study-level prevalence estimates were available. The national 
numbers of people with cataract and ARC were calculated by applying the age- and sex-
specific prevalence to the corresponding demographic data in the years 1990-2050. Similar to 
the case of secondary glaucoma, as described in Chapter 4, the number of people with cataract 
blindness was also generated by multiplying the population size from 1990-2050. This was 
done under the assumption that the prevalence of cataract blindness stayed and will continue 
to be constant during 1990-2050. By taking the effects of age, sex and geography, the national 
cataract cases were finally distributed into the six geographic regions in China. 
The work presented in this chapter has been published in the Journal of Global Health cited as 
“Song, P., Wang, H., Theodoratou, E., Chan, K. Y., & Rudan, I. (2018). The national and 
subnational prevalence of cataract and cataract blindness in China: a systematic review and 
meta-analysis. Journal of Global Health, 8(1), 010804. http://doi.org/10.7189/jogh.08-
010804”.  
I fully participated in the whole process of this project, including study conceptualisation and 
design, development of search strategy, systematic review, data extraction, data analysis and 
interpretation. I prepared the first draft of manuscript, which has been subsequently revised 
according to the comments from co-authors and anonymous peer reviewers during the 
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publishing process. The specific contributions of co-authors are as follows: Rudan, I. 
conceptualised and designed the study, Wang, H. conducted the dual systematic review and 
data extraction, Theodoratou, E., Chan, K. Y. and Rudan, I. critically reviewed the manuscript 
and approved the final manuscript.  
5.2 Background 
Cataract, defined as any opacity of the crystalline lens in the eye that affects clear vision, is a 
common condition in later life (Asbell et al., 2005, Kanski and Bowling, 2011, Liu et al., 2017). 
If left untreated, cataract can eventually progress to severe visual impairment or even blindness 
(Brian and Taylor, 2001, Pascolini and Mariotti, 2011). Compared with the general population, 
people with cataract are more likely to have substantially reduced vision-related quality of life 
and increased risk of comorbidity and mortality (Broman et al., 2002, Polack et al., 2007, Song 
et al., 2014, Hu et al., 2001, Nemet et al., 2010, Liu et al., 2017). Surgery is cost-effective and 
successful in restoring cataract-related vision loss (Busbee et al., 2002, Busbee et al., 2003, 
Lansingh et al., 2007). However, in many resource-deprived areas, especially remote and poor 
areas in developing countries, barriers in access to appropriate preventative eye care and 
surgical treatments still exist, presenting an enormous problem to the society in terms of social 
and economic burden (Nirmalan et al., 2004, Rabiu, 2001, Yin et al., 2009, Khanna et al., 
2011). Based on aetiology, cataract can be broadly classified as age-related, congenital, 
traumatic, secondary and drug-induced, etc., with age-related cataract (ARC) being the 
predominant subtype (Asbell et al., 2005, Liu et al., 2017).  
Despite the fact that cataract can be easily, safely and cost-efficiently treated with a standard 
procedure, cataract still remains the second leading cause of visual impairment and the first of 
blindness globally (Age-Related Eye Disease Study Research Group, 2001b, Liu et al., 2017, 
Pascolini and Mariotti, 2011). According to the latest estimates in 2010, 94 million people 
were visually impaired and 20 million were blind because of cataract, accounting for one third 
(33%) of all individuals with visual impairment and more than half (51%) of blind cases 
worldwide (Pascolini and Mariotti, 2011). Cataract is a multifactorial disease, with ageing 
being the major risk factor by far (Asbell et al., 2005, Liu et al., 2017). As people live longer, 
the prevalence of cataract is expected to rise correspondingly, posing challenges for health 
systems. From the public health perspective, understanding the magnitude of cataract and 
cataract blindness is the first step in prevention and treatment, and can provide a basis for 
evidence-based policy making and public health resources allocation (Klein and Klein, 2013). 
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Despite this, a comprehensive review of data regarding the prevalence and burden of cataract 
on a global basis has never, to the best of my knowledge, been documented previously. This 
may largely due to the difficulty of combining prevalence data from different national, regional, 
racial and ethnic groups, especially in cases where inconsistent definitions of cataract were 
adopted and a universally recognised standardisation was lacking.  
Similarly, in the largest developing country, China, few national-representative investigations 
have been conducted to provide precise estimates of the prevalence of cataract or cataract 
blindness in the general Chinese population. Nevertheless, a growing number of population-
based studies on the epidemiology of cataract have been conducted across the nation during 
the past decades, which have reported an overall cataract prevalence of from less than 10% to 
more than 50% in various samples (Sheng et al., 2016, Zhou and Jia, 2011, Fung, 2008, Xia 
et al., 2008). The substantial variations might largely come from the disparities of cataract 
definitions (e.g. with reduced visual acuity or not, different cut-offs for defining reduced visual 
acuity), as well as the different characteristics of individual studies (e.g. the age structure of 
the investigated population and the geographic location of the study sites) (Wong et al., 2006a, 
Zhou and Jia, 2011, Guan et al., 2012, Wang et al., 2014b). Until recently, no information has 
been compiled for the prevalence of cataract and cataract blindness in China, and the 
magnitude of the national number of people with cataract and cataract blindness in general 
Chinese population remains unclear. As Chinese population is progressively ageing, an 
increasing burden of cataract and cataract blindness is also expected (United Nations, 2015a, 
Zhang et al., 2012, Woo et al., 2002, Mai et al., 2013). If nothing else alters, the corresponding 
increased demand for cataract surgery will present new challenges for the Chinese health 
system.  
In view of uncertainties about the prevalence of cataract and cataract blindness in China, I 
conducted a comprehensive systematic review, in both Chinese and English databases, to 
retrieve all population-based studies that reported the prevalence of cataract or cataract 
blindness in China from 1990 onwards. By using standardised definitions of cataract and 
cataract blindness, I quantitatively summarised the prevalence of cataract and cataract 
blindness in China. Furthermore, the geographic patterns and secular trend of cataract/cataract 
blindness prevalence were also examined to add insights to the public health domain, assisting 
both researchers and policymakers to prioritise health-care resources needed. The principal 
aims of this study were: 1) to determine the prevalence and number of people affected by 
cataract and cataract blindness at the national level from 1990 to 2015; 2) to project the 
prevalence and number of people with cataract and cataract blindness at the national level till 
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2050; and 3) to examine regional differences in the prevalence of cataract and the number of 
affected people from 2000 to 2010. 
5.3 Methods 
5.3.1 Systematic review  
This systematic review and meta-analysis conforms to the Preferred Reporting Items for 
Systematic reviews and Meta-Analyses (PRISMA) guidelines and the Guidelines for Accurate 
and Transparent Health Estimates Reporting (GATHER) statement (Moher et al., 2009, 
Stevens et al., 2016). 
5.3.1.1 Search strategy 
Three Chinese and three English bibliographic databases, including China National 
Knowledge Infrastructure (CNKI), Wanfang, Chinese Biomedicine Literature Database 
(CBM-SinoMed), PubMed, Embase, and Medline, were searched using a comprehensive 
search strategy to identify all relevant articles on the prevalence of cataract or cataract 
blindness in general Chinese population published from January 1990 onwards. Search terms 
that related to cataract (“cataract” or “cataracts”), prevalence (“incidence”, “prevalence”, 
“morbidity”, “mortality”, “epidemiology”) and China (“China”, “Chinese”, “Hong Kong”, 
“Macau”, “Taiwan”) were combined in forms of controlled vocabularies (e.g. Medical Subject 
Heading terms) and free text terms. No language restrictions were placed in the search or in 
the selection process. The complete search strategies are described in Appendix table 19, 
which were conceived and adapted to fit features of different bibliographic databases. To 
supplement the database searches, reference lists of all included articles were also scrutinised 
to identify additional data sources. 
5.3.1.2 Inclusion and exclusion criteria 
To be included in the systematic review, studies needed to be population-based primary studies, 
reporting the prevalence of cataract or cataract blindness in Chinese population of a defined 
age and sex structure. Herein, the prevalence of cataract or cataract blindness should be 
calculated based on the number of affected individuals, rather than the number of affected eyes. 
Definitions of cataract/cataract blindness and measurements of visual acuity should be clearly 
stated. To avoid potentially biased information, I excluded hospital-based studies, studies that 
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were conducted among populations of Chinese origin but residing outside China, and those 
confined to a specific population that was not representative of the general population (people 
with a specific health condition, people covered by health insurance, etc.). Narrative reviews, 
case reports, commentaries, editorials, conference proceedings and studies without primary 
data or explicit methodologies were additionally excluded. Furthermore, studies that reported 
prevalence rates based on self-reported data were also excluded because an underestimation 
was very likely. For multiple articles that reported duplicated or overlapping data of the same 
single study, the one with the most representative results or largest sample size was kept.  
During the systematic review process, the definition of cataract was found to vary dramatically 
among studies (Appendix table 20): some studies defined cataract as the presence of lens 
opacities without diminished visual acuity, whereas other studies documented cataract in 
people with reduced visual acuity, which was determined by either best corrected visual acuity 
(BCVA) or presenting visual acuity (PVA) (Wang et al., 2014b, Zhou and Jia, 2011, Li et al., 
1999, Guan et al., 2012). The cut-offs of reduced visual acuity in different studies varied 
widely from 0.50 decimal Snellen (6/12) to 0.70 decimal Snellen (6/9) (Zhou and Jia, 2011, 
Wang et al., 2014b), and those for defining blindness ranged from 0.05 decimal Snellen (6/120) 
to 0.10 decimal Snellen (6/60) (Li et al., 1999, Guan et al., 2012). To ensure maximum 
comparability across studies and the ability to synthesise data from various studies, only 
studies that adopted a standardised definition of cataract or cataract blindness were eligible for 
the meta-analysis. Herein the standardised definitions of cataract and cataract blindness refer 
to the definitions that were most widely taken in Chinese epidemiological surveys (Table 5.1). 
In summary, cataract could be unilateral or bilateral, with reduced visual acuity (BCVA ≤0.70), 
and include pseudophakia/aphakia. Cataract was further categorised as any cataract (including 
all subtypes of cataract without further sub-classifications) or ARC (being explicitly indicated 
as the age-related subtype of cataract). Cataract blindness must be bilateral and include 
operated cases. Since it is generally impossible to obtain the preoperative visual acuity of an 
operated eye, if one person’s both eyes were operated on for cataract, he/she was presumed to 
have been bilaterally cataract blind preoperatively; or if only one eye was operated on for 
cataract and the fellow eye was blind because of cataract at the time of examination, then this 
person was also presumed to have bilateral cataract blindness (Guan et al., 2012, Sapkota et 
al., 2006, Nirmalan et al., 2002). Those basic assumptions about cataract blindness should be 
compiled into the included studies that reported the prevalence of cataract blindness. 
According to different cut-offs of visual acuity for defining blindness, cataract blindness was 
categorised as cataract blindness by BCVA <0.05, by BCVA <0.10 and by PVA <0.10 
respectively. 
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Table 5.1. The standardised definitions of cataract and cataract blindness in the 
systematic review 
Cataract 
1) Lens opacities presenting in at least one eye (unilateral or bilateral); 
2) With BCVA ≤0.70 in the cataract-affected eye;  
3) Including pseudophakia/aphakia. 
Cataract blindness 
1) being blind in the better-seeing eye caused by cataract;  
2) Including pseudophakia/aphakia. 
5.3.1.3 Study selection and data extraction 
All duplicate records within and between different bibliographic databases were identified and 
eliminated before conducting the formal systematic review. After screening the titles and 
abstracts of all retained records, the full texts of potentially relevant articles were retrieved and 
further appraised for inclusion against the eligibility criteria. All discrepancies were resolved 
through discussions until consensuses were reached. The quality of each included study was 
assessed based on the STROBE guideline (Table 2.1), where five bias components- sample 
population, sample size, participation rate, outcome assessment, and analytical methods were 
scored respectively. For each component, low risk was scored as 2, moderate risk as 1 and 
high risk and unclear as 0. The total score of the five components represented the overall 
quality of each study (Von Elm et al., 2007, Song et al., 2018). 
Finally, relevant data were extracted from the eligible articles by using a pilot tested and 
refined extraction table, which included three main categories: 
1) Characteristics of the study: authors, publication year, study setting, survey year, 
sampling method, study design (cross-sectional or cohort), case definition and 
assessment method; 
2) Characteristics of the investigated population: sample size, population type (urban or 
rural), sex (male or female), and age (age range, mean or median age, or midpoint of 
the age range); 
3) Prevalence data: the number of people with cataract/cataract blindness and the number 
of participants who had been tested, by age group, sex, setting and cataract/cataract 
blindness subtype where possible. 
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In cases where stratified prevalence estimates were not available by sex and setting, and only 
the overall estimates were reported, sex or setting were labelled as “mixed”. Studies were 
grouped into six geographic regions according to their study sites. Those geographic regions 
included North China, Northeast China, East China, South Central China, Southwest China 
and Northwest China, which were delineated by the National Bureau of Statistics of China 
(Table 2.2 and Figure 2.2) (National Bureau of Statistics, 2002, National Bureau of Statistics, 
2012, Song et al., 2017c, Song et al., 2017b). If people in different geographic areas were 
examined in the same study, prevalence data were extracted for each geographic area 
separately, where available. For four studies where the years of survey were not specified, 
three years were subtracted from their publication years to impute the survey years, which was 
based on the average time lag from survey to publication in studies that provided such 
information (see Appendix table 21). For studies that reported censoring age groups, e.g. 
older than 80 years, less than 50 years, the missing age band was imputed by taking the same 
width as other age groups in the same study. 
5.3.2 Statistical analysis 
5.3.2.1 Epidemiological modelling of cataract prevalence and 
pooled prevalence of cataract blindness 
Before synthesising the abstracted data, unadjusted prevalence of cataract (any cataract and 
ARC) and cataract blindness (by BCVA <0.05, by BCVA <0.10 and by PVA <0.10) was firstly 
calculated on the basis of crude numerators and denominators derived from individual studies. 
In this study, random-effects meta-analysis was performed throughout because sizeable 
heterogeneity of reported prevalence in different studies was suggested (Appendix table 22).  
For cataract, multiple outcome measurements were available within a single study. To 
accommodate for this hierarchical data structure (clustering of different stratum-specific 
prevalence rates from the same study), a multilevel mixed-effects meta-regression model was 
fitted (Hox et al., 2010, Viechtbauer, 2010). Before constructing models for estimating the 
prevalence of cataract, the associations of prevalence rates and study-level variables of interest, 
i.e., age, sex (male and female), setting (urban, rural and mixed), geographic region and survey 
year were first explored using univariable meta-regression. This was done for any cataract and 
ARC separately. Age and sex were identified as variables that were commonly associated with 
the prevalence of both any cataract and ARC (Table 5.2).  
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Table 5.2. The Unadjusted odds ratios for any cataract and ARC in terms of 
demographic and geographic factors from univariable meta-regression models, with 95% 
confidence intervals 
Variable 
Any cataract ARC 
Number of 
studies 
OR (95% CI) 
Number of 
studies 
OR (95% CI) 
Age (per decade increase) 35 3.34 (3.29-3.40)* 10 2.74 (2.65-2.84)* 
Sex$     
Female 29 Reference 10 Reference 
Male 29 0.79 (0.77-0.80)* 10 0.67 (0.64-0.71)* 
Setting     
Mixed 10 Reference 2 Reference 
Rural 14 1.35 (0.86-2.12) 5 1.19 (0.20-7.12) 
Urban 13 0.76 (0.49-1.20) 4 1.71 (0.25-11.61) 
Geographic region     
East 15 Reference   
North 6 0.48 (0.22-1.05)^   
Northeast 2 0.87 (0.30-2.49)   
Northwest 5 0.74 (0.34-1.63)   
South Central 4 1.56 (0.71-3.43)   
Southwest 3 1.08 (0.44-2.61)   
Survey year (per decade 
increase) 
35 1.27 (0.85-1.89) 10 0.50 (0.15-1.65) 
Note: * statistically significant (p<0.05); ^ p<0.1; $ the effect of sex was estimated based on 
studies that reported sex-specific cataract prevalence; the effect of geographic region on the 
prevalence of ARC was not conducted because of the deficiency of available information. 
For the purpose of producing the national “envelopes” (total number of cases) of any cataract 
and ARC, the age- and sex-specific prevalence estimates of any cataract and ARC were 
developed. Given that: 




Then, the prevalence rates were transformed using a logit link (Barendregt et al., 2013): 
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logit(𝑝) = log𝑒 (
𝑝
1 − 𝑝
) = log𝑒(𝑜𝑑𝑑𝑠) = 𝛼 + 𝛽1 ∗ 𝑥1 + 𝛽2 ∗ 𝑥2 + ⋯ 𝛽𝑛 ∗ 𝑥𝑛 
Given age and sex were the prespecified variables: 
logit(𝑝) = 𝛼 + 𝛽1 ∗ (𝑎𝑔𝑒) + 𝛽2 ∗ (𝑠𝑒𝑥) 





For cataract blindness, the stratum-specific prevalence rates were not universally available in 
the included studies. Therefore, the pooled prevalence, with 95% confidence intervals (CIs), 
was obtained from a random-effects meta-analysis model (DerSimonian and Laird method) 
with inverse-variance weighting. The variance of prevalence was also stabilised with the logit 
transformation (Barendregt et al., 2013). To check whether a single study disproportionally 
influenced the pooled results, the sensitivity analysis was conducted by removing one study at 
a time to run the meta-analysis without it (Wallace et al., 2009). I also assessed the publication 
bias by visual inspection of funnel plots test (Egger et al., 1997). Due to the small number of 
studies that reported the prevalence of cataract blindness, Egger's regression test for funnel 
plot asymmetry and Begg’s rank correlation test were not performed (Egger et al., 1997, Begg 
and Mazumdar, 1994, Peters et al., 2006) 
5.3.2.2 Estimation of the national number of people with 
cataract and cataract blindness from 1990 to 2015 
The total number of people affected by cataract (“cataract envelope”, including post-surgical 
cases) in China was generated by applying the modelled age- and sex-specific prevalence for 
each 5-year age group to the corresponding population subgroup in China, available from the 
United Nations Population Division (UNPD) (United Nations, 2015b). This was performed 
for any cataract and ARC respectively in the years 1990, 2000, 2010 and 2015. 
For cataract blindness, the age- and sex-specific prevalence estimates were not specifically 
constructed, the overall number of people affected by cataract blindness (including post-
surgical cases) was, therefore, estimated by multiplying the pooled prevalence of cataract 
blindness by the national population. This was conducted for the three subgroups of cataract 
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blindness determined by different definitions of blindness (by BCVA <0.05, by BCVA <0.10 
and by PVA <0.10) from 1990 to 2015. 
5.3.2.3 Projection of the national number of people with 
cataract and cataract blindness from 2020 to 2050 
To derive the projected number of people with cataract/cataract blindness (including post-
surgical cases) for the period 2020-2050, the age- and sex-specific prevalence of cataract and 
the pooled prevalence of cataract blindness were assumed to stay constant over time. For 
cataract, this assumption was supported by the univariable meta-regression models, where no 
significant association between survey year and the prevalence of cataract (both any cataract 
and ARC) was detected (Table 5.2). The national number of people living with cataract and 
cataract blindness from 2020 to 2050 was projected by following the same approach as used 
for deriving the national number of cataract and cataract blindness cases from 1990 to 2015. 
The demographic projection was taken from the UNPD medium variant population scenario, 
which was underpinned by assumptions about future fertility and mortality (United Nations, 
2015b, Lee and Zhou, 2017). 
5.3.2.4 Effects of demographic and geographic factors on the 
prevalence of cataract 
Where appropriate (at least seven contributing estimates should be available for each variable 
(Vittinghoff and McCulloch, 2007)), the effects of demographic (i.e., age, sex) and geographic 
features (i.e., setting, geographic region) on the prevalence of cataract were initially assessed 
by univariable meta-regression models. The effect of survey year on the prevalence of cataract 
was also explored by introducing the survey year into the models. Finally, all variables with p 
values of less than 0.1 in univariable meta-regression models were entered into the 
multivariable meta-regression. 
5.3.2.5 Estimation of the subnational number of people with 
cataract from 2000 to 2010 
To generate the number of people with cataract in the six geographic regions, an “envelope” 
approach was adopted. This “envelope” approach was previously endorsed by the Child Health 
Epidemiology Reference Group (CHERG), and has, since, been widely advocated in the 
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disease burden domain (Rudan et al., 2004, Fowkes et al., 2013, Song et al., 2016, Song et al., 
2017b, Song et al., 2017c, Bourne et al., 2017). First, based on the final multivariable meta-
regression that took the effects of demographic and geographic features into account, cataract 
prevalence in each geographic region was calculated respectively. Then the regional cases of 
cataract were estimated by multiplying the regional cataract prevalence by their corresponding 
population. Finally, the regional cataract cases were adjusted to fit into the national “cataract 
envelope”. This was done for the years 2000 and 2010, where the regional population data 
could be derived from the fifth and sixth censuses respectively (National Bureau of Statistics, 
2002, National Bureau of Statistics, 2012).  
The overall study design is shown in Figure 5.1. All statistical analyses were done with R, 
version 3.3.0 (R Foundation for Statistical Computing, Vienna, Austria) with the packages 
meta (version 4.8-4), metafor (version 2.0-2) and ggplot2 (version 2.2.1) (R Core Team, 2013). 
A two-sided p-value of less than 0.05 was regarded as indicative of statistically significant, 
unless otherwise specified. All maps were created using ArcMap version 10.1 (Environmental 
Systems Research Institute, Redlands, CA, USA), based on the China base map (in shapefile 
format) obtained from the Global Administrative Areas (GADM) database (GADM, 2015, 
version 2.0; www.gadm.org). 
 
Figure 5.1. Overall study design flowchart for the prevalence and burden of cataract and 
cataract blindness study in China 
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5.4 Results 
5.4.1 Summary of systematic review 
The initial literature search yielded a total of 16345 citations. After removing 8181 duplicates, 
the titles and abstracts of 8164 unique records were screened for relevance. Of these, 1414 
potentially relevant articles were reviewed in full-text form and 1359 were subsequently 
excluded. Finally, 55 studies met the eligibility criteria and were included in the systematic 
review and meta-analysis. The review process is summarised in Figure 5.2 as a PRISMA 
flowchart. A list of the included studies is available in Appendix table 23. 
 
Figure 5.2. Systematic review flow diagram of studies on cataract and cataract blindness 
prevalence in China 
Note: *Reason 1-Studies that were conducted in in people with unrepresentative 
characteristics of general population (hypertensive patients, people with reduced vision, etc.); 
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*Reason 2-Studies that were not population-based; *Reason 3-Studies that relied on self-
reported diagnoses of cataract or cataract blindness; *Reason 4-Articles with no numerical 
prevalence measure of cataract or cataract blindness; *Reason 5-Studies that didn’t adopt the 
standardised definitions of cataract and cataract blindness; *Reason 6-Multiple publications 
of the same study; *Reason 7-Studies that were not based in China. 
Table 5.3 summarises the main characteristics of the 55 included studies. All those studies 
were cross-sectional in design, among which the majority were published in this decade (from 
2010 onwards). Most studies were relatively large, with more than 2000 participants. Almost 
all studies provided sex-specific data, enabling the exploration of sex difference in cataract 
prevalence. Of the included studies, 35 studies examined the prevalence of any cataract, ten 
provided prevalence data on ARC; eight studies focused on the prevalence of cataract 
blindness by BCVA<0.05, nine on the prevalence of cataract blindness by BCVA<0.10, and 
12 on the prevalence of cataract blindness by PVA<0.10. The diverse geographical areas 
covered by the included studies are shown in Figure 5.3, and the detailed characteristics and 
quality assessments of all included studies are demonstrated in Appendix table 24 and 
Appendix table 25. 
Table 5.3. Main characteristics of the included studies on cataract and cataract blindness 
in China (n=55) 
Characteristic 


















Year published      
1990-1999 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (8.3) 
2000-2009 10 (28.6) 6 (60.0) 4 (50.0) 0 (0.0) 4 (33.3) 
2010-2017 25 (71.4) 4 (40.0) 4 (50.0) 9 (100.0) 7 (58.3) 
Setting      
Urban 11 (31.4) 3 (30.0) 3 (37.5) 0 (0.0) 4 (33.3) 
Rural 12 (34.3) 4 (40.0) 3 (37.5) 5 (55.6) 5 (41.7) 
Mixed 10 (28.6) 2 (20.0) 1 (12.5) 4 (44.4) 2 (16.7) 
Both 2 (5.7) 1 (10.0) 1 (12.5) 0 (0.0) 1 (8.3) 
Sex      
Mixed 4 (11.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
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Characteristic 


















Both 31 (88.6) 10 (100.0) 8 (100.0) 9 (100.0) 12 (100.0) 
Sample size      
≤2000 7 (20.0) 4 (40.0) 1 (12.5) 1 (11.1) 1 (8.3) 
2001-5000 11 (31.4) 2 (20.0) 5 (62.5) 1 (11.1) 6 (50.0) 
5001–10000 12 (34.3) 3 (30.0) 2 (25.0) 5 (55.6) 4 (33.3) 
>10000 5 (14.3) 1 (10.0) 0 (0.0) 2 (22.2) 1 (8.3) 
Geographic region$      
North China 6 (17.1) 3 (20.0) 2 (25.0) 2 (15.4) 2 (16.7) 
Northeast China 2 (5.7) 1 (6.7) 1 (12.5) 1 (7.7) 0 (0.0) 
East China 15 (42.9) 3 (20.0) 2 (25.0) 7 (53.8) 4 (33.3) 
South Central China 4 (11.4) 2 (13.3) 0 (0.0) 1 (7.7) 1 (8.3) 
Southwest China 3 (8.6) 2 (13.3) 2 (25.0) 1 (7.7) 5 (41.7) 
Northwest China 5 (14.3) 4 (26.7) 1 (12.5) 1 (7.7) 0 (0.0) 
Quality score      
10 10 (28.6) 1 (10.0) 3 (37.5) 7 (77.8) 5 (41.7) 
9 9 (25.7) 3 (30.0) 2 (25.0) 1 (11.1) 4 (33.3) 
8 3 (8.6) 2 (20.0) 1 (12.5) 0 (0.0) 2 (16.7) 
7 10 (28.6) 3 (30.0) 1 (12.5) 1 (11.1) 1 (8.3) 
6 3 (8.6) 1 (10.0) 1 (12.5) 0 (0.0) 0 (0.0) 
Note: *Some studies reported the prevalence estimates of any cataract, ARC, cataract 
blindness by BCVA<0.05, cataract blindness by BCVA<0.10 and cataract blindness by 
PVA<0.10 simultaneously, therefore the sum of the number of studies exceeded 55. $ Some 
studies covered more than one geographic region, therefore the sum of coved geographic 
regions exceeded the sum of studies.  
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Figure 5.3. Geographical distribution of the included studies on cataract and cataract 
blindness prevalence in China (n=55) 
5.4.2 Age- and sex-specific prevalence of cataract and 
pooled prevalence of cataract blindness 
For cataract, a substantial number of data points from the included studies guaranteed my 
ability to construct the relation between age and prevalence (Figure 5.4). The age range 
covered by informative data points for any cataract was wider than that for ARC. To ensure 
the comparability of the estimated prevalence of any cataract and ARC, the age range in this 
study was set as from 45 to 89 years, where the most informative data points concentrated. 
The effect of sex on the prevalence of cataract was also assessed based on studies that provided 
sex-specific cataract prevalence (Table 5.2). 
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Figure 5.4. Age-specific prevalence of cataract and ARC based on informative data 
points from the included studies 
Note: The size of each bubble is proportional to the sample size. For cataract, there were 143 
data points for constructing the relation between age and prevalence; For ARC, there were 
66. 
Table 5.4 and Figure 5.5 demonstrate the estimated age- and sex-specific prevalence of any 
cataract and ARC. Generally, the prevalence of any cataract and ARC was higher in females 
than in males, and both showed a steady rise with advanced age. In males, the prevalence of 
any cataract ranged from 6.71% (95% CI: 5.06-8.83) in people aged 45-49 years to 73.01% 
(95% CI: 65.78-79.2) in elderly aged 85-89 years. In females, the prevalence of any cataract 
increased from 8.39% (95% CI: 6.36-10.98) in individuals aged 45-49 years to 77.51% (95% 
CI: 71.00-82.90) in those aged 85-89 years. In the case of ARC, the prevalence rates ranged 
from 3.23% (95% CI: 1.51-6.80) in males aged 45-49 years to 65.78% (95% CI: 46.72-80.82) 
in those aged 85-89 years. The prevalence of ARC in females was consistently higher than 
that in males, ranging from 4.72% (95% CI: 2.22-9.76) in the 45-49 years age group to 74.03% 
(95% CI: 56.53-86.21) in the 85–89 years age group. 




Prevalence of any cataract (%, 95% CI) Prevalence of ARC (%, 95% CI) 
Male Female Male Female 
45-49 
years 
6.71  8.39  3.23  4.72  
(5.06-8.83) (6.36-10.98) (1.51-6.80) (2.22-9.76) 
50-54 
years 
10.16  12.59  5.25  7.59  
(7.91-12.97) (9.86-15.95) (2.48-10.76) (3.64-15.17) 
15.11  18.49  8.42  12.00  
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Age 
group 
Prevalence of any cataract (%, 95% CI) Prevalence of ARC (%, 95% CI) 
Male Female Male Female 
55-59 
years (12.06-18.77) (14.88-22.73) (4.07-16.64) (5.91-22.84) 
60-64 
years 
21.89  26.30  13.24  18.46  
(17.86-26.53) (21.69-31.50) (6.58-24.87) (9.46-32.92) 
65-69 
years 
30.60  35.97  20.22  27.31  
(25.45-36.29) (30.31-42.05) (10.47-35.45) (14.78-44.88) 
70-74 
years 
40.97  46.92  29.60  38.41  
(34.69-47.55) (40.36-53.59) (16.23-47.71) (22.33-57.50) 
75-79 
years 
52.20  58.18  41.10  50.86  
(45.07-59.25) (51.10-64.94) (24.30-60.28) (32.25-69.24) 
80–84 
years 
63.22  68.65  53.67  63.21  
(55.73-70.12) (61.59-74.93) (34.67-71.65) (44.05-78.94) 
85-89 
years 
73.01  77.51  65.78  74.03  
(65.78-79.20)  (71.00-82.90)  (46.72-80.82) (56.53-86.21) 
 
Figure 5.5. Estimated age- and sex-specific prevalence of any cataract and ARC in China, 
with 95% confidence intervals 
For cataract blindness, the pooled prevalence estimates by random-effects meta-analyses are 
shown in Figure 5.6. Overall, the pooled prevalence of cataract blindness by BCVA <0.05 
was 2.30% (95% CI: 1.72-3.07) and that of cataract blindness by BCVA <0.10 was 2.56% (95% 
CI: 1.94-3.38). At a more relaxed threshold level for defining blindness, the pooled prevalence 
of cataract blindness by PVA <0.10 was 4.51% (95% CI: 3.53-5.75). According to the leave-
one-out sensitivity analysis, no single study had a substantial influence on the overall 
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prevalence of cataract blindness, where the pooled prevalence of cataract blindness by 
BCVA<0.05 ranged from 2.11% (95% CI: 1.59-2.81) to 2.45% (95% CI: 1.82-3.30), that of 
cataract blindness by BCVA<0.10 from 2.38% (95% CI: 1.98-2.87) to 2.67% (95% CI: 2.00-
3.55), and that of cataract blindness by PVA<0.10 from 4.28% (95% CI: 3.32-5.49) to 4.81% 
(95% CI: 3.81-6.06) (Figure 5.7). The asymmetrical shape of funnel plots revealed some 
evidence of potential publication bias (Figure 5.8). 
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Figure 5.6. Forest plots of cataract blindness prevalence in China 
Note: Data were pooled by a random-effects model; the size of the blue shaded areas is 
proportional to the weight of each study. 
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Figure 5.7. Leave-one-out sensitivity analysis of the influence of single study on the 
pooled prevalence of cataract blindness in China 
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Figure 5.8. Funnel plot for the assessment of publication bias of the studies on the 
prevalence of cataract blindness in China 
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5.4.3 National number of people with cataract and 
cataract blindness from 1990 to 2015 
For cataract, the numbers of people with any cataract and ARC were computed by applying 
the age- and sex-specific prevalence rates to the correspondingly stratified national population 
aged 45-89 years in the years 1990, 2000, 2010 and 2015 (Table 5.5 and Appendix table 26). 
At the national level, the prevalence of any cataract in people aged 45-89 years slightly 
decreased by 1.13%, from 22.21% (95% CI: 18.46-26.42) in 1990 to 21.96% (95% CI: 18.26-
26.10) in 2015. During this period, the prevalence of ARC in people 45-89 years of age ranged 
from 15.65% (95% CI: 8.67-26.06) to 15.53% (95% CI: 8.67-25.71), indicating an overall 
decreasing rate of 0.79%. Despite the gentle decline in prevalence estimates within this time 
frame, there was a considerable increase in the national number of people with cataract. In 
people aged 45-89 years, the number of any cataract cases was 50.75 million (95% CI: 42.17-
60.37) in 1990 and 111.74 million (95% CI: 92.94-132.84) in 2015, and that of ARC cases 
rose from 35.77 million (95% CI: 19.81-59.55) in 1990 to 79.04 million (95% CI: 44.14-
130.85) in 2015, which yielded overall increasing rates of 120.19% and of 120.96% 
respectively throughout this period. In 2015, around 71% of the cataract cases were the age-
related subtype, and the age group that contributed the most cases was 60-64 years for both 
any cataract and ARC (Figure 5.9). 
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Table 5.5. Estimated prevalence and number of people with cataract and cataract blindness in China from 1990 to 2015 
Type 
Prevalence (%, 95% CI) Relative rate of change 
(%, 1990-2015) 1990 2000 2010 2015 
Any cataract 22.21 (18.46-26.42) 21.62 (17.97-25.72) 21.96 (18.26-26.11) 21.96 (18.26-26.10) -1.13 
ARC 15.65 (8.67-26.06) 15.27 (8.51-25.31) 15.53 (8.67-25.71) 15.53 (8.67-25.71) -0.79 
Cataract blindness (BCVA<0.05) 2.3 (1.72-3.07) - 
Cataract blindness (BCVA<0.10) 2.56 (1.94-3.38) - 
Cataract blindness (PVA<0.10) 4.51 (3.53-5.75) - 
Type 
Number of people with disease (million, 95% CI) Relative rate of change 
(%, 1990-2015) 1990 2000 2010 2015 
Any cataract 50.75 (42.17-60.37) 68.33 (56.79-81.29) 94.07 (78.24-111.84) 111.74 (92.94-132.84) +120.19 
ARC 35.77 (19.81-59.55) 48.26 (26.89-79.99) 66.54 (37.15-110.14) 79.04 (44.14-130.85) +120.96 
Cataract blindness (BCVA<0.05) 5.26 (3.93-7.02) 7.27 (5.44-9.70) 9.85 (7.37-13.15) 11.71 (8.75-15.62) +122.72 
Cataract blindness (BCVA<0.10) 5.85 (4.43-7.72) 8.09 (6.13-10.68) 10.97 (8.31-14.48) 13.03 (9.87-17.20) +122.72 
Cataract blindness (PVA<0.10) 10.31 (8.07-13.14) 14.25 (11.16-18.17) 19.32 (15.12-24.63) 22.95 (17.97-29.26) +122.72 
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Figure 5.9. Estimated sex-specific number of people with any cataract and ARC in China 
from 1990 to 2015, with contributing age groups 
For cataract blindness, the overall prevalence was assumed to be constant over the period 
1990-2015, but even so, an increasing trend in cataract-blind cases was witnessed (Table 5.5). 
From 1990 to 2015, the number of people with cataract blindness by BCVA<0.05 (aged 45-
89 years) increased from 5.26 million (95% CI: 3.93-7.02) to 11.71 million (95% CI: 8.75-
15.62), and those with cataract by BCVA<0.10 rose from 5.85 million (95% CI: 4.43-7.72) to 
13.03 million (95% CI: 9.87-17.20). By using the cut-off of PVA<0.10 for defining blindness, 
the number of people with cataract blindness (aged 45-89 years) ranged from 10.31 million 
(95% CI: 8.07-13.14) to 22.95 million (95% CI: 17.97-29.26) within the same time frame.  
5.4.4 Projection of national number of people with 
cataract and cataract blindness from 2020 to 
2050 
For cataract, the projection of national affected cases from 2020 to 2050 was based on the 
assumption that the age- and sex-specific prevalence of any cataract and ARC would remain 
constant over time. By extrapolating the estimated age- and sex-specific prevalence of any 
cataract and ARC to the UNPD data, the numbers of people with any cataract and ARC were 
projected up to the year 2050 (Table 5.6 and Appendix table 26). Given the demographic 
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changes over the next three decades, the prevalence of any cataract in people aged 45-89 years 
is expected to increase from 22.78% (95% CI: 18.98-27.03) to 33.34% (95% CI: 28.53-38.40), 
and that of ARC from 16.21% (95% CI: 9.07-26.72) to 25.93% (95% CI: 15.67-38.94) 
between the years 2020 and 2050, which will indicate increasing rates of 46% and 60% 
respectively. In people aged 45-89 years, the total number of affected cases is projected to 
keep increasing, with the number of those with ARC at a higher rate than those with any 
cataract (100% vs. 83%). In 2020, the total number of people with any cataract (aged 45-89 
years) will be 131.92 million (95% CI: 109.91-156.49), and this figure is projected to increase 
to 240.83 million (95% CI: 206.07-277.35) by the year 2050. Among them, the number of 
people with ARC is projected to grow relatively rapidly from 93.83 million (95% CI: 52.52-
154.69) in 2020 to 187.26 million (95% CI: 113.17-281.23) in 2050. By then, ARC will 
account for 78% of all cataract cases in China, and the age group where most cases concentrate 
will be 75-79 years for any cataract and 80-84 years for ARC (Figure 5.10).  
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Table 5.6. Projected prevalence and number of people with cataract and cataract blindness in China from 2020 to 2050 
Type 
Prevalence (%, 95% CI) Relative rate of change 
(%, 2020-2050) 2020 2000 2010 2050 
Any cataract 22.78 (18.98-27.03) 26.64 (22.40-31.27) 29.33 (24.88-34.12) 33.34 (28.53-38.40) +46.35 
ARC 16.21 (9.07-26.72) 19.53 (11.15-31.32) 22.17 (13.02-34.38) 25.93 (15.67-38.94) +59.98 
Cataract blindness (BCVA<0.05) 2.30 (1.72-3.07) - 
Cataract blindness (BCVA<0.10) 2.56 (1.94-3.38) - 
Cataract blindness (PVA<0.10) 4.51 (3.53-5.75) - 
Type 
Number of people with disease (million, 95% CI) Relative rate of change 
(%, 2020-2050) 2020 2030 2040 2050 
Any cataract 131.92 (109.91-156.49) 175.01 (147.16-205.46) 218.41 (185.24-254.01) 240.83 (206.07-277.35) +82.56 
ARC 93.83 (52.52-154.69) 128.33 (73.24-205.78) 165.08 (96.98-255.97) 187.26 (113.17-281.23) +99.57 
Cataract blindness (BCVA<0.05) 13.32 (9.96-17.78) 15.11 (11.30-20.17) 17.12 (12.81-22.86) 16.61 (12.42-22.17) +24.75 
Cataract blindness (BCVA<0.10) 14.82 (11.23-19.57) 16.82 (12.75-22.21) 19.06 (14.44-25.17) 18.49 (14.01-24.41) +24.75 
Cataract blindness (PVA<0.10) 26.11 (20.44-33.29) 29.63 (23.19-37.78) 33.58 (26.28-42.81) 32.58 (25.50-41.53) +24.75 
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Figure 5.10. Projected sex-specific number of people with any cataract and ARC in 
China from 2020 to 2050, with contributing age groups 
For cataract blindness (Table 5.6), the number of people with cataract blindness by 
BCVA<0.05 (aged 45-89 years) is projected to rise from 13.32 million (95% CI: 9.96-17.78) 
in 2020 to 16.61 million (95% CI: 12.42-22.17) in 2050, while those with cataract by 
BCVA<0.10 (aged 45-89 years) from 14.82 million (95% CI: 11.23-19.57) to 18.49 million 
(95% CI: 14.01-24.41) during this period. When applying a less stringent cut-off of PVA<0.10 
for blindness, the number of people with cataract blindness (aged 45-89 years) is expected to 
grow from 26.11 million (95% CI: 20.44-33.29) in 2020 to 32.58 million (95% CI: 25.50-
41.53) in 2050. 
5.4.5 Effects of demographic and geographic factors 
on the prevalence of cataract 
Results from the univariable meta-regression analyses revealed that age and sex were 
significantly associated with the prevalence of both any cataract and ARC, with older people 
and females having higher prevalence rates. No secular trend or urban-rural difference in the 
prevalence of any cataract or ARC were revealed (Table 5.2). In addition, a weaker association 
was seen for the geographic distribution of any cataract prevalence, where people living in 
North China were suggested to be with a relatively lower prevalence than those in East China 
(p<0.1).  
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For the purpose of constructing a multivariable regression model, insufficient data were 
available for ARC. Therefore, a multivariable regression model that took the effects of age, 
sex and geographic region simultaneously was only developed for any cataract: 
logit(𝑝) = −6.740 + 0.091 ∗ 𝐴𝑔𝑒 + (−0.242) ∗ 𝐺𝑒𝑛𝑑𝑒𝑟𝑚𝑎𝑙𝑒 + 𝑈𝑟𝑒𝑔𝑖𝑜𝑛 + 𝑢𝑖 
Where 𝑝 indicates the prevalence of any cataract; 𝐴𝑔𝑒 refers to the absolute value of age, 
𝐺𝑒𝑛𝑑𝑒𝑟𝑚𝑎𝑙𝑒=1 for males and =0 for females; 𝑈𝑟𝑒𝑔𝑖𝑜𝑛 represents the region-level effect, which 
equals to 0 for East China, -0.269 for North China, 0.486 for Northeast China, -0.075 for 
Northwest China, 0.636 for South Central China and 0.125 for Southwest China; 𝑢𝑖=variance 
of the study level random effect. 
5.4.6 Regional number of people with any cataract 
from 2000 to 2010 
Based on the final formula for developing the age- and sex-specific prevalence of any cataract 
in different regions, the national cases of any cataract in the years 2000 and 2010 were 
respectively allocated into the six geographic regions in China (Table 5.7; see Appendix table 
27 for more details). In 2000, the prevalence of any cataract in people aged 45-89 years was 
21.62% (95% CI: 17.97-25.72) in China, varying from 15.05% (95% CI: 11.39-19.43) in North 
China to 28.38% (95% CI: 23.80-32.92) in South Central China. In 2010, the national 
prevalence of any cataract in people aged 45-89 years rose to 21.96% (95% CI: 18.26-26.11). 
The region with the highest prevalence of any cataract was still South Central China (28.50% 
[95% CI: 23.91-33.07]) and that with the lowest prevalence of any cataract was still North 
China (15.03% [95% CI: 11.39-19.43]). During 2000-2010, the prevalence of any cataract 
slightly increased by 1.57%, with the most pronounced increase occurring in Southwest China 
(7.31%). Northeast China was the only region with a declining rate in the prevalence of any 
cataract (0.11%) during this period. 
Table 5.7. Estimated prevalence and number of people with any cataract in China from 
2000 to 2010, by geographic region 
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Region 
Prevalence of any cataract (%, 
95% CI) 
Number of people with any 
cataract (million, 95% CI) 
Relative rate of 
change (%, 2000-
2010) 
2000 2010 2000 2010 Prevalence Cases 
North China 
15.05  15.03  5.62  8.13  
-0.11 +44.53 
(11.39-19.43) (11.39-19.43) (4.26-7.26) (6.16-10.50) 
Northeast 
China 
24.14  24.57  6.80  10.30  
+1.77 +51.34 
(15.86-33.25) (16.20-33.80) (4.47-9.37) (6.79-14.16) 
East China 
19.36  19.53  18.89  25.72  
+0.88 +36.17 
(18.85-20.32) (19.05-20.49) (18.39-19.83) (25.09-26.98) 
South Central 
China 
28.38  28.50  23.50  31.79  
+0.41 +35.25 
(23.80-32.92) (23.91-33.07) (19.70-27.26) (26.67-36.88) 
Southwest 
China 
20.24  21.72  10.14  13.28  
+7.31 +30.94 
(14.75-26.47) (16.01-28.02) (7.39-13.26) (9.79-17.13) 
Northwest 
China 
16.83  17.33  3.37  4.87  
+3.00 +44.30 
(12.88-21.51) (13.34-22.01) (2.58-4.31) (3.75-6.18) 
China 
21.62  21.96  68.33  94.07  
+1.57 +37.67 
(17.97-25.72) (18.26-26.11) (56.79-81.29) (78.24-111.84) 
As demonstrated in Table 5.7 and Figure 5.11, a total of 68.33 million (95% CI: 56.79-81.29) 
people aged 45-89 years were affected by any cataract in 2000. Among them, more than one-
third (34%) were living in South Central China (23.50 million [95% CI: 19.70-27.26]) and 
only 5% were in Northwest China (3.37 million [95% CI: 2.58-4.31]). With the demographic 
ageing trend in China, the national number of people (aged 45-89 years) with any cataract 
reached to 94.07 million (95% CI: 78.24-111.84) by 2010. At the regional level, the number 
of people with any cataract was still the largest in South Central China (31.79 million [95% 
CI: 26.67-36.88]) and the smallest in Northwest China (4.87 million [95% CI: 3.75-6.18])-
equivalent to 34% and 5% of the national cases of any cataract in 2010 respectively. Over the 
decade from 2000 to 2010, the number of people with any cataract increased by 38% at the 
national level. For the six geographic regions, the most marked increase was seen in Northeast 
China (51%) and the least in Southwest China (31%). In 2010, the age group that contributed 
the most cases of any cataract was 55-59 years in North China, Northeast China and South 
Central China, 65-69 years in Southwest China, and 70-74 years in East China and Northwest 
China. 
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Figure 5.11. Estimated regional number of people with any cataract and contributing 
age groups in the years 2000 and 2010 
5.5 Discussion 
5.5.1 Statement of principal findings 
By using all published evidence on the prevalence of cataract and cataract blindness in general 
Chinese population, this systematic review and meta-analysis, for the first time, provides the 
most comprehensive figures for the prevalence of cataract and cataract blindness in China at 
both the national and subnational levels. The data-driven estimates show that the number of 
people affected by cataract and cataract blindness in China is dramatic. From 1990 to 2015, 
more than one in five (around 22%) people aged 45-89 years were affected by any cataract, 
representing a total of 50.75 million and 111.74 million cases in the years 1990 and 2015 
respectively. Among them, around 71% were with the age-related subtype of cataract. For 
cataract blindness, the pooled prevalence varied substantially according to different cutoffs for 
defining blindness, from 2.30% for cataract blindness by BCVA <0.05 to 4.51% for cataract 
blindness by PVA <0.10. As the Chinese population ages, the prevalence of cataract and the 
number of affected people will correspondingly increase in years to come. By the year 2050, 
the national cases of any cataract in people aged 45-89 years are projected to more than double 
to 240.83 million, giving a prevalence of one-third (33.34%). At that time, ARC will account 
for 78% of all cataract cases in China. Moreover, substantial geographic variations were also 
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highlighted in the prevalence of any cataract, which was the highest in South Central China 
and the lowest in North China during 2000-2010. Meanwhile, in terms of the number of people 
affected by any cataract, the largest share of cases was in South Central China, while the 
smallest in Northwest China. 
5.5.2 Strengths and limitations 
This systematic review and meta-analysis provides the first and most complete description of 
the prevalence of cataract and cataract blindness in China, which can be used as the basis for 
the formulation of public-health strategies to ease the burden of cataract and cataract blindness. 
The strengths of this study include comprehensive and reproducible search strategies 
incorporated both Chinese and English databases, a dual review process and rigorous selection 
criteria, which reduced the potential for information bias due to selection and methodological 
heterogeneity to a minimum. During the systematic review process, only studies that were 
conducted in general Chinese population were included, thus the generalisability of the whole 
results presented in this study was largely ensured. With an aim of enhancing the comparability 
of prevalence estimates from different individual studies, standardised definitions of cataract 
and cataract blindness based on the available evidence were specified, which made the 
quantitative synthesis of prevalence rates possible. Moreover, the included studies that 
reported the prevalence of any cataract were sufficient and with a large geographical diversity, 
guaranteeing my ability to synthesise the prevalence of any cataract at the subnational level in 
China. 
However, this study is still subject to several potential limitations. First, despite my extensive 
efforts on minimising variations by means of strict eligibility criteria and unified definitions, 
meta-analyses of observational studies are generally vulnerable to bias and confounders 
inherent in the component studies (Egger et al., 1998). Second, in this study, the prevalence of 
cataract was estimated based on multilevel mixed-effects meta-regression models, by taking 
the effects of both demographic and geographic features into account. However, the examined 
demographic and geographic features were cluster-level data, any differences in effects at the 
individual level might be hidden. Other potential risk factors for cataract, such as economic 
status, smoking and diabetes, could not be included in the models owing to the absence of 
relevant information. As a further limitation, the prevalence of cataract could only be estimated 
at the regional level at best, adequate estimates at the provincial level were not attainable 
because insufficient studies were from each province in China. For cataract blindness, the 
roughly pooled estimates of prevalence were based on scant epidemiological evidence, and 
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the limited availability of data points restricted further exploration of heterogeneity and bias 
by sub-group meta-analysis or meta-regression, therefore several key differences pertinent to 
variations in risk factors, such as age and sex, might have been obscured. In terms of the 
cataract blindness prevalence, the assumption that all cataract-operated eyes were blind 
preoperatively might lead to an overestimation. Third, although the standardised definitions of 
cataract and cataract blindness served as a basis for this meta-analysis, on the other hand, 
cataract was not defined primarily based on any specific grading systems of cataract, but rather 
according to lens opacity in conjunction with reduced visual acuity. This approach, however, 
does not accord with modern grading systems, such as the Lens Opacities Classification 
System (LOCS), the Wisconsin Cataract Grading System (WCGS) and the Age-Related Eye 
Disease Study (AREDS) system, consequently the comparison of the estimates in this study 
with studies in other western countries would be difficult (Rochtchina et al., 2003, Congdon 
et al., 2004, Chylack et al., 1989, Leske et al., 1988, Chylack et al., 1993, Group, 2001, 
Mitchell et al., 1997). Of particular note, the cataract/cataract blindness cases referred to 
people who were suffering from cataract/cataract blindness and those who had already been 
operated. The currently prevalent cases of cataract/cataract blindness were not able to be 
estimated with this research approach. Therefore, the national and subnational prevalence of 
cataract and cataract blindness presented in this study could only be compared with studies 
(both domestic and international) that adopted similar definitions of cataract and cataract 
blindness, hindering the generalisation of my results to some extent. Fourth, in the projection 
analysis, the prevalence of cataract and cataract blindness was assumed to remain constant 
over time. In fact, any changes in risk exposure in the future might increase or decrease the 
incidence of cataract, and implementation of preventive care might substantially delay the 
onset of cataract or cataract blindness. The rise of prevalence and number of affected people 
as indicated in this study mainly relied on the UNPD demographic statistics, and therefore 
could be argued to be a reflection of population ageing. With the above limitations in mind, 
several findings in this study should be interpreted with considerable caution. 
5.5.3 Interpretation of findings 
In a synthesised analysis for estimating the prevalence of cataract in the United States (US), it 
was estimated that 20.5 million (17.2%) Americans older than 40 years had cataract in either 
eye in 2000, including those who had pseudophakia/aphakia (Congdon et al., 2004). In this 
study, a higher cataract prevalence of 22% was observed in Chinese people aged 45-89 years, 
corresponding to 68 million people living with cataract in the year 2000. The higher prevalence 
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of cataract in China compared with that in Americans seems to stand by previous statements 
that cataract is more prevalent in Asians than in Western populations (Vashist et al., 2011, Das 
et al., 1994, Liu et al., 2017). When compared with studies using comparable measurements 
of cataract blindness, the prevalence of cataract blindness by PVA<0.10 was noted to be 
slightly higher in China (4.5%) than in Nepal (4.1%) (Sapkota et al., 2006). Given the large 
population size in China, this prevalence rate of cataract blindness actually represents a large 
group of people who need surgery (if they have not received) and extensive care from both 
household and community (World Health Organization, 2017a, Brian and Taylor, 2001).  
As revealed in this study and many previous studies, the prevalence of any cataract and ARC 
grows dramatically with advanced age and reaches the highest in older people. The prominent 
role of ageing as a cause of cataract has also been reinforced in this study, with increased age 
being the constant risk factor for both any cataract and ARC (Liu et al., 2017, Asbell et al., 
2005, Michael and Bron, 2011, Abraham et al., 2006, McCarty et al., 1999, Vashist et al., 
2011). After age-adjustment, females were found to exhibit a greater tendency to develop 
cataract and ARC than males, which accords with a large body of evidence across racial groups 
(Abraham et al., 2006, McCarty et al., 1999, Vashist et al., 2011, Liu et al., 2017). Although 
the mechanism behind sex disparity in cataract formation has not been fully clarified, the 
protective effect of hormone therapy in cataract development as suggested in previous studies 
offers a clue for future research (Asbell et al., 2005, Lai et al., 2013, Zetterberg and Celojevic, 
2015). Taken the effects of ageing population and women’s greater longevity together, the 
numbers of people living with any cataract and ARC in China will both more than double from 
2015 to 2050 based on my projection analysis. Cataract, therefore, will continue to be a leading 
public health concern and pose wide-ranging effects on its social, economic and health systems.  
In view of the geographic patterns of cataract in China, the variations in the prevalence of 
cataract in different geographic regions could be speculated as a combined result of different 
distributions of risk factors across the whole country. It has long been suggested that 
cataractogenesis is a multifactorial process, where individual factors, environmental factors 
and genetic factors all play a role (Asbell et al., 2005, Liu et al., 2017). Risk factors with robust 
evidence on cataract mainly include advanced age, female sex, smoking, excessive ultraviolet 
B (UVB) exposure, diabetes, etc. (Ye et al., 2012, Kelly et al., 2005, Liu et al., 2017, Asbell 
et al., 2005, Robman and Taylor, 2005). As revealed by my analysis, the geographic region 
with the highest prevalence of cataract was South Central China in the years of 2000 and 2010. 
A possible reason is the relatively lower latitude (as a surrogate for a higher UVB exposure 
level) in south China, but it is still not absolutely clear whether any other factors have 
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contributed to this because relevant information was not universally examined in included 
studies. 
With rapidly ageing populations in China, the question of how best to care for older people 
with functional impairment is an ever-present concern (World Health Organization, 2017a, 
Brian and Taylor, 2001, Woo et al., 2002). The large cases of cataract and cataract blindness, 
and the uneven distribution across the nation, suggest that efforts to ameliorate the current and 
future burden of cataract are urgently needed. In China, the cataract surgical rate (cataract 
operations per million population per year) has been reported to be 446 in 2004, which was 
almost the lowest among Asian countries (World Health Organization, 2017a, Shen et al., 2013, 
China Disabled Person's Federation (CDPF), 2005). This might be resulted by the shortage of 
qualified eye care practitioners and health resources, in the meanwhile, the uncertain prognosis 
might also hider affected people to approach such operations (He et al., 2007, World Health 
Organization, 2017a, Fang et al., 2010). The estimates presented in this study should be 
interpreted with the most recent cataract surgical rate in China (if available) to better inform 
policymakers and healthcare providers for adequate preparation for the increasing burden of 
cataract. 
5.5.4 Implications for policy, practice and future 
research 
Our data also have important implications for adding new evidence into research. In the past 
decades, despite the advance in diagnostic and surgical techniques, uncertainties and 
discrepancy in the definitions and assessments of cataract still largely remain in 
epidemiological studies (Asbell et al., 2005, Liu et al., 2017). Until improved large-scale data 
using comparable definitions and assessments of cataract become available, the systematic 
review and meta-analysis approach will still be an important option for providing inputs by 
synthesising available evidence. This is also the case in China, where improvement in the 
quality of population-level information on the prevalence of cataract should be a priority for 
the national statistical agency, notably detailed age categories, classification of different 
subtypes of cataract, international grading systems, should be adopted as are often the cases. 
With the emergence of high-quality epidemiological studies on cataract in the foreseen future, 
reliable prevalence estimates of cataract, and its subtypes could be well achieved. Further, 
although no confirmed methods to prevent cataract formation are being advocated, well-
established risk and protective factors demonstrate possible pathways for slowing cataract 
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progression, such as smoking cessation, wearing hats and sunglasses (Liu et al., 2017, Asbell 
et al., 2005). Given the impact of cataract, the need for further research on preventing and 
delaying disease is still highlighted. 
5.6 Conclusions 
In conclusion, the first and most comprehensive estimates of the prevalence of cataract and 
cataract blindness in China were provided in this study, at both the national and subnational 
levels. The prevalence of cataract varied considerably among different demographic and 
geographic groups. In the coming decades, cataract and cataract blindness will continue to be 
a leading public-health issue in China. Future work should be prioritised on the promotion of 
high-quality epidemiological studies on cataract. 
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Chapter 6 The national and subnational 
prevalence and burden of diabetic 
retinopathy in China  
6.1 Summary 
The study approach in this chapter is greatly different from those in Chapters 3-5, which 
included both secondary data analysis (systematic review and meta-analysis) and primary data 
analysis. For developing the overall prevalence of DR in both the general population and 
people with DM, a systematic review and meta-analysis was first conducted. Given the disease 
course of DR, age- and DM duration-specific prevalence of DR was further generated by using 
sub-group meta-analysis. To develop the national number of DR cases, the number of DM 
patients should be provided as the basis. For this purpose, the 2011 national baseline survey 
of China Health and Retirement Longitudinal Study, a nationally representative survey of 
Chinese people aged 45 years and older, was used to calculate the national prevalence of DM 
for the year 2010. After developing the national envelope of DR (national DR cases) in 2010, 
the regional number of DR cases was generated by the “risk-factor based model”, as described 
in Chapter 2. The risk factors that were taken into the regional distribution model included 
rural setting, insulin treatment, elevated FBG level and higher HbA1c concentration. 
The work presented in this chapter has been published in the Journal of Global Health cited as 
“Song, P., Yu, J., Chan, K. Y., Theodoratou, E., & Rudan, I. (2018). Prevalence, risk factors 
and burden of diabetic retinopathy in China: a systematic review and meta-analysis. Journal 
of Global Health, 8(1), 010803. http://doi.org/10.7189/jogh.08.010803.  
I was involved in the whole process of this project, including study conceptualisation and 
design, development of search strategy, systematic review, data extraction, data analysis and 
interpretation of findings. I prepared the first draft of manuscript for publication, which has 
been subsequently revised according to the comments from anonymous peer reviewers and 
journal editors during the publishing process. The specific contributions of co-authors are as 
follows: Rudan, I. conceptualised and designed the study, Yu, J. conducted the dual systematic 
review and data extraction, Chan, K. Y., Theodoratou, E., and Rudan, I. critically reviewed 
the manuscript and approved the final manuscript. 
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6.2 Background 
Diabetic retinopathy (DR), the primary retinal vascular complication of diabetes mellitus 
(DM), is a leading cause of vision impairment and blindness in the working-age population 
(Cheung et al., 2010, Yau et al., 2012, Frank, 2004, Kempen et al., 2004). In the early course 
of the disease, DR is generally asymptomatic. If left untreated, DR can seriously impair vision, 
and eventually progress to blindness (Frank, 2004, Cheung et al., 2010). Apart from its 
devastating visual effects that might lead to reduced mobility, depression and lower quality of 
life, DR is also associated with a higher risk of systemic vascular complications, imposing a 
noteworthy burden on individuals, households, communities and societies (Saaddine et al., 
2008, Mazhar et al., 2011, Sharma et al., 2005). DR is a progressive disease that can be broadly 
divided into two stages according to its severity: nonproliferative and proliferative. 
Nonproliferative DR (NPDR) is characterised by microaneurysms, cotton-wool spots, 
intraretinal microvascular abnormalities, hard exudates and venous beading, whereas 
proliferative DR (PDR) is hallmarked by neovascularization of the optic disc or elsewhere, 
pre-retinal and vitreous haemorrhage (Wu et al., 2013, Cheung et al., 2010). Taken 
individually, PDR is less common but more sight-threatening than NPDR (Cheung et al., 2010, 
Frank, 2004, Yau et al., 2012, Sivaprasad et al., 2012, Wu et al., 2013).  
Although available diagnostic and therapeutic advancements, such as optimum management 
of DM and early detection of DR, can substantially reduce the risk of visual deterioration, DR 
remains an important cause of visual impairment and blindness globally (Early Treatment 
Diabetic Retinopathy Study Research Group, 1991a, Group, 1981, Wilkinson et al., 2003, 
Leasher et al., 2016, Pascolini and Mariotti, 2011, Klein, 2007, Mohamed et al., 2007). In 
2010, 3.7 million people were visually impaired and 0.8 million were blind because of DR, 
accounting for 1.9% of all visually impaired cases and 2.6% of all blind cases worldwide 
(Leasher et al., 2016). With DM having reached epidemic proportions worldwide, estimating 
the prevalence of DR in both the general population and those with DM is imperative for 
driving better health policy making and improved programming (Klein, 2007, Leasher et al., 
2016). By pooling data from 35 population-based studies across the world, the Global DR 
Study estimated that the prevalence of any DR, PDR and vision-threatening DR (severe 
retinopathy and macular oedema) were 34.6 %, 7.0 % and 10.2 % respectively among 
individuals with DM, translating to approximately 93 million people with any DR, 17 million 
with PDR and 28 million with vision-threatening DR worldwide in 2010 (Yau et al., 2012). 
Unless substantial improvements occur in the prevention and treatment of DR, the prevalence 
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and burden of DR will continue to escalate as the global population ages and the epidemic of 
DM expands (Zheng et al., 2012, Shaw et al., 2010, Guariguata et al., 2014). In addition, 
evaluation of risk factors for DR is of special importance in optimal clinical management. 
Similar to other common complications of DM, DR is a sentinel indicator of the progression 
of DM, thus its prevalence, not surprisingly, associated with the duration and severity of DM 
(Kempen et al., 2004, Yau et al., 2012, Williams et al., 2004). In the Global DR Study, longer 
DM duration has been recognised as a key risk factor for DR in people with DM, as well as 
higher levels of haemoglobin A1c (HbA1c) and blood pressure. Moreover, individuals with 
type 1 DM (T1DM) are more likely to develop DR than those with type 2 DM (T2DM) 
(Kempen et al., 2004, Yau et al., 2012). 
Despite mounting concerns about the emergence of DM as a major public health problem in 
the largest developing country, China, epidemiological data on DR in Chinese population are 
still rather scarce or inconsistent (Wong et al., 2006a, Sivaprasad et al., 2012, Liu et al., 2012, 
Xu et al., 2013). Thus far, there is still no national population-based data on the prevalence 
and burden of DR in China, and the existing surveys on DR are restricted to local 
characteristics, study methodologies, ascertainment and classification of DR, limiting direct 
comparisons between individual studies (Liu et al., 2012). A systematic review and meta-
analysis by Liu and colleagues, dating back to 2012, has provided the first overview of the DR 
prevalence in China. Based on 19 individual studies, their meta-analysis suggested that the 
pooled prevalence rates of any DR, NPDR and PDR in general Chinese population were 1.3%, 
1.1%, and 0.1% and those in people with DM were 23.0%, 19.1%, and 2.8% respectively (Liu 
et al., 2012). Thereafter, a growing body of epidemiological data on DR has become available 
in China, yet virtually none of them has been systematically appraised, underscoring the need 
for an updated analysis (Xia et al., 2008, Fung, 2008). Moreover, the effects of major risk 
factors for DR are still discrepant and inconclusive among the Chinese population, which need 
to be systematically evaluated in an evidence-based fashion. 
To fill the gaps outlined above, I conducted a comprehensive systematic review, in both 
Chinese and English databases, to retrieve studies that reported the epidemiology of DR in 
China from 1990 onwards. Based on the existing evidence, I aimed to: (1) pool the overall 
prevalence of DR in both general Chinese population and people with DM; (2) estimate the 
effects of demographic and geographic variables on the prevalence of DR in people with DM; 
(3) assess the major risk factors for DR in people with DM; and (4) quantify the national and 
subnational burden of DR in 2010. 
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6.3 Methods 
6.3.1 Systematic review  
This systematic review and meta-analysis adheres to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the Guidelines for 
Accurate and Transparent Health Estimates Reporting (GATHER) statement (Moher et al., 
2009, Stevens et al., 2016). 
6.3.1.1 Search strategy 
Three Chinese and three English electronic bibliographic databases, namely China National 
Knowledge Infrastructure (CNKI), Wanfang, Chinese Biomedicine Literature Database 
(CBM-SinoMed), PubMed, Embase, and Medline, were searched to locate all relevant 
publications that reported the epidemiology of DR in China. My comprehensive search 
strategies combined terms of diabetic retinopathy, epidemiology (incidence, prevalence, 
morbidity, mortality, epidemiology) and China (China, Chinese, Hong Kong, Macau, Taiwan) 
using both controlled vocabularies (e.g. Medical Subject Heading terms) and free text words. 
Search queries were optimised to fit the specific features of each database, and the full search 
strategies are detailed in Appendix table 28. To supplement the electronic database search, 
reference lists of eligible publications and related reviews were also scanned to identify other 
potentially pertinent studies. The literature search was limited to studies published between 
January 1990 and December 2017. No language restrictions were imposed on searches or 
search results. 
6.3.1.2 Inclusion and exclusion criteria 
To be included in the systematic review and meta-analysis, studies had to be population-based 
and reported the prevalence of DR or risk factors for DR. Depending on how the study 
population was sought, the identified population-based studies can be classified into three 
categories: community-based, primary health care management (PHCM)-based and registry-
based. Community-based studies derived their study sample from the general population (e.g. 
cluster sampling of households), whereas PHCM-based and registry-based studies derived 
their study sample from all the primary care settings or primary care systems in a defined 
geographical area. Thus, both PHCM-based and registry-based studies attempted to capture 
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all, or at least a random sample, of people with DM in a defined geographical area. For the 
purpose of pooling prevalence rates of DR, the included studies must be community-based, 
and of particular note, include both newly detected and physician-diagnosed DM cases 
simultaneously (to avoid overestimation); To assess the risk factors for DR in people with DM, 
the included studies could be community-based, PHCM-based or registry-based, where DM 
cases could be either newly detected or physician-diagnosed, or both. To avoid suspected bias 
inherent to univariate analysis, the estimation of odds ratios (ORs) in studies that reported the 
risk factors for DR must be based on a multivariate study design.  
Studies that were conducted in the T1DM group were excluded, whereas those focused on 
people with T2DM were retained. Studies that contained both T1DM and T2DM cases were 
not excluded if the proportion of people with T1DM was small (<10%). For studies where the 
type of DM was not specified but all other criteria were fulfilled, it was assumed that those 
studies contained both T2DM cases and a small proportion of T1DM cases. Otherwise, the 
type of DM could be speculated by the age at diagnosis of DM (if available), where people 
diagnosed before 30 years were deemed as with T1DM and those after 30 years were T2DM 
(Klein et al., 1984b, Yau et al., 2012). To be eligible for inclusion, studies must have 
undertaken fundus photography (FP) to ascertain DR and provided numerical estimates of DR 
prevalence. Reviews, commentaries and studies where the prevalence rates were calculated 
based on the number of eyes with DR rather than the number of affected individuals were 
excluded.  
6.3.1.3 Study selection and data extraction 
After deleting duplicate records within and between different bibliographic databases, the 
remaining titles and abstracts were reviewed to identify potentially eligible articles that 
required a full appraisal. In cases of multiple publications from the same study or overlapping 
data, preference was given to the most recent one or the one with the most inclusive 
information. Consensus was achieved for any discrepancies in study eligibility through 
discussion. For each included study, the quality was assessed from five aspects: sample 
population, sample size, participation rate, outcome assessment, and analytical methods. Each 
of the five components could be scored as 2 for low risk, 1 for moderate risk and 0 for high 
risk and unclear. The total score of those five components represented the overall quality of 
each study (Table 2.1) (Von Elm et al., 2007, Song et al., 2018). 
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With a predefined data-collection form, the following information was extracted from the 
included studies, where possible: 
1) Characteristics of the study: author(s), publication year, study year, study type 
(community-based, PHCM-based or registry-based), sampling method, study design 
(cross-sectional or cohort), study setting (urban, rural or mixed) and location, 
geographic region, DR assessment method and grading system; 
2) Characteristics of the sample (general population and people with DM): number of the 
sample, age (age range, mean or median age), sex (male, female or mixed), DM 
definition, DM classification (T1DM or T2DM, newly detected or physician-
diagnosed), and duration of DM; 
3) Prevalence data: the number of people with DR and the number of participants who 
had been tested for DR, by age, DM duration, sex, setting and DR subtype; 
4) Risk factor data: definition of risk factor, OR and corresponding confidence intervals 
(CIs). 
According to the definitions from National Bureau of Statistics of China, the geographic 
regions where the studies were carried out were classified into six categories: East China, 
North China, Northeast China, Northwest China, South Central China, and Southwest China 
(see Table 2.2 and Figure 2.2) (National Bureau of Statistics, 2002, National Bureau of 
Statistics, 2012). Missing values for the median year of study were imputed by subtracting 
three years (the average time-lag from investigation to publication in studies with available 
data, see Appendix table 29) from their publication years, and this was done for six individual 
studies. In this study, I further classified DR as NPDR and PDR. Therefore, relevant data were 
extracted from the included studies for different subtypes of DR respectively, wherever 
available. 
6.3.2 Statistical analysis 
6.3.2.1 Pooling prevalence of DR in China 
The crude prevalence of DR was firstly computed for each study and then double-arcsine 
transformed by using the Freeman-Tukey method (Freeman and Tukey, 1950, Barendregt et 
al., 2013, Nyaga et al., 2014). Heterogeneity among eligible studies was assessed with the 
Cochran's Q statistic and I2 index (the proportion of total variability due to true between-study 
heterogeneity beyond chance) (Higgins et al., 2003, Higgins and Thompson, 2002). A p-value 
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of less than 0.1 showed the presence of heterogeneity, and I2 values of less than 25% 
corresponded to mild heterogeneity, of from 25% to 50% reflected moderate heterogeneity, 
and of greater than 50% represented high heterogeneity, respectively (Higgins et al., 2003, 
Higgins and Thompson, 2002, Higgins and Green, 2008). Because of the substantial 
heterogeneity noted between individual studies, a random-effects (DerSimonian and Laird 
method) meta-analysis was used to adjust for variability and pool the study-specific prevalence 
rates (Barendregt et al., 2013, Higgins and Green, 2008). For each meta-analysis, a leave-one-
out sensitivity analysis was developed to assess the robustness of the pooled results. By 
removing one study at a time to run the meta-analysis without it, the sensitivity analysis could 
test whether single studies had disproportionally excessive influence on the pooled results 
(Wallace et al., 2009). Publication bias was checked by visual inspection of funnel plots, and 
tested for significance with Egger's regression test for funnel plot asymmetry and Begg’s rank 
correlation test (Egger et al., 1997, Begg and Mazumdar, 1994, Peters et al., 2006). The 
prevalence rates of any DR, NPDR and PDR in both the general population and people with 
DM were pooled with this approach respectively. 
6.3.2.2 Subgroup meta-analysis and meta-regression of DR 
prevalence in people with DM 
For the prevalence of any DR in people with DM, potential sources of heterogeneity were 
investigated using subgroup meta-analysis and meta-regression. In subgroup meta-analysis, 
the prevalence of any DR was estimated for different age groups and DM duration groups. 
This was done because age- and DM duration-specific prevalence of any DR in people with 
DM was universally provided by the included studies. Moreover, the individual associations 
between prevalence of any DR and study-level variables were evaluated by univariable meta-
regression using the unrestricted maximum likelihood method. The prespecified variables 
included sex (male vs. female), setting (urban, rural and mixed), geographic region and study 
year. Because only a few variables were individually significant, a multivariable meta-
regression was not subsequently performed. 
6.3.2.3 Meta-analysis of risk factors for DR in people with DM 
To investigate the risk factors for any DR in people with DM, a random-effects meta-analysis 
was employed a priori because of anticipated variation in study populations, geography and 
study design. As a rule, I only included risk factors that were investigated in at least three 
studies using multivariate design, and the definitions of the same risk factor should be similar 
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across all included studies. Finally, 11 factors (advanced age, male sex, DM duration, insulin 
treatment, fasting blood glucose [FBG], 2-hour postprandial blood glucose [2h-PBG], glycated 
HbA1c, total cholesterol [TC], triglyceride [TG], body mass index [BMI], systolic blood 
pressure [SBP]) met the pre-set criteria and were included in meta-analysis.  
6.3.2.4 Estimation of national and subnational burden of DR 
in 2010 
At the final stage, the national number of cases with any DR (“any DR envelope”) was 
estimated by multiplying the age-specific prevalence of any DR in people with DM with the 
corresponding number of people with DM in China. For this purpose, the 2011 national 
baseline survey of China Health and Retirement Longitudinal Study (CHARLS) was used to 
provide prevalence estimates of DM in China for the year 2010. CHARLS is a nationally 
representative survey of Chinese people aged 45 years and older. In CHARLS, samples were 
drawn by using a four-stage, stratified, cluster sampling procedure: First, all counties in 28 
provinces of China (except Tibet province, Hainan province and Ningxia Hui Autonomous 
Region) were stratified by geographic region, setting (urban and rural) and economic level 
(per capita statistics on the gross domestic product). Among them, 150 counties were randomly 
chosen by a probability-proportional-to-size (PPS) sampling technique (Figure 6.1). Second, 
three primary sampling units (PSU, communities in urban areas or administrative villages in 
rural areas) were randomly selected from each of those 150 counties. Third, all the dwellings 
within the 450 chosen PSU were outlined on Google Earth maps using the specifically 
designed “CHARLS-GIS” software, among which at least 24 households were randomly 
selected. Fourth, in the selected households, if there were more than one member aged 45 years, 
one such member was randomly selected, and his/her spouse was also interviewed. 
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Figure 6.1. Geographic distribution of the sampled counties in CHARLS 2011 (source: 
(Zhao et al., 2013)) 
The study design and implement of CHARLS have been previously published and detailed 
(Zhao et al., 2013, Zhao et al., 2012). Overall, the household response rate was 80.5%, and 
17,708 individual participants in 10,257 households successfully completed at least one 
module of the survey. In the household interview, the participants’ information on 
demographics (i.e. age, sex, residence), socioeconomic status (i.e. educational attainment, 
marital status, income and expenditure), medical history and health-related behaviours (i.e. 
smoking, drinking) was collected by a structured questionnaire. Among all participants, 13978 
(78.9%) took part in anthropometric and physical-performance module and 11847 (66.9%) 
provided venous blood samples (8ml each individual). DM was defined as a self-reported 
physician-diagnosed diabetes, or a fasting blood glucose (FBG) ≥126 mg/dl, or a random 
blood glucose ≥200 mg/dl, or a HbA1c concentration of 6.5% or above, or currently taking 
antidiabetic medications. People who had already been diagnosed with DM or were taking 
antidiabetic medications were classified as the diagnosed DM phenotype, and those who were 
not with diagnosed DM before the investigation but had an FBG ≥126 mg/dl, or a random 
blood glucose ≥200 mg/dl, or a HbA1c concentration of 6.5% or above were classified as the 
newly detected DM phenotype. All calculations in CHARLS 2011 took into account the 
complex survey design and adopted the blood weight with household and individual response 
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adjustment. The weighted mean FBG, mean HbA1c and prevalence of DM were stratified by 
age, sex, setting and geographic region. The flow diagram for selecting subjects in DM 
prevalence analysis is shown in Figure 6.2. 
 
Figure 6.2. Flow chart for subjects included in the analysis of DM prevalence 
The number of people with DM was estimated with the prevalence of DM and the 
corresponding population size, available from the United Nations Population Division (UNPD) 
(United Nations, 2015b). Then the national number of people with any DR (“any DR 
envelope”) was distributed into six geographical regions in China (East China, North China, 
Northeast China, Northwest China, South Central China, Southwest China, see Table 2.2 and 
Figure 2.2 for more details) by taking the effects of major risk factors on the prevalence of 
any DR in those regions (Fowkes et al., 2013, Rudan et al., 2004). Four statistically significant 
risk factors (advanced age, rural setting, elevated FBG level and higher HbA1c concentration) 
were chosen because they were all objective indicators. DM duration and insulin treatment, 
although being significantly associated with the prevalence of any DR, were not selected 
because they were highly subject to the diagnosis and treatment of DM, socioeconomic 
circumstances or geography, and therefore might introduce bias in my estimation of DR 
burden at the subnational level.  
The overall study design is shown in Figure 6.3. A two-sided p-value of less than 0.05 
indicated statistical significance except for the Q statistics, in which a significance level of less 
than 0.1 was specified. All statistical analyses were done with R version 3.3.0 (R Foundation 
for Statistical Computing, Vienna, Austria) and STATA version 14.0 (STATA Corporation, 
College Station, TX, USA). All maps were drawn by ArcMap version 10.1 (Environmental 
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Systems Research Institute, Redlands, CA) using the China base map obtained from the Global 
Administrative Areas (GADM) database (GADM, 2015, version 2.0; www.gadm.org). 
 
Figure 6.3. Overall study design flowchart for the prevalence, risk factor and burden of 
DR study in China 
6.4 Results 
6.4.1 Summary of systematic review 
The initial search strategy yielded 9982 records. After removal of 4644 duplicates, a total of 
5338 records were reviewed for relevance by titles and abstracts, of which 1147 were assessed 
in full-text form. Finally, 41 articles met eligibility criteria and were included in the systematic 
review. Of these, 31 studies provided information on the prevalence of DR and 21 explored 
potential risk factors for DR. The process of study selection is summarised in Figure 6.4 
according to the PRISMA guidelines. A full list of the included studies is shown in Appendix 
table 30. 
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Figure 6.4. Systematic review flow diagram of studies on the prevalence of and risk 
factors for DR in China 
Note: PHCM, Primary Health Care Management; *Reason 1-Studies that were not 
community-based, PHCM-based or registry-based; *Reason 2-Articles with no numerical 
measure of DR prevalence or didn’t report risk factor for DR in people with DM; *Reason 3-
Studies with no clear assessment methods or grading systems of DR; *Reason 4-Studies that 
were specifically conducted in people with unrepresentative characteristics (hypertensive 
patients, people with reduced vision, etc.); *Reason 5-Studies that didn’t include both newly 
detected and diagnosed DM cases; *Reason 6-Multiple publications of the same study; 
*Reason 7-Studies that were not based in China. 
All included studies were cross-sectional in design and assessed DR by using FP. Table 6.1 
summarises the main characteristics of all included studies, and Appendix table 31 lists the 
detailed characteristics of every study. The quality assessments of the included studies are in 
Appendix table 32. For the 31 studies that reported the prevalence of DR and the 21 studies 
on risk factors for DR, the majority were published after 2010, implying the necessity for an 
updated analysis of the epidemiology of DR in China. The studies on the prevalence of DR 
were all community-based investigations, covering all the six geographic regions across China 
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(see Figure 6.5). For those on risk factors for DR, more than half were community-based (71%, 
n=15), whereas more than one third were conducted in East China (38%, n=8). There were no 
studies from Northwest China on which to base estimates of risk factors for DR (see Figure 
6.5). 
Table 6.1. Main characteristics of the included studies on the prevalence of and risk 
factors for DR in China 
Characteristic 
Number of studies (%) 
Studies on DR 
prevalence (n=31) 
Studies on risk 
factors for DR (n=21) 
Year published   
1990-1999 4 (12.9) 1 (4.8) 
2000-2009 7 (22.6) 5 (23.8) 
2010-2017 20 (64.5) 15 (71.4) 
Study design   
Community-based 31 (100.0) 15 (71.4) 
PHCM-based 0 (0.0) 5 (23.8) 
Registry-based 0 (0.0) 1 (4.8) 
Setting   
Urban 12 (38.7) 15 (71.4) 
Rural 7 (22.6) 3 (14.3) 
Mixed 12 (38.7) 3 (14.3) 
Sex   
Mixed 13 (41.9) 3 (14.3) 
Both 18 (58.1) 18 (85.7) 
Sample size of DM   
≤200 6 (19.4) 2 (9.5) 
201-500 12 (38.7) 5 (23.8) 
501–1000 9 (29.0) 6 (28.6) 
>1000 4 (12.9) 8 (38.1) 
Grading system   
ICDRDSS 12 (38.7) 11 (52.4) 
ETDRS 6 (19.4) 7 (33.3) 
NOFDG 3 (9.7) 1 (4.8) 
NCOFD 9 (29.0) 2 (9.5) 
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Characteristic 
Number of studies (%) 
Studies on DR 
prevalence (n=31) 
Studies on risk 
factors for DR (n=21) 
CBM 1 (3.2) 0 (0.0) 
Geographic regions    
North China 11 (35.5) 7 (33.3) 
Northeast China 5 (16.1) 3 (14.3) 
East China 5 (16.1) 8 (38.1) 
South Central China 4 (12.9) 2 (9.5) 
Southwest China 1 (3.2) 1 (4.8) 
Northwest China 5 (16.1) 0 (0.0) 
Quality score   
10 3 (9.7) 1 (4.8) 
9 7 (22.6) 7 (33.3) 
8 8 (25.8) 4 (19.0) 
7 8 (25.8) 6 (28.6) 
6 5 (16.1) 3 (14.3) 
Note: 11 studies reported both prevalence of DR and risk factors for DR, therefore the sum of 
the number of studies exceeded 41. PHCM, Primary Health Care Management; ICDRDSS, 
International Clinical Diabetic Retinopathy Disease Severity Scale; ETDRS, Early Treatment 
of Diabetic Retinopathy Study; NOFDG, National Ocular Fundus Diseases Group; NCOFD, 
National Conference on Ocular Fundus Diseases; CBM, China Medical Board. 
 
Figure 6.5. Geographical distribution of included studies on prevalence of and risk 
factors for DR in China 
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6.4.2 Pooled prevalence of DR in China during 1990 
and 2017 
By using random-effects meta-analysis, the pooled prevalence of any DR in general Chinese 
population was 1.14% (95% CI: 0.80-1.52), and that in people with DM was 18.45% (95% 
CI:14.77-22.43) (Figure 6.6). According to the leave-one-out sensitivity analysis (Figure 6.7), 
the pooled prevalence of any DR in general population varied from 1.08% (95% CI: 0.76-1.46) 
to 1.19% (95% CI: 0.86-1.58), and that in people with DM ranged from 17.67% (95% CI: 
14.12-21.53) to 19.01% (95% CI: 15.38-22.94), no single study significantly influenced the 
overall pooled prevalence in the meta-analysis. No publication bias was evident based on the 
visual evaluation of the funnel plot, Egger’s test and Begg’s test (Figure 6.8). 
 
Figure 6.6. Pooled prevalence of any DR in general population and in people with DM 
by random-effects meta-analysis 
Note: There were 28 studies for synthesising the prevalence of any DR in general population 
and 31 in people with DM.  
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Figure 6.7. Leave-one-out sensitivity analysis of the influence of single study on the 
pooled prevalence of any DR in general population and people with DM 
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Figure 6.8. Publication bias of the studies on the prevalence of any DR in general 
population and people with DM 
Note: (A) Funnel plot; (B) Egger’s test (studies on DR prevalence in general population: t= 
0.703, p= 0.488; studies on DR prevalence in people with DM: t= -1.128, p= 0.269); (C) 
Begg’s test (studies on DR prevalence in general population: z= 0.553, p= 0.580; studies on 
DR prevalence in people with DM: z=- 0.493, p= 0.622). 
For NPDR, the pooled prevalence in general population was 0.90% (95% CI: 0.56-1.31), and 
that in people with DM was 15.06% (95% CI:11.59-18.88) by use of random-effects meta-
analysis (Figure 6.9). The leave-one-out sensitivity analysis suggested that no individual study 
significantly influenced the overall pooled prevalence in the meta-analysis (Figure 6.10), 
where the pooled prevalence of NPDR in general population ranged from 0.79% (95% 
CI:0.49-1.14) to 0.99% (95% CI: 0.63-1.42) and that in people with DM from 13.92% (95% 
CI:11.20-16.87) to 15.85% (95% CI: 12.48-19.53). Among studies that reported the 
prevalence of NPDR in general population, potential publication bias was revealed by the 
asymmetrical shape of funnel plot, Egger’s test and Begg’s test, whereas no publication bias 
was suggested for studies that reported the prevalence of NPDR in people with DM (Figure 
6.11). 
 
Figure 6.9. Pooled prevalence of NPDR in general population and in people with DM by 
random-effects meta-analysis 
Note: There were 14 studies for synthesising the prevalence of NPDR in general population 
and 17 in people with DM. 
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Figure 6.10. Leave-one-out sensitivity analysis of the influence of single study on the 
pooled prevalence of NPDR in general population and people with DM 
 
Figure 6.11. Publication bias of the studies on the prevalence of NPDR in general 
population and people with DM 
Note: (A) Funnel plot; (B) Egger’s test (studies on DR prevalence in general population: t= 
2.858, p= 0.014; studies on DR prevalence in people with DM: t= 0.162, p= 0.873); (C) 
Begg’s test (studies on DR prevalence in general population: z= 2.135, p= 0.033; studies on 
DR prevalence in people with DM: z= 0.494, p= 0.621). 
As shown in Figure 6.12, the pooled prevalence of PDR from random-effects meta-analysis 
was 0.07% (95% CI: 0.02-0.14) in general population and 0.99% (95% CI: 0.40-1.80) in 
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people with DM. The subsequent sensitivity analysis showed that the pooled prevalence of 
PDR was not affected unduly by a single study, where the pooled prevalence rates ranged from 
0.05% (95% CI: 0.01-0.10) to 0.08% (95% CI: 0.03-0.16) in general population, and from 
0.76% (95% CI: 0.30-1.39) to 1.07% (95% CI: 0.43-1.95) in people with DM (Figure 6.13). 
For studies that reported the prevalence of PDR in general population, visual inspection of the 
funnel plot and Begg’s test demonstrated some evidence of significant publication bias, which 
was not confirmed by the Egger’s test. No publication bias was detected in the meta-analysis 
of PDR prevalence in people with DM (Figure 6.14). 
 
Figure 6.12. Pooled prevalence of PDR in general population and in people with DM by 
random-effects meta-analysis 
Note: There were 14 studies for synthesising the prevalence of PDR in general population and 
17 in people with DM. 
 
Figure 6.13. Leave-one-out sensitivity analysis of the influence of single study on the 
pooled prevalence of PDR in general population and people with DM 
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Figure 6.14. Publication bias of the studies on the prevalence of PDR in general 
population and people with DM 
Note: (A) Funnel plot; (B) Egger’s test (studies on DR prevalence in general population: t= 
1.4635, p= 0.169; studies on DR prevalence in people with DM: t= 0.11095, p= 0.9131); (C) 
Begg’s test (studies on DR prevalence in general population z= 2.1351, p= 0.03276; studies 
on DR prevalence in people with DM: z= 1.2358, p= 0.2165). 
6.4.3 Subgroup meta-analysis and meta-regression of 
DR prevalence in people with DM 
The age-specific prevalence of any DR in people with DM was derived based on subgroup 
meta-analysis (Figure 6.15). The following age categories were adopted: 30-39 years, 40-49 
years, 50-59 years, 60-69 years, 70-79 years and 80 years and older. Before the age of 70 years, 
the prevalence of any DR in people with DM kept rising from 12.55% (95% CI: 4.93-22.52) 
in adults aged 30-39 to 20.44% (95% CI: 15.04-26.36) in those were 60-69 years old. Then 
the prevalence of any DR in people with DM started to decrease, until 11.22% (95% CI: 2.57-
23.12) in elderly aged 80 years and above. The detailed process of synthesising the prevalence 
of any DR in people with DM in each age category can be found in Appendix figure 14. 
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Figure 6.15. Age-specific prevalence of any DR in people with DM by random-effects 
meta-analysis 
Note: The numbers of individual studies contributing to the synthesis of prevalence in each 
age group are 4 (for 30-39 years), 10 (for 40-49 years), 15 (for 50-59 years), 16 (for 60-69 
years), 10 (for 70-79 years) and 9 (for 80-89 years) respectively. 
By pooling the prevalence of any DR in strata of DM duration group, it was revealed that the 
prevalence of any DR in people with DM substantially increased with the duration of DM. 
Four different DM duration groups were used: 0 year (newly detected), 1-4 years, 5-9 years 
and 10 years and longer. According to the subgroup meta-analysis (Figure 6.16), the DM 
duration-specific prevalence of any DR ranged from 9.00% (95% CI: 5.15-13.75) in people 
with newly detected DM to 55.52% (95% CI: 47.90-63.02) in those who had been diagnosed 
with DM for 10 years and longer. The process of synthesising the prevalence of any DR in 
each DM duration group is detailed in Appendix figure 15. 
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Figure 6.16. The prevalence of any DR by DM duration group, using random-effects 
meta-analysis 
Note: The numbers of individual studies contributing to the synthesis of prevalence in each 
DM duration group are 13 (for newly diagnosed), 7 (for 1-4 years), 8 (for 5-9 years) and 9 
(for ≥10 years) respectively 
According to the univariable meta-regression (Table 6.2), DM patients living in rural areas 
were more likely to have any DR than those in urban areas, with an OR of 1.22 (95% CI: 1.10-
1.35). However, no evidence of sex difference, geographical variation or a secular trend in the 
prevalence of any DR in individuals with DM was observed. 
Table 6.2. Odds ratios for any DR in terms of setting, geographic region and study year 




OR (95% CI) z value P value 
Sex$     
Female 
18 
Reference Reference Reference 
Male 0.98 (0.88-1.08) -0.47 0.639 
Setting     
Urban 12 Reference Reference Reference 
Rural 7 1.22 (1.10-1.35) 3.74 <0.001 
Mixed 12 1.01 (0.93-1.10) 0.24 0.810 
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OR (95% CI) z value P value 
Geographic region     
North China 11 Reference Reference Reference 
Northeast China 5 0.96 (0.82-1.13) -0.48 0.632 
East China 5 0.99 (0.85-1.17) -0.07 0.946 
South Central China 4 0.95 (0.80-1.13) -0.55 0.582 
Southwest China 1 0.94 (0.69-1.28) -0.39 0.699 
Northwest China 5 0.97 (0.82-1.15) -0.34 0.735 
Study year (per decade) 31 1.01 (0.93-1.09) 0.22 0.826 
Note: $ the effect of sex was estimated based on studies where sex-specific prevalence was 
available; 
6.4.4 Synthesised effect size of risk factors for DR in 
people with DM 
A total of 21 studies described the risk factors for any DR in people with DM by multivariate 
logistic regression (Appendix table 33). Risk factors for any DR were reported in various 
ways, among which 11 were with consistent definitions and sufficient information, and 
therefore were included in evidence synthesis (Table 6.3). Advanced age was found to be 
negatively associated with any DR, which was partly in line with my estimates on the age-
specific prevalence of any DR, where the prevalence of any DR started to decrease from 70 
years onwards. In accordance with the estimated DM duration-specific prevalence of any DR 
in subgroup meta-analysis, longer DM duration was additionally recognised as a significant 
risk factor for any DR. DM patients receiving insulin treatment were almost two times more 
likely to have any DR than those who were not treated by insulin (OR 1.99 [95% CI: 1.34-
2.95]). Moreover, elevated FBG level and higher HbA1c concentration were all identified as 
important risk factors for any DR, with ORs per unit increase of 1.33 (95% CI: 1.12-1.59) and 
1.15 (95% CI: 1.09-1.20) respectively. Individual forest plots of meta-analyses for each risk 
factor can be found in Appendix table 34. 
Table 6.3. Synthesised effect size of 11 risk factors for any DR in people with DM 
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Risk factor 1-Advanced age (per year increase) 4 0.96 (0.93-1.00) 2.26 0.024 
Risk factor 2-Male 5 1.41 (0.88-2.27) 1.42 0.156 
Risk factor 3-DM duration (per year increase) 12 1.09 (1.06-1.12) 5.93 <0.001 
Risk factor 4-Insulin treatment 5 1.99 (1.34-2.95) 3.4 0.001 
Risk factor 5-FBG (per mmol/l increase) 9 1.33 (1.12-1.59) 3.23 0.001 
Risk factor 6-2h PBG (per mmol/l increase) 3 1.94 (0.81-4.65) 1.48 0.138 
Risk factor 7-HbA1c (per % increase) 7 1.15 (1.09-1.20) 5.80 <0.001 
Risk factor 8-TC (per mmol/l increase) 3 0.97 (0.78-1.20) 0.32 0.749 
Risk factor 9-TG (per mmol/l increase) 3 1.66 (0.74-3.73) 1.24 0.216 
Risk factor 10-BMI (per kg/m2 increase) 6 1.07 (0.94-1.21) 1.06 0.289 
Risk factor 11-SBP (per mmHg increase) 5 1.03 (1.00-1.07) 1.96 0.05 
Note: OR, odds ratio; CI, confidence interval; DM, diabetes mellitus; FBG, fasting blood 
glucose; PBG, postprandial blood glucose; HbA1c, glycated haemoglobin A1c; TC, total 
cholesterol; TG, triglyceride; BMI, body mass index; SBP, systolic blood pressure. 
6.4.5 National and subnational number of people with 
DR in 2010 
According to the CHARLS 2011, the weighted prevalence of DM was 17.22% (95% CI: 
15.57-19.00) in middle-aged and older Chinese in 2010 (Table 6.4). By applying the age-
specific prevalence of any DR in people with DM and the corresponding age-specific DM 
cases, the number of middle-aged and older Chinese with any DR was estimated to be 13.16 
million (95% CI: 8.95-18.00) in 2010, translating to an overall prevalence of 3.06% (95% CI: 
2.08-4.19) in general middle-aged and older Chinese and of 18.24% (95% CI: 12.41-24.95) in 
middle-aged and older Chinese with DM (Table 6.5). Based on the variations of population 
age structure, setting, mean FBG and mean HbA1c levels, the national DR cases were 
distributed into six geographic regions. As illustrated in Table 6.5 (see Appendix table 35 for 
more details) and Figure 6.17, South Central China harboured the most DR cases (3.71 million 
[95% CI: 2.52-5.09]), while Northwest China had the least (0.87 million [95% CI: 0.60-1.18]). 
Regarding the prevalence of any DR at regional level, it was estimated that the prevalence of 
any DR in general middle-aged and older Chinese was the highest in North China (3.76% [95% 
CI: 2.56-5.12]) and the lowest in Southwest China (2.55% [95% CI: 1.74-3.48]); For the 
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prevalence of any DR in middle-aged and older Chinese with DM, it was the highest in 
Northwest China, while the lowest in East China (17.67% [95% CI: 11.97-24.24]). In 2010, 
most DR cases were concentrated in people aged 50-59 years across the six geographic regions. 
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Mean FBG, mmol/l 
(95% CI) 
Mean HbA1c, % 
(95% CI) 
Prevalence of DM, % 
(95% CI) 
Proportion within DM, % (95% CI) 
KDM NDM 
Age group 
      
45-49 years 2109 (18.65) 5.85±1.62 5.18±0.77 10.76 (8.59-13.40) 30.63 (23.96-38.21) 69.37 (61.79-76.04) 
50-59 years 4007 (35.44) 6.09±1.93 5.26±0.84 16.06 (14.14-18.19) 40.22 (33.53-47.28) 59.78 (52.72-66.47) 
60-69 years 3285 (29.05) 6.15±2.11 5.33±0.90 19.99 (17.29-22.99) 50.35 (40.94-59.74) 49.65 (40.26-59.06) 
70-79 years 1548 (13.69) 6.16±1.95 5.29±0.82 21.78 (17.91-26.23) 45.48 (31.82-59.86) 54.52 (40.14-68.18) 
≥80 years 359 (3.17) 6.25±1.05 5.24±0.59 25.25 (13.64-41.94) 10.17 (3.83-24.35) 89.83 (75.65-96.17) 
Sex 
      
Male 5349 (47.30) 6.08±1.84 5.23±0.73 16.78 (14.54-19.28) 37.32 (32.55-42.35) 62.68 (57.65-67.45) 
Female 5959 (52.70) 6.07±1.93 5.30±0.92 17.64 (15.98-19.43) 44.20 (36.57-52.10) 55.80 (47.90-63.43) 
Setting 
      
Urban 4210 (37.23) 6.14±1.65 5.29±0.75 20.51 (18.02-23.26) 47.28 (40.26-54.41) 52.72 (45.59-59.74) 
Rural 7098 (62.77) 6.01±2.07 5.24±0.88 14.09 (12.76-15.54) 32.14 (27.30-37.39) 67.86 (62.61-72.70) 
Region 
      
North China 1656 (14.64) 6.16±2.23 5.22±0.97 20.83 (16.25-26.30) 42.55 (30.92-55.08) 57.45 (44.92-69.08) 
Northeast China 804 (7.11) 6.21±1.77 5.35±0.80 17.50 (13.27-22.72) 44.75 (35.06-54.86) 55.25 (45.14-64.94) 
East China 3420 (30.24) 6.04±1.77 5.20±0.81 15.97 (13.93-18.25) 46.61 (39.41-53.94) 53.39 (46.06-60.59) 
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Mean FBG, mmol/l 
(95% CI) 
Mean HbA1c, % 
(95% CI) 
Prevalence of DM, % 
(95% CI) 
Proportion within DM, % (95% CI) 
KDM NDM 
South Central China 2570 (22.73) 6.01±1.44 5.29±0.75 18.95 (15.09-23.53) 39.28 (25.76-54.67) 60.72 (45.33-74.24) 
Southwest China 1930 (17.07) 6.05±2.50 5.33±0.96 13.99 (10.92-17.76) 30.64 (22.16-40.68) 69.36 (59.32-77.84) 
Northwest China 928 (8.21) 6.19±2.26 5.29±0.75 16.39 (12.91-20.58) 35.69 (20.29-54.75) 64.31 (45.25-79.71) 
Overall 11308 (100.00) 6.07±1.88 5.26±0.83 17.22 (15.57-19.00) 40.92 (35.51-46.56) 59.08 (53.44-64.49) 
Note: Calculations were weighted by taking into account the complex survey design and adopted the blood weight with household and individual response 
adjustment; data were presented as n (%), proportion (95% CI), means ± SD; KDM, known (diagnosed) diabetes mellitus; NDM, newly detected diabetes 
mellitus. 
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Table 6.5. Estimated prevalence and number of middle-aged and older Chinese with any 
DR in China in 2010, by geographic region  
Region 
Prevalence of any 
DR in general 
people (%, 95% CI) 
Prevalence of any DR 
in people with DM 
(%, 95% CI) 
Number of people 
with DR (million, 
95% CI) 
North China 3.76 (2.56-5.12) 18.54 (12.66-25.28) 2.03 (1.39-2.77) 
Northeast China 3.22 (2.20-4.39) 18.93 (12.94-25.81) 1.35 (0.92-1.84) 
East China 2.74 (1.86-3.76) 17.67 (11.97-24.24) 3.63 (2.46-4.98) 
South Central China 3.31 (2.25-4.54) 17.97 (12.19-24.63) 3.71 (2.52-5.09) 
Southwest China 2.55 (1.74-3.48) 18.73 (12.76-25.59) 1.56 (1.07-2.14) 
Northwest China 3.09 (2.12-4.20) 19.39 (13.30-26.35) 0.87 (0.60-1.18) 
China 3.06 (2.08-4.19) 18.24 (12.41-24.95) 13.16 (8.95-18.00) 
 
Figure 6.17. Estimated regional number of middle-aged and older Chinese with any DR 
and contributing age groups in 2010 
6.5 Discussion 
6.5.1 Statement of principal findings 
By combining all available epidemiological data on the prevalence of DR in China from 1990 
onwards, I estimated that in general population, the pooled prevalence of any DR, NPDR and 
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PDR was 1.14% (95% CI: 0.80-1.52), 0.90% (95% CI: 0.56-1.31) and 0.07% (95% CI: 0.02-
0.14); In people with DM, the pooled prevalence rates were 18.45% (95% CI: 14.77-22.43), 
15.06% (95% CI: 11.59-18.88) and 0.99% (95% CI: 0.40-1.80) for any DR, NPDR and PDR, 
respectively. The prevalence of any DR in DM patients peaked between 60 and 69 years of 
age, and increased steeply with the duration of DM. DM patients residing in rural China were 
at a higher risk to have any DR than those in urban areas. In addition, insulin treatment, 
elevated FBG level and higher HbA1c concentration were confirmed to be associated with a 
higher prevalence of any DR in people with DM. In 2010, a total of 13.16 million (95% CI: 
8.95-18.00) Chinese aged 45 years and above were living with any DR, among whom the most 
were in South Central China and the least were in Northwest China. Collectively, these data 
suggest a considerable burden of DR in China. 
6.5.2 Strengths and limitations 
To the best of my knowledge, this systematic review and meta-analysis provides a 
comprehensive estimation of the prevalence, risk factors and burden of DR in China. Although 
this study is subsequent to the first synthesised analysis by Liu and colleagues, many new 
merits are highlighted (Liu et al., 2012). The principal strengths of this study include a 
comprehensive search strategy in both Chinese and English databases and a dual review 
process, which increased my ability to capture all studies on DR epidemiology in China. 
Ultimately, my estimation of DR prevalence was based on a total of 31 studies, which was 
more than 1.5 times the number of studies included in the first systematic review on DR in 
China. Another important feature that distinguished this study with the previous systematic 
review by Liu and colleagues was that only community-based studies incorporating both 
newly detected and already diagnosed DM cases were included for the estimation of DR 
prevalence, therefore the representativeness of my estimates can be greatly guaranteed. 
Regarding risk factors for DR, only studies that provided estimates of OR using multivariate 
study designs were included, therefore community-based, PHCM-based and registry-based 
studies could all contribute, ensuring sufficient power for conducting reliable synthesised 
assessments. Furthermore, the definitions of risk factors in included studies were similar, as 
well as in the CHARLS 2011 (Zhao et al., 2013, Zhao et al., 2012). Before pooling, an arcsine 
transformation was conducted to stabilise the variance of prevalence rates, which reduced the 
bias associated with small and large prevalence values on the pooled estimates to a large extent 
(Barendregt et al., 2013, Nyaga et al., 2014). Although differences existed in the prevalence 
rates of DR across different subgroups, my detailed assessment of any DR prevalence by age 
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and DM duration group, and identification of risk factors for any DR could serve as a source 
of primary information and guide policy making and rational planning of health services, 
especially in areas where local investigations on the epidemiology of DR are absent. 
Before interpreting the findings, potential limitations of this systematic review and meta-
analysis should be carefully considered. First, the pooled prevalence of NPDR and PDR in 
general population might have been affected by publication bias. Generally, publication bias 
arises because statistically significant results are more likely to be published than non-
significant results, combining these studies for analysis could, therefore, introduce bias (Peters 
et al., 2006, Sterne et al., 2000, Stroup et al., 2000). Unfortunately, I could not completely rule 
out publication bias because of the observational nature of this study. Second, there are 
inherent disadvantages in pooling prevalence form disparate studies. Due to the absence of 
stratified prevalence data for NPDR and PDR, I was not able to further explore sources of 
heterogeneity by subgroup meta-analysis and meta-regression for these two subtypes of DR. 
For any DR, sufficient data were available to pool the prevalence estimates and no publication 
was detected. However, my subgroup analysis on the prevalence of any DR by age group and 
DM duration group was only based on a limited number of studies that provided 
correspondingly stratified prevalence estimates. Third, only 11 risk factors with similar 
definitions across the included studies were systematically assessed, among which advanced 
age, longer DM duration, insulin treatment, elevated FBG level and higher HbA1c 
concentration were identified to be associated with a higher prevalence of any DR. However, 
because of the paucity of reported ORs, the effects of TC, TG and SBP should be further 
confirmed with new data coming in from future studies. In addition, previous studies have 
suggested that socioeconomic factors, including the availability and costs of DM management, 
were also likely to contribute to the disparities in DM severity and DR prevalence rates in 
different subgroups, but could not to be assessed in the current study (Yau et al., 2012, 
Sivaprasad et al., 2012, Cheung et al., 2010). Fourth, the number of DM cases in China for 
generating the national and subnational burden of any DR was derived from the CHARLS 
2011, which was nationally representative but only conducted in middle-aged and older 
population (Zhao et al., 2012, Zhao et al., 2013). Therefore, the estimated number of people 
with any DR in this study was only for people aged 45 years and above. When distributing the 
national DR cases into the six geographic regions, I only took the effects of four objective 
indicators into account, namely, advanced age, rural setting, elevated FBG level and higher 
HbA1c concentration. Other subjective risk factors (e.g. insulin treatment and DM duration) 
and potential factors that might be associated with the prevalence of DR were not included in 
my analysis of regional burden of DR in China, which might reduce the reliability of my 
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estimation at the subnational level. Bearing those limitations in mind, the results presented in 
this study should be interpreted judiciously. 
6.5.3 Interpretation of findings 
In this study, significant heterogeneity was noted in pooling the prevalence rates of DR. The 
main sources of heterogeneity in the included studies pertained to the different characteristics 
of study population. After omitting each study at a time, the pooled prevalence of any DR was 
robust and consistent. The pooled prevalence of any DR in Chinese people with DM was lower 
in my study than that in the global DR study (18.45% vs. 25.08%) (Yau et al., 2012). Given 
that the estimated prevalence of any DR in Chinese people with DM presented in the global 
DR study was based on studies that were conducted both within and outside China, any 
differences in exposure levels of risk factors might explain this discrepancy. Compared with 
the pooled prevalence of any DR in Chinese people with DM reported by Liu and colleagues, 
my study revealed a relatively lower prevalence rate (23.0% vs. 18.45%) (Liu et al., 2012). 
There are a number of possible reasons for this difference. First, the improvement of primary 
health care management in China might have resulted in a lower incidence of DR in recent 
years. Second, more recent investigations might include more newly detected DM patients. 
The incidence of DM is higher than that of DR, resulting in a relatively larger denominator for 
calculating the prevalence of DR. Most importantly, individual studies included in the 
systematic review and meta-analysis by Liu and colleagues were not solely focused on 
generally Chinese population, where both newly detected and diagnosed DM (self-reported 
physician diagnosed DM in some studies) cases should exist simultaneously. Two individual 
studies that were conducted in people with diagnosed DM were included in their final synthesis, 
the erroneous omission of people with newly detected or early-stage DM from the sample 
denominator would, therefore, lead to an overestimation of DR prevalence (Liu et al., 2012). 
Furthermore, a study included in their synthesised analysis was specifically conducted in a 
group of people with higher risk for pre-diabetes (e.g. people with familial DM history, 
hypertension, overweight/obesity, dyslipidemia, cardiovascular disease /stroke or a gestational 
history of large babies [for women]) rather than in general population, which will also add 
further possibility of an overestimation (Liu et al., 2012, Pang et al., 2012). 
In my analysis, the prevalence of any DR was found to peak between 60 and 69 years of age, 
which is in line with the age-specific prevalence estimates of DR among Americans (Kempen 
et al., 2004, Cheng et al., 2013b). In elderly with DM, the incidence of DR is relatively lower 
than that in younger people (Varma et al., 2010, Sivaprasad et al., 2012). Given that DR is a 
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marker for severe DM and other life-threatening complications, a reduced survival rate has 
been observed in older people living with DR (Bragg et al., 2017, Targher et al., 2008, Hecke 
et al., 2005, Kramer et al., 2011, Varma et al., 2004). Therefore, this pattern of declining DR 
prevalence in the elderly seems to be driven by the combination of reduced incidence and 
improved mortality. Unsurprisingly, the prevalence of DR is strongly associated with the 
duration of DM, which has been validated by both sub-group meta-analysis and my meta-
analysis on major risk factors for DR in this present study. This finding is consistent with other 
previous investigations and synthesised analyses (Zhang et al., 2010b, Yau et al., 2012, Varma 
et al., 2004). As revealed by my analysis, more than half of all patients with DM for 10 years 
and longer will develop some degree of DR, underscoring the importance of optimal 
management of DM and early detection of DM complications in those living with DM. In this 
study, I noticed a higher prevalence of DR in DM patients living in rural China than that in 
those living in urban areas. This urban-rural disparity of DR prevalence in people with DM is 
in line with the study by Liu and colleagues (Liu et al., 2012). In the Chinese context, 
awareness (a history of physician-diagnosed), treatment (proportion of individuals taking 
diabetes medications), and control (the proportion of individuals with an HbA1c concentration 
of less than 7.0%) of DM among rural dwellers are all lower than that in urban dwellers, partly 
due to lower economic development level and restricted primary health resources in rural 
China (Xu et al., 2013, Bragg et al., 2017, Xu et al., 2016). The delayed diagnosis and non-
optimal management of DM might be the primary causes of a higher prevalence of DR in rural 
China, but still need further confirmation in future studies. 
Good glycemic control has long been recognised as one important factor for reducing vascular 
complications of DM, and it is also important in the prevention of DR (Mohamed et al., 2007, 
Corcóstegui et al., 2017). In this study, higher levels of FBG and HbA1c have both been 
suggested as risk factors for DR in people with DM, which is in line with many previous 
investigations and synthesised results (Zhang et al., 2010b, Ding and Wong, 2012). In addition, 
insulin treatment was identified to be with a higher odds of DR in DM patients according to 
my meta-analysis. Herein insulin treatment should not be simply concluded as a “bad treatment” 
which directly causes DR. In previous studies, it was suggested that a larger proportion of 
participants using insulin therapy were those with T1DM or with longer-duration of DM, and 
people with DR may have already been preferentially treated with insulin therapy (Rema et 
al., 2005, Zhao et al., 2014, Zhang et al., 2010b). In previous studies, higher SBP has been 
suggested as a risk factor for DR (Corcóstegui et al., 2017, Yau et al., 2012). However, my 
meta-analysis of risk factors for DR only showed a slightly significant association between 
elevated SBP and DR. Given the effect of SBP on DR was only assessed based on five 
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individual studies in my synthesised analysis, the lack of sufficient evidence logically calls for 
an updated analysis to better understand the role of SBP in the development of DR with new 
data coming in. 
6.5.4 Implications for policy, practice and future 
research 
The increasing burden of DR might bring a higher pressure on available infrastructure and 
resources. Ideally, periodic eye examinations should be conducted by all patients with DM. 
Regular follow-up to detect significant retinopathy, together with prompt interventions when 
necessary, is believed to be the most effective method to reduce potential DR-related visual 
disabilities (Frank, 2004, Cheung et al., 2010, Ferris III, 1993). In China, screening of DR has 
not been well established into the primary health care system, and the need for adequate DR 
eye care remains largely unaddressed (Vela et al., 2012, Wang et al., 2010a). Generally, DR 
screening could be evaluated in office or through telemedicine, and the latter has been 
suggested to be accurate and more cost-effective (Ting et al., 2016, Jones and Edwards, 2010, 
Mansberger et al., 2015). Furthermore, with the development of technology, a wholly 
automated approach with the assistance of artificial intelligence might be especially beneficial 
in under-developed areas. Even in established screening centres, those techniques also have 
the potential to substantially reduce the grading workload (Usher et al., 2004, Wong and 
Bressler, 2016).  
With new epidemiological investigations emerging, the results of this study should be updated 
in a timely and regular manner. In addition, there remains a genuine need for prompting 
international standardised DR classification systems in Chinese scientific society, to facilitate 
communication and comparison across the world. 
6.6 Conclusions 
To conclude, this contemporary systematic review and meta-analysis estimated the prevalence, 
risk factors and burden of DR in China. The results from this study revealed a substantial 
burden of DR in China. Optimal screening of and interventions on DR should be implemented 
in the Chinese health system. Improved epidemiological studies on DR are still required to 
guide eye care programmes in China. 
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Chapter 7 Overall discussion 
The discussions about study findings, strengths and limitations, and implications for policy, 
practice and future research have been respectively presented in each project chapter (Chapters 
3-6). In this overall discussion chapter, I will first summarise the overall findings from this 
thesis, based on which the possible implications on the eye health care and disease 
management in China will be discussed. The strengths and limitations of methodological 
approaches adopted in this thesis have been previously considered but more general issues will 
be emphasised in this chapter. Suggestions for future research will also be provided.  
7.1 Key findings  
As presented in the introduction chapter (Chapter 1), this thesis has four main objectives, 
which are 1) estimating the prevalence and burden of AREDs from 1990 to 2015; 2) projecting 
the prevalence and burden of AREDs from 2020 to 2050; 3) identifying cluster- or individual-
level factors that are associated with the prevalence of AREDs; 4) generating the regional 
burden of AREDs in 2000 and 2010. Those objectives were exactly achieved in the projects 
of AMD, glaucoma and cataract. Given that DR could only be assessed in people with DM, 
the estimation of DR prevalence and burden, however, was only performed for the year 2010 
by using the DM prevalence from a national representative investigation (CHARLS 2011). 
Taken together, this project has demonstrated that AREDs, including AMD, glaucoma, 
cataract and DR, represent a huge disease burden on the Chinese public health system. Based 
on the estimation in 2010, cataract was the most prevalent disease among the four major 
AREDs, followed by AMD, DR and glaucoma. As stated in the overall methods in Chapter 2, 
the estimation of AREDs prevalence was based on the number of affected individuals, rather 
than the number of affected eyes. When interpreting the findings in this thesis as a whole, one 
should note that the overall burden of AREDs in a specific year cannot be the total cases of 
AMD, glaucoma, cataract and DR, given the possible coexistence of two or more AREDs in 
the same individual (Vizzeri and Weinreb, 2010). 
The national and subnational disease burden of age-related eye diseases in China 
Overall discussion  197 
7.2 Implications on disease management  
As estimated in this thesis, the increasing burden of AREDs will place a larger demand in the 
current health system. The latest national five-year plan for eye health in China (“The 13th 5-
Year National Eye Health Plan 2016-2020”) also emphasises the provision of universal eye 
health as integrated into health care system (National Health and Family Planning Commission 
of the People's Republic of China, 2016). The current health insurance systems in China 
include three programs: New Rural Cooperative Medical Scheme (NRCMS) for rural residents, 
Urban Employee Basic Medical Insurance (UEBMI) for urban residents with formal 
employment and Urban Resident Basic Medical Insurance (URBMI) for urban residents 
without formal employment. Despite the success of universal health insurance coverage, 
where 95% of China’s total population were covered by the current health insurance system, 
the financial burden remains large for the insured. In 2011, the reimbursement rate of inpatient 
care was only around 50% in these three insurance systems (68% in UEBMI, 48% in URBMI 
and 44% in NRCMS in 2011). UEBMI could cover both inpatient and outpatient care, whereas 
NRCMS and URBMI mainly target on inpatient and critical outpatient care. In 2011, 
outpatient care could be universally covered though UEBMI in all Chinese counties or cities, 
but only partly available though NRCMS and URBMI in only 58% and 79% of Chinese 
counties or cities (Yu, 2015, Wang et al., 2014c).  
The large burden of AMD has placed a huge burden on the Chinese public health and medical 
systems. For patients with advanced AMD in one eye, there is a substantial chance that the 
other eye would be affected within five years (Jager et al., 2008, Age-Related Eye Disease 
Study Research Group, 2001a). Since AMD cannot be fully cured and possible treatments are 
not universally available, especially for GA, it is rather important to accept periodic eye exams 
and identify preventive strategies that can lead to better visual outcomes (Gehrs et al., 2006, 
Wong et al., 2008a).  
Prevention of AMD is mainly focused on diminishing risk factor effects, with specific 
interventions including lifestyle modification and antioxidant therapy (Wong et al., 2011). The 
smoking cessation has been highlighted as an effective strategy, because of its adverse 
association with AMD is unequivocal (Khan et al., 2006b, Thornton et al., 2005). Although 
the association between sunlight exposure and AMD is still controversial, in the ten-year 
follow-up of the Beaver Dam Eye Study, in individuals who reported the highest summer sun 
exposure levels in their teens and 30s, those who wore hats or sunglasses at least half the time 
were less likely to develop soft indistinct drusen (RR: 0.55 [95% CI: 0.33-0.90]) and retinal 
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pigment epithelial depigmentation (RR: 0.51 [95% CI: 0.29-0.91]). This suggests that the use 
of hats and sunglasses might be regarded as a protective measure in slowing the development 
of AMD (Tomany et al., 2004). Some studies on nutrient supplementation, such as the Age-
Related Eye Disease Study formula, provide other clues for investigation of well-known 
supplements, including lutein and zeaxanthin, omega-3 fatty acid, and berry extracts (Wong 
et al., 2011, Chong et al., 2007, Evans and Lawrenson, 2012). 
Currently, there is no satisfying treatment that would have a significant influence on blindness 
caused by AMD. Thermal laser photocoagulation is a traditional treatment for wet AMD in 
the last decades, using intense laser beams to coagulate the abnormal choroidal neovascular 
membrane (Bressler, 2002, Wong et al., 2008a). This treatment is very effective in reducing 
the risk of vision loss in patients with wet AMD. However, recurrence is very common after 
treatment, and the procedure itself may cause permanent retina scars and scotomas that 
permanently impair vision, especially when the targeted vessels are close to the fovea (Bressler, 
2002, Cook et al., 2008). Photodynamic therapy involves intravenous injection of verteporfin 
and then a photoactive laser, verteporfin, can accumulate in the abnormal vessels and the 
following photoactive laser that results in thrombosis of the abnormal blood vessels 
(Blumenkranz et al., 2002). This therapy has been proven to reduce the risk of vision loss 
safely, although recurrences are also common (Potter and Szabo, 2007). Since the mid-2000s, 
antiangiogenic therapy, involving delivery of anti-vascular endothelial growth factor (VEGF) 
agents directly into the eye, has become the mainstay for the treatment of wet AMD (Cook et 
al., 2008). Currently, there are four anti-VEGF agents in use: Pegaptanib, Ranibizumab, 
Bevacizumab and Aflibercept (Agrawal et al., 2013). While Pegaptanib was the first approved 
anti-VEGF agent for the treatment of wet AMD, its effectiveness has been shown to be inferior 
to that of Ranibizumab, thereby the use of Pegaptanib is relatively limited (Takeda et al., 2007). 
Ranibizumab is a recombinant humanised monoclonal antibody fragment that inhibits VEGF, 
Bevacizumab is the parent molecule from which Ranibizumab is derived, and both are the 
effective known therapies (Comparison of Age-related Macular Degeneration Treatments 
Trials (CATT) Research Group et al., 2012). However, Bevacizumab has been widely used 
off-label in the US because its costs are considerably smaller than Ranibizumab costs when 
administered intravitreally ($50 vs. $1,950 per dose) (Brechner et al., 2011). Aflibercept is a 
novel recombinant fusion protein consisting of all isoforms of VEGF-A, VEGF-B, and 
placental growth factor (Ohr and Kaiser, 2012). Verteporfin and Ranibizumab have been 
licensed for AMD treatment in China. However, these agents are not covered by medical 
insurance. The high cost of these two agents has posed a considerable financial burden on 
patients and limited their widespread use in Chinese clinical practice. At present, Bevacizumab 
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has also been approved to treat cancers. However, its similar efficacy and much lower cost 
than Ranibizumab have stimulated the off-label use of Bevacizumab for wet AMD (Li et al., 
2012, Wu et al., 2016). Currently, unlike exudative AMD, there are no effective medical 
treatments to cure or slow the progress of GA, but increasing evidence suggests that there are 
some protective effects of some micronutrients and vitamins. Furthermore, advances in gene 
therapy and stem cell therapy are promising in their potential to alleviate vision loss and slow 
its development (Damico et al., 2012). 
For glaucoma, the major characteristic of this disease is that the progress of glaucoma is 
painless and asymptomatic until at advanced stages, by which point considerable damage to 
vision has already occurred. Even in developed countries, only fewer than 50% of those with 
glaucoma are aware of the existence of glaucoma, and this proportion is probably even lower 
in developing countries (Quigley, 1996). However, most of the risk factors for glaucoma are 
impossible to remedy, such as age, ethnicity, and genetics, thereby early detection of glaucoma 
is crucial in reducing morbidity and improving quality of life (Nduaguba and Lee, 2006). 
However, unlike diabetic retinopathy, which largely benefits from screening programs, early 
detection or prediction of glaucoma remains challenging. Furthermore, universal screening for 
glaucoma has been found not to be cost-effective, thereby the targeted screening of high-risk 
groups may be more practical and cost-effective (Nduaguba and Lee, 2006, Burr et al., 2007). 
In China, misunderstanding about the asymptomatic nature of glaucoma among patients and 
physicians, especially those in rural areas, makes identifying patients with glaucoma a special 
challenge (Yan et al., 2012). Public health initiatives for raising disease awareness might be 
useful in encouraging routinely comprehensive eye examinations among the elderly. However, 
it is also suggested that in rural China, the acceptance of comprehensive eye examinations 
could only be improved when making comprehensive eye examinations free (Dan et al., 2015). 
In China’s primary health system, free comprehensive eye examinations are still not 
universally provided, restricting the surveillance for and early treatment of glaucoma to a large 
extent. 
Despite the fact that visual loss caused by glaucoma is irreversible and no preventive scheme 
is under recommendation, it remains possible to slow further progression when adequate 
therapies are available. The only proven treatment strategy for primary glaucoma is lowering 
IOP by, either, reducing the amount of aqueous fluid or increasing the size of the drainage 
channels. Lowering IOP can be achieved by several modalities, including medication (e.g. eye 
drop), laser treatment (e.g. the older Argon Laser Trabeculoplasty [ALT] or the newer 
Selective Laser Trabeculectomy [SLT]), and surgery (e.g. trabeculectomy with augmentation) 
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(The Royal College of Ophthalmologists, 2016, Rulli et al., 2013). Topical administration of 
ocular medication is usually the initial therapy in mitigating the progression of hypertension 
associated disease. Commonly used topical medications include beta-blockers and carbonic 
anhydrase inhibitors for suppressing aqueous inflow, and prostaglandin analogues for increase 
aqueous inflow (Crowston and Weinreb, 2005, Barton and Hitchings, 2013, Congdon and 
Friedman, 2003). Although being applied topically to the eye, these agents may have unusual 
side-effects, such as gradual irreversible darkening of the iris. In addition, daily application of 
ocular medication is expensive and subject to poor compliance (Weinreb and Khaw, 2004, 
Weinreb et al., 2014). The most widely adopted laser treatment for POAG as an adjunct to 
medications is laser trabeculoplasty, which directs laser light at the trabecular meshwork to 
decrease the resistance to aqueous humour outflow. However, the 5-year success rate is only 
about 50 % with the majority of patients responding in the first few months, before the effects 
decrease gradually over time with a failure rate of around 10% per annual (Weinreb and Khaw, 
2004, Shingleton et al., 1993, Shingleton et al., 1987). Trabeculectomy is the most widely 
adopted incisional surgery to enhance aqueous humour drainage, where a fistula is created to 
allow aqueous humour flowing out from the anterior chamber into the sub-Tenon's space. To 
inhibit a fibroproliferative response and improve the success rates, adjunctive antiscarring 
agents are usually applied, but may increase the rate of complications (Weinreb et al., 2014). 
Moreover, although trabeculectomy is regarded as highly effective in reducing the pressure, 
the associated high risk of complications cannot be overlooked (Rulli et al., 2013). 
As a degenerative disease, cataract is not fully preventable, but lowering the risk of cataract 
by decreasing exposure to well-established risk factors is still beneficial. Wearing a hat and 
UV-B protecting sunglasses to avoid direct sunlight have been suggested as effective 
preventative measures for cortical cataract (McCarty and Taylor, 2002, McCarty et al., 2000). 
Smoking cessation has also been indicated as an effective measure for reducing the risk of 
age-related cataract, particular nuclear cataract (Kelly et al., 2005, Ye et al., 2012). Despite 
the fact that cataract is the most prevalent ARED, as revealed in this thesis. The bright side of 
cataract is that restoring sight is possible by surgery (Solomon and Donnenfeld, 2003). The 
most widely adopted surgery is cataract extraction with implantation of an artificial intraocular 
lens for the restoration of vision. Three main surgical techniques are available for the treatment 
of cataract, namely, intra-capsular cataract extraction, extra-capsular cataract extraction and 
phaco-emulsification (Tabin et al., 2008, Asbell et al., 2005). In intra-capsular cataract 
extraction, a large incision is opened for removal of the entire lens and capsule, and then an 
artificial intraocular lens is inserted in front of the iris. In extracapsular cataract extraction, a 
small incision is opened to remove the nucleus, cortex and anterior capsule, but the posterior 
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capsule is retained, and then an artificial intraocular lens is inserted behind the iris. Phaco-
emulsification is an advanced technique of extra-capsular cataract extraction with no damage 
to the anterior chamber. In this procedure, an ultrasonic hand piece, together with aspiration, 
was used to emulsify opaque lens into small pieces (Linebarger et al., 1999). Phaco-
emulsification is superior to the other two options due to rapid visual recovery and a shorter 
hospital stay, and has become the standard surgical procedure in most developed countries. 
However, this advanced technique relied heavily on high-technology equipment, well-trained 
surgeons and support staff and regular maintenance. Therefore, it is still prohibitive to 
implement in high volume in developing countries, especially in poor and rural areas (Tabin 
et al., 2008). 
Despite its success on visual outcomes, cataract surgery is still hampered by high costs, the 
need for professional surgeons and post-surgical complications in developing countries. In 
China, it appears that cost has no longer been a major barrier to cataract surgical uptake due 
to the implementation of universal health insurance (Yu, 2015, Huang et al., 2012, Chen et al., 
2011). However, the availability of such treatment and its accessibility are still limited, even 
in developed countries, with longer waiting times hampering its implementation (Brian and 
Taylor, 2001, Access Economics, 2010). In China, the cataract surgery rate was still the lowest 
in Asia (446 per million per year), which might be caused by the insufficiency of well-
developed ophthalmic infrastructures. Under those circumstances, alternative preventions and 
treatments are still worthy of investigation. At present, no pharmacological treatments have 
been developed to stop the formation of cataract or elimination of existing cataract. Some 
potential anti-cataract therapeutic agents are still under investigations, such as aspirin and 
aspirin-like drugs, which have shown effects in delaying cataract in animal models. However, 
the systematic side effects (e.g. gastric ulcer and renal impairment) and ocular side effects (e.g. 
stinging and corneal disorders), alongside with the drug usage, outweigh the potential benefits, 
thus limiting its wide adoption (Abdelkader et al., 2015). However, most of the agents were 
tested on animal lenses, mostly rodent (Tauseef et al., 2008, Yan et al., 2008), and ocular 
devilry, long-term ocular safety and tolerability have yet to be evaluated in human lenses. 
For DR, intensive control of diabetic abnormalities and hypertension remains a primary 
measure for delaying the progression of diabetic microvascular complications (Mohamed et 
al., 2007). At initial stages, DR is normally asymptomatic, even for PDR at its most treatable 
stages. Thus the majority of the diabetic patients are not aware of the existence of this condition, 
and yet without proper management, DR will affect vision and lead to blindness in end-stages, 
when it is too late for effective treatment (Stefánsson et al., 2000). Therefore, timely and active 
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screening and early intervention are critical. Among most widely practised interventions for 
diabetes, only diabetic retinopathy screening, treatment and pre-conception care were proven 
to have a “clearly cost-saving” effect (Klonoff and Schwartz, 2000, Jones and Edwards, 2010). 
Regular eye care services for diabetic patients has also been recommended as essential in the 
management of DR, this followed by appropriate laser treatment if required (World Health 
Organization, 2006). Many developed countries have initiated retinal screening to detect the 
onset of progression of DR. In the UK, DR is the only ocular disease that is actively screened 
for. Both type 1 and type 2 diabetic patients aged 12 years old are offered annual retinal 
examination through the National Health Service (NHS) diabetic retinopathy screening 
program (The Royal College of Ophthalmologists, 2012). In many developing countries, 
however, DR has been largely neglected in health-care research and planning, and the 
proportion of recommended eye care among diabetic patients is not optimal (Zheng et al., 2012, 
Burgess et al., 2013). In China, annual screening of DR in diabetic patients has been 
recommended by the national diagnosis and treatment guidelines for DR (Chinese 
Ophthalmological Society, 2014). Some economically developed areas have made annual DR 
screening free in the primary health care system. However, this is not a common case across 
the whole country, especially in poor and rural areas, where the need for adequate DR eye care 
still remains largely unmet (Vela et al., 2012, Wang et al., 2010a). With this said, the 
proportion of diabetic patients undergoing annual eye examinations has not been estimated in 
China, it may be speculated as lower than that in the United States, where this proportion was 
only 40%-50% (Peng et al., 2011). Increasing the proportion of diabetic patients receiving 
regular eye examination is one of the vision goals set out in the latest national eye health plan 
for 2016-2020 (National Health and Family Planning Commission of the People's Republic of 
China, 2016). Although DR screening is generally performed in office, telemedicine or a 
wholly automated approach with the assistance of artificial intelligence could largely reduce 
cost and grading workload, especially in settings where availability of regular screening for 
DR may be inadequate, and access to trained ophthalmic professionals may be limited (Ting 
et al., 2016, Jones and Edwards, 2010, Mansberger et al., 2015).  
For individuals with DR, it is still possible to prevent further visual impairment and blindness, 
this outcome mainly depending on the timing of treatment (Stefánsson et al., 2000, Mohamed 
et al., 2007). Present guidelines for optimum eye care of patients with diabetes are tight 
glycemic and blood pressure control in conjunction with timely laser therapy as needed. Laser 
treatment for PDR has been available more than five decades ago (Neubauer and Ulbig, 2007, 
Stefánsson et al., 2000), and its effectiveness at reducing the risk of visual impairment and 
blindness in patients with PDR or DMO has been well established in previous studies (Group, 
The national and subnational disease burden of age-related eye diseases in China 
Overall discussion  203 
1981, Early Treatment Diabetic Retinopathy Study Research Group, 1991a, Ferris III, 1993). 
Although laser treatment is a remarkable success, it is, however, frequently associated with 
visual field reduction and other ocular side-effects and, thus any new effective therapies for 
treatment may of potentials to be important advances (Aiello, 2003).  
In recent years, several new treatment approaches have emerged, including vitreoretinal 
surgery and intravitreal administration of anti-vascular endothelial growth factor (VEGF) for 
patients with PDR (Elman et al., 2010). Vitreoretinal surgery has an important role in 
managing advanced PDR, including extensive haemorrhage in or behind the vitreous cavity or 
a fibrous mass, tractional retinal detachment and severe fibrovascular proliferation, and most 
patients will benefit from good visual outcomes after the surgery (Newman, 2010, Yorston et 
al., 2008). However, some significant post-operative complications may occur, including 
cataract formation, recurrent vitreous haemorrhages and rhegmatogenous retinal detachment, 
etc. (Newman, 2010). The use of intravitreal anti-VEGF as a preoperative adjunct before 
vitrectomy surgery has shown some benefit (Yang et al., 2008, Rizzo et al., 2008, Da R Lucena 
et al., 2009). Moreover, anti-VEGF agents are also beneficial in the treatment of PDR and 
DMO, especially in cases with neovascular glaucoma and persistent vitreous haemorrhage 
(Osaadon et al., 2014, Simó and Hernandez, 2008). However, the high cost may limit its 
applications, especially in low-income settings. 
7.3 Methodological strengths and limitations 
One of the most important issues in reliable estimation of the prevalence and burden of AREDs 
is the source of information. Several nationally representative or large-scale investigations in 
China have reported the epidemiology of cataract and glaucoma, however, the assessments of 
cataract and glaucoma were based on self-reporting, as is the case for the great majority of 
investigated diseases in those studies (Popkin et al., 2009, Zhao et al., 2012). Although self-
reported data provide valuable information in epidemiological studies, the self-reported 
physician diagnosed-based prevalence estimates might represent a considerable 
underestimation, or suffer from retrospective biases. To avoid the shortcomings of self-
reported data, only studies that specifically assessed the presence of AREDs by using 
professional equipment were eligible for inclusion in the systematic reviews. From the 
methodological perspective, this project provides an example and a strong incentive to utilise 
the large volume of Chinese literature in understanding the epidemiology of diseases in China. 
By performing comprehensive literature search in a wide array of databases (including grey 
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literature), additional reference search, dual systematic review and data extraction, I made 
extensive efforts to minimise the potential bias in the study identification stage. Therefore, the 
reviews of those projects are likely to represent the most complete data to address the 
prevalence of AREDs in China from 1990 onwards. During the study selection process, bias 
that might arise from inconsistent disease definitions and sampling methods was intensively 
minimised by using stringent inclusion and exclusion criteria. The quality of the included 
studies was also assessed, and all the included studies had at least moderate quality scores, as 
assessed by the STROBE guideline.  
Meta-analysis represents a manner of combining results from different studies. In the most 
basic (or simplest) form, meta-analysis could identify a common effect of interest in all studies 
(Impellizzeri and Bizzini, 2012). Given the descriptive nature of this study, only observational 
studies are included. In observational studies, stratum-specific prevalence is commonly 
reported. For example, age subgroup analysis is commonly presented to illustrate how the 
epidemiological parameters differ by age (Flaxman et al., 2015). In this thesis, I aimed to make 
full use of information that could be extracted from the eligible studies. Wherever available, 
stratum-specific prevalence data were extracted in the data extraction stage, which can be seen 
as a methodological innovation compared with previous systematic reviews on the prevalence 
of AREDs in China (glaucoma and DR) (Cheng et al., 2013a, Liu et al., 2012). However, a 
typical concern with this hierarchical data structure is the considerable amount of 
heterogeneity between and within studies, especially when the reported age groups are not 
homogeneous. Although heterogeneity appears to be the norm rather than exception in meta-
analyses of observational studies, high amounts of heterogeneity across the included studies 
could be reasonably reduced by sub-group meta-analysis or meta-regression (Thompson and 
Higgins, 2002, Borenstein et al., 2009). In this study, the individual associations of AREDs 
prevalence and multiple factors (age, sex, geographic factors, etc.) were extensively explored 
using the extracted stratum-specific prevalence data points, based on which a substantial 
amount of heterogeneity could be explained and the stratum-specific prevalence could be 
modelled. The exploration of sources of heterogeneity in different strata can be seen as an 
important function of these meta-analyses and one strength of this work. However, it should 
be noted that no causal interpretations of the observed associations between AREDs and other 
factors (age, sex, geographic factors, etc.) could be made due to the cross-sectional nature of 
this study. Other limitations adherent to each project have been previously stated within the 
respective chapters (Chapters 3-6). 
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Despite the increased amount of published meta-analyses of disease prevalence and the 
existence of reporting guidelines (e.g., PRISMA, GATHER), the absence of a consensus on 
the ways of conducting a meta-analysis of prevalence is apparent in the literature and 
represents a large barrier to standardising the research pathway in this research field 
(Barendregt et al., 2013, Kawasaki et al., 2010, Yau et al., 2012, Tham et al., 2014, Wong et 
al., 2014, Stroup et al., 2000, Murad and Wang, 2017). The study approach, as adopted 
throughout this thesis, has been previously promoted by the Global Health Epidemiology 
Research Group (GHERG) (Chan et al., 2017, Chan et al., 2013). By systematically 
demonstrating the process of estimating prevalence and burden of diseases, this thesis set out 
with the intention of being an example of synthesising epidemiological evidence within the 
same country. The development of a guideline for conducting the meta-analysis of prevalence 
is recommended as a priority for the future research direction.  
Important sources of bias in this study could have arisen in two ways: inadequate amount of 
information from the included studies and poor ability to control confounding factors. 
Although only individual studies that were conducted in samples with general characteristics 
(general population for the AMD, glaucoma and cataract projects, and DM patients for the DR 
project) were included, the included studies were not evenly distributed across the whole 
country. If the prevalence of AREDs in a specific group of people is particularly high or low, 
the inclusion of individual studies that were conducted in such groups could have resulted in 
a selection bias, especially when the characteristics of those groups were not able to be 
evaluated (e.g., ethnicity). When assessing the potentially associated factors of AREDs, the 
number of available variables was limited, largely restricting the analyses that could be 
conducted for different risk strata. In the projects of AMD, glaucoma and cataract, the 
available variables were all stratum- or study-level characteristics, including age, sex, setting, 
geographic features (location, latitude, longitude, etc.), individual-level characteristics were 
not able to be evaluated. Even when individual-level factors were available for synthesis, as 
in the DR project, the selection of risk factors for meta-analysis was still largely restricted by 
the limited information extracted from the included studies. Therefore, when distributing the 
national burden into different geographic regions, not all confounding factors of AREDs were 
controlled, which could influence the accuracy of regional estimation to some extent. 
The national and subnational disease burden of age-related eye diseases in China 
Overall discussion  206 
7.4 Suggestions for future work 
Generally, meta-analyses were conducted using aggregated results from individual studies. On 
the other hand, meta-analyses could be performed based on individual participant data, where 
the full dataset of each individual study should be requested from researchers (Stewart and 
Tierney, 2002). Apparently, this kind of meta-analysis with data coming from the individual 
level could largely overcome the above-mentioned methodological limitations and is 
recognised as with higher quality compared with the aggregate-level meta-analysis. However, 
the process of collecting individual-level data from researchers could be extremely time 
consuming and heavily rely on the researchers’ willingness for cooperation. In some cases, the 
final database might only include a minority of all the eligible studies, which was the reason 
why this approach was not considered in this thesis. With more epidemiological investigations 
being performed, the updated meta-analysis of AREDs prevalence in China could definitely 
benefit from a larger amount of eligible studies. If time and funding allow, an individual 
participant data-based meta-analysis of all eligible studies or a nationally representative 
investigation are probably more accurate and more appropriate approaches to addressing the 
epidemiology of AREDs in China. 
As stated in each project chapter, there is a need to improve the application of international 
classifications or grading systems in Chinese research society, such as the WARMGS 
(Wisconsin age-related maculopathy grading system) for AMD and the comprehensive LOCS 
(Lens Opacities Classification System) for cataract (Klein et al., 1991, Chylack et al., 1988, 
Chylack et al., 1989, Chylack et al., 1993). This could make the comparison of ARESs in 
China and other countries a possibility and reduce the bias introduced by methodological 
disparity to a large extent. Due to the existence of several subtypes of AREDs, it is also 
important that future epidemiological studies on AREDs focus on all of these, whenever 
possible. Moreover, standardised reporting should be advocated in future research, with 
adherence to relevant guidelines or checklists (Von Elm et al., 2007). This should not be only 
restricted to studies on the topic of AREDs or Chinese epidemiological investigations, but also 
applicable to all kinds of observational studies across the international research society.  
During the dramatic ageing process in China, the epidemiology of many other degenerative 
diseases is also worthy of further assessment, such as osteoporosis, Parkinson's disease and 
rheumatoid arthritis. By using the study approaches demonstrated in this thesis, the prevalence 
and disease burden of major NCDs in China will be evaluated one by one, based on which a 
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complete picture of disease burden on NCDs for China will be portrayed in the foreseeable 
future. 
7.5 Conclusions 
In conclusion, this thesis demonstrates a comprehensive estimation of the prevalence and 
burden of AREDs in China. By systematically incorporating data from published population-
based studies on AREDs in China, the prevalence and burden of AMD, glaucoma and cataract 
were successfully estimated for the period between 1990 and 2015 and projected to 2050. The 
prevalence and burden of DR were estimated for the year 2010. In addition, the variations of 
AREDs prevalence by demographics, geographic features and other associated factors were 
assessed, based on which the subnational/regional prevalence and burden of AREDs were 
generated. 
According to the results in this thesis, the most common feature of the four AREDs is that they 
are all highly age-related. Given the ageing trend in China in the next decades, as presented in 
Chapter 1, the prevalence and burden of AREDs will continue to increase. More elaborate 
epidemiological studies are needed to optimise public health strategies for mitigating this 
important health problem. Primary and secondary prevention, treatment and effective 
government response are urgently needed to optimise public health strategies for mitigating 
this important health problem. 
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APPENDICES 
Appendix table 1. level-one ethical self-assessment 
University of Edinburgh, 
Usher Institute of Population Health Sciences and Informatics 
RESEARCH ETHICS SUBGROUP 
 
Self-Audit Checklist for Level 1 Ethical Review for PGR projects 
See Intra website for further information: http://www.cphs.mvm.ed.ac.uk/intra/research/ethicalReview.php  
NOTE to student:  Completion of this form should be under the oversight of your supervisor.  A good strategy would be to complete 
a draft as best you can, then discuss with your supervisor before completing a final copy for your supervisor to sign.  
1. Bringing the University into disrepute 
Is there any aspect of the proposed research which might bring the University into disrepute?             YES/ NO√ 
2. Data protection and consent 
Are there any issues of DATA PROTECTION or CONSENT which are NOT adequately  
dealt with via established procedures? YES/ NO √ 
These include well-established sets of undertakings. For example, a ‘No’ answer is justified only if: 
(a) There is compliance with the University of Edinburgh’s Data Protection procedures (see   
       www.recordsmanagement.ed.ac.uk); 
(b) Respondents give consent regarding the collection, storage and, if appropriate, archiving and destruction of 
data; 
(c) Identifying information (eg consent forms)  is held separately from data; 
(d) There is Caldicott Guardian approval for  (or approval will be obtained prior to) obtaining/ analysing NHS 
patient-data. 
(e) There are no other special issues arising about confidentiality/consent. 
3. Study participants  
a) Will a study researcher be in direct contact with participants to collect data, whether face-to-
face, or by telephone, electronic means or post, or by observation? (eg interviews, focus groups, 







Proposed Project (State research question and topic area, and briefly describe method/ data. Specify also countries 
in which data will be collected.): 
Project title: The national and subnational disease burden of age-related eye diseases in China 
In this project, the prevalence and disease burden of four major age-related eye diseases, including age-related 
macular degeneration, glaucoma, cataract and diabetic retinopathy will be estimated. The primary research methods 
will be systematic review and meta-analysis. For the project of diabetic retinopathy, a open-accessed dataset- China 
Health and Retirement Longitudinal Study will be additionally used. This project will be conducted in the UK. 
b) Answer this only if qu. 3 above = ‘YES’:   
In ethical terms, could any participants in the research be considered to be ‘vulnerable’?                                          
e.g. children & young people under age of 16,  people who are in                               Please tick one:                                              
custody or care (incl. school), a marginalised/stigmatised group                       ‘vulnerable’          not ‘vulnerable’ 
 
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4. Moral issues and Researcher/Institutional Conflicts of Interest 
Are there any SPECIAL MORAL ISSUES/CONFLICTS OF INTEREST? YES/ NO√ 
(a)  An example of conflict of interest for a researcher would be a financial or non-financial benefit for 
him/herself or for a relative of friend. 
(b)  Particular moral issues or concerns could arise, for example where the purposes of research are 
concealed, where respondents are unable to provide informed consent, or where research findings could 
impinge negatively/ differentially upon the interests of participants.  
(c)  Where there is a dual relationship between researcher and participant (eg where research is undertaken 
by practitioners so that the participant might be unclear as to the distinction between ‘care’ and research) 
 
5. Protection of research subject confidentiality 
Are there any issues of CONFIDENTIALITY which are NOT adequately handled by  
normal tenets of confidentiality for academic research?                     YES/ NO√ 
These include well-established sets of undertakings that should be agreed with collaborating and 
participating individuals/organisations. For example, a ‘No’ answer is justified only if: 
(a) There will be no attribution of individual responses;  
(b) Individuals (and, where appropriate, organisations) are anonymised in stored data, publications and 
presentation;  
(c) There has been specific agreement with respondents regarding feedback to collaborators and publication.  
6. Potential physical or psychological harm, discomfort or stress 
(a) Is there a FORSEEABLE POTENTIAL for PSYCHOLOGICAL HARM or 
 STRESS for participants? YES/ NO√ 
(b) Is there a FORSEEABLE POTENTIAL for PHYSICAL HARM or  
 DISCOMFORT for participants?  YES/ NO√ 
(c) Is there a FORSEEABLE RISK to the researcher? YES/ NO√ 
Examples of issues/ topics that have the potential to cause psychological harm, discomfort or distress and 
should lead you to answer ‘yes’ to this question include, but are not limited to:  
relationship breakdown;  bullying; bereavement;   mental health difficulties; trauma / PTSD; violence or 
sexual violence; physical, sexual or emotional abuse in either children or adults. 
 
7. Duty to disseminate research findings  
Are there issues which will prevent all relevant stakeholders* having access to a clear, 
understandable and accurate summary of the research findings if they wish?  YES/ NO√ 
* If, and only if, you answered ‘yes’ to 3 above,  ‘stakeholders’ includes the participants in the research  
Overall assessment 
➢ If every answer above is a definite NO, the self-audit has been conducted and confirms the  
ABSENCE  OF  REASONABLY FORESEEABLE  ETHICAL RISKS – please tick box 
This means that regarding this study, as currently self-audited, no further ethical review actions are required 
within Usher.  However, if in the coming weeks/months there is any change to the research plan envisaged now 
(and outlined above), the study should be re-audited against a Level 1 form, because it may be that the change 
made negates the absence of ethical risks signed off here. 
Two copies of this form should be taken for inclusion in the final dissertation/thesis and the original should be 
returned to Usher Ethics admin – usher.ethics@ed.ac.uk  
The Usher Ethics Subgroup cannot check validity of responses made here (the light touch Level 1 form means 
we have insufficient detail to do so).  Receipt of this form will be acknowledged, but no formal letter of approval 
can be/will be sent. If some formal letter is required e.g.for a funder, please ask in your covering email. We will 
then send a form of words re the self-audit process.  
➢ If one or more answers are YES, then risks have been identified and prior to commencing any 
data collection formal ethical review is required - either: 
 by NHS REC (NB a copy of ethics application and decision letter, and this level 1 form, must be sent 
to Usher Ethics usher.ethics@ed.ac.uk); or  
√ 
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 if not to be formally reviewed by NHS REC, then Usher level 2/3 ethical review required.                         [If 
either 4 is ‘yes’ or 3b is ‘vulnerable’ then it is possible level 3 review is required.] 
 
Peige Song____________________   Kit Yee Chan________________________ 
Student Name      Supervisor Name 
 
______________________________   _____________________________ 
Student Signature     Supervisor Signature * 
* NOTE to supervisor: By counter-signing this check-list as truly warranting all ‘No’ answers, you are taking responsibility, on 
behalf of Usher and UoE, that the research proposed truly poses no potential ethical risks. Therefore, if there is any doubt on any 
issue, it would be a wise precaution to mark it as ‘uncertain’ and contact the Ethics Subgroup as to whether a level 2 form might 
be required as well. (See Intra Ethics website – URL at top of form)                                                                    28 Oct 2018 
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Appendix table 2. Search strategy to identify studies reporting the prevalence of age-
related macular degeneration in China 
CNKI 
Access Date: 26 JUN 2016 
Subject category: Medicine & Public Health 
Sub-database: Journal, Featured journal, Doctoral dissertation, Master dissertation, 
Domestic conferences, International conferences  
检索表达式： 
(SU % '年龄相关黄斑变性' + '年龄相关性黄斑变性' + '老年黄斑变性'+ '老年性黄斑变
性' + '年龄相关黄斑病变'+ '年龄相关性黄斑病变' + '老年黄斑病变'+ '老年性黄斑病变
') AND (SU % '发病率' + '发生率' + '患病率'+ '罹患率' + '现患率'+ '死亡率' + '病死率'+ 
'流行' + '负担'+ '现况调查'+ '现况研究') 
发表时间：从 1990-01-01 到 2016-06-26 
Search Terms: (SU % 'nianlingxiangguanhuangbanbianxing' + 
'nianlingxiangguanxinghuangbanbianxing' + 'laonianhuangbanbianxing'+ 
'laonianxinghuangbanbianxing' + 'nianlingxianghguanhuangbanbingbian'+ 
'nianlingxiangguanxinghuangbanbingbian' + 'laonianhuangbanbingbian'+ 
'laonianxinghuangbanbingbian') AND (SU % 'fabinglv' + 'fashenglv' + 'huanbinglv'+ 
'lihuanlv' + 'xianhuanlv'+ 'siwanglv' + 'bingsilv'+ 'liuxing' + 'fudan'+ 'xiankuangdiaocha'+ 
'xiankuangyanjiu') 
Published time：From 01/01/1990 to 26/06/2016 
 
Wanfang 
Access Date: 26 Jun 2016 
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Sub-database: Journal articles, Dissertations, Conference articles, Foreign journals, Foreign 
conferences 
检索表达式：(主题:(年龄相关黄斑变性) + 主题:(年龄相关性黄斑变性) + 主题:(老年
黄斑变性) + 主题:(老年性黄斑变性) + 主题:(年龄相关黄斑病变) + 主题:(年龄相关性
黄斑病变) + 主题:(老年黄斑病变) + 主题:(老年性黄斑病变)) * (主题:(发病率) + 主
题:(发生率) + 主题:(患病率) +主题:(罹患率) + 主题:(现患率) + 主题:(死亡率) +主
题:(病死率) + 主题:(流行) + 主题:(负担)+ 主题:(现况调查) + 主题:(现况研究)) 
时间：1990-2016 
Search Terms: (subject: (nianlingxiangguanhuangbanbianxing) + subject: 
(nianlingxiangguanxinghuangbanbianxing) + subject: (laonianhuangbanbianxing) + 
subject: (laonianxinghuangbanbianxing) + subject: 
(nianlingxianghguanhuangbanbingbian)+ subject: 
(nianlingxiangguanxinghuangbanbingbian) + subject: (laonianhuangbanbingbian) + 
subject: (laonianxinghuangbanbingbian))* (subject: (fabinglv) + subject: (fashenglv) + 
subject: (huanbinglv)+ subject: (lihuanlv) + subject: (xianhuanlv) + subject: (siwanglv)+ 





Access Date: 26 Jun 2016 
Journal category: All journals 
检索表达式： 
((年龄相关黄斑变性) OR (年龄相关性黄斑变性) OR (老年黄斑变性) OR (老年性黄斑
变性) OR (年龄相关黄斑病变) OR (年龄相关性黄斑病变) OR (老年黄斑病变) OR (老
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年性黄斑病变)) AND ((发病率) OR (发生率) OR (患病率) OR (罹患率) OR (现患率) 
OR (死亡率) OR (病死率) OR (流行) OR (负担) OR (现况调查) OR (现况研究)) 
时间：1990-2016 
Search Terms: ( (nianlingxiangguanhuangbanbianxing) OR 
(nianlingxiangguanxinghuangbanbianxing) OR (laonianhuangbanbianxing) OR 
(laonianxinghuangbanbianxing) OR (nianlingxianghguanhuangbanbingbian) OR 
(nianlingxiangguanxinghuangbanbingbian) OR (laonianhuangbanbingbian) OR 
(laonianxinghuangbanbingbian))* ( (fabinglv) OR (fashenglv) OR (huanbinglv) OR 
(lihuanlv) OR (xianhuanlv) OR (siwanglv) OR (bingsilv) OR (liuxing) OR (fudan) OR 




Access Date: 16 Sep 2016 
Search Terms:  
 ((age-related macular degeneration OR age related macular degeneration OR age-related 
maculopathy OR age related maculopathy) AND (China OR Chinese OR Hongkong OR 
Macao OR Taiwan) AND (inciden* OR prevalen* OR morbidity OR mortality OR 
epidemiology)) AND ("1990/01/01"[Date - Publication] : "2016/09/17"[Date - 
Publication]) 
Embase (Ovid) 
Access Date: 17 Sep 2016 
# Searches 
1 age-related macular degeneration.mp. or exp retina macula age related 
degeneration/ or exp age related macular degeneration/ or exp retina 
macula degeneration/ 
2 exp retina maculopathy/ or age-related maculopathy.mp. 
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3 China.mp. or exp China/ 
4 exp Chinese/ or Chinese.mp. 
5 Hong Kong.mp. or exp Hong Kong/ 
6 Macao.mp. or exp Macao/ 
7 Taiwan.mp. or exp Taiwan/ 
8 exp incidence/ or inciden*.mp. 
9 exp prevalence/ or prevalen*.mp. 
10 morbidity.mp. or morbidity/ 
11 mortality/ or Mortality.mp. 
12 exp epidemiology/ or Epidemiology.mp. 
13 1 or 2 
14 3 or 4 or 5 or 6 or 7 
15 8 or 9 or 10 or 11 or 12 
16 13 and 14 and 15 
17 limit 16 to yr="1990 -Current" 
 
Medline (Ovid) 
Access Date: 17 Sep 2016 
Search Terms:  
# Searches 
1 age-related macular degeneration.mp. or exp Macular Degeneration/ 
2 age-related maculopathy.mp. 
3 China.mp. or exp China/ 
4 Chinese.mp. 
5 Hong Kong.mp. or exp Hong Kong/ 
6 Macao.mp. or exp Macau/ 
7 Taiwan.mp. or exp Taiwan/ 
8 exp Incidence/ or inciden*.mp. 
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9 exp Prevalence/ or prevalen*.mp. 
10 morbidity.mp. or exp Morbidity/ 
11 mortality.mp. or exp Mortality/ 
12 epidemiology.mp. or exp Epidemiology/ 
13 1 or 2 
14 3 or 4 or 5 or 6 or 7 
15 8 or 9 or 10 or 11 or 12 
16 13 and 14 and 15 
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Appendix table 3. The year of publication and investigation and corresponding time-lag 
in the included studies on AMD prevalence in China (n=25) 






AMD-01 Huang P et al. (1992) 1992 1987 5 
AMD-02 Tang JQ et al. (1992) 1992  -  - 
AMD-03 Wu ZQ et al. (1992) 1992 1989 3 
AMD-04 Chen YH et al. (1993) 1993 1991 2 
AMD-05 Yu Q et al. (1994) 1994 1990 4 
AMD-06 Wang K et al. (1994) 1994 1989 5 
AMD-07 He MG et al. (1998) 1998 1997 1 
AMD-08 Zou HD et al. (2005) 2005 2003 2 
AMD-09 Tian MN et al. (2005) 2005  -  - 
AMD-10 Bai ZL et al. (2005) 2005 2003 2 
AMD-11 Shi K et al. (2009) 2009 2006 3 
AMD-12 Li HL et al. (2009) 2009 2009 0 
AMD-13 Zhao X et al. (2011) 2011 2006 5 
AMD-14 Huang XB et al. (2012) 2012 2008 4 
AMD-15 Yang Z (2014) 2014 2013 1 
AMD-16 Cao J (2014) 2014 2010 4 
AMD-17 Xiang W et al. (2015) 2015 2014 1 
AMD-18 Wang Y et al. (2015) 2015 2015 0 
AMD-19 Li WL et al. (2015) 2015 2013 2 
AMD-20 Li Y et al. (2006) 2006 2001 5 
AMD-21 Chen SJ et al. (2008) 2008 1999 9 
AMD-22 Huang TL et al. (2010) 2010  -  - 
AMD-23 Yang K et al. (2011) 2011 2006 5 
AMD-24 Ye H et al. (2014) 2014 2013 1 
AMD-25 Huang EJ et al. (2014) 2014 2011 3 
Note: “-” represents unavailable data; Based on the information from 22 studies, the average 
time-lag between year of publication and year of investigation was 3.05. 
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Appendix table 4. Meta-analysis of the prevalence of AMD for assessing heterogeneity 
between studies  
To assess heterogeneity between studies that reported prevalence rates of AMD, standard meta-
analyses were performed. First, the variances of the raw prevalence estimates were stabilised by 
using logit transformation. Then the heterogeneity between studies was assessed by the 
Cochran's Q and I2 statistics, a p-value<0.05 indicates heterogeneity between studies in Q 
statistic, and I2 represents the proportion of total variation that is due to heterogeneity rather than 
chance, where a value of 0% indicates no observed heterogeneity and values of <25%, 25–75%, 
and >75% reflect low, moderate and high heterogeneity, respectively (Higgins and Thompson, 
2002, Higgins et al., 2003). As shown in Appendix figures 1-5, significant high heterogeneity 
was indicated between studies that reported prevalence rates of any AMD (I2=98.4%, p<0.0001), 
early AMD (I2=98.7%, p<0.0001), late AMD (I2=96.8%, p<0.0001), GA (I2=90.5%, p<0.0001) 
and NVAMD (I2=94.0%, p<0.0001). 
 
Appendix figure 1. Meta-analysis of the prevalence of any AMD (n=25) 
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Appendix figure 2. Meta-analysis of the prevalence of early AMD (n=9) 
 
 
Appendix figure 3. Meta-analysis of the prevalence of late AMD (n=9) 
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Appendix figure 4. Meta-analysis of the prevalence of GA (n=6) 
 
 
Appendix figure 5. Meta-analysis of the prevalence of NVAMD (n=15) 
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Appendix table 5. Full list of the included studies on AMD prevalence in China (n=25) 
Study ID Reference 
AMD-01 Ping Huang, Ren-xiu He, Guo-zhen He, et al. 黄平，何仁秀，何国桢，等. The investigation of Age-related Macular Degeneration in Hunan 
Province* (湖南省老年黄斑变性流行病学调查) [J]. Chinese Ophthal Res (眼科研究). 1992(01): 60-61. 
AMD-02 Jia-quan Tan, Ai-guang Nie, De-yong Jiang, et al. 谭家铨，聂爱光，姜德泳，等. The investigation of Age-related Macular Degeneration* (老年性
黄斑变性流行病学调查) [J]. Hunan Medical Journal (湖南医学). 1992(05): 274-275. 
AMD-03 Zheng-qing Wu, Jin-e Cao, Xiu-heng Yao, et al. 武正清，曹金娥，姚秀衡，等. Epidemiologic survey of senile macular degeneration (老年黄斑变
性的流行病学调查) [J]. Chinese Journal of Ophthalmology (中华眼科杂志). 1992, 28(4): 246-247. 
AMD-04 Yu-hua Chen, Ji-kui Shen, Yu-hong Zhang, et al. 陈玉华，申济奎，张宇弘，等. Senile macular degeneration in plateau aerea (高原地区老年性黄
斑变性) [J]. Journal of High Altitude Medicine (实用眼科杂志). 1993(04): 57-58. 
AMD-05 Qiang Yu, Jing-jing Xu, Si-ping Zhu, et al. 于强，许京京，朱斯平，等. Epidemiologic survey of Age-related Macular Degeneration in Doumen 
County, Guangdong province* (广东省斗门县老年黄斑变性流行病学调查) [J]. Chinese Journal of Ocular Fundus Diseases (中华眼底病杂志). 
1994(2). 
AMD-06 Kuang Wang, Jin Zhao, Jie-kai Jiang, et al. 王况，赵瑾，姜节凯，等. Epidemiologic survey of Age-related Macular Degeneration* (老年性黄斑变
性的流行病学调查) [J]. Journal of Zhejiang Medical University (浙江医科大学学报). 1994(2). 
AMD-07 Ming-guang He, Jing-jing Xu, Kai-li Wu, et al. 何明光，许京京，吴开力，等. The prevalence of age-related macular degeneration in Doumen 
county, Guangdong (广东省斗门县老年性黄斑变性流行病学调查) [J]. Chin J Ocul Fundus Dis (中华眼底病杂志). 1998(02): 61-63. 
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Study ID Reference 
AMD-08 Hai-dong Zou, Zhe Zhang, Xun Xu, et al. 邹海东，张晳，许迅，等. Prevalence study of age-related macular degeneration in Caojiadu blocks, 
Shanghai (上海市静安区曹家渡街道年龄相关性黄斑变性的患病率调查) [J]. Chin J Ophthalmol (中华眼科杂志). 2005, 41(1): 15-19. 
AMD-09 Man-nan Tian, Yue-mei Zhang, Li Li, et al. 田蔓男，张月梅，李丽，等. Epidemiologic survey of Age-related Macular Degeneration* (老年性黄
斑变性的流行病学调查)[J]. Journal of Lanzhou University (Medical Sciences) (兰州大学学报（医学版）). 2005, 31(2): 70-71. 
AMD-10 Zhi-lan Bai, Bai-chao Ren, Jian-gang Yang, et al. 白芝兰，任百超，杨建刚，等. Epidemiological investigation on age-related macular degeneration 
in rural area of Shaanxi Province, China (中国陕西省农村年龄相关性黄斑变性流行病学调查) [J]. International Journal of Ophthalmology (国际眼
科杂志). 2005, 5(6): 1114-1121. 
AMD-11 Kai Shi, Wen-fang Zhang, Xiao-yan Zhou, et al. 史凯，张文芳，周晓燕，等. Epidemiological investigation of ocular funds disease in Mongol above 
40 years in Henan county (青海省河南县 40岁以上世居蒙古族人群眼底病的流行病学调查) [J]. Chin Ophthal Res (眼科研究). 2009, 27(3): 239-
242. 
AMD-12 Hui-li Li, Ai-lin You, Di-ling Wan, et al. 李慧丽，犹爱林，万迪玲，等. Prevalence study of age-related macular degeneration in central urban area 
of Chongqing (重庆市主城区年龄相关性黄斑变性患病率调查) [J]. Chin J Pract Ophthalmol (中国实用眼科杂志). 2009, 27(12): 1425-1429. 
AMD-13 Xin Zhao, Bi-qi Tian, Yun-he Hao, et al. 赵欣，田碧琪，郝云赫，等. Prevalence of age-related maculopathy in community of Xi Chang'an street of 
Beijing (北京西长安街社区 50岁以上人群年龄相关性黄斑变性患病率调查) [J]. Int J Ophthalmol (国际眼科杂志). 2011, 11(8): 1364-1368. 
AMD-14 Xiao-bo Huang, Hai-dong Zou, Ning Wang, et al. 黄晓波，邹海东，王宁，等. Prevalence of age-related macular degeneration in Beixinjing 
Community of Shanghai (上海市北新泾街道老年人年龄相关性黄斑变性的患病率调查) [J]. Journal of Shanghai Jiaotong University (Medical 
Science) (上海交通大学学报(医学版)). 2012(02): 155-159. 
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AMD-15 Zhen Yang 杨桢. Prevalence and Associated Risk Factors of Age-Related Macular Degeneration in 50 years and older Population in ShunQing District, 
NanChong (南充市顺庆区 50岁及以上人群年龄相关性黄斑变性患病率及相关因素分析) [D]. North Sichuan Medical University (川北医学院), 
2014. 
AMD-16 Jia Cao 曹葭. Prevalence study of age-related macular degeneration over the age of 50's in Wuxi (无锡市 50岁及以上人群年龄相关性黄斑变性流
行病学调查)[D]. Nanjing Medical University (南京医科大学), 2014. 
AMD-17 Wei Xiang, Hui-ping Li, Yang Liu, et al. 向伟，李慧平，刘洋，等. Prevalence Investigation of Age-related Macular Degeneration among Population 
Aged 50 Years or Above in Tongxin County of Ningxia (宁夏同心县≥50岁人群年龄相关性黄斑变性患病率、危险因素及致盲情况分析) [J]. 
Journal of Ningxia Medical University (宁夏医科大学学报). 2015, 37(8): 927-930. 
AMD-18 Ying Wang, Huai-jin Guan, Hong Lu, et al. 汪颖，管怀进，陆宏，等. The Prevalence of age-related macular degeneration in the rural area of Qidong 
County, Jiangsu Province (江苏省启东市农村地区老年性黄斑变性流行病学调查分析) [J]. Chin J Ocul Fundus Dis (中华眼底病杂志). 2015, 
31(5): 459-461. 
AMD-19 Wu-liang Li, Hui-ping Li, Na Li, et al. 李武靓，李慧平，李娜，等. Prevalence of age-related macular degeneration in elderly population in the rural 
area of Ningxia (宁夏农村地区 60 岁以上人群年龄相关性黄斑变性的患病率调查) [J]. Ningxia Medical Journal (宁夏医学杂志). 2015, 37(5): 
401-404. 
AMD-20 Li Y, Xu L, Jonas JB, et al. Prevalence of age-related maculopathy in the adult population in China: the Beijing eye study. AM J OPHTHALMOL 
2006;142:788-793 
AMD-21 Chen SJ, Cheng CY, Peng KL, et al. Prevalence and associated risk factors of age-related macular degeneration in an elderly Chinese population in 
Taiwan: the Shihpai Eye Study. Invest Ophthalmol Vis Sci 2008;49:3126-3133 
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Study ID Reference 
AMD-22 Huang TL, Hsu SY, Tsai RK, Sheu MM. Etiology of ocular diseases in elderly Amis aborigines in Eastern Taiwan (The Amis Eye Study). JPN J 
OPHTHALMOL 2010;54:266-271 
AMD-23 Yang K, Liang YB, Gao LQ, et al. Prevalence of age-related macular degeneration in a rural Chinese population: the Handan Eye Study. 
OPHTHALMOLOGY 2011;118:1395-1401 
AMD-24 Ye H, Zhang Q, Liu X, et al. Prevalence of age-related macular degeneration in an elderly urban chinese population in China: the Jiangning Eye Study. 
Invest Ophthalmol Vis Sci 2014;55:6374-6380 
AMD-25 Huang EJ, Wu SH, Lai CH, et al. Prevalence and risk factors for age-related macular degeneration in the elderly Chinese population in south-western 
Taiwan: the Puzih eye study. Eye (Lond) 2014;28:705-714 
Note: The Chinese publication list employed the journals’ official English names or abbreviations, English titles were obtained from journals or literature 
databases (CNKI, Wanfang and CBM). Where official English translation of journal names is not available, a pinyin title is adopted; where the English 
translation of titles is not available, I translated the titles, labelled with “*” and marked as green. 
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Appendix table 6. Detailed characteristics of the included studies on AMD prevalence in China (n=25) 

















AMD-01 Huang P et al. (1992) Hunan Mixed Both 1987 FI CMA1986 1589 145 - - - 19  
AMD-02 Tang JQ et al. (1992) Hunan Mixed Both 1989 FI CMA1986 1040 191 - - - - 
AMD-03 Wu ZQ et al. (1992) Hunan Mixed Both 1989 FI CMA1986 3351 197 - - - 21  
AMD-04 Chen YH et al. (1993) 
Shaanxi 
Qinghai 
Mixed Mixed 1991 FI CMA1986 849 70 - - - 37  
AMD-05 Yu Q et al. (1994) Guangdong Rural Both 1990 FI CMA1986 932 50 - - - - 
AMD-06 Wang K et al. (1994) Zhejiang Mixed Both 1989 FI CMA1986 730 54 - - - - 
AMD-07 He MG et al. (1998) Guangdong Rural Both 1997 FI CMA1986 5342 451 - - - - 
AMD-08 Zou HD et al. (2005) Shanghai Urban Both 2003 FI CMA1986 1023 159 - - - 19  
AMD-09 Tian MN et al. (2005) Gansu Mixed Mixed 2002 FI CMA1986 7563 579 - - - 5  
AMD-10 Bai ZL et al. (2005) Shaanxi Rural Both 2003 FI IC 2835 85 - - 44  41  
AMD-11 Shi K et al. (2009) Qinghai Rural Mixed 2006 FI CMA1986 2112 132 - - - 33  
AMD-12 Li HL et al. (2009) Chongqing Urban Both 2009 FI 
"Ophthalmology" 
(7th version) 
1513 122 - - - 5  
AMD-13 Zhao X et al. (2011) Beijing Urban Both 2006 FI CARMS 2348 77 70  7  3  4  
AMD-14 Huang XB et al. (2012) Shanghai Urban Both 2008 FI CMA1986 3571 477 - - - 64  
AMD-15 Yang Z (2014) Sichuan Urban Both 2013 FI CARMS 2097 207 194  13  10  3  
AMD-16 Cao J (2014) Jiangsu Urban Both 2010 FI CMA1986 6150 482 - - - 38  
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AMD-17 Xiang W et al. (2015) Ningxia Rural Both 2014 FI CARMS 4812 54 46  8  - - 
AMD-18 Wang Y et al. (2015) Jiangsu Rural Both 2015 FI CARMS 2985 97 71  26  15  11  
AMD-19 Li WL et al. (2015) Ningxia Rural Both 2013 FI CARMS 679 25 17  8  - - 
AMD-20 Li Y et al. (2006) Beijing Mixed Mixed 2001 FI WARM 4376 70 63  7  1  6  
AMD-21 Chen SJ et al. (2008) Taiwan Mixed Both 1999 FI WARM 1058 117 97  20  1  19  
AMD-22 Huang TL et al. (2010) Taiwan Rural Both 2007 FI WARM 2316 121 - - - - 
AMD-23 Yang K et al. (2011) Hebei Rural Mixed 2006 FI WARM 6581 204 200 4 - - 
AMD-24 Ye H et al. (2014) Shanghai Urban Both 2013 FI WARM 2005 229 206  23  - - 
AMD-25 Huang EJ et al. (2014) Taiwan Mixed Both 2011 FI WARM 673 150 101  49  - - 
Note: “-” represents unavailable data; FI, Fundus imaging; CAM 1986, the “Age-related Macular Degeneration Clinical Diagnosis Standard” proposed 
by the China Medical Association in 1986; WARMGS, the Wisconsin age-related maculopathy system; CARMS, the Clinical Age-Related Maculopathy 
Grading System; IC, the International Classification and Grading system. 
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Appendix table 7. Risk of bias scores of the included studies on AMD prevalence in China (n=25) 
Study ID Study 
Quality score 
Sample population Sample size Participation Outcome assessment Analytical methods Total scores 
AMD-01 Huang P et al. (1992) 2 1 2 2 2 9 
AMD-02 Tang JQ et al. (1992) 2 0 0 2 2 6 
AMD-03 Wu ZQ et al. (1992) 2 1 2 2 2 9 
AMD-04 Chen YH et al. (1993) 2 0 0 2 2 6 
AMD-05 Yu Q et al. (1994) 2 1 2 2 2 9 
AMD-06 Wang K et al. (1994) 2 1 2 2 2 9 
AMD-07 He MG et al. (1998) 2 1 2 2 2 9 
AMD-08 Zou HD et al. (2005) 2 2 2 2 2 10 
AMD-09 Tian MN et al. (2005) 1 1 0 2 2 6 
AMD-10 Bai ZL et al. (2005) 2 1 1 2 2 8 
AMD-11 Shi K et al. (2009) 2 2 0 2 2 8 
AMD-12 Li HL et al. (2009) 1 1 0 2 2 6 
AMD-13 Zhao X et al. (2011) 2 2 2 2 2 10 
AMD-14 Huang XB et al. (2012) 2 2 2 2 2 10 
AMD-15 Yang Z (2014) 2 2 2 2 2 10 
AMD-16 Cao J (2014) 2 2 2 2 2 10 
AMD-17 Xiang W et al. (2015) 2 2 2 2 2 10 
AMD-18 Wang Y et al. (2015) 2 1 1 2 2 8 
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Study ID Study 
Quality score 
Sample population Sample size Participation Outcome assessment Analytical methods Total scores 
AMD-19 Li WL et al. (2015) 2 0 0 2 2 6 
AMD-20 Li Y et al. (2006) 2 2 1 2 2 9 
AMD-21 Chen SJ et al. (2008) 2 1 0 2 2 7 
AMD-22 Huang TL et al. (2010) 2 1 0 2 2 7 
AMD-23 Yang K et al. (2011) 2 1 2 2 2 9 
AMD-24 Ye H et al. (2014) 2 2 1 2 2 9 
AMD-25 Huang EJ et al. (2014) 1 1 2 2 2 8 
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Appendix table 8. Estimated and projected number of people with any AMD, early AMD, 
late AMD, GA and NVAMD in China from 1990 to 2050, by age group (million, 95% CI) 
1990 
Age group Any AMD Early AMD Late AMD GA NVAMD 
45-49 years 
1.19  1.09  0.23  0.09  0.14  
(0.90-1.56) (0.87-1.32) (0.13-0.42) (0.04-0.20) (0.09-0.22) 
50-54 years 
1.45  1.27  0.29  0.11  0.18  
(1.11-1.90) (1.02-1.52) (0.17-0.51) (0.05-0.23) (0.12-0.27) 
55-59 years 
1.71  1.42  0.35  0.13  0.22  
(1.32-2.23) (1.16-1.70) (0.21-0.59) (0.06-0.26) (0.15-0.33) 
60-64 years 
1.78  1.41  0.37  0.13  0.24  
(1.37-2.29) (1.16-1.67) (0.23-0.61) (0.06-0.26) (0.17-0.35) 
65-69 years 
1.75  1.33  0.37  0.12  0.25  
(1.35-2.24) (1.09-1.56) (0.23-0.61) (0.06-0.25) (0.17-0.35) 
70-74 years 
1.73  1.26  0.38  0.12  0.26  
(1.35-2.21) (1.05-1.47) (0.24-0.62) (0.06-0.25) (0.18-0.37) 
75-79 years 
1.32  0.93  0.30  0.09  0.21  
(1.03-1.67) (0.77-1.07) (0.19-0.50) (0.04-0.19) (0.14-0.30) 
80-84 years 
0.77  0.52  0.19  0.05  0.13  
(0.60-0.96) (0.44-0.60) (0.11-0.31) (0.02-0.12) (0.09-0.19) 
85-89 years 
0.32  0.21  0.08  0.02  0.06  
(0.25-0.40) (0.18-0.24) (0.05-0.14) (0.01-0.05) (0.04-0.09) 
Total  
(45-89 years) 
12.01  9.44  2.58  0.87  1.71  
(9.29-15.46) (7.74-11.15) (1.56-4.30) (0.40-1.83) (1.16-2.47) 
2000 
Age group Any AMD Early AMD Late AMD GA NVAMD 
45-49 years 
2.09  1.91  0.41  0.16  0.25  
(1.59-2.75) (1.53-2.32) (0.23-0.75) (0.07-0.36) (0.16-0.39) 
50-54 years 
1.94  1.69  0.39  0.14  0.24  
(1.48-2.54) (1.37-2.03) (0.23-0.67) (0.07-0.31) (0.16-0.36) 
55-59 years 
1.91  1.59  0.39  0.14  0.25  
(1.47-2.48) (1.29-1.89) (0.23-0.66) (0.06-0.29) (0.17-0.36) 
60-64 years 
2.23  1.77  0.47  0.16  0.31  
(1.72-2.88) (1.45-2.09) (0.29-0.77) (0.08-0.33) (0.21-0.43) 
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65-69 years 
2.42  1.84  0.52  0.17  0.35  
(1.88-3.11) (1.52-2.16) (0.32-0.84) (0.08-0.35) (0.24-0.49) 
70-74 years 
2.19  1.59  0.48  0.15  0.33  
(1.71-2.79) (1.32-1.85) (0.30-0.78) (0.07-0.32) (0.23-0.47) 
75-79 years 
1.72  1.21  0.40  0.12  0.28  
(1.35-2.18) (1.00-1.40) (0.24-0.65) (0.06-0.25) (0.19-0.39) 
80-84 years 
1.23  0.84  0.30  0.09  0.21  
(0.97-1.55) (0.70-0.96) (0.18-0.49) (0.04-0.19) (0.14-0.31) 
85-89 years 
0.58  0.38  0.15  0.04  0.11  
(0.46-0.72) (0.32-0.44) (0.09-0.25) (0.02-0.09) (0.07-0.16) 
Total  
(45-89 years) 
16.31  12.81  3.50  1.18  2.32  
(12.62-20.99) (10.51-15.13) (2.11-5.86) (0.54-2.50) (1.57-3.36) 
2010 
Age group Any AMD Early AMD Late AMD GA NVAMD 
45-49 years 
2.47  2.26  0.49  0.19  0.30  
(1.87-3.25) (1.81-2.75) (0.27-0.88) (0.08-0.42) (0.19-0.46) 
50-54 years 
2.60  2.27  0.52  0.19  0.33  
(1.98-3.40) (1.83-2.72) (0.03-0.90) (0.09-0.42) (0.21-0.49) 
55-59 years 
3.42  2.84  0.70  0.25  0.45  
(2.63-4.44) (2.32-3.39) (0.42-1.18) (0.12-0.53) (0.30-0.65) 
60-64 years 
3.06  2.43  0.64  0.22  0.42  
(2.36-3.95) (1.99-2.87) (0.39-1.05) (0.10-0.45) (0.29-0.60) 
65-69 years 
2.81  2.13  0.60  0.20  0.40  
(2.18-3.60) (1.76-2.50) (0.37-0.98) (0.09-0.41) (0.28-0.57) 
70-74 years 
2.90  2.11  0.64  0.20  0.44  
(2.26-3.70) (1.75-2.46) (0.40-1.04) (0.10-0.42) (0.30-0.62) 
75-79 years 
2.58  1.81  0.59  0.18  0.41  
(2.02-3.26) (1.51-2.09) (0.37-0.97) (0.08-0.38) (0.28-0.59) 
80-84 years 
1.72  1.17  0.42  0.12  0.30  
(1.36-2.16) (0.98-1.35) (0.25-0.69) (0.05-0.26) (0.20-0.43) 
85-89 years 
0.88  0.58  0.22  0.06  0.16  
(0.70-1.09) (0.49-0.66) (0.13-0.38) (0.03-0.14) (0.11-0.24) 
Total  
(45-89 years) 
22.43  17.60  4.83  1.62  3.21  
(17.36-28.85) (14.45-20.78) (2.91-8.07) (0.75-3.43) (2.16-4.64) 
2015 
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Age group Any AMD Early AMD Late AMD GA NVAMD 
45-49 years 
3.02  2.76  0.59  0.23  0.36  
(2.29-3.97) (2.22-3.36) (0.33-1.08) (0.10-0.52) (0.23-0.56) 
50-54 years 
3.19  2.78  0.64  0.24  0.40  
(2.43-4.16) (2.25-3.34) (0.37-1.11) (0.11-0.51) (0.26-0.59) 
55-59 years 
3.31  2.75  0.68  0.24  0.43  
(2.54-4.30) (2.25-3.28) (0.41-1.14) (0.11-0.51) (0.29-0.63) 
60-64 years 
4.26  3.38  0.89  0.31  0.58  
(3.29-5.50) (2.78-3.99) (0.55-1.46) (0.14-0.63) (0.40-0.83) 
65-69 years 
3.64  2.76  0.78  0.26  0.52  
(2.82-4.67) (2.28-3.24) (0.48-1.27) (0.12-0.53) (0.36-0.74) 
70-74 years 
3.10  2.26  0.69  0.22  0.47  
(2.42-3.96) (1.88-2.63) (0.43-1.11) (0.10-0.45) (0.32-0.66) 
75-79 years 
2.85  2.00  0.66  0.20  0.46  
(2.24-3.61) (1.67-2.32) (0.41-1.07) (0.09-0.42) (0.31-0.65) 
80-84 years 
2.15  1.46  0.52  0.15  0.37  
(1.69-2.70) (1.22-1.68) (0.31-0.86) (0.07-0.33) (0.25-0.53) 
85-89 years 
1.13  0.75  0.29  0.08  0.21  
(0.89-1.40) (0.63-0.85) (0.17-0.49) (0.04-0.18) (0.14-0.31) 
Total  
(45-89 years) 
26.65  20.91  5.74  1.93  3.81  
(20.62-34.27) (17.16-24.68) (3.46-9.59) (0.89-4.08) (2.57-5.51) 
2020 
Age group Any AMD Early AMD Late AMD GA NVAMD 
45-49 years 
2.88  2.65  0.57  0.22  0.35  
(2.19-3.79) (2.12-3.22) (0.32-1.03) (0.10-0.50) (0.22-0.54) 
50-54 years 
3.90  3.41  0.78  0.29  0.49  
(2.98-5.10) (2.76-4.10) (0.46-1.36) (0.13-0.63) (0.32-0.73) 
55-59 years 
4.07  3.39  0.83  0.30  0.54  
(3.13-5.28) (2.77-4.04) (0.50-1.40) (0.14-0.63) (0.36-0.77) 
60-64 years 
4.14  3.29  0.87  0.30  0.57  
(3.20-5.34) (2.71-3.89) (0.53-1.43) (0.14-0.62) (0.39-0.81) 
65-69 years 
5.11  3.89  1.10  0.36  0.74  
(3.97-6.55) (3.22-4.56) (0.68-1.79) (0.17-0.75) (0.51-1.04) 
70-74 years 
4.08  2.99  0.91  0.29  0.62  
(3.18-5.21) (2.48-3.48) (0.56-1.47) (0.14-0.59) (0.43-0.88) 
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75-79 years 
3.12  2.20  0.72 0.22  0.50  
(2.45-3.96) (1.83-2.55) (0.45-1.18) (0.10-0.46) (0.34-0.72) 
80-84 years 
2.45  1.67  0.60  0.17  0.42  
(1.93-3.08) (1.40-1.92) (0.36-0.98) (0.08-0.37) (0.28-0.61) 
85-89 years 
1.46  0.97  0.38  0.11  0.27  
(1.16-1.83) (0.82-1.11) (0.22-0.64) (0.05-0.23) (0.18-0.40) 
Total  
(45-89 years) 
31.23  24.47  6.76  2.26  4.50  
(24.18-40.14) (20.1-28.87) (4.08-11.28) (1.04-4.78) (3.04-6.50) 
2030 
Age group Any AMD Early AMD Late AMD GA NVAMD 
45-49 years 
2.38  2.21  0.48  0.18  0.29  
(1.80-3.13) (1.78-2.69) (0.27-0.86) (0.08-0.41) (0.19-0.45) 
50-54 years 
2.97  2.63  0.60  0.22  0.38  
(2.26-3.88) (2.13-3.16) (0.35-1.05) (0.10-0.49) (0.25-0.56) 
55-59 years 
4.79  4.04  0.99  0.36  0.64  
(3.68-6.21) (3.30-4.81) (0.60-1.67) (0.17-0.75) (0.43-0.92) 
60-64 years 
6.29  5.08  1.34  0.46  0.88  
(4.86-8.12) (4.17-5.99) (0.82-2.20) (0.22-0.95) (0.60-1.25) 
65-69 years 
6.22  4.80  1.36  0.45  0.91  
(4.83-7.98) (3.97-5.62) (0.84-2.20) (0.21-0.92) (0.63-1.28) 
70-74 years 
5.76  4.27  1.30  0.41  0.89  
(4.49-7.35) (3.54-4.97) (0.81-2.10) (0.19-0.85) (0.61-1.25) 
75-79 years 
6.10  4.36  1.43  0.44  1.00  
(4.78-7.73) (3.63-5.04) (0.88-2.33) (0.20-0.91) (0.68-1.42) 
80-84 years 
3.84  2.66  0.95  0.28  0.67  
(3.03-4.83) (2.22-3.05) (0.57-1.56) (0.12-0.59) (0.45-0.97) 
85-89 years 
2.05  1.38  0.53  0.15  0.38  
(1.62-2.55) (1.15-1.57) (0.31-0.90) (0.06-0.33) (0.25-0.57) 
Total  
(45-89 years) 
40.40  31.42  8.98  2.95  6.03  
(31.36-51.78) (25.90-36.90) (5.45-14.87) (1.36-6.20) (4.09-8.67) 
2040 
Age group Any AMD Early AMD Late AMD GA NVAMD 
45-49 years 
2.52  2.37  0.51  0.20  0.31  
(1.91-3.32) (1.91-2.87) (0.29-0.92) (0.09-0.44) (0.20-0.48) 
50-54 years 4.00  3.58  0.82  0.31  0.52  
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(3.05-5.23) (2.91-4.29) (0.48-1.42) (0.14-0.66) (0.34-0.76) 
55-59 years 
3.97  3.39  0.83  0.30  0.53  
(3.05-5.16) (2.77-4.02) (0.50-1.40) (0.14-0.62) (0.36-0.77) 
60-64 years 
4.83  3.93  1.04  0.36  0.68  
(3.73-6.24) (3.24-4.63) (0.64-1.70) (0.17-0.73) (0.47-0.96) 
65-69 years 
7.46  5.81  1.64  0.54  1.10  
(5.79-9.56) (4.81-6.79) (1.02-2.66) (0.26-1.11) (0.76-1.55) 
70-74 years 
9.08  6.79  2.07  0.66  1.41  
(7.08-11.57) (5.65-7.88) (1.29-3.33) (0.31-1.35) (0.98-1.99) 
75-79 years 
7.88  5.68  1.87  0.57  1.30  
(6.17-9.98) (4.74-6.55) (1.15-3.03) (0.26-1.18) (0.89-1.85) 
80-84 years 
5.93  4.14  1.47  0.43  1.04  
(4.67-7.46) (3.47-4.74) (0.89-2.43) (0.19-0.92) (0.70-1.51) 
85-89 years 
4.55  3.10  1.20  0.34  0.86  
(3.61-5.67) (2.60-3.52) (0.71-2.01) (0.15-0.74) (0.56-1.27) 
Total  
(45-89 years) 
50.22  38.78  11.45  3.69  7.76  
(39.07-64.18) (32.10-45.28) (6.97-18.90) (1.71-7.76) (5.26-11.13) 
2050 
Age group Any AMD Early AMD Late AMD GA NVAMD 
45-49 years 
1.77  1.68  0.36  0.14  0.22  
(1.35-2.33) (1.36-2.03) (0.20-0.65) (0.06-0.31) (0.14-0.34) 
50-54 years 
2.42  2.19  0.50  0.19  0.32  
(1.85-3.17) (1.78-2.62) (0.29-0.87) (0.08-0.40) (0.21-0.47) 
55-59 years 
4.23  3.65  0.90  0.32  0.58  
(3.25-5.50) (2.99-4.32) (0.54-1.50) (0.15-0.67) (0.39-0.83) 
60-64 years 
6.58  5.41  1.42  0.49  0.93  
(5.08-8.49) (4.47-6.35) (0.88-2.33) (0.23-1.01) (0.65-1.32) 
65-69 years 
6.29  4.95  1.40  0.46  0.94  
(4.88-8.07) (4.12-5.77) (0.87-2.26) (0.22-0.94) (0.65-1.32) 
70-74 years 
7.19  5.43  1.65  0.52  1.13  
(5.60-9.16) (4.53-6.29) (1.03-2.66) (0.25-1.07) (0.78-1.58) 
75-79 years 
9.95  7.25  2.38  0.72  1.66  
(7.80-12.60) (6.07-8.34) (1.48-3.86) (0.34-1.51) (1.14-2.35) 
80-84 years 
10.15  7.16  2.55  0.74  1.80  
(7.99-12.76) (6.01-8.18) (1.55-4.18) (0.34-1.59) (1.21-2.60) 
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85-89 years 
6.60  4.54  1.75  0.49  1.26  
(5.23-8.23) (3.82-5.15) (1.04-2.94) (0.22-1.08) (0.82-1.86) 
Total (45-89 
years) 
55.19  42.26  12.92  4.09  8.84  
(43.04-70.30) (35.15-49.05) (7.89-21.26) (1.89-8.59) (6.00-12.66) 
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Appendix table 9. Estimation of age-specific number of people with any AMD in China from 2000 to 2010, by geographical region (million, 95% 
CI) 
2000 
Age group North China Northeast China East China South Central China Southwest China Northwest China 
45-49 years 0.17 (0.12-0.24) 0.11 (0.07-0.18) 0.67 (0.53-0.85) 0.70 (0.53-0.94) 0.36 (0.28-0.47) 0.09 (0.06-0.12) 
50-54 years 0.15 (0.11-0.21) 0.09 (0.06-0.15) 0.62 (0.49-0.78) 0.66 (0.50-0.87) 0.34 (0.27-0.44) 0.08 (0.06-0.11) 
55-59 years 0.14 (0.10-0.19) 0.09 (0.05-0.14) 0.59 (0.47-0.74) 0.63 (0.48-0.83) 0.37 (0.29-0.47) 0.09 (0.07-0.13) 
60-64 years 0.17 (0.12-0.24) 0.11 (0.07-0.18) 0.68 (0.54-0.85) 0.75 (0.58-0.97) 0.41 (0.32-0.52) 0.11 (0.08-0.15) 
65-69 years 0.19 (0.14-0.26) 0.11 (0.07-0.18) 0.79 (0.63-0.97) 0.82 (0.63-1.05) 0.41 (0.33-0.51) 0.10 (0.07-0.13) 
70-74 years 0.16 (0.12-0.22) 0.10 (0.06-0.16) 0.73 (0.60-0.89) 0.73 (0.57-0.91) 0.38 (0.30-0.47) 0.07 (0.06-0.10) 
75-79 years 0.12 (0.09-0.17) 0.07 (0.04-0.11) 0.60 (0.49-0.72) 0.57 (0.45-0.71) 0.28 (0.22-0.34) 0.06 (0.04-0.08) 
80-84 years 0.08 (0.06-0.11) 0.04 (0.03-0.07) 0.44 (0.36-0.52) 0.42 (0.34-0.52) 0.20 (0.16-0.24) 0.04 (0.03-0.05) 
85-89 years 0.04 (0.03-0.05) 0.02 (0.01-0.03) 0.21 (0.17-0.24) 0.21 (0.17-0.25) 0.10 (0.08-0.12) 0.02 (0.01-0.02) 
Total (45-89 years) 1.23 (0.88-1.70) 0.76 (0.47-1.21) 5.32 (4.29-6.57) 5.50 (4.24-7.05) 2.85 (2.26-3.56) 0.66 (0.49-0.89) 
2010 
Age group North China Northeast China East China South Central China Southwest China Northwest China 
45-49 years 0.21 (0.15-0.30) 0.13 (0.08-0.21) 0.81 (0.64-1.03) 0.90 (0.67-1.21) 0.38 (0.30-0.50) 0.12 (0.09-0.16) 
50-54 years 0.25 (0.18-0.35) 0.16 (0.10-0.25) 0.84 (0.67-1.07) 0.88 (0.66-1.17) 0.36 (0.28-0.47) 0.12 (0.09-0.16) 
55-59 years 0.29 (0.21-0.41) 0.18 (0.11-0.29) 1.11 (0.88-1.39) 1.13 (0.86-1.48) 0.57 (0.44-0.72) 0.14 (0.10-0.19) 
60-64 years 0.24 (0.17-0.34) 0.15 (0.09-0.23) 0.99 (0.79-1.23) 1.02 (0.78-1.32) 0.52 (0.41-0.66) 0.13 (0.10-0.17) 
The national and subnational disease burden of age-related eye diseases in China 
Appendices  273 
65-69 years 0.21 (0.15-0.29) 0.13 (0.08-0.20) 0.88 (0.71-1.08) 0.91 (0.71-1.17) 0.52 (0.42-0.65) 0.13 (0.10-0.18) 
70-74 years 0.23 (0.17-0.31) 0.14 (0.09-0.22) 0.90 (0.73-1.10) 0.96 (0.75-1.21) 0.51 (0.41-0.63) 0.14 (0.10-0.18) 
75-79 years 0.20 (0.15-0.27) 0.12 (0.07-0.18) 0.87 (0.71-1.05) 0.86 (0.68-1.06) 0.41 (0.34-0.50) 0.10 (0.08-0.13) 
80-84 years 0.13 (0.09-0.17) 0.08 (0.05-0.12) 0.61 (0.50-0.72) 0.56 (0.45-0.68) 0.28 (0.23-0.34) 0.05 (0.04-0.07) 
85-89 years 0.06 (0.04-0.08) 0.04 (0.02-0.05) 0.33 (0.27-0.38) 0.29 (0.24-0.35) 0.13 (0.11-0.16) 0.03 (0.02-0.03) 
Total (45-89 years) 1.82 (1.31-2.51) 1.11 (0.69-1.76) 7.33 (5.91-9.04) 7.52 (5.80-9.64) 3.70 (2.94-4.62) 0.95 (0.71-1.28) 
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Appendix table 10. Search strategy to identify studies reporting the prevalence of 
glaucoma in China 
CNKI 
Access Date: 18 Aug 2017 
Subject category: Medicine & Public Health 
Sub-database: Journal, Featured journal, Doctoral dissertation, Master dissertation  
检索表达式： 
(SU % '青光眼') AND (SU % '发病率' + '发生率' + '患病率'+ '罹患率' + '现患率'+ '死亡
率' + '病死率'+ '流行' + '负担'+ '现况调查'+ '现况研究') 
发表时间：从 1990-01-01 到 2017-08-18 
Search Terms: (SU % 'qingguangyan') AND (SU % 'fabinglv' + 'fashenglv' + 'huanbinglv'+ 
'lihuanlv' + 'xianhuanlv'+ 'siwanglv' + 'bingsilv'+ 'liuxing' + 'fudan'+ 'xiankuangdiaocha'+ 
'xiankuangyanjiu') 
Published time：From 01/01/1990 to 26/06/2016 
 
Wanfang 
Access Date: 18 Aug 2017 
Sub-database: Journal articles, Dissertations 
检索表达式：检索表达式：(主题:(青光眼)) * (主题:(发病率) + 主题:(发生率) + 主
题:(患病率) +主题:(罹患率) + 主题:(现患率) + 主题:(死亡率) +主题:(病死率) + 主
题:(流行) + 主题:(负担)+ 主题:(现况调查) + 主题:(现况研究)) 
时间：1990-2017 
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Search Terms: (subject: (qingguangyan))* (subject: (fabinglv) + subject: (fashenglv) + 
subject: (huanbinglv)+ subject: (lihuanlv) + subject: (xianhuanlv) + subject: (siwanglv)+ 





Access Date: 18 Aug 2017 
Journal category: All journals 
检索表达式： 
(青光眼) AND (发病率 or 发生率 or 患病率 or 罹患率 or 现患率 or 死亡率 or 病死率 
or 流行 or 负担 or 现况调查 or 现况研究) 
时间：1990-2017 
Search Terms: ( (qingguangyan))* ( (fabinglv) OR (fashenglv) OR (huanbinglv) OR 
(lihuanlv) OR (xianhuanlv) OR (siwanglv) OR (bingsilv) OR (liuxing) OR (fudan) OR 




Access Date: 18 Aug 2017 
Search Terms:  
 ((Glaucoma) AND (China OR Chinese OR Hongkong OR Macao OR Taiwan) AND 
(inciden* OR prevalen* OR morbidity OR mortality OR epidemiology)) AND 
("1990/01/01"[Date - Publication] : "2017/08/18"[Date - Publication]) 
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Embase (Ovid) 
Access Date: 18 Aug 2017 
# Searches 
1 exp glaucoma/ or Glaucoma.mp. 
2 China.mp. or exp China/ 
3 exp Chinese/ or Chinese.mp. 
4 Hong Kong.mp. or exp Hong Kong/ 
5 Macao.mp. or exp Macao/ 
6 Taiwan.mp. or exp Taiwan/ 
7 exp incidence/ or inciden*.mp. 
8 exp prevalence/ or prevalen*.mp. 
9 morbidity.mp. or morbidity/ 
10 mortality/ or Mortality.mp. 
11 exp epidemiology/ or Epidemiology.mp. 
12 2 or 3 or 4 or 5 or 6 
13 7 or 8 or 9 or 10 or 11 
14 1 and 12 and 13 
15 limit 14 to yr="1990 -Current" 
 
Medline (Ovid) 
Access Date: 18 Aug 2017 
Search Terms:  
# Searches 
1 Glaucoma.mp. or exp Glaucoma/ 
2 China.mp. or exp China/ 
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3 Chinese.mp. 
4 Hong Kong.mp. or exp Hong Kong/ 
5 Macao.mp. or exp Macau/ 
6 Taiwan.mp. or exp Taiwan/ 
7 exp Incidence/ or inciden*.mp. 
8 exp Prevalence/ or prevalen*.mp. 
9 morbidity.mp. or exp Morbidity/ 
10 mortality.mp. or exp Mortality/ 
11 epidemiology.mp. or exp Epidemiology/ 
12 2 or 3 or 4 or 5 or 6 
13 7 or 8 or 9 or 10 or 11 
14 1 and 12 and 13 
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Appendix table 11. The year of publication and investigation and corresponding time-
lag in the included studies on glaucoma prevalence in China (n=30) 






G-01 Gao ZF (1995) 1995 1987 8 
G-02 Yu Q et al. (1995) 1995 1990 5 
G-03 He MG et al. (2000) 2000 1997 3 
G-04 Zhao JL et al. (2002) 2002 1996 6 
G-05 Xu L et al. (2004) 2004 2001 3 
G-06 Bai ZL et al. (2005) 2005 2003 2 
G-07 Xu L et al. (2005) 2005 2001 4 
G-08 Sun HM et al. (2005) 2005 2003 2 
G-09 Ren BC et al. (2005) 2005 2003 2 
G-10 Bai YQ et al. (2007) 2007 2006 1 
G-11 Yuan HP et al. (2007) 2007 2004 3 
G-12 Deng ZF et al. (2008) 2008 - - 
G-13 Song SF et al. (2009) 2009 2005 4 
G-14 Zhao X et al. (2010) 2010 2006 4 
G-15 Zhang LJ et al. (2010) 2010 2009 1 
G-16 Yu YY et al. (2013) 2013 - - 
G-17 Sheng WD (2014) 2014 2013 1 
G-18 Yin LR et al. (2014) 2014 2010 4 
G-19 Gao ZZ et al. (2015) 2015 2011 4 
G-20 Pan YJ (2015) 2015 2014 1 
G-21 He M et al. (2006) 2006 2003 3 
G-22 Wang YX et al. (2010) 2010 2001 9 
G-23 Liang YB et al. (2011) 2011 2007 4 
G-24 Liang Y et al. (2011) 2011 2007 4 
G-25 Qu W et al. (2011) 2011 2007 4 
G-26 Song W et al. (2011) 2011 2009 2 
G-27 Sun J et al. (2012) 2012 2007 5 
G-28 Zhong H et al. (2012) 2012 2010 2 
G-29 He J et al. (2015) 2015 2011 4 
G-30 Pan CW et al. (2016) 2016 2010 6 
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Note: “-” represents unavailable data; Based on the information from 28 studies, the average 
time-lag between year of publication and year of investigation was 3.61. 
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Appendix table 12. Meta-analysis of the prevalence of glaucoma for assessing 
heterogeneity between studies 
To address the issue of heterogeneity across all eligible studies, the Cochran's Q and I2 statistics 
were calculated. A p-value<0.05 indicates heterogeneity between studies in Q statistic, and I2 
represents the proportion of total variation that is due to heterogeneity rather than chance, where 
values of <25%, 25–75%, and >75% representing low, moderate and high heterogeneity, 
respectively (Higgins and Thompson, 2002, Higgins et al., 2003). As shown in Appendix figures 
6-8, significant high heterogeneity was detected between studies that reported prevalence rates 
of POAG (I2=92.5%, p<0.0001), PACG (I2=88.2%, p<0.0001), and moderate heterogeneity 
existed between studies on secondary glaucoma (I2=63.6%, p=0.0015). 
 
Appendix figure 6. Meta-analysis of the prevalence of POAG (n=20) 
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Appendix figure 7. Meta-analysis of the prevalence of PACG (n=25) 
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Appendix figure 8. Meta-analysis of the prevalence of secondary glaucoma (n=12) 
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Appendix table 13. Full list of the included studies on glaucoma prevalence in China (n=30) 
Study ID Reference 
G-01 Zong-feng Gao. 高宗峰. An epidemiologic study of glaucoma in Tongcheng county, Anhui province (安徽省桐城县青光眼流行病学调
查)[J]. Chinese Journal of Ophthalmology (中华眼科杂志). 1995(02):149-51. 
G-02 Qiang Yu, Jing-jing Xu, Si-ping Zhu, et al. 于强, 许京京, 朱斯平, 柳青. An epidemiological survey of primary angle-closure glaucoma in 
Doumen county Guangdong (广东省斗门县原发性闭角型青光眼流行病学调查)[J]. Chinese Journal of Ophthalmology (中华眼科杂志). 
1995(02):118-21. 
G-03 Ming-guang He, Jing-jing Xu, Kai-li Wu, et al. 何明光, 许京京, 吴开力, 李绍珍. The prevalence of primary angle-closure glaucoma in 
elderly rural population (斗门县农村中老年人群原发闭角性青光眼流行病学调查 )[J]. Acad J SUMS (中山医科大学学报 ). 
2000(03):212-4. 
G-04 Jia-liang Zhao, Rui-fang Sui, Li-jun Jia, et al. 赵家良, 睢瑞芳, 贾丽君, et al. Prevalence of glaucoma and normal intraocular pressure 
among adults aged 50 years or above in Shunyi county of Beijing (北京市顺义县 50岁及以上人群中青光眼患病率和正常眼眼压的调
查)[J]. Chin J Ophthalmol (中华眼科杂志). 2002(06):18-22. 
G-05 Liang Xu, Jian-hua Chen, Jian-jun Li, et al. 徐亮, 陈建华, 李建军, et al. The prevalence and its screening methods of primary open angle 
glaucoma in defined population-based study of rural and urban in Beijing (北京农村及城市特定人群原发性开角型青光眼的患病率调
查及其筛查方法评价)[J]. Chin J Ophthalmol (中华眼科杂志). 2004(11):9-15. 
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Study ID Reference 
G-06 Lan-zhi Bai, Bai-chao Ren, Jian-gang Yang, et al. 白芝兰, 任百超, 杨建刚, 何媛, 陈莉, 孙乃学. Epidemiology of primary angle-closure 
glaucoma in a rural population in Shaanxi province of China (中国陕西省农村原发性闭角型青光眼流行病学调查)[J]. International 
journal of ophthalmology (国际眼科杂志). 2005;5(5):872-80. 
G-07 Liang Xu, Li Zhang, Cui-ran Xia, et al. 徐亮, 张莉, 夏翠然, et al. The prevalence and its effective factors of primary angle-closure glaucoma 
in defined population of rural and urban in Beijing (北京农村及城市特定人群原发性闭角型青光眼的患病率及其影响因素)[J]. Chin J 
Ophthalmol (中华眼科杂志). 2005(01):12-8. 
G-08 Hui-min Sun, Xiu-juan Zhang, Zhi-qing Li, et al. 孙慧敏, 张秀娟, 李志清, et al. Prevalence of glaucoma in Sangzi village, Ji county of 
Tianjin aged 40 years and above (天津市蓟县桑梓村 40岁及以上人群中青光眼患病率调查)[J]. Chin J Pract Ophthalmol (中国实用眼
科杂志). 2005(08):782-4. 
G-09 Bai-chao Ren, Yuan He, Li Chen, et al. 任百超, 何媛, 陈莉, 杨建刚, 孙乃学. Epidemiology of glaucoma in a rural population in Shaanxi 
province (陕西省农村人群青光眼的流行病学调查)[J]. International journal of ophthalmology (国际眼科杂志). 2005(05):214-9. 
G-10 Yong-quan Bai, Jing-lin Yi, Hui Xie, et al. 白永泉, 易敬林, 谢晖, et al. Epidemiological survey of primary angle-closure glaucoma in rural 
population aged 50 and elderly (吉安县农村 50 岁以上人群原发性闭角型青光眼流行病学调查)[J]. Medical Information section of 
operative surgery (医学信息(手术学分册)). 2007(09):774-7. 
G-11 Hui-ping Yuan, Hong Yu, Zheng Xiao, et al. 原慧萍, 于泓, 肖铮, et al. The prevalence of primary angle-closure glaucoma and its causes 
in rural area of Shuangyang district in Changchun, Jilin province (吉林省长春市双阳区齐家乡原发性闭角青光眼的患病率调查及其影
响因素)[J]. Chin J Ophthalmol (中华眼科杂志). 2007;43(9):775-8. 
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G-12 Zhi-feng Deng, Hong-juan Zhang. 邓志峰, 张洪娟. Epidemiology of primary open angle glaucoma in rural population in Heze (农村原发
性开角型青光眼流行病学研究)[J]. Journal of Heze Medical College (菏泽医学专科学校学报). 2008(03):58-9. 
G-13 Sheng-fang Song, Yong-ye Zhang, Xiang-ge He, et al. 宋胜仿, 张永烨, 贺翔鸽, et al. Prevalence of glaucoma among adults aged 50 years 
or above in Yongchuan district of Chongqing (重庆市永川地区 50岁以上人群中青光眼患病率调查)[J]. Chin J Pract Ophthalmol (中国
实用眼科杂志). 2009;27(2):168-72. 
G-14 Xin Zhao, Yun-he He, Bi-qi Tian, et al. 赵欣, 郝云鹤, 田碧琪, et al. Glaucoma survey in population of 50 years old or more in the Xi 
Chang'an street community of Beijing (北京市西长安街社区 50岁以上人群青光眼调查)[J]. Ophthalmol CHN (眼科). 2010(01):37-42. 
G-15 Li-juan Zhang, Li Shan, Pan Fan, et al. 张丽娟, 单丽, 樊攀, 宋武莲, 原慧萍. Prevalence investigation on primary glaucoma in Kailu 
county, Inner Mongolia* (内蒙古开鲁县蒙古族原发性青光眼的患病率调查 )[J]. Inner Mongolia Med J (内蒙古医学杂志 ). 
2010(07):817-9. 
G-16 Yang-yang Yu, Su-yun Wang, Shao-wei Wang. 于洋洋, 王素云, 王绍伟. Survey of prevalence of primary angle-closure glaucoma in rural 
population of Zhaozhou county (肇州县农村房角关闭疾病患病率调查)[J]. Chin J School Doctor (中国校医). 2013(08):599-601. 
G-17 Wei-dong Sheng. 绳伟东. Epidemiological investigation on primary angle-closure glaucoma in middle-and-old aged people in Zhalantun 
city, Inner Mongolia* (内蒙古扎兰屯市中老年人群中原发性闭角型青光眼流行病学调查)[J]. China Prac Med (中国实用医药). 
2014(24):261-3. 
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G-18 Lian-rong Yin, Hua Yang, Xin Li, et al. 尹连荣, 杨华, 李欣, 高健生. Primary discussion for education and screening on glaucoma in the 
western community in Beijing (京西社区青光眼宣教及筛查的初步探讨)[J]. Chinese Journal of Chinese Ophthalmology (中国中医眼科
杂志). 2014(06):437-9. 
G-19 Zhi-zhuo Gao, Tong Li, Yi-yuan Sun, et al. 高志卓, 李童, 孙艺源, et al. Epidemiological investigation of primary glaucoma in cold region 
of northern China (我国北方寒冷地区原发性青光眼流行病学调查分析 )[J]. Chin J of Public Health Eng (中国卫生工程学). 
2015(06):552-4. 
G-20 Yu-jin Pan. 潘裕锦. Prevalence of primary angle-closure glaucoma: a over 55 years population based survey in Sijihuacheng community 
of Shenzhen (深圳市四季花城社区 55岁以上人群原发性闭角型青光眼的流行病学调查)[D]. Jinan University (暨南大学), 2015. 
G-21 He M, Foster PJ, Ge J, et al. Prevalence and clinical characteristics of glaucoma in adult Chinese: a population-based study in Liwan District, 
Guangzhou. Invest Ophthalmol Vis Sci 2006;47(7):2782-8. 
G-22 Wang YX, Xu L, Yang H, Jonas JB. Prevalence of glaucoma in North China: the Beijing Eye Study. AM J OPHTHALMOL 
2010;150(6):917-24. 
G-23 Liang YB, Friedman DS, Zhou Q, et al. Prevalence of primary open angle glaucoma in a rural adult Chinese population: the Handan eye 
study. Invest Ophthalmol Vis Sci 2011;52(11):8250-7. 
G-24 Liang Y, Friedman DS, Zhou Q, et al. Prevalence and characteristics of primary angle-closure diseases in a rural adult Chinese population: 
the Handan Eye Study. Invest Ophthalmol Vis Sci 2011;52(12):8672-9. 
G-25 Qu W, Li Y, Song W, et al. Prevalence and risk factors for angle-closure disease in a rural Northeast China population: a population-based 
survey in Bin County, Harbin. ACTA OPHTHALMOL 2011;89(6):e515-20. 
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G-26 Song W, Shan L, Cheng F, et al. Prevalence of glaucoma in a rural northern China adult population: a population-based survey in kailu 
county, inner Mongolia. OPHTHALMOLOGY 2011;118(10):1982-8. 
G-27 Sun J, Zhou X, Kang Y, et al. Prevalence and risk factors for primary open-angle glaucoma in a rural northeast China population: a 
population-based survey in Bin County, Harbin. Eye (Lond) 2012;26(2):283-91. 
G-28 Zhong H, Li J, Li C, et al. The prevalence of glaucoma in adult rural Chinese populations of the Bai nationality in Dali: the Yunnan Minority 
Eye Study. Invest Ophthalmol Vis Sci 2012;53(6):3221-5. 
G-29 He J, Zou H, Lee RK, et al. Prevalence and risk factors of primary open-angle glaucoma in a city of Eastern China: a population-based study 
in Pudong New District, Shanghai. BMC OPHTHALMOL 2015;15:134. 
G-30 Pan CW, Zhao CH, Yu MB, et al. Prevalence, types and awareness of glaucoma in a multi-ethnic population in rural China: the Yunnan 
Minority Eye Study. Ophthalmic Physiol Opt 2016;36(6):664-70. 
Note: The Chinese publication list employed the journals’ official English names or abbreviations, English titles were obtained from journals or literature 
databases (CNKI, Wanfang and CBM). Where official English translation of journal names was not available, a pinyin title was adopted; where the 
English translation of titles was not available, the authors translated the titles, labelled with “*” and marked as green. 
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Appendix table 14. Detailed characteristics of the included studies on glaucoma prevalence in China (n=30) 
Study 
ID 
























G-01 Gao ZF 
(1995) 




0-94 4531 3 14  5  
G-02 Yu Q et al. 
(1995) 
Guangdong South Central 
China 




51+ 932  - 6   - 
G-03 He MG et al. 
(2000) 
Guangdong South Central 
China 
Rural Both 1997 Yes, all Yes, all Yes, all Yes, 
suspects 
50-98 5342  - 54   - 
G-04 Zhao JL et 
al. (2002) 
Beijing North China Mixed Both 1996 Yes, all Yes, all Yes, all Yes, 
suspects 
50+ 4880 14 81  6  
G-05 Xu L et al. 
(2004) 
Beijing North China Both Both 2001 Yes, suspects Yes, all Yes, all Yes, all 40+ 4451 81  -  - 




Rural Both 2003 Yes, all Yes, all Yes, all Yes, 
suspects 
40-91 2835  - 31   - 
G-07 Xu L et al. 
(2005) 
Beijing North China Both Both 2001 Yes, suspects Yes, all Yes, all Yes, all 40+ 4431  - 62  -  
G-08 Sun HM et 
al. (2005) 
Tianjin North China Rural Both 2003 Yes, all Yes, all Yes, all Yes, 
suspects 
40+ 1701 6 19  2  




Rural Both 2003 Yes, all Yes, all Yes, all Yes, 
suspects 
50-91 1775 7 29  2 
G-10 Bai YQ et al. 
(2007) 
Jiangxi East China Rural Both 2006 Yes, all Yes, 
suspects 
Yes, all Yes, 
suspects 
50-87 5013  - 76   - 
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Study 
ID 




























Rural Both 2004 Yes, all Yes, all Yes, all Yes, 
suspects 
41-96 1139  - 29   - 
G-12 Deng ZF et 
al. (2008) 
Shandong East China Rural Both 2005* Yes, all Yes, all Yes, all Yes, 
suspects 
40+ 1166 15  -  - 




Mixed Both 2005 Yes, all Yes, all Yes, all Yes, 
suspects 
50+ 5938 51 148  12  
G-14 Zhao X et al. 
(2010) 
Beijing North China Urban Both 2006 Yes, all Yes, all Yes, all Yes, 
suspects 
50+ 2410 15 40  2  




North China Rural Both 2009 Yes, all Yes, all Yes, all Yes, 
suspects 
40+ 579 10 13   - 




Rural Both 2010* Yes, all Yes, all Yes, all Yes, 
suspects 
40+ 2056  - 33   - 




North China Mixed Both 2013 Yes, all Yes, all Yes, all Yes, 
suspects 
50-93 1068  - 16   - 
G-18 Yin LR et al. 
(2014) 
Beijing North China Urban Mixed 2010 Yes, all Yes, all Yes, all Yes, all 40-80 13016 136 110   - 




Urban Both 2011 Yes, all Yes, all Yes, all Yes, 
suspects 
40+ 2359 33 48   - 
G-20 Pan YJ 
(2015) 
Guangdong South Central 
China 
Urban Both 2014 Yes, all Yes, all Yes, all Yes, 
suspects 
55-96 2422 46 37  3  
G-21 He M et al. 
(2006) 
Guangdong South Central 
China 
Urban Both 2003 Yes, all Yes, all Yes, all Yes, 
suspects 
50-93 1504 29 21  2  
The national and subnational disease burden of age-related eye diseases in China 
Appendices  290 
Study 
ID 
























G-22 Wang YX et 
al. (2010) 
Beijing North China Both Both 2001 Yes, all Yes, all Yes, all Yes, all 40-
101 
4315 111  44 3  
G-23 Liang YB et 
al. (2011) 
Hebei North China Rural Both 2007 Yes, all Yes, all Yes, all Yes, 
suspects 
30+ 6716 125   -  - 
G-24 Liang Y et 
al. (2011) 
Hebei North China Rural Both 2007 Yes, all Yes, all Yes, all Yes, 
suspects 
30+ 6716  - 51  - 




Rural Both 2007 Yes, all Yes, all Yes, all Yes, 
suspects 
40+ 4956  - 78  - 




North China Rural Both 2009 Yes, all Yes, all Yes, all Yes, 
suspects 
40-87 5158 73  90 6  




Rural Both 2007 Yes, all Yes, all Yes, all Yes, 
suspects 
40+ 4956 35   -  - 




Rural Both 2010 Yes, all Yes, all Yes, all Yes, 
suspects 
50+ 2133 22  20 5  
G-29 He J et al. 
(2015) 




2528 72   -  - 




Rural Both 2010 Yes, all Yes, all Yes, all Yes, 
suspects 
50+ 6546 137  46 29  
Note: “-” represents unavailable data; “*” indicates studies whose survey year was imputed. 
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Appendix table 15. Risk of bias scores of the included studies on glaucoma prevalence in China (n=30) 
Study ID Study 
Quality score 
Sample population Sample size Participation Outcome assessment Analytical methods Total scores 
G-01 Gao ZF (1995) 2 2 2 2 2 10 
G-02 Yu Q et al. (1995) 2 1 2 2 2 9 
G-03 He MG et al. (2000) 2 1 2 2 2 9 
G-04 Zhao JL et al. (2002) 2 2 2 2 2 10 
G-05 Xu L et al. (2004) 2 1 1 2 2 8 
G-06 Bai ZL et al. (2005) 2 1 1 2 2 8 
G-07 Xu L et al. (2005) 2 1 1 2 2 8 
G-08 Sun HM et al. (2005) 2 1 2 2 2 9 
G-09 Ren BC et al. (2005) 2 2 1 2 2 9 
G-10 Bai YQ et al. (2007) 2 1 2 2 2 9 
G-11 Yuan HP et al. (2007) 2 1 1 2 2 8 
G-12 Deng ZF et al. (2008) 2 1 2 2 2 9 
G-13 Song SF et al. (2009) 2 2 2 2 2 10 
G-14 Zhao X et al. (2010) 2 1 2 2 2 9 
G-15 Zhang LJ et al. (2010) 2 1 2 2 2 9 
G-16 Yu YY et al. (2013) 2 1 2 2 2 9 
G-17 Sheng WD (2014) 2 1 2 2 2 9 
G-18 Yin LR et al. (2014) 2 1 0 2 2 7 
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Study ID Study 
Quality score 
Sample population Sample size Participation Outcome assessment Analytical methods Total scores 
G-19 Gao ZZ et al. (2015) 2 1 0 2 2 7 
G-20 Pan YJ (2015) 2 2 2 2 2 10 
G-21 He M et al. (2006) 2 1 1 2 2 8 
G-22 Wang YX et al. (2010) 2 1 1 2 2 8 
G-23 Liang YB et al. (2011) 2 1 0 2 2 7 
G-24 Liang Y et al. (2011) 2 1 1 2 2 8 
G-25 Qu W et al. (2011) 2 1 2 2 2 9 
G-26 Song W et al. (2011) 2 1 2 2 2 9 
G-27 Sun J et al. (2012) 2 1 2 2 2 9 
G-28 Zhong H et al. (2012) 2 1 1 2 2 8 
G-29 He J et al. (2015) 2 2 1 2 2 9 
G-30 Pan CW et al. (2016) 2 2 1 2 2 9 
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Appendix table 16. Estimated and projected number of people with POAG and PACG 




Male Female Overall Male Female Overall 
45-49 years 
0.19  0.12  0.31  0.12  0.21  0.33  
(0.12-0.29) (0.08-0.19) (0.20-0.48) (0.10-0.15) (0.17-0.26) (0.27-0.41) 
50-54 years 
0.21  0.14  0.35  0.15  0.25  0.40  
(0.14-0.32) (0.09-0.21) (0.23-0.53) (0.12-0.18) (0.21-0.29) (0.33-0.47) 
55-59 years 
0.22  0.15  0.38  0.17  0.29  0.46  
(0.15-0.34) (0.10-0.23) (0.25-0.57) (0.14-0.20) (0.25-0.34) (0.39-0.54) 
60-64 years 
0.21  0.15  0.36  0.17  0.30  0.47  
(0.14-0.32) (0.10-0.22) (0.23-0.54) (0.14-0.20) (0.26-0.35) (0.40-0.55) 
65-69 years 
0.18  0.14  0.32  0.16  0.30  0.46  
(0.12-0.28) (0.09-0.21) (0.21-0.48) (0.13-0.19) (0.26-0.35) (0.39-0.53) 
70-74 years 
0.16  0.13  0.29  0.15  0.30  0.45  
(0.11-0.25) (0.08-0.20) (0.19-0.44) (0.12-0.18) (0.26-0.36) (0.38-0.54) 
75-79 years 
0.10  0.10  0.20  0.10  0.25  0.35  
(0.07-0.16) (0.06-0.15) (0.13-0.31) (0.08-0.13) (0.21-0.30) (0.29-0.42) 
80–84 years 
0.05  0.06  0.11  0.05  0.16  0.21  
(0.03-0.07) (0.04-0.09) (0.07-0.17) (0.04-0.06) (0.13-0.20) (0.17-0.26) 
85-89 years 
0.02  0.03  0.04  0.02  0.07  0.09  
(0.01-0.03) (0.02-0.04) (0.03-0.07) (0.01-0.02) (0.06-0.09) (0.07-0.12) 
Total  
(45-89 years) 
1.35  1.01  2.35  1.09  2.13  3.22  




Male Female Overall Male Female Overall 
45-49 years 
0.32  0.23  0.55  0.21  0.38  0.59  
(0.21-0.50) (0.15-0.35) (0.36-0.85) (0.17-0.26) (0.31-0.46) (0.48-0.73) 
50-54 years 
0.27  0.19  0.46  0.19  0.35  0.54  
(0.18-0.42) (0.13-0.29) (0.30-0.71) (0.16-0.23) (0.29-0.41) (0.45-0.64) 
55-59 years 
0.25  0.17  0.42  0.19  0.33  0.51  
(0.16-0.38) (0.11-0.26) (0.27-0.64) (0.16-0.22) (0.28-0.38) (0.44-0.60) 
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60-64 years 
0.27  0.18  0.45  0.22  0.37  0.59  
(0.18-0.40) (0.12-0.27) (0.29-0.68) (0.18-0.25) (0.32-0.43) (0.50-0.68) 
65-69 years 
0.26  0.19  0.44  0.22  0.41  0.63  
(0.17-0.39) (0.12-0.28) (0.29-0.67) (0.19-0.27) (0.35-0.47) (0.54-0.74) 
70-74 years 
0.21  0.16  0.37  0.19  0.38  0.57  
(0.14-0.31) (0.10-0.25) (0.24-0.56) (0.16-0.23) (0.32-0.44) (0.48-0.67) 
75-79 years 
0.14  0.13  0.27  0.14  0.32  0.45  
(0.09-0.21) (0.08-0.19) (0.17-0.41) (0.11-0.17) (0.26-0.38) (0.38-0.55) 
80–84 years 
0.09  0.09  0.18  0.09  0.24  0.33  
(0.06-0.13) (0.06-0.14) (0.11-0.27) (0.07-0.12) (0.19-0.29) (0.27-0.41) 
85-89 years 
0.03  0.04  0.08  0.04  0.12  0.16  
(0.02-0.05) (0.03-0.07) (0.05-0.12) (0.03-0.05) (0.10-0.15) (0.13-0.20) 
Total  
(45-89 years) 
1.84  1.37  3.21  1.49  2.88  4.37  




Male Female Overall Male Female Overall 
45-49 years 
0.38  0.27  0.65  0.25  0.45  0.70  
(0.25-0.59) (0.17-0.41) (0.42-1.00) (0.20-0.31) (0.37-0.55) (0.57-0.86) 
50-54 years 
0.36  0.26  0.62  0.26  0.46  0.72  
(0.24-0.56) (0.17-0.39) (0.41-0.95) (0.21-0.31) (0.39-0.55) (0.60-0.86) 
55-59 years 
0.44  0.31  0.75  0.33  0.60  0.93  
(0.29-0.66) (0.20-0.47) (0.49-1.13) (0.28-0.39) (0.51-0.70) (0.79-1.09) 
60-64 years 
0.35  0.26  0.61  0.29  0.53  0.81  
(0.23-0.54) (0.17-0.39) (0.40-0.93) (0.24-0.34) (0.46-0.61) (0.70-0.95) 
65-69 years 
0.30  0.21  0.51  0.26  0.47  0.73  
(0.20-0.46) (0.14-0.33) (0.34-0.78) (0.22-0.31) (0.41-0.54) (0.63-0.85) 
70-74 years 
0.28  0.21  0.49  0.26  0.49  0.75  
(0.18-0.43) (0.14-0.32) (0.32-0.75) (0.22-0.31) (0.42-0.57) (0.63-0.89) 
75-79 years 
0.22  0.18  0.40  0.22  0.46  0.67  
(0.14-0.33) (0.12-0.28) (0.26-0.61) (0.18-0.27) (0.38-0.55) (0.56-0.81) 
80–84 years 
0.13  0.12  0.25  0.13  0.32  0.46  
(0.08-0.19) (0.08-0.19) (0.16-0.38) (0.11-0.17) (0.26-0.40) (0.37-0.57) 
85-89 years 
0.06  0.06  0.12  0.06  0.18  0.24  
(0.03-0.09) (0.04-0.10) (0.07-0.19) (0.05-0.08) (0.14-0.22) (0.19-0.31) 
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Total  
(45-89 years) 
2.51  1.88  4.39  2.05  3.95  6.01  




Male Female Overall Male Female Overall 
45-49 years 
0.46  0.33  0.79  0.30  0.55  0.86  
(0.30-0.71) (0.21-0.51) (0.51-1.22) (0.24-0.38) (0.45-0.68) (0.70-1.05) 
50-54 years 
0.45  0.32  0.76  0.31  0.57  0.88  
(0.29-0.68) (0.21-0.48) (0.50-1.16) (0.26-0.38) (0.48-0.67) (0.74-1.05) 
55-59 years 
0.42  0.30  0.72  0.32  0.58  0.90  
(0.28-0.64) (0.20-0.46) (0.47-1.10) (0.27-0.38) (0.50-0.67) (0.76-1.05) 
60-64 years 
0.49  0.36  0.85  0.40  0.73  1.13  
(0.32-0.75) (0.23-0.54) (0.56-1.29) (0.34-0.47) (0.64-0.85) (0.97-1.32) 
65-69 years 
0.38  0.28  0.66  0.33  0.63  0.96  
(0.25-0.58) (0.19-0.43) (0.44-1.01) (0.28-0.39) (0.54-0.72) (0.82-1.11) 
70-74 years 
0.30  0.22  0.52  0.28  0.53  0.80  
(0.20-0.46) (0.15-0.34) (0.34-0.80) (0.23-0.33) (0.45-0.62) (0.68-0.95) 
75-79 years 
0.25  0.20  0.44  0.24  0.50  0.74  
(0.16-0.38) (0.13-0.31) (0.29-0.68) (0.20-0.30) (0.41-0.60) (0.61-0.90) 
80–84 years 
0.16  0.15  0.31  0.17  0.40  0.57  
(0.10-0.25) (0.10-0.23) (0.20-0.48) (0.14-0.21) (0.32-0.49) (0.46-0.70) 
85-89 years 
0.07  0.08  0.15  0.08  0.22  0.31  
(0.05-0.11) (0.05-0.12) (0.10-0.24) (0.06-0.11) (0.17-0.28) (0.24-0.39) 
Total  
(45-89 years) 
2.98  2.24  5.22  2.44  4.70  7.14  




Male Female Overall Male Female Overall 
45-49 years 
0.44  0.31  0.76  0.29  0.52  0.81  
(0.29-0.68) (0.20-0.48) (0.49-1.17) (0.23-0.36) (0.43-0.64) (0.66-1.00) 
50-54 years 
0.54  0.39  0.93  0.38  0.70  1.08  
(0.35-0.83) (0.25-0.60) (0.61-1.42) (0.31-0.46) (0.59-0.83) (0.90-1.29) 
55-59 years 
0.52  0.37  0.89  0.39  0.71  1.10  
(0.34-0.79) (0.24-0.56) (0.58-1.35) (0.33-0.46) (0.61-0.83) (0.94-1.29) 
60-64 years 0.48  0.35  0.82  0.39  0.71  1.10  
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(0.32-0.73) (0.23-0.53) (0.54-1.25) (0.33-0.46) (0.62-0.82) (0.94-1.28) 
65-69 years 
0.53  0.40  0.93  0.46  0.88  1.34  
(0.35-0.81) (0.26-0.61) (0.61-1.42) (0.39-0.55) (0.76-1.02) (1.15-1.57) 
70-74 years 
0.38  0.30  0.69  0.36  0.71  1.07  
(0.25-0.59) (0.20-0.46) (0.45-1.05) (0.30-0.43) (0.60-0.83) (0.90-1.26) 
75-79 years 
0.27  0.22  0.49  0.27  0.55  0.81  
(0.17-0.41) (0.14-0.34) (0.31-0.75) (0.22-0.33) (0.45-0.66) (0.67-0.98) 
80–84 years 
0.19  0.17  0.35  0.20  0.45  0.65  
(0.12-0.29) (0.11-0.26) (0.23-0.55) (0.16-0.25) (0.36-0.55) (0.52-0.80) 
85-89 years 
0.10  0.10  0.20  0.11  0.28  0.40  
(0.06-0.15) (0.06-0.16) (0.13-0.31) (0.09-0.14) (0.22-0.36) (0.31-0.50) 
Total  
(45-89 years) 
3.45  2.60  6.06  2.84  5.51  8.36  




Male Female Overall Male Female Overall 
45-49 years 
0.37  0.26  0.62  0.24  0.43  0.67  
(0.24-0.57) (0.17-0.40) (0.40-0.96) (0.19-0.30) (0.35-0.53) (0.55-0.83) 
50-54 years 
0.42  0.29  0.71  0.29  0.53  0.82  
(0.27-0.64) (0.19-0.45) (0.46-1.08) (0.24-0.35) (0.44-0.63) (0.68-0.98) 
55-59 years 
0.61  0.43  1.04  0.46  0.83  1.29  
(0.40-0.93) (0.28-0.66) (0.68-1.59) (0.39-0.55) (0.72-0.97) (1.10-1.52) 
60-64 years 
0.72  0.53  1.25  0.58  1.09  1.68  
(0.48-1.10) (0.35-0.81) (0.82-1.90) (0.49-0.69) (0.94-1.26) (1.44-1.95) 
65-69 years 
0.65  0.48  1.14  0.57  1.06  1.63  
(0.43-0.99) (0.32-0.74) (0.75-1.73) (0.48-0.67) (0.92-1.23) (1.40-1.90) 
70-74 years 
0.55  0.42  0.97  0.51  0.99  1.50  
(0.36-0.83) (0.27-0.65) (0.63-1.48) (0.42-0.61) (0.84-1.16) (1.27-1.77) 
75-79 years 
0.52  0.43  0.95  0.51  1.08  1.59  
(0.34-0.79) (0.28-0.66) (0.61-1.46) (0.42-0.63) (0.90-1.30) (1.32-1.93) 
80–84 years 
0.29  0.27  0.55  0.31  0.71  1.02  
(0.18-0.45) (0.17-0.42) (0.36-0.86) (0.24-0.38) (0.58-0.87) (0.82-1.26) 
85-89 years 
0.14  0.14  0.28  0.16  0.39  0.55  
(0.09-0.22) (0.09-0.22) (0.18-0.44) (0.12-0.20) (0.31-0.50) (0.43-0.70) 
Total  4.26  3.25  7.51  3.63  7.12  10.75  
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Male Female Overall Male Female Overall 
45-49 years 
0.40  0.27  0.66  0.26  0.45  0.71  
(0.26-0.62) (0.17-0.41) (0.43-1.03) (0.21-0.32) (0.36-0.54) (0.57-0.87) 
50-54 years 
0.57  0.39  0.96  0.40  0.70  1.10  
(0.37-0.87) (0.25-0.60) (0.63-1.47) (0.33-0.48) (0.59-0.83) (0.92-1.32) 
55-59 years 
0.51  0.36  0.87  0.38  0.69  1.07  
(0.33-0.77) (0.23-0.55) (0.57-1.32) (0.32-0.46) (0.59-0.80) (0.91-1.26) 
60-64 years 
0.56  0.40  0.96  0.45  0.83  1.28  
(0.37-0.85) (0.26-0.61) (0.63-1.46) (0.38-0.54) (0.72-0.95) (1.10-1.49) 
65-69 years 
0.79  0.58  1.36  0.68  1.27  1.95  
(0.52-1.20) (0.38-0.88) (0.90-2.07) (0.58-0.81) (1.09-1.47) (1.67-2.28) 
70-74 years 
0.86  0.66  1.53  0.80  1.56  2.36  
(0.57-1.32) (0.43-1.01) (1.00-2.33) (0.67-0.96) (1.33-1.83) (2.00-2.79) 
75-79 years 
0.68  0.55  1.23  0.67  1.37  2.05  
(0.44-1.04) (0.35-0.84) (0.79-1.89) (0.55-0.83) (1.14-1.65) (1.69-2.47) 
80–84 years 
0.46  0.40  0.86  0.49  1.07  1.56  
(0.29-0.71) (0.26-0.63) (0.55-1.33) (0.39-0.61) (0.87-1.32) (1.26-1.93) 
85-89 years 
0.31  0.31  0.62  0.35  0.87  1.22  
(0.20-0.48) (0.19-0.49) (0.39-0.97) (0.27-0.45) (0.69-1.10) (0.96-1.56) 
Total  
(45-89 years) 
5.14  3.91  9.04  4.49  8.81  13.3  




Male Female Overall Male Female Overall 
45-49 years 
0.29  0.18  0.47  0.19  0.31  0.49  
(0.19-0.44) (0.12-0.28) (0.30-0.72) (0.15-0.23) (0.25-0.37) (0.40-0.61) 
50-54 years 
0.35  0.23  0.58  0.25  0.41  0.66  
(0.23-0.54) (0.15-0.35) (0.38-0.89) (0.20-0.30) (0.35-0.49) (0.55-0.79) 
55-59 years 
0.56  0.37  0.93  0.42  0.71  1.13  
(0.37-0.85) (0.24-0.56) (0.61-1.41) (0.35-0.50) (0.61-0.83) (0.96-1.33) 
60-64 years 
0.78  0.54  1.32  0.63  1.11  1.74  
(0.51-1.18) (0.35-0.82) (0.86-2.00) (0.53-0.74) (0.96-1.28) (1.49-2.02) 
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65-69 years 
0.67  0.48  1.15  0.58  1.06  1.64  
(0.44-1.02) (0.31-0.73) (0.76-1.75) (0.49-0.69) (0.91-1.23) (1.41-1.92) 
70-74 years 
0.70  0.51  1.21  0.65  1.21  1.86  
(0.46-1.07) (0.33-0.79) (0.79-1.85) (0.54-0.78) (1.03-1.42) (1.57-2.20) 
75-79 years 
0.88  0.68  1.55  0.87  1.70  2.57  
(0.57-1.34) (0.44-1.04) (1.01-2.39) (0.71-1.07) (1.41-2.04) (2.13-3.10) 
80–84 years 
0.80  0.67  1.47  0.85  1.80  2.65  
(0.51-1.24) (0.43-1.05) (0.94-2.29) (0.68-1.07) (1.46-2.21) (2.13-3.28) 
85-89 years 
0.47  0.43  0.90  0.53  1.22  1.76  
(0.30-0.73) (0.27-0.68) (0.57-1.41) (0.41-0.69) (0.96-1.55) (1.37-2.24) 
Total  
(45-89 years) 
5.49  4.10  9.59  4.97  9.52  14.49  
(3.57-8.41) (2.65-6.31) (6.23-14.72) (4.07-6.07) (7.94-11.41) (12.01-17.48) 
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Appendix table 17. Estimation of age-specific number of people with POAG in China from 2000 to 2010, by geographical region (million, 95% 
CI) 
2000 
Age group North China Northeast China East China South Central China Southwest China Northwest China 
45-49 years 0.072 (0.047-0.109) 0.061 (0.042-0.088) 0.173 (0.114-0.263) 0.142 (0.091-0.220) 0.081 (0.051-0.130) 0.034 (0.021-0.053) 
50-54 years 0.056 (0.037-0.086) 0.046 (0.031-0.066) 0.146 (0.096-0.221) 0.121 (0.078-0.187) 0.070 (0.044-0.112) 0.030 (0.019-0.047) 
55-59 years 0.047 (0.031-0.071) 0.039 (0.027-0.056) 0.127 (0.084-0.192) 0.107 (0.069-0.165) 0.069 (0.043-0.111) 0.030 (0.019-0.046) 
60-64 years 0.054 (0.036-0.080) 0.044 (0.032-0.062) 0.133 (0.088-0.201) 0.116 (0.075-0.178) 0.070 (0.044-0.112) 0.032 (0.021-0.049) 
65-69 years 0.054 (0.036-0.081) 0.041 (0.029-0.057) 0.141 (0.093-0.213) 0.116 (0.075-0.179) 0.064 (0.040-0.102) 0.027 (0.017-0.041) 
70-74 years 0.042 (0.028-0.064) 0.033 (0.023-0.046) 0.120 (0.079-0.182) 0.094 (0.060-0.147) 0.054 (0.034-0.086) 0.018 (0.012-0.029) 
75-79 years 0.029 (0.019-0.044) 0.021 (0.015-0.031) 0.090 (0.059-0.137) 0.069 (0.043-0.108) 0.037 (0.023-0.058) 0.013 (0.008-0.021) 
80-84 years 0.017 (0.011-0.027) 0.013 (0.009-0.018) 0.061 (0.039-0.092) 0.047 (0.029-0.074) 0.025 (0.015-0.039) 0.008 (0.005-0.013) 
85-89 years 0.007 (0.005-0.011) 0.006 (0.004-0.008) 0.026 (0.017-0.040) 0.021 (0.013-0.033) 0.011 (0.007-0.018) 0.003 (0.002-0.005) 
Total (45-89 years) 0.379 (0.250-0.573) 0.304 (0.212-0.433) 1.016 (0.669-1.540) 0.832 (0.534-1.292) 0.482 (0.301-0.768) 0.194 (0.124-0.303) 
2010 
Age group North China Northeast China East China South Central China Southwest China Northwest China 
45-49 years 0.087 (0.058-0.131) 0.070 (0.047-0.103) 0.205 (0.136-0.309) 0.178 (0.116-0.273) 0.085 (0.054-0.134) 0.045 (0.029-0.071) 
50-54 years 0.092 (0.061-0.139) 0.076 (0.051-0.112) 0.195 (0.130-0.291) 0.159 (0.104-0.244) 0.073 (0.046-0.115) 0.041 (0.026-0.065) 
55-59 years 0.098 (0.065-0.149) 0.079 (0.053-0.117) 0.234 (0.155-0.354) 0.188 (0.121-0.290) 0.104 (0.065-0.166) 0.044 (0.028-0.070) 
60-64 years 0.075 (0.049-0.113) 0.058 (0.039-0.086) 0.191 (0.126-0.289) 0.155 (0.100-0.239) 0.088 (0.055-0.141) 0.037 (0.024-0.059) 
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65-69 years 0.058 (0.039-0.087) 0.046 (0.032-0.068) 0.156 (0.103-0.237) 0.128 (0.082-0.200) 0.081 (0.051-0.131) 0.035 (0.022-0.055) 
70-74 years 0.058 (0.039-0.086) 0.046 (0.032-0.066) 0.148 (0.097-0.224) 0.125 (0.080-0.193) 0.073 (0.046-0.117) 0.033 (0.021-0.051) 
75-79 years 0.047 (0.031-0.070) 0.035 (0.024-0.050) 0.130 (0.085-0.199) 0.103 (0.065-0.161) 0.055 (0.034-0.087) 0.022 (0.014-0.034) 
80-84 years 0.027 (0.018-0.040) 0.021 (0.014-0.030) 0.084 (0.055-0.129) 0.063 (0.040-0.099) 0.035 (0.021-0.056) 0.011 (0.007-0.017) 
85-89 years 0.012 (0.008-0.017) 0.009 (0.006-0.013) 0.042 (0.027-0.064) 0.031 (0.019-0.049) 0.015 (0.010-0.025) 0.005 (0.003-0.007) 
Total (45-89 years) 0.554 (0.367-0.832) 0.440 (0.299-0.644) 1.385 (0.913-2.097) 1.129 (0.728-1.748) 0.610 (0.382-0.972) 0.274 (0.175-0.429) 
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Appendix table 18. Estimation of age-specific number of people with PACG in China from 2000 to 2010, by geographical region (million, 95% 
CI) 
2000 
Age group North China Northeast China East China South Central China Southwest China Northwest China 
45-49 years 0.081 (0.075-0.086) 0.092 (0.081-0.104) 0.157 (0.123-0.200) 0.117 (0.096-0.143) 0.098 (0.077-0.124) 0.044 (0.034-0.056) 
50-54 years 0.070 (0.067-0.073) 0.076 (0.068-0.085) 0.144 (0.114-0.182) 0.109 (0.091-0.130) 0.092 (0.073-0.115) 0.043 (0.034-0.054) 
55-59 years 0.062 (0.061-0.064) 0.069 (0.063-0.076) 0.135 (0.107-0.170) 0.104 (0.088-0.122) 0.098 (0.079-0.121) 0.046 (0.036-0.057) 
60-64 years 0.075 (0.074-0.076) 0.083 (0.075-0.090) 0.154 (0.121-0.194) 0.122 (0.104-0.142) 0.107 (0.087-0.131) 0.051 (0.041-0.065) 
65-69 years 0.083 (0.082-0.084) 0.082 (0.074-0.090) 0.179 (0.140-0.227) 0.135 (0.116-0.156) 0.107 (0.087-0.131) 0.047 (0.037-0.059) 
70-74 years 0.072 (0.071-0.074) 0.072 (0.064-0.079) 0.170 (0.132-0.218) 0.123 (0.106-0.142) 0.099 (0.080-0.121) 0.035 (0.027-0.045) 
75-79 years 0.055 (0.053-0.057) 0.051 (0.046-0.058) 0.143 (0.110-0.186) 0.101 (0.087-0.118) 0.074 (0.060-0.092) 0.028 (0.022-0.036) 
80-84 years 0.036 (0.034-0.038) 0.033 (0.029-0.037) 0.107 (0.081-0.141) 0.077 (0.066-0.090) 0.055 (0.044-0.068) 0.020 (0.015-0.025) 
85-89 years 0.017 (0.015-0.018) 0.016 (0.014-0.019) 0.052 (0.038-0.069) 0.039 (0.033-0.046) 0.028 (0.022-0.035) 0.008 (0.006-0.010) 
Total (45-89 years) 0.552 (0.532-0.570) 0.574 (0.514-0.637) 1.242 (0.967-1.587) 0.927 (0.786-1.089) 0.758 (0.610-0.938) 0.321 (0.252-0.407) 
2010 
Age group North China Northeast China East China South Central China Southwest China Northwest China 
45-49 years 0.095 (0.089-0.102) 0.107 (0.094-0.121) 0.184 (0.144-0.234) 0.145 (0.118-0.177) 0.100 (0.078-0.126) 0.058 (0.045-0.074) 
50-54 years 0.111 (0.106-0.115) 0.127 (0.114-0.142) 0.189 (0.149-0.239) 0.141 (0.118-0.170) 0.094 (0.075-0.117) 0.058 (0.046-0.073) 
55-59 years 0.129 (0.126-0.133) 0.145 (0.131-0.160) 0.251 (0.198-0.316) 0.183 (0.155-0.216) 0.149 (0.120-0.184) 0.069 (0.054-0.086) 
60-64 years 0.108 (0.106-0.110) 0.117 (0.106-0.128) 0.223 (0.175-0.282) 0.164 (0.140-0.192) 0.137 (0.111-0.168) 0.064 (0.050-0.080) 
65-69 years 0.090 (0.088-0.091) 0.099 (0.089-0.109) 0.197 (0.154-0.251) 0.149 (0.128-0.172) 0.136 (0.111-0.167) 0.064 (0.050-0.081) 
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70-74 years 0.096 (0.093-0.098) 0.104 (0.093-0.115) 0.204 (0.158-0.261) 0.157 (0.135-0.182) 0.132 (0.107-0.163) 0.063 (0.049-0.080) 
75-79 years 0.086 (0.082-0.089) 0.084 (0.075-0.094) 0.201 (0.154-0.261) 0.146 (0.125-0.170) 0.109 (0.088-0.135) 0.046 (0.036-0.059) 
80-84 years 0.054 (0.051-0.058) 0.055 (0.048-0.063) 0.147 (0.110-0.193) 0.101 (0.085-0.118) 0.077 (0.061-0.096) 0.024 (0.018-0.031) 
85-89 years 0.026 (0.024-0.028) 0.026 (0.022-0.030) 0.081 (0.060-0.108) 0.056 (0.047-0.066) 0.038 (0.030-0.047) 0.012 (0.009-0.016) 
Total (45-89 years) 0.795 (0.765-0.823) 0.864 (0.772-0.962) 1.676 (1.301-2.146) 1.242 (1.050-1.463) 0.972 (0.780-1.204) 0.457 (0.358-0.580) 
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Appendix table 19. Search strategy to identify studies reporting the prevalence of 
cataract and cataract blindness in China 
CNKI 
Access Date: 21 Nov 2017 
Subject category: Medicine & Public Health 
Sub-database: Journal, Featured journal, Doctoral dissertation, Master dissertation  
检索表达式： 
(SU % '白内障') AND (SU % '发病率' + '发生率' + '患病率'+ '罹患率' + '现患率'+ '死亡
率' + '病死率'+ '流行' + '负担'+ '现况调查'+ '现况研究') 
发表时间：从 1990-01-01 到 2017-11-21 
Search Terms: (SU % 'baineizhang') AND (SU % 'fabinglv' + 'fashenglv' + 'huanbinglv'+ 
'lihuanlv' + 'xianhuanlv'+ 'siwanglv' + 'bingsilv'+ 'liuxing' + 'fudan'+ 'xiankuangdiaocha'+ 
'xiankuangyanjiu') 
Published time：From 01/01/1990 to 21/11/2017 
 
Wanfang 
Access Date: 21 Nov 2017 
Sub-database: Journal articles, Dissertations 
检索表达式：(主题:(白内障)) * (主题:(发病率) + 主题:(发生率) + 主题:(患病率) +主
题:(罹患率) + 主题:(现患率) + 主题:(死亡率) +主题:(病死率) + 主题:(流行) + 主题:(负
担)+ 主题:(现况调查) + 主题:(现况研究)) 
时间：1990-2017 
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Search Terms: (subject: (baineizhang))* (subject: (fabinglv) + subject: (fashenglv) + 
subject: (huanbinglv)+ subject: (lihuanlv) + subject: (xianhuanlv) + subject: (siwanglv)+ 





Access Date: 21 Nov 2017 
Journal category: All journals 
检索表达式： 
(白内障) AND (发病率 or 发生率 or 患病率 or 罹患率 or 现患率 or 死亡率 or 病死率 
or 流行 or 负担 or 现况调查 or 现况研究) 
时间：1990-2017 
Search Terms: ( (baineizhang))* ( (fabinglv) OR (fashenglv) OR (huanbinglv) OR 
(lihuanlv) OR (xianhuanlv) OR (siwanglv) OR (bingsilv) OR (liuxing) OR (fudan) OR 




Access Date: 22 Nov 2017 
Search Terms:  
 ((cataract*) AND (China OR Chinese OR Hongkong OR Macau OR Taiwan) AND 
(inciden* OR prevalen* OR morbidity OR mortality OR epidemiology)) AND 
("1990/01/01"[Date - Publication] : "2017/11/22"[Date - Publication]) 
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Embase (Ovid) 
Access Date: 22 Nov 2017 
# Searches 
1 cataract*.mp. or exp cataract/ 
2 China.mp. or exp China/ 
3 exp Chinese/ or Chinese.mp. 
4 Hong Kong.mp. or exp Hong Kong/ 
5 Macau.mp. or exp Macau/ 
6 Taiwan.mp. or exp Taiwan/ 
7 exp incidence/ or inciden*.mp. 
8 exp prevalence/ or prevalen*.mp. 
9 morbidity.mp. or exp morbidity/ 
10 exp mortality/ or Mortality.mp. 
11 exp epidemiology/ or Epidemiology.mp. 
12 2 or 3 or 4 or 5 or 6 
13 7 or 8 or 9 or 10 or 11 
14 1 and 12 and 13 
15 limit 14 to yr="1990 -Current" 
  
Medline (Ovid) 
Access Date: 22 Nov 2017 
Search Terms:  
# Searches 
1 exp Cataract/ or cataract*.mp. 
2 China.mp. or exp China/ 
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3 Chinese.mp. 
4 Hong Kong.mp. or exp Hong Kong/ 
5 Macau.mp. or exp Macau/ 
6 Taiwan.mp. or exp Taiwan/ 
7 exp Incidence/ or inciden*.mp. 
8 exp Prevalence/ or prevalen*.mp. 
9 Morbidity.mp. or exp Morbidity/ 
10 Mortality.mp. or exp Mortality/ 
11 Epidemiology.mp. or exp Epidemiology/ 
12 2 or 3 or 4 or 5 or 6 
13 7 or 8 or 9 or 10 or 11 
14 1 and 12 and 13 
15 limit 14 to yr="1990 -Current" 
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Appendix table 20. A “data microarray” illustrating the definitions of cataract and cataract blindness adopted in population-based studies in 
China 
Study ID Study 


























CA-01 Li SZ et al. (1999)                           
CA-02 Zhao JL et al. (2001)                           
CA-03 Tang X (2008)                           
CA-04 Tang XY (2002)                           
CA-05 Wang YX et al. (2003)                           
CA-06 Li ZQ et al. (2004)                           
CA-07 Chen L et al. (2004)                           
CA-08 Ding L et al. (2005)                           
CA-10 Li L et al. (2006)                           
CA-12 Li ZJ et al. (2007)                           
CA-14 Huang XB et al. (2009)                           
CA-15 Zhou Y et al. (2011)                           
CA-16 Tang B et al. (2011)                           
CA-17 Xie TY et al. (2011)                           
CA-18 Zhao MG et al. (2011)                           
CA-19 Zhang HF (2013)                           
CA-20 Li FR et al. (2012)                           
CA-21A Bi JX (2012)                           
CA-21B Guan HJ et al. (2012)                           
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Study ID Study 


























CA-22 Luo R et al. (2012)                           
CA-23A Guan HJ et al. (2013)                           
CA-23B J M et al. (2015)                           
CA-23C Cai N et al. (2013)                           
CA-24 Jiao WZ (2014)                           
CA-25A Wang GM (2013)                           
CA-25B Tang HY (2012)                           
CA-26 Tian F et al. (2014)                           
CA-27 Shen W (2015)                           
CA-28 Shen W et al. (2013)                           
CA-29 Wang TY (2015)                           
CA-32 Jiang HF et al. (2015)                           
CA-33 Long XX (2015)                           
CA-34 Hu Y et al. (2016)                           
CA-35 Cai HB (2016)                           
CA-36 Zhou J et al. (2017)                           
CA-37 Yao HY et al. (2012)                           
CA-38 Gao RF et al. (2012)                           
CA-39 Geng JQ (2017)                           
CA-30 Luan L et al. (2014)                           
CA-09 Zhao JL et al. (2010)                           
CA-11 Fu YZ et al. (2005)                           
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Study ID Study 


























CA-13 Xu P (2003)                           
CA-31 Wu SF et al. (2015)                           
ARC-9 Peng YS et al. (2007)                           
ARC-6 Quan YL et al. (2006)                           
ARC-1A Feng J et al. (2008)                           
ARC-1B Bai JS et al. (2012)                           
ARC-2 Xiang W et al. (2015)                           
ARC-3 Zheng H et al. (2001)                           
ARC-4 Cui W et al. (2012)                           
ARC-5 Zeng H et al. (2011)                           
ARC-7 Sheng Y et al. (2016)                           
ARC-8 Liu WJ (2009)                           
ARC-10 Chang L et al. (2009)                           
ARC-11 Yue Y (2001)                           
Note: The full reference list can be found in Appendix table 23. 
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Appendix table 21. The year of publication and investigation and corresponding time-
lag in the included studies on cataract or cataract blindness prevalence in China (n=55)  






CA-01 Li SZ et al. (1999) 1999 1997 2 
CA-02 Zhao JL et al. (2001) 2001 1996 5 
CA-03 Tang X (2008) 2008 2007 1 
CA-04 Tang XY (2002) 2002 - - 
CA-05 Wang YX et al. (2003) 2003 2002 1 
CA-06 Li ZQ et al. (2004) 2004 2003 1 
CA-07 Chen L et al. (2004) 2004 2002 2 
CA-08 Ding L et al. (2005) 2005 2002 3 
CA-09 Li L et al. (2006) 2006 2003 3 
CA-10 Li ZJ et al. (2007) 2007 2007 0 
CA-11 Huang XB et al. (2009) 2009 2008 1 
CA-12 Zhou Y et al. (2011) 2011 2007 4 
CA-13 Tang B et al. (2011) 2011 2007 4 
CA-14 Xie TY et al. (2011) 2011 2009 2 
CA-15 Zhao MG et al. (2011) 2011 2007 4 
CA-16 Zhang HF (2013) 2013 2012 1 
CA-17 Li FR et al. (2012) 2012 2006 6 
CA-18 Bi JX (2012) 2012 2010 2 
CA-19 Guan HJ et al. (2012) 2012 2006 6 
CA-20 Luo R et al. (2012) 2012 2006 6 
CA-21A Guan HJ et al. (2013) 2013 2010 3 
CA-21B J M et al. (2015) 2015 2010 5 
CA-22 Cai N et al. (2013) 2013 2012 1 
CA-23A Jiao WZ (2014) 2014 2008 6 
CA-23B Wang GM (2013) 2013 2008 5 
CA-23C Tang HY (2012) 2012 2008 4 
CA-24 Tian F et al. (2014) 2014 2011 3 
CA-25A Shen W (2015) 2015 2010 5 
CA-25B Shen W et al. (2013) 2013 2010 3 
CA-26 Wang TY (2015) 2015 2013 2 
CA-27 Jiang HF et al. (2015) 2015 2014 1 
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CA-28 Long XX (2015) 2015 2011 4 
CA-29 Hu Y et al. (2016) 2016 2015 1 
CA-30 Cai HB (2016) 2016 2014 2 
CA-31 Zhou J et al. (2017) 2017 2008 9 
CA-32 Yao HY et al. (2012) 2012 2011 1 
CA-33 Gao RF et al. (2012) 2012 2007 5 
CA-34 Geng JQ (2017) 2017 - - 
CA-35 Luan L et al. (2014) 2014 2010 4 
CA-36 Zhao JL et al. (2010) 2010 2006 4 
CA-37 Fu YZ et al. (2005) 2005 2004 1 
CA-38 Xu P (2003) 2003 2002 1 
CA-39 Wu SF et al. (2015) 2015 2014 1 
ARC-1A Peng YS et al. (2007) 2007 2003 4 
ARC-1B Quan YL et al. (2006) 2006 2003 3 
ARC-2 Feng J et al. (2008) 2008 - - 
ARC-3 Bai JS et al. (2012) 2012 2008 4 
ARC-4 Xiang W et al. (2015) 2015 2014 1 
ARC-5 Zheng H et al. (2001) 2001 1997 4 
ARC-6 Cui W et al. (2012) 2012 2010 2 
ARC-7 Zeng H et al. (2011) 2011 2009 2 
ARC-8 Sheng Y et al. (2016) 2016 2014 2 
ARC-9 Liu WJ (2009) 2009 2008 1 
ARC-10 Chang L et al. (2009) 2009 2005 4 
ARC-11 Yue Y (2001) 2001 - - 
Note: “-” represents unavailable data; Based on the information from 51 studies, the average 
time-lag between year of publication and year of investigation was 2.98. 
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Appendix table 22. Meta-analysis of the prevalence of cataract and cataract blindness 
for assessing heterogeneity between studies 
Heterogeneity across included studies was assessed using the χ2 test on Cochran's Q statistic, and 
quantified using the I2 statistics, with a two-sided p value of less than 0.05 being indicative of 
heterogeneity between studies in Q statistic and I2 represents the proportion of total variation that is 
due to heterogeneity rather than chance (with values of <25%, 25–75%, and >75% indicating low, 
moderate and high heterogeneity, respectively) (Higgins and Thompson, 2002, Higgins et al., 2003). 
As shown in Appendix figures 9-13, significant high heterogeneity was detected between studies 
that reported prevalence rates of any cataract (I2=99.8% [95% CI: 99.8-99.9], p<0.0001), ARC 
(I2=99.9% [95% CI: 99.9-99.9], p<0.0001), cataract blindness by BCVA<0.05 (I2=94.0% [95% CI: 
90.3-96.2], p<0.0001), cataract blindness by BCVA<0.10 (I2=97.4% [95% CI: 96.4-98.2], p<0.0001) 
and cataract blindness by PVA<0.10 (I2=97.6% [95% CI: 96.8-98.2], p<0.0001). 
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Appendix figure 9. Meta-analysis of the prevalence of any cataract (n=35) 
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Appendix figure 10. Meta-analysis of the prevalence of ARC (n=10) 
 
Appendix figure 11. Meta-analysis of the prevalence of cataract blindness by BCVA<0.05 (n=8) 
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Appendix figure 12. Meta-analysis of the prevalence of cataract blindness by BCVA<0.10 (n=9) 
 
Appendix figure 13. Meta-analysis of the prevalence of cataract blindness by PVA<0.10 (n=12) 
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Appendix table 23. Full list of the included studies on cataract and cataract blindness prevalence in China (n=55) 
Study ID Reference 
CA-01 Li S, Xu J, He M, Wu K, Munoz SR, Ellwein LB. A survey of blindness and cataract surgery in Doumen County, China. OPHTHALMOLOGY 
1999;106(8):1602-8. 
CA-02 Jia-liang Zhao, Rui-fang Sui, Li-jun Jia, et al. 赵家良, 睢瑞芳, 贾丽君, et al. Prevalence of cataract and surgical coverage among adults aged 
50 or above in Shunyi district of Beijing, China (北京市顺义区白内障患病和手术状况的调查)[J]. Chin J Ophthalmol (中华眼科杂志). 
2001(01):6-11. 
CA-03 Xiang Tang. 唐香. Prevalence of cataract and surgical coverage among adults aged 50 or above in Luxi county of Yunnan province (云南省泸
西县 50 岁及以上人群白内障患病情况及手术状况调查)[D]. Kunming Medical University (昆明医科大学), 2008. 
CA-04 Xiao-yun Tang. 唐晓云. Investigation of the cataract epidemiology and surgery in Jiagedaqi District* (加格达奇区患白内障情况和手术状况
的调查)[J]. Heilongjiang Medical Journal (黑龙江医学). 2002(02):148. 
CA-05 Yun-xun Wang, Yan Zhao, Yong-mei Sun, et al. 王云旭, 赵艳, 孙永梅, et al. Establishment and implementation of cataract blindness 
prevention and treatment in Mongolian* (蒙古族白内障防盲治盲三级网站建立与实施)[J]. Ophthalmol CHN (眼科). 2003(03):160-1. 
CA-06 Zhi-qing Li, Xiu-juan Zhang, Hui-min Sun, et al. 李志清, 张秀娟, 孙慧敏, et al. Investigation of cataract prevalence in people aged 40 years 
and above in Sangzi village, Ji County, Tianjin* (天津蓟县桑梓村 40 岁及以上人群白内障患病率调查)[J]. Chin J Pract Ophthalmol (中国
实用眼科杂志). 2004(09):749-50. 
CA-07 Lu Chen, Li-na Huang, Xiao-xia Li, et al. 陈璐, 黄丽娜, 李晓霞, 赖小兰, 曾平. Prevalence of cataract and surgical coverage among adults 
aged 50 or above in Baoan district of Shenzhen, China (深圳宝安区 50 岁及以上人群白内障患病情况及手术状况调查)[J]. International 
Journal of Ophthalmology (国际眼科杂志). 2004(05):919-21. 
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Study ID Reference 
CA-08 Lin Ding, Xiu-rong Zhao, Xin Yang, et al. 丁琳, 赵秀蓉, 杨昕, 史韶华. Epidemiological investigation of cataract in Urumqi, Xinjiang* (新疆
乌鲁木齐市白内障的流行病学调查)[J]. Xinjiang Medical Journal (新疆医学). 2005(01):40-2. 
CA-09 Lin Li, Huai-jin Guan, Ji-bo Zhou, et al. 李琳, 管怀进, 周激波, et al. An epidemiological survey of cataract among adults aged 60 years and 
above in Xinchengqiao Blocks, Nantong (南通市新城桥街道 60 岁及以上人群白内障流行病学调查)[J]. Chin J Pract Ophthalmol (中国实
用眼科杂志). 2006(07):752-7. 
CA-10 Zhi-jian Li, Hao Cui, Ping Liu, et al. 李志坚, 崔浩, 刘平, 张丽琼, 李彬. Survey of cataract among the people aged 50 years and older in a rural 
area of Harbin (哈尔滨南部 50 岁及以上农村人口白内障的调查 )[J]. International Journal of Ophthalmology (国际眼科杂志 ). 
2007(05):1460-3. 
CA-11 Xiao-bo Huang, Hai-dong Zou, Ning Wang, et al. 黄晓波, 邹海东, 王宁, et al. Epidemiological survey of cataract among the elder in Beixinjing 
Blocks, Shanghai (上海北新泾老人白内障流行病学调查)[J]. Int J Ophthalmol (国际眼科杂志). 2009(07):1321-4. 
CA-12 Yan Zhou, Xue-ping Jia. 周燕, 贾雪平. An investigation of cataract prevalence in elderly in one community* (某社区老年人口白内障患病
率调查)[J]. Guide of China Medicine (中国医药指南). 2011(16):136-7. 
CA-13 Bin Tang, Zhi Li, Yi Luo, et al. 唐斌, 李治, 罗羿, et al. The survey comparisons on the epidemiology of cataracts among the old aged 50 and 
above in the urban and rural areas in Jiangbei district of Chongqing (重庆市江北区城乡 50 岁及以上人群白内障的流行病学调查)[J]. 
Chongqing Medicine (重庆医学). 2011(06):561-4. 
CA-14 Ting-yu Xie, Yan Wang, Liang Gao, et al. 谢婷玉, 王燕, 高亮, et al. Prevalence of cataract and surgical coverage among Urger adults aged 40 
or above in Kuche rural area of Xinjiang, China (新疆库车县维吾尔族农民白内障患病状况调查)[J]. Chin J Epidemiol (中华流行病学杂
志). 2011;32(1):95-6. 
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Study ID Reference 
CA-15 Ming-gui Zhao, Shi-hong Zhang, Le-xin Wang. 赵明贵, 张士红, 王乐新. An investigation report of cataract epidemiology in adults aged 50 
years and above in rural Lanshan, Rizhao* (日照市岚山区农村 50 岁以上人群白内障流行病学调查报告)[J]. Chinese Community Doctors 
(中国社区医师（医学专业）). 2011(14):311-2. 
CA-16 Hai-fang Zhang. 张海芳. An investigation on the prevalence of cataract and its surgical situation in Binhu district, Wuxi city * (无锡市滨湖区
白内障患病和手术状况的调查) [J]. China Health Care and Nutrition (中国保健营养（下旬刊)). 2013;23(12):7654-5. 
CA-17 Feng-rong Li, Jia-liang Zhao, Hong Lu, et al. 李凤荣, 赵家良, 陆宏, et al. Prevalence and surgery status of cataract among adults aged 50 years 
or above in the Shunyi district of Beijing: the China Nine-Province Survey (我国九省眼病调查中北京市顺义区 50 岁及以上人群白内障患
病率和手术状况的调查)[J]. Chin J Ophthalmol (中华眼科杂志). 2012;48(3):211-8. 
CA-18 Jing-xiang Bi. 毕经香. An epidemiological survey on cataract in different professions* (不同职业人群白内障患病情况的流行病学调查)[J]. 
Hebei Medicine (河北医学). 2012(09):1328-30. 
CA-19 Huai-jin Guan, Hong Lu, Zhui Dai, et al. 管怀进, 陆宏, 戴追, et al. Prevalence and surgery status of cataract among adults aged 50 years or 
above in Qidong city of Jiangsu Province: the China Nine-Province Survey (我国九省眼病调查中江苏省启东市 50 岁及以上人群白内障患
病率和手术状况的调查)[J]. Chin J Ophthalmol (中华眼科杂志). 2012;48(3):219-25. 
CA-20 Rong Luo, Jia-liang Zhao, Jing-lin Yi, et al. 罗荣, 赵家良, 易敬林, et al. Province of blindness and low vision among adults aged 50 years or 
above in Ji'an county of Jiangxi province: the China Nine-Province Survey (我国九省眼病调查中江西省吉安县 50 岁及以上人群白内障患
病率和手术状况的调查)[J]. Chin J Ophthalmol (中华眼科杂志). 2012;48(6):530-6. 
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Study ID Reference 
CA-21A Huai-jin Guan, Yong Yao, Cong-kai Liang, et al. 管怀进, 姚勇, 梁从凯, et al. Prevalence and surgical status of cataract among adults aged 50 
years or above in rural Jiangsu Province (江苏省农村 50 岁及以上人群白内障患病率和手术状况调查)[J]. Natl Med J China (中华医学杂
志). 2013;93(5):330-5. 
CA-21B Min Ji, Mei Yang, Rong-rong Zhu, et al. 季敏, 杨梅, 朱蓉嵘, et al. An investigation on reasons of bad prognosis after cataract surgery in people 
aged 50 years and above in rural Funing, Jiangsu* (江苏省阜宁县农村 50 岁及以上人群白内障术后视力恢复不良原因调查)[J].Med J of 
Communications (交通医学). 2015;29(5):457-9. 
CA-22 Ning Cai, Miao-miao Chen, Yuan-sheng Yuan, et al. 蔡宁, 陈苗苗, 袁援生, 蔡山. Prevalence rate and surgery status of cataract in Luxi county 
of Yunnan Province (云南省泸西县白内障患病率及手术覆盖率调查)[J]. Journal of Kunming Medical University (昆明医科大学学报) 
2013;34(5):74-8. 
CA-23A Wan-zhen Jiao. 焦万珍. Prevalence of visual impairment and blindness, prevalence and surgery status of cataract in rural older adults in 
Shandong province (山东省农村50岁及以上人群盲与视力损伤、白内障患病率及白内障手术状况的调查研究)[D]. Shandong University 
(山东大学), 2014. 
CA-23B Gui-min Wang. 王桂敏. Prevalence and surgery status of cataract among adults aged 50 years and above in Tengzhou city of Shandong province 
(山东省滕州市 50 岁及以上居民白内障患病率及手术服务利用研究)[D].Shandong University (山东大学), 2013. 
CA-23C Hong-ying Tang. 唐红迎. A prevalence study on blindness and vision impairment with moderate and severe degree due to cataract among rural 
residents aged 50 years and above in Juancheng county (鄄城县 50 岁及以上农村居民白内障致盲与中重度视力损伤现况研究)[D]. 
Shandong University (山东大学), 2012. 
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Study ID Reference 
CA-24 Fang Tian, Bai-chao Chen, Yuan He, et al. 田芳, 任百超, 何媛, 贾俊, 刘慧峰, 裴金枝. An epidemiological survey of cataract among adults 
aged 50 years and above in rural, Shaanxi Province (陕西省农村 50 岁及以上人群白内障流行病学调查)[J]. Int Eye Sci (国际眼科杂志). 
2014;14(4):629-32. 
CA-25A Wei Shen. 沈蔚. Prevalence and surgery status of cataract in adult rural Bai, Yi and Han nationality in Yunnan province (云南省白族、彝族
和汉族农村人群白内障流行病学调查)[D]. Kunming Medical University (昆明医科大学), 2015. 
CA-25B Shen W, Yang Y, Yu M, et al. Prevalence and outcomes of cataract surgery in adult rural Chinese populations of the Bai nationality in Dali: the 
Yunnan minority eye study. PLOS ONE 2013;8(4):e60236. 
CA-26 Tian-yu Wang. 王天宇. An epidemiological survey of cataract among adults aged 50 or above in Jing'an district in Shanghai (上海市静安区
江宁街道 50 岁及以上人群白内障流行病学调查)[D].Shanghai Jiao Tong University School of Medicine (上海交通大学), 2015. 
CA-27 Hui-fang Jiang, Yun Peng, Wen-quan Zhang, et al. 蒋惠芳, 彭云, 张文权, 孙伟, 俞正娟. Investigation of the prevalence of cataract and 
operation status in the elderly of Sanlin community (三林社区老年人白内障患病和手术状况调查)[J]. Chinese community doctors (中国社
区医师). 2015(23):78-9. 
CA-28 Xiao-xiang Long. 龙小香. An investigation of prevalence situation among cataract patients in Taizhou* (台州市白内障患者的患病情况调
查)[J]. Journal of Traditional Chinese Medicine Management (中医药管理杂志). 2015(04):18-20. 
CA-29 Yi Hu, Jian-ping Chen, Shu-xiang He, et al. 胡煜, 陈建萍, 贺书香, 林燕梅. Survey on status of cataract in Xiangdong district of Pingxiang 
Jiangxi in 2015 (2015 年江西萍乡湘东区各乡镇白内障情况的调查)[J]. China Modern Medicine (中国当代医药). 2016;23(7):164-6, 169. 
CA-30 Hong-bing Cai. 蔡红兵. An epidemiological survey of cataract among people aged 50 and over in Luxi County of Yunnan Province (云南省
泸西县 50 岁及以上人群白内障流行病学调查)[D]. Kunming Medical University (昆明医科大学), 2016. 
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Study ID Reference 
CA-31 Jing Zhou, Yuan Yuan, Xu Zhang, et al. 周婧, 袁媛, 张徐, 杨梅, 管怀进. Prevalence and surgery status of cataract among adults aged 60 years 
or above in two villages of Nantong (2008 年江苏省南通市两个自然村 60 岁及以上人群白内障患病率和手术状况调查)[J]. Chin J 
Ophthalmol (中华眼科杂志). 2017;53(7):514-21. 
CA-32 Hong-yan Yao, Hong-jian Zhou, Shan-jun Wu, et al. 姚红艳, 周宏健, 吴善君, 李黎. An epidemiological investigation of eye diseases in people 
aged 50 years and above in Beilun district, Ningbo city * (宁波市北仑区 50 岁以上人群眼病流行病学调查)[J]. Modern Practical Medicine 
(现代实用医学). 2012(5):544-5. 
CA-33 Rui-fang Gao, Peng Li, Ai-min Sang, et al. 高瑞芳, 李鹏, 桑爱民, 谌绍林. Analysis on the prevalence of cataract of Hui and Han people in 
Xiji county (西吉县回汉族 50 岁以上人群白内障患病率分析)[J]. Modern Prevention Medicine (现代预防医学). 2012(02):342-4. 
CA-34 Jian-qiong Geng. 耿剑琼. Analysis of prevalence and related factors of cataract among residents aged 50 years and above in Wushan county 
(武山县 50 岁及以上人群白内障患病率及相关因素分析)[D].Lanzhou University (兰州大学). 2017. 
CA-35 Lan Luan, Yong Yao, Dong-hong Fu, et al. 栾兰, 姚勇, 傅东红, et al. Survey of the cataract prevalence and surgical coverage rate among 50 
or above in Wuxi city (无锡市 50 岁及以上人群白内障患病率和手术情况调查)[J]. Chin J Exp Ophthalmol (中华实验眼科杂志). 
2014;32(6):551-5. 
CA-36 Zhao J, Ellwein LB, Cui H, et al. Prevalence and outcomes of cataract surgery in rural China the China nine-province survey. 
OPHTHALMOLOGY 2010;117(11):2120-8. 
CA-37 Yi-zhou Fu, Huan-ran Chen, Zhong-ming Wang, et al. 伏奕舟, 陈焕然, 王仲明, 洪仲思. A survey of 5248 cases for eye diseases screening in 
Zhuhai (珠海市 5248例体检者眼病患病率调查分析)[J]. Journal of Chinese Modern Ophthalmology (中华现代眼科学杂志). 2005(4). 
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Study ID Reference 
CA-38 Ping Xu.徐萍. The situation and related factors of cataract and glaucoma in 729 university staffs * (高校教职工 729 名白内障、青光眼患病
情况及相关因素分析)[J]. Chin J School Health (中国学校卫生) 2003(4). 
CA-39 Su-feng Wu, Jing-xin Guo, You Lai. 吴素锋, 郭景新, 赖友. An investigation and analysis of the prevalence of cataract and surgeries in people 
aged 50 years and above in Yangdong area* (阳东地区 50 岁白内障患病及手术状况的调查与分析)[J]. China Medical Engineering (中国医
学工程). 2015 (11):52, 55. 
ARC-1A Yang-sheng Peng, Ai-yi Zhou, Li Chen, et al. 彭秧生, 周爱意, 陈莉, 何媛, 任百超. Prevalence of age related cataract and blindness in rural 
areas of Shaanxi province (陕西省农村 50 岁以上人群白内障和盲的患病率调查)[J]. International Journal of Ophthalmology (国际眼科杂
志). 2007;7(1):220-3. 
ARC-1B Yan-long Quan, Jian-gang Yang, Bai-chao Ren. 权彦龙, 杨建刚, 任百超. Epidemic survey for cataract in Yang county, Shaanxi Province (陕
西省洋县白内障的流行病学调查)[D]. International Journal of Ophthalmology (国际眼科杂志). 2006;6(6):1464-7. 
ARC-2 Jie Feng, Yu-jing Wan, Guo-hui Yang, et al. 冯洁, 万玉景, 杨国慧, et al. Contrast observation of cataract and surgical coverage in rural and 
urban defined population in Jining (社区与农村白内障患病及手术状况的对比观察)[J]. China Clin Prac Med (中国临床实用医学). 
2008;2(5):36-7. 
ARC-3 Jin-song Bai, Pei-lin An, Yu-ling Liu, et al. 柏劲松, 安培林, 刘玉玲, 付瑜. An investigation of cataract prevalence among adults aged 55 years 
and above in one rural area of Beijing* (北京市某区农村≥55 岁人群白内障患病情况调查)[J]. Guide of China Medicine (中国医药指南). 
2012(17):113-4. 
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Study ID Reference 
ARC-4 Wei Xiang, Feng Gao, Xun-lun Sheng, et al. 向伟, 高峰, 盛迅伦, et al. Prevalence investigation of age related cataract among population aged 
50 years or elder in Tongxin of Ningxia (宁夏同心县 50 岁及以上人群年龄相关性白内障患病率调查)[J]. Ningxia Med J (宁夏医学杂志). 
2015;37(5):405-7. 
ARC-5 Hong Zheng, Pu-lin Yu, Yi-shu Hong, et al. 郑宏, 于普林, 洪依舒, 段春波, 杨泽, 高芳坤. A survey of the current status and distribution of 
cataract in the elderly (我国城乡老年人白内障的患病情况调查)[J]. Chin J Epidemiol (中华流行病学杂志). 2001(06):52-4. 
ARC-6 Wei Cui, Zhi-ying Liu, Gui-bin Yu. 崔巍, 刘志英, 于桂斌. Survey of cataract rate and surgical coverage in agricultural and pastoral area of 
Keshenketeng in Inner Mongolia (内蒙古赤峰市克什克腾旗农牧区白内障患病率及手术覆盖率调查)[J]. Chin J Exp Ophthalmol (中华实
验眼科杂志). 2012;30(5):462-6. 
ARC-7 Hua Zeng, Yu-juan Zhan. 曾华, 詹玉娟. An investigation on age-related cataract in Haikougang, Haikou city * (海口市海口港区年龄相关性
白内障发病状况调查)[J]. Hainan Medical Journal (海南医学). 2011(16):131-3. 
ARC-8 Sheng Y, He F, Lin JF, Shen W, Qiu YW. Tea and Risk of Age-Related Cataracts: A Cross-Sectional Study in Zhejiang Province, China. J 
EPIDEMIOL 2016;26(11):587-92. 
ARC-9 Wen-jie Liu. 刘文洁. Epidemiological survey of cataract among adults aged 40 or above in Gongshan County of Yunnan province (云南省怒
江州贡山县 40 岁及以上人群白内障的流行病学调查)[D]. Tianjin Medical University (天津医科大学), 2009. 
ARC-10 Li Chang, Li-juan Zhang, Jian Zhao, et al. 常莉, 张丽娟, 赵健, 赵媚鲜, 饶华祥. A survey of age-related cataract epidemiology in Taiyuan city 
(太原市年龄相关性白内障的流行病学调查)[J]. Proceeding of Clinical Medicine (临床医药实践). 2009(16):420-2. 
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Study ID Reference 
ARC-11 Yong Yue. 岳镛. Investigation analysis of cataract among retired personnel of southwest university for nationalities (西南民族学院退离休职
工白内障的调查)[J]. Journal of Southwest University for Nationalities. Natural Science Edition (西南民族学院学报(自然科学版)). 
2001(03):378-80. 
Note: The Chinese publication list employed the journals’ official English names or abbreviations, English titles were obtained from journals or literature 
databases (CNKI, Wanfang and CBM). Where official English translation of journal names is not available, a pinyin title is adopted; where the English 
translation of titles is not available, I translated the titles, labelled with “*” and marked as green. 
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Appendix table 24. Detailed characteristics of the included studies on cataract and cataract blindness prevalence in China (n=55) 












































1997 Unclear 5288 - - - 206 
CA-02 































1999* Unclear 3508 737 58 - - 
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2002 Unclear 4346 443 - - - 
CA-06 





Both Rural 40+ 
Cluster 
sampling 
2003 Unclear 1776 294 - - - 
CA-07 










2002 Unclear 3428 1016 - - - 
CA-08 









2002 Unclear 2055 714 - - - 
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2003 Unclear 3040 - 65 - 75 
CA-10 





















2008 Unclear 3851 - - - 149 
CA-12 






Both Urban 60+ 
Cluster 
sampling 
2007 Unclear 3620 2499 - - - 
CA-13 





Both Both 50+ 
Cluster 
sampling 
2007 Unclear 4587 - 188 - 323 
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Both Rural 50+ 
Cluster 
sampling 











2012 Unclear 4907 776 - - - 
CA-17 
















Mixed Mixed 40+ 
Cluster 
sampling 
2010 Unclear 22565 6542 - - - 
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2006 Unclear 5141 1098 - 108 - 
CA-20 





















2010 Unclear 6106 720 - 113 - 
CA-21B 









2010 Unclear 5947 1488 - 120 - 
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2008 Unclear 4866 1937 - - - 
CA-24 





Both Rural 50-92 
Stratified rand
om 
2011 Unclear 1912 701 - - - 
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2010 Unclear 6546 3172 - - 518 
CA-25B 
















Both Urban 50+ 
Random 
sampling 








Both Urban 65+ 
Cluster 
sampling 
2014 Unclear 13101 5369 - - 481 
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Both Both 60-85 
Stratified clust
er sampling 
2011 Unclear 1452 641 - - - 
CA-29 





Mixed Mixed 50-90 
Cluster 
sampling 











2014 Unclear 5592 - - - 436 
CA-31 





Both Rural 60-89 
Cluster 
sampling 
2008 Unclear 1305 - - 42 - 
CA-32 









2011 Unclear 1805 1084 - - - 
CA-33 





Both Mixed 50-88 
Cluster 
sampling 
2007 Unclear 75197 5983 - - - 
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2014* Unclear 1576 617 - - - 
CA-35 









2010 Unclear 6150 1785 112 - - 
CA-36 

















2006 Unclear 30478 - - 1324 - 
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Both Urban 50+ 
General health 
screening 







Mixed Urban 40+ 
General health 
screening 
2002 Unclear 634 124 - - - 
CA-39 






Both Urban 50+ 
General health 
screening 
2014 Unclear 6870 2900 - - - 
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2003 Yes 1536 135 - - - 
ARC-2 





Both Both 50-100 
Cluster sampli
ng 
2005* Yes 2084 285 - - - 
ARC-3 





Both Rural 55-109 
Cluster sampli
ng 
2008 Yes 80673 2953 - - - 
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Both Mixed 60+ 
Stratified clust
er sampling 
1997 Yes 8252 3865 - - - 
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2010 Yes 3826 - 128 - 233 
ARC-7 






Both Urban 60+ 
Cluster 
sampling 























2008 Yes 1117 - 14 - 40 
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Both Urban 50+ 
Random health 
screening 







Both Urban 50+ 
Health 
screening 
1998* Yes 423 74 - - - 
Note: “-” represents unavailable data; “*” indicates studies whose survey year was imputed. 
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Appendix table 25. Risk of bias scores of the included studies on cataract and cataract blindness prevalence in China (n=55) 
Study ID Study 
Quality score 
Sample population Sample size Participation Outcome assessment Analytical methods Total scores 
CA-01 Li SZ et al. (1999) 2 2 2 2 2 10 
CA-02 Zhao JL et al. (2001) 2 2 2 2 2 10 
CA-03 Tang X (2008) 2 2 0 2 2 8 
CA-04 Tang XY (2002) 2 0 0 2 2 6 
CA-05 Wang YX et al. (2003) 2 1 2 2 2 9 
CA-06 Li ZQ et al. (2004) 2 1 2 2 2 9 
CA-07 Chen L et al. (2004) 2 1 0 2 2 7 
CA-08 Ding L et al. (2005) 2 2 2 2 2 10 
CA-09 Li L et al. (2006) 2 2 0 2 2 8 
CA-10 Li ZJ et al. (2007) 2 1 2 2 2 9 
CA-11 Huang XB et al. (2009) 2 2 2 2 2 10 
CA-12 Zhou Y et al. (2011) 2 0 0 2 2 6 
CA-13 Tang B et al. (2011) 2 1 0 2 2 7 
CA-14 Xie TY et al. (2011) 2 1 2 2 2 9 
CA-15 Zhao MG et al. (2011) 2 1 2 2 2 9 
CA-16 Zhang HF (2013) 2 1 0 2 2 7 
CA-17 Li FR et al. (2012) 2 2 2 2 2 10 
CA-18 Bi JX (2012) 2 0 0 2 2 6 
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Study ID Study 
Quality score 
Sample population Sample size Participation Outcome assessment Analytical methods Total scores 
CA-19 Guan HJ et al. (2012) 2 2 2 2 2 10 
CA-20 Luo R et al. (2012) 2 2 2 2 2 10 
CA-21A Guan HJ et al. (2013) 2 2 2 2 2 10 
CA-21B J M et al. (2015) 2 1 0 2 2 7 
CA-22 Cai N et al. (2013) 2 1 0 2 2 7 
CA-23A Jiao WZ (2014) 2 2 2 2 2 10 
CA-23B Wang GM (2013) 2 2 2 2 2 10 
CA-23C Tang HY (2012) 2 2 2 2 2 10 
CA-24 Tian F et al. (2014) 2 1 2 2 2 9 
CA-25A Shen W (2015) 2 2 1 2 2 9 
CA-25B Shen W et al. (2013) 2 2 1 2 2 9 
CA-26 Wang TY (2015) 2 1 1 2 2 8 
CA-27 Jiang HF et al. (2015) 2 1 2 2 2 9 
CA-28 Long XX (2015) 2 1 2 2 2 9 
CA-29 Hu Y et al. (2016) 2 1 0 2 2 7 
CA-30 Cai HB (2016) 2 2 2 2 2 10 
CA-31 Zhou J et al. (2017) 2 2 2 2 2 10 
CA-32 Yao HY et al. (2012) 2 1 0 2 2 7 
CA-33 Gao RF et al. (2012) 2 1 0 2 2 7 
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Study ID Study 
Quality score 
Sample population Sample size Participation Outcome assessment Analytical methods Total scores 
CA-34 Geng JQ (2017) 2 2 0 2 2 8 
CA-35 Luan L et al. (2014) 2 2 2 2 2 10 
CA-36 Zhao JL et al. (2010) 2 1 2 2 2 9 
CA-37 Fu YZ et al. (2005) 2 1 0 2 2 7 
CA-38 Xu P (2003) 2 1 0 2 2 7 
CA-39 Wu SF et al. (2015) 2 1 0 2 2 7 
ARC-1A Peng YS et al. (2007) 2 1 1 2 2 8 
ARC-1B Quan YL et al. (2006) 2 2 0 2 2 8 
ARC-2 Feng J et al. (2008) 2 1 2 2 2 9 
ARC-3 Bai JS et al. (2012) 2 1 2 2 2 9 
ARC-4 Xiang W et al. (2015) 2 2 2 2 2 10 
ARC-5 Zheng H et al. (2001) 2 1 2 2 2 9 
ARC-6 Cui W et al. (2012) 2 1 2 2 2 9 
ARC-7 Zeng H et al. (2011) 2 1 0 2 2 7 
ARC-8 Sheng Y et al. (2016) 1 1 0 2 2 6 
ARC-9 Liu WJ (2009) 2 2 2 2 2 10 
ARC-10 Chang L et al. (2009) 2 1 0 2 2 7 
ARC-11 Yue Y (2001) 2 1 0 2 2 7 
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Appendix table 26. Estimated and projected number of people with any cataract and 
ARC in China from 1990 to 2050, by sex and age group (million, 95% CI) 
1990 
Age group 
Any cataract ARC 
Male Female Overall Male Female Overall 
45-49 years 
1.71  1.93  3.64  0.83  1.08  1.91  
(1.29-2.26) (1.46-2.52) (2.76-4.78) (0.38-1.74) (0.51-2.24) (0.89-3.98) 
50-54 years 
2.45  2.68  5.12  1.26  1.61  2.88  
(1.90-3.12) (2.10-3.39) (4.00-6.51) (0.6-2.59) (0.77-3.23) (1.37-5.82) 
55-59 years 
3.24  3.59  6.83  1.80  2.33  4.14  
(2.58-4.02) (2.89-4.42) (5.48-8.44) (0.87-3.56) (1.15-4.44) (2.02-8.01) 
60-64 years 
3.67  4.13  7.80  2.22  2.90  5.12  
(3.00-4.45) (3.41-4.95) (6.40-9.40) (1.10-4.17) (1.48-5.17) (2.59-9.34) 
65-69 years 
3.72  4.45  8.17  2.46  3.38  5.84  
(3.09-4.41) (3.75-5.20) (6.84-9.61) (1.27-4.31) (1.83-5.55) (3.10-9.86) 
70-74 years 
3.70  4.61  8.31  2.67  3.77  6.45  
(3.13-4.29) (3.96-5.26) (7.10-9.56) (1.47-4.31) (2.19-5.65) (3.66-9.95) 
75-79 years 
2.52  3.67  6.20  1.99  3.21  5.20  
(2.18-2.86) (3.23-4.10) (5.41-6.96) (1.17-2.91) (2.04-4.37) (3.21-7.29) 
80–84 years 
1.20  2.20  3.40  1.02  2.02  3.04  
(1.06-1.33) (1.97-2.40) (3.03-3.73) (0.66-1.36) (1.41-2.53) (2.07-3.89) 
85-89 years 
0.39  0.89  1.28  0.35  0.85  1.20  
(0.35-0.43) (0.81-0.95) (1.17-1.37) (0.25-0.43) (0.65-0.99) (0.90-1.42) 
Total  
(45-89 years) 
22.60  28.15  50.75  14.61  21.17  35.77  
(18.59-27.17) (23.58-33.19) (42.17-60.37) (7.78-25.39) (12.03-34.16) (19.81-59.55) 
2000 
Age group 
Any cataract ARC 
Male Female Overall Male Female Overall 
45-49 years 
2.93  3.51  6.44  1.41  1.97  3.39  
(2.21-3.86) (2.66-4.59) (4.88-8.45) (0.66-2.97) (0.93-4.08) (1.59-7.05) 
50-54 years 
3.14  3.73  6.87  1.62  2.25  3.87  
(2.44-4.01) (2.92-4.73) (5.37-8.74) (0.77-3.33) (1.08-4.50) (1.85-7.82) 
55-59 years 
3.58  4.04  7.62  2.00  2.62  4.62  
(2.86-4.45) (3.25-4.97) (6.11-9.42) (0.96-3.95) (1.29-4.99) (2.26-8.94) 
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60-64 years 
4.65  5.13  9.78  2.82  3.60  6.42  
(3.80-5.64) (4.23-6.15) (8.03-11.79) (1.40-5.29) (1.85-6.42) (3.24-11.71) 
65-69 years 
5.29  6.04  11.33  3.49  4.58  8.08  
(4.40-6.27) (5.09-7.06) (9.49-13.33) (1.81-6.13) (2.48-7.53) (4.29-13.66) 
70-74 years 
4.74  5.73  10.47  3.42  4.69  8.12  
(4.01-5.50) (4.93-6.55) (8.94-12.05) (1.88-5.52) (2.73-7.02) (4.61-12.54) 
75-79 years 
3.41  4.67  8.08  2.68  4.09  6.77  
(2.94-3.87) (4.11-5.22) (7.05-9.08) (1.59-3.93) (2.59-5.56) (4.18-9.49) 
80–84 years 
2.16  3.27  5.43  1.83  3.01  4.84  
(1.90-2.39) (2.93-3.57) (4.83-5.96) (1.18-2.44) (2.10-3.76) (3.28-6.20) 
85-89 years 
0.83  1.48  2.31  0.75  1.41  2.16  
(0.75-0.90) (1.36-1.58) (2.10-2.48) (0.53-0.92) (1.08-1.65) (1.61-2.56) 
Total  
(45-89 years) 
30.73  37.60  68.33  20.03  28.24  48.26  
(25.31-36.89) (31.48-44.41) (56.79-81.29) (10.77-34.47) (16.12-45.52) (26.89-79.99) 
2010 
Age group 
Any cataract ARC 
Male Female Overall Male Female Overall 
45-49 years 
3.46  4.15  7.61  1.67  2.33  4.00  
(2.61-4.55) (3.15-5.43) (5.76-9.98) (0.78-3.51) (1.10-4.82) (1.87-8.33) 
50-54 years 
4.21  5.00  9.20  2.17  3.01  5.19  
(3.27-5.37) (3.91-6.33) (7.19-11.70) (1.03-4.45) (1.44-6.02) (2.47-10.47) 
55-59 years 
6.26  7.42  13.69  3.49  4.82  8.31  
(5.00-7.78) (5.97-9.13) (10.97-16.91) (1.68-6.90) (2.37-9.17) (4.06-16.07) 
60-64 years 
6.17  7.28  13.45  3.73  5.11  8.84  
(5.03-7.48) (6.00-8.72) (11.04-16.20) (1.85-7.01) (2.62-9.11) (4.47-16.12) 
65-69 years 
6.15  6.96  13.11  4.06  5.29  9.35  
(5.12-7.29) (5.86-8.14) (10.98-15.43) (2.10-7.13) (2.86-8.69) (4.96-15.81) 
70-74 years 
6.47  7.39  13.86  4.68  6.05  10.72  
(5.48-7.51) (6.36-8.44) (11.83-15.95) (2.56-7.53) (3.52-9.05) (6.08-16.59) 
75-79 years 
5.34  6.73  12.07  4.21  5.88  10.09  
(4.61-6.06) (5.91-7.51) (10.52-13.57) (2.49-6.17) (3.73-8.01) (6.22-14.18) 
80–84 years 
3.13  4.45  7.58  2.66  4.10  6.76  
(2.76-3.47) (4.00-4.86) (6.76-8.33) (1.72-3.55) (2.86-5.12) (4.58-8.67) 
85-89 years 
1.33  2.17  3.50  1.20  2.07  3.27  
(1.20-1.44) (1.99-2.32) (3.19-3.77) (0.85-1.47) (1.58-2.42) (2.44-3.89) 
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Total  
(45-89 years) 
42.52  51.56  94.07  27.86  38.67  66.54  
(35.08-50.96) (43.16-60.88) (78.24-111.84) (15.07-47.72) (22.08-62.42) (37.15-110.14) 
2015 
Age group 
Any cataract ARC 
Male Female Overall Male Female Overall 
45-49 years 
4.20  5.11  9.31  2.02  2.87  4.90  
(3.17-5.53) (3.87-6.68) (7.05-12.21) (0.94-4.26) (1.35-5.94) (2.29-10.20) 
50-54 years 
5.15  6.14  11.29  2.66  3.70  6.36  
(4.00-6.57) (4.81-7.78) (8.81-14.35) (1.26-5.45) (1.77-7.40) (3.03-12.85) 
55-59 years 
6.06  7.18  13.24  3.38  4.66  8.04  
(4.84-7.53) (5.78-8.82) (10.61-16.35) (1.63-6.68) (2.30-8.87) (3.93-15.54) 
60-64 years 
8.58  10.15  18.73  5.19  7.13  12.32  
(7.00-10.40) (8.37-12.16) (15.37-22.56) (2.58-9.75) (3.65-12.71) (6.23-22.46) 
65-69 years 
7.78  9.26  17.04  5.14  7.03  12.17  
(6.47-9.23) (7.80-10.82) (14.27-20.05) (2.66-9.01) (3.80-11.55) (6.46-20.56) 
70-74 years 
6.87  7.97  14.84  4.96  6.53  11.49  
(5.81-7.97) (6.86-9.11) (12.67-17.07) (2.72-8.00) (3.79-9.77) (6.51-17.77) 
75-79 years 
6.04  7.33  13.36  4.75  6.41  11.16  
(5.21-6.85) (6.44-8.18) (11.65-15.03) (2.81-6.97) (4.06-8.72) (6.87-15.69) 
80–84 years 
3.99  5.45  9.45  3.39  5.02  8.41  
(3.52-4.43) (4.89-5.95) (8.41-10.38) (2.19-4.53) (3.50-6.27) (5.69-10.80) 
85-89 years 
1.77  2.72  4.49  1.60  2.60  4.20  
(1.60-1.92) (2.49-2.91) (4.09-4.83) (1.13-1.96) (1.98-3.03) (3.12-4.99) 
Total  
(45-89 years) 
50.44  61.30  111.74  33.10  45.94  79.04  
(41.63-60.43) (51.31-72.41) (92.94-132.84) (17.93-56.61) (26.21-74.25) (44.14-130.85) 
2020 
Age group 
Any cataract ARC 
Male Female Overall Male Female Overall 
45-49 years 
4.04  4.84  8.88  2.87  2.72  4.67  
(3.05-5.32) (3.67-6.33) (6.72-11.65) (1.35-5.94) (1.28-5.63) (2.19-9.73) 
50-54 years 
6.26  7.57  13.83  3.70  4.57  7.80  
(4.87-7.99) (5.93-9.59) (10.80-17.58) (1.77-7.40) (2.19-9.12) (3.72-15.75) 
55-59 years 
7.44  8.83  16.27  4.66  5.74  9.88  
(5.94-9.24) (7.11-10.86) (13.05-20.1) (2.30-8.87) (2.83-10.92) (4.83-19.11) 
60-64 years 8.35  9.85  18.20  7.13  6.91  11.97  
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(6.81-10.12) (8.12-11.80) (14.93-21.92) (3.65-12.71) (3.54-12.33) (6.05-21.81) 
65-69 years 
10.93  12.99  23.92  7.03  9.87  17.09  
(9.09-12.96) (10.95-15.19) (20.04-28.15) (3.80-11.55) (5.34-16.21) (9.08-28.87) 
70-74 years 
8.83  10.73  19.55  6.53  8.78  15.16  
(7.48-10.25) (9.23-12.25) (16.70-22.50) (3.79-9.77) (5.10-13.15) (8.60-23.43) 
75-79 years 
6.57  8.06  14.63  6.41  7.05  12.22  
(5.67-7.46) (7.08-9.00) (12.75-16.45) (4.06-8.72) (4.47-9.59) (7.53-17.18) 
80–84 years 
4.67  6.12  10.79  5.02  5.63  9.60  
(4.12-5.18) (5.49-6.68) (9.61-11.86) (3.50-6.27) (3.93-7.03) (6.49-12.33) 
85-89 years 
2.36  3.48  5.84  2.60  3.32  5.45  
(2.12-2.56) (3.19-3.72) (5.31-6.28) (1.98-3.03) (2.54-3.87) (4.05-6.48) 
Total  
(45-89 years) 
59.45  72.47  131.92  45.94  54.59  93.83  
(49.15-71.08) (60.76-85.42) (109.91-156.49) (26.21-74.25) (31.21-87.85) (52.52-154.69) 
2030 
Age group 
Any cataract ARC 
Male Female Overall Male Female Overall 
45-49 years 
3.35  3.98  7.32  1.61  2.24  3.85  
(2.53-4.40) (3.02-5.21) (5.55-9.61) (0.75-3.39) (1.05-4.63) (1.80-8.02) 
50-54 years 
4.81  5.70  10.51  2.48  3.44  5.92  
(3.74-6.14) (4.46-7.22) (8.20-13.35) (1.17-5.09) (1.65-6.86) (2.82-11.95) 
55-59 years 
8.77  10.36  19.13  4.89  6.73  11.62  
(7.00-10.89) (8.34-12.74) (15.34-23.63) (2.36-9.66) (3.31-12.80) (5.67-22.46) 
60-64 years 
12.62  15.07  27.69  7.64  10.58  18.22  
(10.30-15.30) (12.43-18.05) (22.73-33.35) (3.79-14.34) (5.42-18.86) (9.21-33.20) 
65-69 years 
13.35  15.75  29.11  8.82  11.96  20.78  
(11.11-15.84) (13.27-18.41) (24.38-34.25) (4.57-15.47) (6.47-19.66) (11.04-35.13) 
70-74 years 
12.56  15.02  27.57  9.07  12.29  21.36  
(10.63-14.57) (12.92-17.15) (23.55-31.72) (4.98-14.62) (7.15-18.40) (12.12-33.02) 
75-79 years 
12.66  15.95  28.62  9.97  13.95  23.92  
(10.93-14.37) (14.01-17.81) (24.95-32.18) (5.89-14.62) (8.84-18.98) (14.74-33.61) 
80–84 years 
7.17  9.75  16.92  6.08  8.98  15.06  
(6.32-7.95) (8.75-10.64) (15.07-18.59) (3.93-8.12) (6.26-11.21) (10.19-19.33) 
85-89 years 
3.36  4.79  8.15  3.03  4.57  7.60  
(3.03-3.64) (4.39-5.12) (7.41-8.76) (2.15-3.72) (3.49-5.32) (5.64-9.04) 
Total  78.65  96.36  175.01  53.60  74.73  128.33  
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(45-89 years) (65.58-93.11) (81.58-112.35) (147.16-205.46) (29.60-89.04) (43.64-116.73) (73.24-205.78) 
2040 
Age group 
Any cataract ARC 
Male Female Overall Male Female Overall 
45-49 years 
3.64  4.10  7.74  1.75  2.31  4.06  
(2.75-4.79) (3.11-5.37) (5.86-10.16) (0.82-3.69) (1.09-4.78) (1.90-8.46) 
50-54 years 
6.57  7.58  14.15  3.39  4.57  7.96  
(5.11-8.38) (5.93-9.60) (11.04-17.98) (1.60-6.95) (2.19-9.13) (3.80-16.08) 
55-59 years 
7.31  8.55  15.87  4.08  5.55  9.63  
(5.84-9.08) (6.89-10.52) (12.72-19.60) (1.97-8.05) (2.74-10.57) (4.70-18.62) 
60-64 years 
9.82  11.42  21.24  5.94  8.02  13.96  
(8.01-11.90) (9.42-13.68) (17.43-25.58) (2.95-11.16) (4.11-14.29) (7.06-25.45) 
65-69 years 
16.13  18.74  34.87  10.66  14.23  24.89  
(13.41-19.13) (15.79-21.91) (29.21-41.04) (5.52-18.69) (7.70-23.39) (13.22-42.08) 
70-74 years 
19.82  23.60  43.42  14.32  19.32  33.64  
(16.79-23.01) (20.30-26.96) (37.09-49.96) (7.85-23.08) (11.23-28.92) (19.09-52.01) 
75-79 years 
16.63  20.27  36.90  13.10  17.72  30.82  
(14.36-18.88) (17.80-22.62) (32.16-41.50) (7.74-19.21) (11.24-24.12) (18.98-43.33) 
80–84 years 
11.35  14.74  26.09  9.64  13.57  23.21  
(10.01-12.59) (13.23-16.09) (23.23-28.68) (6.23-12.86) (9.46-16.95) (15.69-29.82) 
85-89 years 
7.45  10.67  18.12  6.71  10.19  16.90  
(6.71-8.08) (9.78-11.41) (16.49-19.49) (4.77-8.24) (7.78-11.87) (12.55-20.11) 
Total  
(45-89 years) 
98.72  119.69  218.41  69.59  95.49  165.08  
(82.98-115.84) (102.26-138.17) (185.24-254.01) (39.44-111.94) (57.53-144.03) (96.98-255.97) 
2050 
Age group 
Any cataract ARC 
Male Female Overall Male Female Overall 
45-49 years 
2.61  2.83  5.44  1.26  1.59  2.85  
(1.97-3.44) (2.14-3.70) (4.12-7.13) (0.59-2.65) (0.75-3.29) (1.33-5.93) 
50-54 years 
4.08  4.47  8.55  2.11  2.69  4.80  
(3.18-5.21) (3.50-5.66) (6.67-10.87) (1.00-4.32) (1.29-5.38) (2.29-9.70) 
55-59 years 
8.01  8.86  16.86  4.46  5.75  10.21  
(6.39-9.94) (7.13-10.89) (13.52-20.83) (2.15-8.82) (2.83-10.94) (4.99-19.76) 
60-64 years 
13.57  15.29  28.86  8.21  10.73  18.94  
(11.07-16.45) (12.61-18.32) (23.68-34.77) (4.08-15.42) (5.50-19.14) (9.58-34.56) 
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65-69 years 
13.74  15.66  29.41  9.08  11.89  20.97  
(11.43-16.30) (13.20-18.31) (24.63-34.61) (4.70-15.92) (6.43-19.54) (11.14-35.47) 
70-74 years 
16.04  18.28  34.32  11.59  14.97  26.56  
(13.58-18.62) (15.73-20.88) (29.31-39.50) (6.36-18.68) (8.70-22.40) (15.06-41.09) 
75-79 years 
21.50  25.05  46.55  16.93  21.90  38.83  
(18.56-24.40) (22.01-27.96) (40.56-52.36) (10.00-24.82) (13.89-29.82) (23.89-54.64) 
80–84 years 
19.90  24.67  44.58  16.90  22.72  39.61  
(17.54-22.08) (22.14-26.93) (39.68-49.01) (10.92-22.56) (15.83-28.37) (26.75-50.93) 
85-89 years 
11.32  14.95  26.27  10.20  14.28  24.48  
(10.19-12.27) (13.70-15.99) (23.89-28.27) (7.24-12.53) (10.91-16.63) (18.15-29.16) 
Total  
(45-89 years) 
110.76  130.07  240.83  80.73  106.53  187.26  
(93.92-128.70) (112.15-148.65) (206.07-277.35) (47.04-125.71) (66.13-155.52) (113.17-281.23) 
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Appendix table 27. Estimation of age-specific number of people with any cataract in China from 2000 to 2010, by geographical region (million, 
95% CI) 
2000 
Age group North China Northeast China East China South Central China Southwest China Northwest China 
45-49 years 0.54 (0.35-0.83) 0.85 (0.45-1.56) 1.66 (1.43-2.00) 2.48 (1.69-3.61) 0.94 (0.56-1.55) 0.31 (0.21-0.48) 
50-54 years 0.55 (0.37-0.82) 0.81 (0.44-1.38) 1.79 (1.59-2.08) 2.63 (1.87-3.61) 1.03 (0.64-1.63) 0.36 (0.24-0.53) 
55-59 years 0.57 (0.40-0.82) 0.83 (0.48-1.29) 1.94 (1.77-2.18) 2.79 (2.08-3.58) 1.27 (0.82-1.88) 0.45 (0.31-0.63) 
60-64 years 0.80 (0.57-1.08) 1.07 (0.66-1.50) 2.48 (2.33-2.69) 3.47 (2.74-4.14) 1.53 (1.04-2.11) 0.57 (0.41-0.76) 
65-69 years 0.97 (0.72-1.25) 1.10 (0.73-1.39) 3.10 (3.01-3.24) 3.89 (3.29-4.29) 1.64 (1.18-2.07) 0.57 (0.43-0.71) 
70-74 years 0.89 (0.70-1.07) 0.95 (0.70-1.09) 3.02 (3.03-3.03) 3.38 (3.07-3.47) 1.54 (1.20-1.79) 0.45 (0.36-0.52) 
75-79 years 0.68 (0.57-0.76) 0.64 (0.52-0.67) 2.47 (2.57-2.37) 2.51 (2.46-2.42) 1.11 (0.94-1.19) 0.35 (0.31-0.38) 
80-84 years 0.43 (0.39-0.45) 0.37 (0.33-0.36) 1.71 (1.85-1.58) 1.65 (1.73-1.52) 0.75 (0.69-0.75) 0.23 (0.22-0.23) 
85-89 years 0.18 (0.18-0.18) 0.16 (0.15-0.14) 0.72 (0.81-0.65) 0.70 (0.77-0.62) 0.33 (0.33-0.31) 0.08 (0.08-0.08) 
Total (45-89 years) 5.62 (4.26-7.26) 6.80 (4.47-9.37) 18.89 (18.39-19.83) 23.50 (19.70-27.26) 10.14 (7.39-13.26) 3.37 (2.58-4.31) 
2010 
Age group North China Northeast China East China South Central China Southwest China Northwest China 
45-49 years 0.64 (0.42-0.99) 1.01 (0.53-1.83) 1.95 (1.68-2.35) 3.08 (2.10-4.48) 0.96 (0.58-1.59) 0.42 (0.28-0.65) 
50-54 years 0.88 (0.60-1.31) 1.37 (0.75-2.32) 2.36 (2.09-2.74) 3.44 (2.44-4.72) 1.06 (0.66-1.67) 0.49 (0.34-0.73) 
55-59 years 1.20 (0.83-1.72) 1.75 (1.01-2.71) 3.61 (3.29-4.06) 4.93 (3.68-6.32) 1.92 (1.24-2.84) 0.68 (0.47-0.95) 
60-64 years 1.14 (0.82-1.55) 1.52 (0.93-2.12) 3.59 (3.38-3.90) 4.70 (3.72-5.60) 1.96 (1.33-2.70) 0.70 (0.51-0.93) 
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65-69 years 1.05 (0.78-1.34) 1.33 (0.89-1.68) 3.45 (3.35-3.60) 4.33 (3.67-4.78) 2.10 (1.52-2.66) 0.77 (0.59-0.96) 
70-74 years 1.20 (0.94-1.43) 1.39 (1.02-1.57) 3.69 (3.71-3.69) 4.40 (4.01-4.52) 2.08 (1.62-2.42) 0.80 (0.65-0.92) 
75-79 years 1.08 (0.90-1.20) 1.05 (0.86-1.09) 3.54 (3.70-3.40) 3.69 (3.62-3.56) 1.66 (1.40-1.77) 0.58 (0.50-0.62) 
80-84 years 0.66 (0.59-0.68) 0.62 (0.56-0.60) 2.37 (2.57-2.19) 2.20 (2.31-2.01) 1.07 (0.98-1.06) 0.29 (0.27-0.29) 
85-89 years 0.28 (0.27-0.28) 0.26 (0.25-0.23) 1.16 (1.31-1.04) 1.01 (1.12-0.89) 0.46 (0.46-0.43) 0.13 (0.13-0.12) 
Total (45-89 years) 8.13 (6.16-10.50) 10.30 (6.79-14.16) 25.72 (25.09-26.98) 31.79 (26.67-36.88) 13.28 (9.79-17.13) 4.87 (3.75-6.18) 
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Appendix table 28. Search strategy to identify studies reporting the prevalence of and 
risk factors for DR in China 
CNKI 
Access Date: 05 Dec 2017 
Subject category: Medicine & Public Health 
Sub-database: Journal, Featured journal, Doctoral dissertation, Master dissertation  
检索表达式： 
(SU % '糖尿病') AND (SU % '视网膜') AND (SU % '发病率' + '发生率' + '患病率'+ '罹
患率' + '现患率'+ '死亡率' + '病死率'+ '流行' + '负担'+ '现况调查'+ '现况研究') 
发表时间：从 1990-01-01 到 2017-12-05 
Search Terms: (SU % 'tangniaobing') AND (SU % 'shiwangmo') AND (SU % 'fabinglv' + 
'fashenglv' + 'huanbinglv'+ 'lihuanlv' + 'xianhuanlv'+ 'siwanglv' + 'bingsilv'+ 'liuxing' + 
'fudan'+ 'xiankuangdiaocha'+ 'xiankuangyanjiu') 
Published time：From 01/01/1990 to 05/12/2017 
 
Wanfang 
Access Date: 04 Dec 2017 
Sub-database: Journal articles, Dissertations 
检索表达式：(主题:(糖尿病)) * (主题:(视网膜)) * (主题:(发病率) + 主题:(发生率) + 主
题:(患病率) +主题:(罹患率) + 主题:(现患率) + 主题:(死亡率) +主题:(病死率) + 主
题:(流行) + 主题:(负担)+ 主题:(现况调查) + 主题:(现况研究)) 
时间：1990-2017 
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Search Terms: (subject: (tangniaobing))* (subject: (shiwangmo))* (subject: (fabinglv) + 
subject: (fashenglv) + subject: (huanbinglv)+ subject: (lihuanlv) + subject: (xianhuanlv) + 
subject: (siwanglv)+ subject: (bingsilv) + subject: (liuxing) + subject: (fudan)+ subject: 




Access Date: 04 Dec 2017 
Journal category: All journals 
检索表达式： 
(糖尿病) AND (视网膜) AND (发病率 or 发生率 or 患病率 or 罹患率 or 现患率 or 死
亡率 or 病死率 or 流行 or 负担 or 现况调查 or 现况研究) 
时间：1990-2017 
Search Terms: ((tangniaobing))* ((shiwangmo))* ((fabinglv) OR (fashenglv) OR 
(huanbinglv) OR (lihuanlv) OR (xianhuanlv) OR (siwanglv) OR (bingsilv) OR (liuxing) 




Access Date: 04 Dec 2017 
Search Terms:  
((diabetic retinopathy) AND (China OR Chinese OR Hongkong OR Macau OR Taiwan) 
AND (inciden* OR prevalen* OR morbidity OR mortality OR epidemiology)) AND 
("1990/01/01"[Date - Publication] : "2017/12/04"[Date - Publication]) 
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Embase (Ovid) 
Access Date: 04 Dec 2017 
# Searches 
1 diabetic retinopathy.mp. or exp diabetic retinopathy/ 
2 China.mp. or exp China/ 
3 exp Chinese/ or Chinese.mp. 
4 Hong Kong.mp. or exp Hong Kong/ 
5 Macau.mp. or exp Macao/ 
6 Taiwan.mp. or exp Taiwan/ 
7 exp incidence/ or inciden*.mp. 
8 exp prevalence/ or prevalen*.mp. 
9 morbidity.mp. or exp morbidity/ 
10 exp mortality/ or Mortality.mp. 
11 exp epidemiology/ or Epidemiology.mp. 
12 2 or 3 or 4 or 5 or 6 
13 7 or 8 or 9 or 10 or 11 
14 1 and 12 and 13 
15 limit 14 to yr="1990 -Current" 
  
Medline (Ovid) 
Access Date: 04 Dec 2017 
Search Terms:  
# Searches 
1 diabetic retinopathy.mp. or exp Diabetic Retinopathy/ 
2 China.mp. or exp China/ 
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3 Chinese.mp. 
4 Hong Kong.mp. or exp Hong Kong/ 
5 Macau.mp. or exp Macau/ 
6 Taiwan.mp. or exp Taiwan/ 
7 exp Incidence/ or inciden*.mp. 
8 exp Prevalence/ or prevalen*.mp. 
9 Morbidity.mp. or exp Morbidity/ 
10 Mortality.mp. or exp Mortality/ 
11 Epidemiology.mp. or exp Epidemiology/ 
12 2 or 3 or 4 or 5 or 6 
13 7 or 8 or 9 or 10 or 11 
14 1 and 12 and 13 
15 limit 14 to yr="1990 -Current" 
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Appendix table 29. The year of publication and investigation and corresponding time-
lag in the included studies on DR prevalence in China (n=41) 






DR_C1 Zhang XM et al. (1996) 1996 1994 2 
DR_C2 He SZ et al. (1997) 1997 - - 
DR_C3 Li SL et al. (1998) 1998 1994 4 
DR_C4 Li N et al. (1999) 1999 1995 4 
DR_C5 Wang GL et al. (2001) 2001 1994 7 
DR_C6 Yang X et al. (2004) 2004 2000 4 
DR_C7 Liu JP (2006) 2006 2005 1 
DR_C8 Hu HY et al. (2007) 2007 2006 1 
DR_C9 Dong B et al. (2008) 2008 - - 
DR_C10 Liu L (2009) 2009 2007 2 
DR_C11 Zhang HX et al. (2009) 2009 2005 4 
DR_C12 Xin Z et al. (2010) 2010 2008 2 
DR_C13 Wang HB et al. (2010) 2010 2008 2 
DR_C14 Shu XW et al. (2010) 2010 2007 3 
DR_C15 Gao LT (2011) 2011 2009 2 
DR_C16 Li BZ et al. (2011) 2011 2007 4 
DR_C17 Hu YD (2011) 2011 2007 4 
DR_C18 Liu QX et al. (2012) 2012 - - 
DR_C19 Zhang J (2012) 2012 2011 1 
DR_C20 Yuan MX et al. (2012) 2012 2010 2 
DR_C21 Cui Y (2013) 2013 2012 1 
DR_C22 Li N et al. (2013) 2013 2010 3 
DR_C23 Xie TH et al. (2013) 2013 2010 3 
DR_C24 Wu PC et al. (2014) 2014 2012 2 
DR_C25 Mou XY et al. (2014) 2014 - - 
DR_C26 Shao L et al. (2014) 2014 2011 3 
DR_C27 Jiang XF et al. (2015) 2015 2012 3 
DR_C28 Wang WC et al. (2015) 2015 2011 4 
DR_C29 Ye BL et al. (2016) 2016 2011 5 
DR_C30 Hu BJ et al. (2016) 2016 2014 2 
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DR_C31 Zhang GS et al. (2017) 2017 2014 3 
DR_C32 Xie XW et al. (2008) 2008 2006 2 
DR_C33 Xie XW et al. (2009) 2009 2001 8 
DR_C34 Wang FH et al. (2011) 2011 2007 4 
DR_C35 Wang B et al. (2016) 2016 2011 5 
DR_P1 Liu LP et al. (2015) 2015 2013 2 
DR_P2 Liang C et al. (2016) 2016 2014 2 
DR_P3 Zhang XH et al. (2016) 2016 - - 
DR_P4 Xu J et al. (2012) 2012 2009 3 
DR_P5 Pan CW et al. (2017) 2017 2015 2 
DR_R1 Wang WJ et al. (2015) 2015 - - 
Note: “-” represents unavailable data; Based on the information from 35 studies, the average 
time-lag between year of publication and year of investigation was 3.03. 
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Appendix table 30. Full list of the included studies on the prevalence of and risk factors for DR in China (n=41) 
Study ID Reference 
Community-based studies 
DR_C1 Xiao-mei Zhang, Shi-hong Hu. 张晓湄 , 胡世红 . Diabetes retinopathy detected in a population in Liuzhou municipal during 
epidemiologic survey of diabetes mellitus (柳州市人群糖尿病调查中视网膜病变检出情况)[J]. Journal of Clinical Ophthalmology (临
床眼科杂志). 1996(04):244-5. 
DR_C2 Shou-zhi He, Yu-luan Guo, Zhao-hui Li, et al. 何守志, 郭玉銮, 李朝辉, et al. Epidemiologic study of diabetic retinopathy in Capital 
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DR_C3 Shou-ling Li, Yan-feng Zhou, Ti Chen, et al. 李寿玲, 周艳枫, 陈逖, 杨明功, 朱美玲. Epidemiologic study about the related factors of 
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DR_C4 Nong Li, Li-jun Ao, Shou-jun Meng, et al. 李农, 敖丽君, 孟寿军, 王华权, 杨媛魁, 许道盛. An analysis of risk factors of diabetic 
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DR_C5 Guang-lu Wang, Feng Zhang, Shen-yuan Yuan, et al. 王光璐, 张风, 袁申元, et al. A screening survey of diabetic retinopathy and other 
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DR_C7 Ju-ping Liu. 刘巨平. Epidemiologic study of diabetic retinopathy in type 2 diabetes mellitus in Tianjin (天津市 2型糖尿病患者糖尿
病视网膜病变流行病学调查)[D]. Tianjin Medical University (天津医科大学). 2006. 
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2007(09):838-40. 
DR_C9 Bin Dong, Xiang-wen Yang, Hong-juan Li, et al. 董斌, 阳湘文, 黎红娟, 周恩林. An analysis of the epidemiology and risk factors of 
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DR_C27 Xue-feng Jiang, Zheng-yu Zhu, Yong-wu He, et al. 江雪丰, 褚征宇, 何勇武, 程玲, 张宏娣. Prevalence and risk factors of Nanchang 
community diabetic retinopathy (南昌市社区糖尿病视网膜病变患病率及危险因素分析)[J]. Rec Adv Ophthalmol (眼科新进展). 
2015(11):1047-50. 
DR_C28 Wei-chao Wang, Jie Zhang, Hong Wang, et al. 王伟超, 张洁, 王虹, et al. Relationship between the levels of tear fluid TNF-α, serum 
TNF-α and serum HbA1c and diabetic retinopathy in middle-aged and elderly diabetes patients (社区中老年糖尿病患者泪液和血清
肿瘤坏死因子 α及血清糖化血红蛋白与糖尿病视网膜病变的关系)[J]. Chinese General Practice (中国全科医学). 2015(35):4288-
92. 
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Dundus Dis (中华眼底病杂志). 2015;31(2):126-9. 
DR_P2 Chen Liang, Rong Shi, Jing-fen Zhu, et al. 梁辰, 施榕, 朱静芬, et al. Prevalence of diabetic retinopathy of type 2 diabetes mellitus 
patients in Shanghai Pudong New Area and influencing factors (上海市浦东新区社区 2型糖尿病患者糖尿病性视网膜病变的患病
情况及影响因素调查)[J]. Chinese General Practice (中国全科医学). 2016(04):474-8. 
DR_P3 Xiao-hua Zhang, Cheng-jun Liu, Wei Zhou, et al. 章小花, 刘成军, 周伟, et al. Survey and analysis on diabetic retinopathy and its factors 
among type 2 diabetic patients in the Southern Suburb of Pudong New Area (浦东新区南郊 2型糖尿病患者视网膜病变及相关因素
调查分析)[J]. Chinese Primary Health Care (中国初级卫生保健). 2016(04):52-4. 
DR_P4 Xu J, Wei WB, Yuan MX, et al. Prevalence and risk factors for diabetic retinopathy: the Beijing Communities Diabetes Study 6. Retina 
2012;32(2):322-9. 
DR_P5 Pan CW, Wang S, Qian DJ, Xu C, Song E. Prevalence, Awareness, and Risk Factors of Diabetic Retinopathy among Adults with Known 
Type 2 Diabetes Mellitus in an Urban Community in China. Ophthalmic Epidemiol 2017;24(3):188-94. 
Registry-based study 
DR_R1 Wei-jie Wang, Yi-nan Liu, Yu-jie Yan, et al. 王伟杰, 刘奕男, 严玉洁, 姚保栋, 周凡, 郦伦强. The investigation of risk factors of 
diabetic retinopathy in type 2 diabetes mellitus in Minhang, Shanghai (上海市闵行区 2型糖尿病患者糖尿病视网膜病变患病率及相
关危险因素分析)[J]. Chinese Primary Health Care (中国初级卫生保健). 2015(08):66-8. 
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Note: The Chinese publication list employed the journals’ official English names or abbreviations, English titles were obtained from journals or literature 
databases (CNKI, Wanfang and CBM); Where official English translation of journal names is not available, a pinyin title is adopted; where the English 
translation of titles is not available, I translated the titles, labelled with “*” and marked as green; PHCM, Primary Health Care Management. 
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Appendix table 31. Detailed characteristics of the included studies on the prevalence of and risk factors for DR in China (n=41) 






























1994 Both Mixed NCOFD Yes No 11866 275 27 26 1 
DR_C2 He SZ et al. (1997) Beijing North China 1994* Both Urban NOFDG Yes Yes 29938 534 90 88 2 
DR_C3 Li SL et al. (1998) Anhui East China 1994 Mixed Mixed NCOFD Yes No 11618 216 67 - - 
DR_C4 Li N et al. (1999) Xinjiang 
Northwest 
China 
1995 Mixed Urban CMB Yes No - 276 54 52 2 
DR_C5 Wang GL et al. (2001) Beijing North China 1994 Mixed Mixed NCOFD Yes No 20682 293 33 28 5 
DR_C6 Yang X et al. (2004) Xinjiang 
Northwest 
China 
2000 Mixed Urban NCOFD Yes No 6542 224 26 - - 
DR_C7 Liu JP (2006) Tianjin North China 2005 Both Mixed ICDRDSS Yes No 23212 650 106 102 4 
DR_C8 Hu HY et al. (2007) Shanghai East China 2006 Both Urban ICDRDSS No Yes - 672 154 145 9 




2005* Mixed Urban NCOFD Yes No 5731 196 22 - - 
DR_C10 Liu L (2009) Liaoning 
Northeast 
China 
2007 Both Urban NCOFD Yes Yes 1534 137 17 17 0 
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DR_C11 Zhang HX et al. (2009) Shanghai East China 2005 Both Urban ICDRDSS Yes Yes - 642 78 76 2 
DR_C12 Xin Z et al. (2010) Beijing North China 2008 Mixed Rural ICDRDSS Yes Yes 1293 114 27 25 2 
DR_C13 Wang HB et al. (2010) Shanxi North China 2008 Mixed Rural NOFDG Yes No 57500 2632 986 - - 
DR_C14 Shu XW et al. (2010) Shandong East China 2007 Both Rural ICDRDSS Yes No 16330 689 181 136 45 
DR_C15 Gao LT (2011) Liaoning 
Northeast 
China 
2009 Both Urban NCOFD Yes No 740 66 6 - - 
DR_C16 Li BZ et al. (2011) Beijing North China 2007 Both Mixed ICDRDSS Yes No 4167 445 130 124 6 
DR_C17 Hu YD (2011) Liaoning 
Northeast 
China 
2007 Both Mixed ETDRS Yes Yes 3201 339 57 - - 
DR_C18 Liu QX et al. (2012) Ningxia 
Northwest 
China 
2009* Mixed Mixed ICDRDSS Yes No 3001 76 13 - - 
DR_C19 Zhang J (2012) Sichuan 
Southwest 
China 
2011 Both Urban NCOFD Yes Yes 7478 1374 214 194 20 
DR_C20 Yuan MX et al. (2012) Beijing North China 2010 Mixed Mixed ICDRDSS Yes No 8155 614 61 59 2 




2012 Both Rural ICDRDSS Yes Yes 8592 1310 235 - - 
DR_C22 Li N et al. (2013) Beijing North China 2010 Both Urban ETDRS No Yes - 1100 353 300 53 
DR_C23 Xie TH et al. (2013) Jiangsu East China 2010 Both Urban ICDRDSS Yes No 6150 663 36 34 2 
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DR_C24 Wu PC et al. (2014) Qinghai 
Northwest 
China 
2012 Mixed Rural NCOFD Yes No 2511 12 5 - - 
DR_C25 Mou XY et al. (2014) Liaoning 
Northeast 
China 
2011* Both Rural ICDRDSS Yes Yes - 603 219 217 2 
DR_C26 Shao L et al. (2014) Beijing North China 2011 Mixed Mixed ETDRS Yes No 3468 246 23 - - 
DR_C27 Jiang XF et al. (2015) Jiangxi East China 2012 Both Urban ICDRDSS Yes Yes 9776 730 223 - - 
DR_C28 Wang WC et al. (2015) Hebei North China 2011 Mixed Urban ICDRDSS No Yes 1447 396 212 149 63 




2011 Both Urban ETDRS Yes Yes 3751 286 82 57 25 
DR_C30 Hu BJ et al. (2016) Xinjiang 
Northwest 
China 
2014 Mixed Mixed ETDRS Yes No 7462 618 77 76 1 
DR_C31 Zhang GS et al. (2017) Inner Mongolia North China 2014 Both Mixed NOFDG Yes No 3967 352 26 25 1 
DR_C32 Xie XW et al. (2008) Beijing North China 2006 Both Mixed ETDRS Yes Yes 3251 362 101 - - 
DR_C33 Xie XW et al. (2009) Beijing North China 2001 Mixed Mixed ETDRS No Yes 4127 232 86 - - 
DR_C34 Wang FH et al. (2011) Hebei North China 2007 Both Rural ETDRS Yes No 5597 368 165 - - 
DR_C35 Wang B et al. (2016) Liaoning 
Northeast 
China 
2011 Mixed Urban ICDRDSS Yes No 8391 1809 233 - - 
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DR_P1 Liu LP et al. (2015) Shanghai East China 2013 Both Urban ICDRDSS No Yes - 1120 264 261 3 
DR_P2 Liang C et al. (2016) Shanghai East China 2014 Both Urban ICDRDSS No Yes - 2083 445 - - 
DR_P3 Zhang XH et al. (2016) Shanghai East China 2013* Both Urban ICDRDSS No Yes - 1437 151 147 4 
DR_P4 Xu J et al. (2012) Beijing North China 2009 Both Urban ETDRS No Yes - 2007 496 429 67 
DR_P5 Pan CW et al. (2017) Jiangsu East China 2015 Both Urban ETDRS No Yes - 880 158 - - 
Registry-based study 
DR_R1 Wang WJ et al. (2015) Shanghai East China 2012* Both Urban ICDRDSS No Yes - 2152 736 687 49 
Note: “-” represents unavailable data; “*” indicates studies whose survey year was imputed. PHCM, Primary Health Care Management; NCOFD, 
National Conference on Ocular Fundus Diseases; NOFDG, National Ocular Fundus Diseases Group; CBM, China Medical Board; ICDRDSS, 
International Clinical Diabetic Retinopathy Disease Severity Scale; ETDRS, Early Treatment of Diabetic Retinopathy Study. 
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Appendix table 32. Risk of bias scores of the included studies on the prevalence of and risk factors for DR in China (n=41) 
Study ID Study 
Quality score 
Sample population Sample size Participation Outcome assessment Analytical methods Total scores 
DR_C1 Zhang XM et al. (1996) 2 1 0 2 2 7 
DR_C2 He SZ et al. (1997) 1 1 2 2 2 8 
DR_C3 Li SL et al. (1998) 2 1 2 2 2 9 
DR_C4 Li N et al. (1999) 1 1 0 2 2 6 
DR_C5 Wang GL et al. (2001) 2 1 2 2 2 9 
DR_C6 Yang X et al. (2004) 2 1 0 2 2 7 
DR_C7 Liu JP (2006) 2 2 0 1 1 6 
DR_C8 Hu HY et al. (2007) 2 1 0 2 2 7 
DR_C9 Dong B et al. (2008) 1 1 0 2 2 6 
DR_C10 Liu L (2009) 2 1 0 2 2 7 
DR_C11 Zhang HX et al. (2009) 2 1 0 2 2 7 
DR_C12 Xin Z et al. (2010) 2 1 0 2 2 7 
DR_C13 Wang HB et al. (2010) 1 1 2 2 2 8 
DR_C14 Shu XW et al. (2010) 2 1 0 2 2 7 
DR_C15 Gao LT (2011) 1 1 0 2 2 6 
DR_C16 Li BZ et al. (2011) 2 2 2 2 2 10 
DR_C17 Hu YD (2011) 2 1 2 2 2 9 
DR_C18 Liu QX et al. (2012) 2 2 0 2 2 8 
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Study ID Study 
Quality score 
Sample population Sample size Participation Outcome assessment Analytical methods Total scores 
DR_C19 Zhang J (2012) 2 1 2 2 2 9 
DR_C20 Yuan MX et al. (2012) 2 1 0 2 2 7 
DR_C21 Cui Y (2013) 2 1 1 2 2 8 
DR_C22 Li N et al. (2013) 1 1 0 2 2 6 
DR_C23 Xie TH et al. (2013) 2 1 2 2 2 9 
DR_C24 Wu PC et al. (2014) 2 2 0 2 2 8 
DR_C25 Mou XY et al. (2014) 2 1 0 2 2 7 
DR_C26 Shao L et al. (2014) 2 1 1 2 2 8 
DR_C27 Jiang XF et al. (2015) 2 1 2 2 2 9 
DR_C28 Wang WC et al. (2015) 2 1 2 2 2 9 
DR_C29 Ye BL et al. (2016) 2 2 2 2 2 10 
DR_C30 Hu BJ et al. (2016) 2 2 0 2 2 8 
DR_C31 Zhang GS et al. (2017) 2 2 2 2 2 10 
DR_C32 Xie XW et al. (2008) 2 1 2 2 2 9 
DR_C33 Xie XW et al. (2009) 2 1 2 2 2 9 
DR_C34 Wang FH et al. (2011) 2 1 1 2 2 8 
DR_C35 Wang B et al. (2016) 1 1 0 2 2 6 
DR_P1 Liu LP et al. (2015) 1 1 2 2 2 8 
DR_P2 Liang C et al. (2016) 1 1 0 2 2 6 
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Study ID Study 
Quality score 
Sample population Sample size Participation Outcome assessment Analytical methods Total scores 
DR_P3 Zhang XH et al. (2016) 1 1 2 2 2 8 
DR_P4 Xu J et al. (2012) 1 1 0 2 2 6 
DR_P5 Pan CW et al. (2017) 2 1 0 2 2 7 
DR_R1 Wang WJ et al. (2015) 1 2 2 2 2 9 
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Appendix figure 14. The prevalence of any DR in people with DM in different age 
groups, by random-effects meta-analysis  
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Appendix figure 15. The prevalence of any DR in people with DM in different DM 
duration groups, by random-effects meta-analysis  
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Appendix table 33. Full list of studies reporting risk factors for DR in China (n=21) 
Study ID Study Reported risk factor 
DR_P2 He SZ et al. (1997) 
DM_Duration (per year), Dietary control, FBG (mmol/l), HbA1c (%), 
Scr, Ucr, TC (mmol/l), TG (mmol/l) 
DR_P8 Hu HY et al. (2007) DM_Duration (per year), FBG (mmol/l) 
DR_P10 Liu L (2009) 
DM_Duration group comparison (>10 vs. <5), FBG (mmol/l), BMI 
(kg/m2), Drinking 
DR_P12 Xin Z et al. (2010) DM_Duration (per year), FBG (mmol/l), SBP (mmHg) 
DR_P19 Li BZ et al. (2011) 
DM_Duration (per year), FBG (mmol/l), BMI (kg/m2), Education 
(literacy vs. illiteracy), Insulin treatment 
DR_P21 Hu YD (2011) DM history, Income 
DR_P23 Zhang J (2012) DM_Duration (per year), HbA1c (%), HDL (mmol/l), Hypertension 
DR_P28 Cui Y (2013) 
DM_Duration group comparison (>=10 vs. 0), FBG level group 
comparison (>=7.0 vs. <5.6), HbA1c level group comparison (>=6.5 
vs. <6.5), SBP level group comparison (>=140 vs. <120), Male sex 
DR_P29 Li N et al. (2013) 
DM_Duration group comparison (>=10 vs. <10), HbA1c level group 
comparison (>=7.0 vs. <7.0), Low-education, Insulin treatment, Low 
income, Male sex 
DR_P34 Mou XY et al. (2014) 
DM_Duration (per year), FBG (mmol/l), BMI (kg/m2), Insulin 
treatment, Weight (kg), Hyperlipidemia 
DR_P36 Jiang XF et al. (2015) 
Age (per year), DM_Duration group comparison (>10 vs. <=5), 2h-
PBG, TC (mmol/l), TG (mmol/l), BMI (kg/m2), SBP (mmHg), DBP 
(mmHg), Male sex, 24h UP (mg.d) 
DR_P37 Wang WC et al. (2015) 
Age group comparison (>65 vs. 45-65), FBG (mmol/l), 2h-PBG, 
HbA1c (%), TG (mmol/l), BMI (kg/m2), WHR, DM family history, 
Male sex, Tear TFN-α (ng/l), Blood TFN-α (ng/l) 
DR_P38 Ye BL et al. (2016) 
DM_Duration group comparison (per year increase vs. 0), FBG 
(mmol/l), Education (literacy vs. illiteracy), Insulin treatment 
DR_P43 Xie XW et al. (2008) 
DM_Duration (per year), FBG (mmol/l), TC (mmol/l), SBP (mmHg), 
Insulin treatment vs. diet only, HDL (mmol/l), Rural, Hyperopic 
refractive error (per diopter) 
DR_P44 Xie XW et al. (2009) 
DM_Duration group comparison (>=20 vs. 5), Insulin treatment vs. 
diet only, Rural 
DR_M7 Liu LP et al. (2015) 
Age (per year), DM_Duration (per year), SBP (mmHg), Insulin 
treatment 
DR_M9 Liang C et al. (2016) Age of DM onset, DM_Duration (per year), 2h-PBG, HbA1c (%) 
DR_M10 Zhang XH et al. (2016) 
DM_Duration group comparison (>15 vs. <5), FBG level group 
comparison (>6.8 vs. <6.8) 
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Study ID Study Reported risk factor 
DR_M13 Xu J et al. (2012) 
Age (per year), DM_Duration (per year), HbA1c (%), BMI (kg/m2), 
SBP (mmHg), BUN (mmol/l) 
DR_M15 Pan CW et al. (2017) 
Age (per year), DM_Duration (per year), HbA1c (%), Smoking, DM 
family history, Hypertension, Male sex 
DR_R1 Wang WJ et al. (2015) DM_Duration (per year), HbA1c (%) 
Note: DM, diabetes mellitus; FBG, fasting blood glucose; PBG, postprandial blood glucose; 
HbA1c, glycated haemoglobin A1c; Scr, serum creatinine; Ucr, urine creatinine; TC, total 
cholesterol; TG, triglyceride; BMI, body mass index; SBP, systolic blood pressure; HDL, 
high-density lipoprotein; DBP, diastolic blood pressure; UP, urine protein; WHR, waist-to-
hip ratio; TFN-α, Tumour necrosis factor alpha; BUN, blood urea nitrogen. Some studies 
didn’t specify the units for some specific risk factors, in circumstances where assumptions 
could not be made, risk factors without units were not included for subsequent meta-analyses. 
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Appendix table 34. Meta-analyses of 11 risk factors for any DR in people with DM 
Risk factor 1-Advanced age (per year increase) 
 
 
Risk factor 2-Male 
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Risk factor 3-DM duration (per year increase) 
 
 
Risk factor 4-Insulin treatment 
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Risk factor 5-FBG (per mmol/l increase) 
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Risk factor 6-2h PBG (per mmol/l increase) 
 
 
Risk factor 7-HbA1c (per % increase) 
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Risk factor 8-TC (per mmol/l increase) 
 
 
Risk factor 9-TG (per mmol/l increase) 
 
 
Risk factor 10-BMI (per kg/m2 increase) 
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Appendix table 35. Estimation of age-specific prevalence and number of middle-aged and older Chinese with any DR in China in 2010, by 
geographic region 
Prevalence of any DR in general people (%, 95% CI) 
Age group North China Northeast China East China South Central China Southwest China Northwest China 
45-49 years 2.07 (1.32-2.95) 1.78 (1.14-2.54) 1.50 (0.95-2.13) 1.82 (1.16-2.59) 1.37 (0.87-1.95) 1.70 (1.08-2.42) 
50-59 years 3.84 (2.69-5.13) 3.31 (2.32-4.42) 2.78 (1.95-3.71) 3.37 (2.36-4.50) 2.54 (1.78-3.39) 3.15 (2.21-4.21) 
60-69 years 5.05 (3.72-6.52) 4.35 (3.20-5.61) 3.66 (2.69-4.71) 4.44 (3.26-5.72) 3.34 (2.46-4.31) 4.15 (3.05-5.35) 
70-79 years 4.69 (3.13-6.47) 4.04 (2.70-5.57) 3.39 (2.27-4.68) 4.12 (2.75-5.68) 3.10 (2.07-4.27) 3.85 (2.57-5.31) 
>=80 years 3.50 (0.80-7.22) 3.02 (0.69-6.22) 2.53 (0.58-5.22) 3.08 (0.70-6.34) 2.31 (0.53-4.77) 2.88 (0.66-5.93) 
Total (>=45 years) 3.76 (2.56-5.12) 3.22 (2.20-4.39) 2.74 (1.86-3.76) 3.31 (2.25-4.54) 2.55 (1.74-3.48) 3.09 (2.12-4.20) 
Prevalence of any DR in people with DM (%, 95% CI) 
Age group North China Northeast China East China South Central China Southwest China Northwest China 
45-49 years 15.75 (10.03-22.44) 16.07 (10.23-22.90) 15.12 (9.63-21.55) 15.38 (9.79-21.91) 15.93 (10.14-22.70) 16.42 (10.45-23.39) 
50-59 years 19.56 (13.72-26.13) 19.96 (14.00-26.66) 18.79 (13.18-25.10) 19.10 (13.40-25.52) 19.79 (13.88-26.44) 20.39 (14.30-27.24) 
60-69 years 20.68 (15.22-26.68) 21.11 (15.53-27.22) 19.87 (14.62-25.63) 20.20 (14.86-26.05) 20.93 (15.39-26.99) 21.56 (15.86-27.81) 
70-79 years 17.62 (11.77-24.29) 17.98 (12.01-24.79) 16.92 (11.30-23.33) 17.20 (11.49-23.72) 17.82 (11.90-24.57) 18.37 (12.27-25.32) 
>=80 years 11.35 (2.60-23.40) 11.59 (2.65-23.88) 10.91 (2.50-22.48) 11.09 (2.54-22.85) 11.49 (2.63-23.67) 11.84 (2.71-24.39) 
Total (>=45 years) 18.54 (12.66-25.28) 18.93 (12.94-25.81) 17.67 (11.97-24.24) 17.97 (12.19-24.63) 18.73 (12.76-25.59) 19.39 (13.30-26.35) 
Number of people with DR (million, 95% CI) 
Age group North China Northeast China East China South Central China Southwest China Northwest China 
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45-49 years 0.27 (0.17-0.38) 0.18 (0.11-0.26) 0.46 (0.29-0.65) 0.49 (0.31-0.70) 0.18 (0.12-0.26) 0.12 (0.08-0.17) 
50-59 years 0.85 (0.60-1.13) 0.58 (0.41-0.77) 1.37 (0.96-1.84) 1.39 (0.98-1.86) 0.55 (0.39-0.74) 0.33 (0.23-0.44) 
60-69 years 0.57 (0.42-0.73) 0.37 (0.27-0.48) 1.07 (0.79-1.38) 1.09 (0.80-1.41) 0.51 (0.38-0.66) 0.27 (0.20-0.34) 
70-79 years 0.29 (0.19-0.40) 0.18 (0.12-0.25) 0.57 (0.38-0.79) 0.58 (0.39-0.81) 0.26 (0.17-0.35) 0.13 (0.09-0.18) 
>=80 years 0.06 (0.01-0.13) 0.04 (0.01-0.08) 0.16 (0.04-0.33) 0.15 (0.03-0.31) 0.06 (0.01-0.13) 0.02 (0.01-0.05) 
Total (>=45 years) 2.03 (1.39-2.77) 1.35 (0.92-1.84) 3.63 (2.46-4.98) 3.71 (2.52-5.09) 1.56 (1.07-2.14) 0.87 (0.60-1.18) 
 
